How many Bevacizumab clinical trials are there?

2548 Bevacizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 367 are actively recruiting participants. 1196 are marked completed.

Are Bevacizumab clinical trials recruiting in 2026?

Yes — 367 Bevacizumab trials are actively recruiting in 2026, with 2914 U.S. sites across 50 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Bevacizumab being studied for?

Bevacizumab is being studied for Colorectal Cancer, Metastatic Colorectal Cancer, Breast Cancer, Ovarian Cancer, Hepatocellular Carcinoma and 2189 more. The trials are grouped by indication on this page.

What phase is Bevacizumab in?

Bevacizumab clinical trials span 73 Phase 4, 336 Phase 3, 1309 Phase 2, 311 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Bevacizumab clinical trials?

The lead sponsor across the most Bevacizumab trials is National Cancer Institute (NCI), with 825 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Bevacizumab Clinical Trials (2026): 2,548 Studies for Colorectal Cancer & Metastatic Colorectal Cancer

Creator: Hipa.ai Research
Published: 2026-05-20T23:34:14.605Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: July 17, 2026.

2,548 Bevacizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 777 indications (including Colorectal Cancer & Metastatic Colorectal Cancer) and 402,810 total planned enrollment. 336 Phase 3 Bevacizumab trials and 1309 Phase 2, 73 Phase 4 are listed. 479 Bevacizumab clinical trials are actively recruiting at 2,914 U.S. sites across 50 states. Most recent activity: NCT05620771 (Jul 2040).

Where to Participate: All Bevacizumab Trial Sites in the U.S. (2,914 sites across 50 states)

Every actively recruiting Bevacizumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Corcept Therapeutics Investigator Site #004	Birmingham35233	NCT06906341	Map
AL	The Kirklin Clinic of University of Alabama Birmingham Hospital	Birmingham35233	NCT05440708	Map
AL	The University of Alabama at Birmingham	Birmingham35233	NCT06787612	Map
AL	University of Alabama	Birmingham35294	NCT05848739	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT06867822	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT06294548	Map
AL	University of Alabama at Birmingham ( Site 0006)	Birmingham35249	NCT06824467	Map
AL	University of Alabama at Birmingham (UAB) Hospital /ID# 274793	Birmingham35294	NCT06890338	Map
AL	University of Alabama at Birmingham Cancer Center	Birmingham35233	NCT07198074	Map
AL	University of Alabama at Birmingham Cancer Center	Birmingham35233	NCT06580314	Map
AL	Central Alabama Research	Homewood35209	NCT07446322	Map
AL	Clinical Study Site	Mobile36604	NCT07228832	Map
AL	The University of South Alabama, Mitchell Cancer Institute	Mobile36604	NCT05281471	Map
AL	Usa Mitchell Cancer Institute /ID# 276022	Mobile36604	NCT06890338	Map
AL	Clinical Study Site	Tuscaloosa35487	NCT07228832	Map
AK	Alaska Breast Care and Surgery LLC	Anchorage99508	NCT06580314	Map
AK	Alaska Oncology and Hematology LLC	Anchorage99508	NCT06580314	Map
AK	Alaska Oncology and Hematology LLC	Anchorage99508	NCT04181060	Map
AK	Alaska Women's Cancer Care	Anchorage99508	NCT07198074	Map
AK	Alaska Women's Cancer Care	Anchorage99508	NCT06580314	Map
AK	Alaska Women's Cancer Care ( Site 0096)	Anchorage99508	NCT06824467	Map
AK	Anchorage Associates in Radiation Medicine	Anchorage98508	NCT06580314	Map
AK	Katmai Oncology Group	Anchorage99508	NCT06580314	Map
AK	Katmai Oncology Group	Anchorage99508	NCT04181060	Map
AK	Providence Alaska Medical Center	Anchorage99508	NCT06580314	Map
AK	Fairbanks Memorial Hospital	Fairbanks99701	NCT04181060	Map
AZ	Ironwood Cancer & Research Centers	Chandler85224	NCT07222800	Map
AZ	Ironwood Cancer and Research Center	Chandler85224	NCT06750094	Map
AZ	Ironwood Cancer and Research Centers	Chandler85224	NCT06445062	Map
AZ	Ironwood Cancer and Research Centers Scottsdale	Chandler85224	NCT06252649	Map
AZ	Banner MD Anderson Cancer Center	Gilbert85234	NCT06750094	Map
AZ	Banner MD Anderson Cancer Center	Gilbert85234	NCT05863195	Map
AZ	Ironwood Cancer & Research Centers	Gilbert85297	NCT07222800	Map
AZ	Ironwood Cancer & Research Centers	Glendale85306	NCT07222800	Map
AZ	Palo Verde Hematology Oncology	Glendale85304	NCT05253651	Map
AZ	City of Hope Phoenix Cancer Center	Goodyear85338	NCT06427941	Map
AZ	Clinical Study Site	Goodyear85338	NCT07228832	Map
AZ	CTCA at Western Regional Medical Center	Goodyear85338	NCT07288034	Map
AZ	Ironwood Cancer & Research Centers	Goodyear85395	NCT07222800	Map
AZ	Ironwood Cancer & Research Centers	Mesa85202	NCT07222800	Map
AZ	Ironwood Cancer & Research Centers	Mesa85206	NCT07222800	Map
AZ	Banner-University Medical Center Phoenix	Phoenix85006	NCT05863195	Map
AZ	Cancer Center at Saint Joseph's	Phoenix85004	NCT07198074	Map
AZ	Cancer Center at Saint Joseph's	Phoenix85004	NCT06580314	Map
AZ	Cancer Center at Saint Joseph's	Phoenix85004	NCT04181060	Map
AZ	Ironwood Cancer & Research Centers	Phoenix85028	NCT07222800	Map
AZ	Mayo Clinic	Phoenix85054	NCT05919264	Map
AZ	Mayo Clinic Arizona	Phoenix85054	NCT06948448	Map
AZ	Mayo Clinic Arizona	Phoenix85259	NCT04929223	Map
AZ	Mayo Clinic Building - Phoenix	Phoenix85054	NCT05253651	Map
AZ	Mayo Clinic Hospital	Phoenix85054	NCT06131840	Map
AZ	Mayo Clinic Hospital	Phoenix85054	NCT05253651	Map
AZ	Mayo Clinic Hospital	Phoenix85054	NCT06445062	Map
AZ	Mayo Clinic Hospital in Arizona	Phoenix85054	NCT06580314	Map
AZ	Research Site	Phoenix85054	NCT06921785	Map
AZ	USOR HonorHealth	Phoenix85016	NCT05579366	Map
AZ	Honor Health	Scottsdale85258	NCT05919264	Map
AZ	Honor Health Research Institute	Scottsdale85251	NCT05405595	Map
AZ	HonorHealth	Scottsdale85258	NCT06400472	Map
AZ	HonorHealth Research Institute	Scottsdale85258	NCT06445062	Map
AZ	Ironwood Cancer & Research Centers	Scottsdale85260	NCT07222800	Map
AZ	Mayo Clinic	Scottsdale85259	NCT06131840	Map
AZ	Mayo Clinic	Scottsdale85259	NCT05253651	Map
AZ	Mayo Clinic in Arizona	Scottsdale85259	NCT05824975	Map
AZ	Research Site	Scottsdale85259	NCT06792695	Map
AZ	Banner Boswell Medical Center	Sun City85351	NCT05863195	Map
AZ	Arizona Cancer Center at University of Arizona	Tucson85719	NCT05919264	Map
AZ	Research Site	Tucson85719	NCT06921785	Map
AZ	Roche Tissue Diagnostics, Companion Diagnostics	Tucson85755	NCT07284849	Map
AZ	University of Arizona Cancer Center	Tucson85719	NCT05281471	Map
AZ	USOR Arizona Oncology Associates	Tucson85711	NCT05579366	Map
AR	Highlands Oncology Group	Fayetteville72703	NCT07222800	Map
AR	Highlands Oncology Group - Fayetteville	Fayetteville72703	NCT07198074	Map
AR	Highlands Oncology Group - Fayetteville	Fayetteville72703	NCT06580314	Map
AR	Mercy Hospital Fort Smith	Fort Smith72903	NCT06580314	Map
AR	NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro	Jonesboro72401	NCT04181060	Map
AR	St. Bernard's Medical Center	Jonesboro72401	NCT06750094	Map
AR	CARTI Cancer Center	Little Rock72205	NCT06580314	Map
AR	University of Arkansas for Medical Sciences	Little Rock72205	NCT07198074	Map
AR	University of Arkansas for Medical Sciences	Little Rock72205	NCT06580314	Map
AR	Highlands Oncology Group	Rogers72758	NCT07222800	Map
AR	Highlands Oncology Group - Rogers	Rogers72758	NCT07198074	Map
AR	Highlands Oncology Group - Rogers	Rogers72758	NCT06580314	Map
AR	Highlands Oncology Group	Springdale72762	NCT07198074	Map
AR	Highlands Oncology Group	Springdale72762	NCT07222800	Map
AR	Highlands Oncology Group	Springdale72762	NCT06750094	Map
AR	Highlands Oncology Group	Springdale72762	NCT06580314	Map
AR	Highlands Oncology Group	Springdale72762	NCT07221357	Map
CA	Los Angeles Cancer Network - Anaheim	Anaheim92801	NCT05253651	Map
CA	Kaiser Permanente-Deer Valley Medical Center	Antioch94531	NCT06580314	Map
CA	Kaiser Permanente-Deer Valley Medical Center	Antioch94531	NCT04181060	Map
CA	Mission Hope Medical Oncology - Arroyo Grande	Arroyo Grande93420	NCT06580314	Map
CA	Sutter Auburn Faith Hospital	Auburn95602	NCT06580314	Map
CA	Sutter Cancer Centers Radiation Oncology Services-Auburn	Auburn95603	NCT06580314	Map
CA	CBCC Global Research	Bakersfield93309	NCT06750094	Map
CA	Kaiser Permanente-Bellflower	Bellflower90706	NCT06580314	Map
CA	Alta Bates Summit Medical Center-Herrick Campus	Berkeley94704	NCT06580314	Map
CA	Alta Bates Summit Medical Center-Herrick Campus	Berkeley94704	NCT07166406	Map
CA	UCSF at Berkeley Outpatient Center	Berkeley94702	NCT07222800	Map
CA	Beverly Hills Cancer Center	Beverly Hills90211	NCT05733598	Map
CA	Clinical Study Site	Beverly Hills90211	NCT07228832	Map
CA	Clinical Study Site	Beverly Hills90212	NCT07228832	Map
CA	Precision NextGen Oncology	Beverly Hills90212	NCT06047379	Map
CA	Disney Family Cancer Center	Burbank91505	NCT06819007	Map
CA	Providence Saint Joseph Medical Center/Disney Family Cancer Center	Burbank91505	NCT06580314	Map
CA	Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center	Burbank91505	NCT07213804	Map
CA	Mills-Peninsula Medical Center	Burlingame94010	NCT06580314	Map
CA	Sutter Cancer Centers Radiation Oncology Services-Cameron Park	Cameron Park95682	NCT06580314	Map
CA	Sutter Cancer Centers Radiation Oncology Services-Cameron Park	Cameron Park95682	NCT07166406	Map
CA	Mercy Cancer Center - Carmichael	Carmichael95608	NCT07198074	Map
CA	Mercy Cancer Center - Carmichael	Carmichael95608	NCT06580314	Map
CA	Mercy San Juan Medical Center	Carmichael95608	NCT07198074	Map
CA	Mercy San Juan Medical Center	Carmichael95608	NCT06580314	Map
CA	Eden Hospital Medical Center	Castro Valley94546	NCT06580314	Map
CA	Clinical Study Site	Cerritos90703	NCT07228832	Map
CA	City of Hope Corona	Corona92882	NCT07288034	Map
CA	Clinical Study Site	Corona92882	NCT07228832	Map
CA	UC Irvine Medical Center	Costa Mesa92627	NCT04524871	Map
CA	Sutter Davis Hospital	Davis95616	NCT06580314	Map
CA	City of Hope	Duarte91010	NCT04524871	Map
CA	City of Hope	Duarte91010	NCT05281471	Map
CA	City of Hope	Duarte91010	NCT06607458	Map
CA	City of Hope (City of Hope National Medical Center, City of Hope Medical Center)	Duarte91010	NCT06131840	Map
CA	City of Hope (City of Hope National Medical Center, City of Hope Medical Center)	Duarte91010	NCT07318805	Map
CA	City of Hope /ID# 261468	Duarte91010	NCT06109272	Map
CA	City of Hope Cancer Center	Duarte91010	NCT06004245	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06625775	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT04929223	Map
CA	City of Hope Medical Center	Duarte91010	NCT05238922	Map
CA	City of Hope Medical Center	Duarte91010	NCT07288034	Map
CA	City of Hope National Medical Center	Duarte91010	NCT05405595	Map
CA	City of Hope National Medical Center	Duarte91010-3012	NCT06427941	Map
CA	City of Hope National Medical Center /ID# 270255	Duarte91010	NCT06820463	Map
CA	City of Hope National Medical Center /ID# 276272	Duarte91010	NCT05005403	Map
CA	Clinical Study Site	Duarte91010	NCT07228832	Map
CA	IP Address: City of Hope Investigational Drug Services(IDS)	Duarte91010	NCT06131840	Map
CA	Research Site	Duarte91010	NCT05797168	Map
CA	Kaiser Permanente Dublin	Dublin94568	NCT06580314	Map
CA	Kaiser Permanente Dublin	Dublin94568	NCT04181060	Map
CA	Mercy Cancer Center - Elk Grove	Elk Grove95758	NCT07198074	Map
CA	Mercy Cancer Center - Elk Grove	Elk Grove95758	NCT06580314	Map
CA	Stanford Cancer Center Emeryville	Emeryville94608	NCT06580314	Map
CA	Clinical Study Site	Fountain Valley92708	NCT07228832	Map
CA	Los Angeles Cancer Network - Fountain Vally	Fountain Valley92708	NCT05253651	Map
CA	Memorial Care Orange Coast Medical Center	Fountain Valley92708	NCT07284849	Map
CA	Kaiser Permanente-Fremont	Fremont94538	NCT06580314	Map
CA	Kaiser Permanente-Fremont	Fremont94538	NCT04181060	Map
CA	Palo Alto Medical Foundation-Fremont	Fremont94538	NCT06580314	Map
CA	Palo Alto Medical Foundation-Fremont	Fremont94538	NCT07166406	Map
CA	Washington Hospital	Fremont94538	NCT04181060	Map
CA	Community Regional Medical Center	Fresno93721-1324	NCT06703073	Map
CA	Community Regional Medical Center	Fresno93721-1324	NCT06701656	Map
CA	Fresno Cancer Center	Fresno93720	NCT06580314	Map
CA	Kaiser Permanente Fresno Orchard Plaza	Fresno93720	NCT06580314	Map
CA	Kaiser Permanente Fresno Orchard Plaza	Fresno93720	NCT04181060	Map
CA	Kaiser Permanente-Fresno	Fresno93720	NCT06580314	Map
CA	Kaiser Permanente-Fresno	Fresno93720	NCT04181060	Map
CA	Los Angeles Cancer Network	Glendale91204	NCT06750094	Map
CA	Los Angeles Hematology Oncology Medical Group	Glendale91204	NCT05253651	Map
CA	Los Angeles Hematology Oncology Medical Group	Glendale91206	NCT05253651	Map
CA	OPN Healthcare, Inc	Glendale91203	NCT06047379	Map
CA	Kaiser Permanente South Bay	Harbor City90710	NCT06580314	Map
CA	City of Hope Seacliff	Huntington Beach92648	NCT07288034	Map
CA	Clinical Study Site	Huntington Beach92648	NCT07228832	Map
CA	City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589	Irvine92618	NCT05005403	Map
CA	City of Hope at Irvine Lennar	Irvine91355	NCT06004245	Map
CA	City of Hope at Irvine Lennar	Irvine92618	NCT07288034	Map
CA	City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669	Irvine92618	NCT06109272	Map
CA	City of Hope Orange County	Irvine92618	NCT05405595	Map
CA	City of Hope-Lennar Foundation Cancer Center	Irvine92618	NCT05238922	Map
CA	Clinical Study Site	Irvine92612	NCT07228832	Map
CA	Clinical Study Site	Irvine92618	NCT07228832	Map
CA	Kaiser Permanente Zion Medical Center	Irvine92618	NCT07213804	Map
CA	Kaiser Permanente-Irvine	Irvine92618	NCT06580314	Map
CA	Research Site	Irvine92618	NCT05797168	Map
CA	UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care	Irvine92612	NCT07166406	Map
CA	University of California, Irvine (UCI) Health - UC Irvine Medical Center	Irvine92612	NCT06697197	Map
CA	GSK Investigational Site	La Jolla92093	NCT06796907	Map
CA	Scripps Clinic	La Jolla92037	NCT06819007	Map
CA	UC San Diego Health	La Jolla92037	NCT06787612	Map
CA	UC San Diego Health - Moores Cancer Center	La Jolla92093	NCT05281471	Map
CA	UC San Diego Health - Moores Cancer Center /ID# 277574	La Jolla92037	NCT07059845	Map
CA	UC San Diego Moores Cancer Center	La Jolla92093	NCT06580314	Map
CA	UC San Diego Moores Cancer Center	La Jolla92093	NCT06445062	Map
CA	UC San Diego Moores Cancer Center	La Jolla92037	NCT05733598	Map
CA	University of California, San Diego (UCSD) - Moores Cancer Center	La Jolla92037	NCT06400472	Map
CA	City of Hope Antelope Valley	Lancaster93534	NCT07288034	Map
CA	City of Hope at Long Beach Elm	Long Beach90813	NCT07288034	Map
CA	City of Hope National Medical Center	Long Beach90813	NCT06252649	Map
CA	Long Beach Memorial Medical Center	Long Beach90806-1701	NCT06703073	Map
CA	Long Beach Memorial Medical Center	Long Beach90806-1701	NCT06701656	Map
CA	Miller Children's and Women's Hospital Long Beach	Long Beach90806	NCT02446431	Map
CA	Cancer and Blood Research Center, LLC	Los Alamitos90720	NCT06252649	Map
CA	Cancer and Blood Specialty Clinic	Los Alamitos90720	NCT06750094	Map
CA	California Research Institute	Los Angeles90027	NCT06252649	Map
CA	Cedars Sinai Medical Center	Los Angeles90048	NCT06580314	Map
CA	Cedars Sinai Medical Center	Los Angeles90048	NCT06787612	Map
CA	Cedars-Sinai Cancer at Cedars-Sinai Medical Center	Los Angeles90048	NCT06445062	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT04929223	Map
CA	Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute	Los Angeles90048	NCT05588388	Map
CA	Clinical Study Site	Los Angeles90027	NCT07228832	Map
CA	Clinical Study Site	Los Angeles90067	NCT07228832	Map
CA	Clinical Study Site	Los Angeles90404	NCT07228832	Map
CA	Kaiser Permanente Los Angeles Medical Center	Los Angeles90027	NCT06580314	Map
CA	Kaiser Permanente West Los Angeles	Los Angeles90034	NCT06580314	Map
CA	Los Angeles General Medical Center	Los Angeles90033	NCT07198074	Map
CA	Los Angeles Hematology Oncology Medical Group	Los Angeles90017	NCT05253651	Map
CA	Los Angeles Hematology Oncology Medical Group ( Site 0084)	Los Angeles90017	NCT06997497	Map
CA	Norris Comprehensive Cancer Center	Los Angeles90033	NCT05440708	Map
CA	Research Site	Los Angeles90089	NCT06792695	Map
CA	Research Site	Los Angeles90095	NCT05489211	Map
CA	START - Los Angeles	Los Angeles90025	NCT07470853	Map
CA	The Angeles Clinic and Research Institute	Los Angeles90025	NCT05836324	Map
CA	The Angeles Clinic and Research Institute - West Los Angeles Office	Los Angeles90025	NCT06697197	Map
CA	UCLA	Los Angeles90095	NCT04929223	Map
CA	UCLA / Jonsson Comprehensive Cancer Center	Los Angeles90095	NCT06543576	Map
CA	UCLA Hematology/Oncology - Westwood (Building 100)	Los Angeles90095	NCT07213804	Map
CA	UCLA Hematology/Oncology- Santa Monica	Los Angeles90404	NCT06445062	Map
CA	UCLA Medical Center	Los Angeles90095	NCT04374305	Map
CA	University of California Los Angeles	Los Angeles90095	NCT06625775	Map
CA	University of California Los Angeles Medical Center	Los Angeles90095	NCT05579366	Map
CA	University of California Los Angeles Medical Center /ID# 274566	Los Angeles90095	NCT06890338	Map
CA	University of California, Los Angeles (UCLA)	Los Angeles90095	NCT05919264	Map
CA	University of Southern California	Los Angeles90033	NCT06047379	Map
CA	USC / Norris Comprehensive Cancer Center	Los Angeles90033	NCT07198074	Map
CA	USC Norris Comprehensive Cancer Center	Los Angeles90033	NCT06948448	Map
CA	USC Norris Comprehensive Cancer Center	Los Angeles90033	NCT06750094	Map
CA	USC Norris Comprehensive Cancer Center	Los Angeles90033	NCT05848739	Map
CA	Usc Norris Comprehensive Cancer Center (Nccc)	Los Angeles90089-1019	NCT06233942	Map
CA	USC Norris Comprehensive Cancer Center /ID# 279603	Los Angeles90033	NCT05005403	Map
CA	USC/Norris Comprehensive Cancer Center	Los Angeles90033	NCT07221357	Map
CA	Valkyrie Clinical Trials	Los Angeles90067	NCT05238922	Map
CA	Valkyrie Clinical Trials	Los Angeles90067	NCT05836324	Map
CA	Mercy Cancer Center	Merced95340	NCT06580314	Map
CA	Kaiser Permanente- Modesto MOB II	Modesto95356	NCT06580314	Map
CA	Kaiser Permanente- Modesto MOB II	Modesto95356	NCT04181060	Map
CA	Kaiser Permanente-Modesto	Modesto95356	NCT06580314	Map
CA	Kaiser Permanente-Modesto	Modesto95356	NCT04181060	Map
CA	Memorial Medical Center	Modesto95355	NCT06580314	Map
CA	Palo Alto Medical Foundation-Camino Division	Mountain View94040	NCT06580314	Map
CA	Palo Alto Medical Foundation-Camino Division	Mountain View94040	NCT07166406	Map
CA	Palo Alto Medical Foundation-Gynecologic Oncology	Mountain View94040	NCT06580314	Map
CA	Clinical Study Site	Murrieta92562	NCT07228832	Map
CA	Providence Queen of The Valley	Napa94558	NCT06580314	Map
CA	City of Hope at Newport Beach Fashion Island	Newport Beach92660	NCT07288034	Map
CA	Hoag Gynecologic Oncology	Newport Beach92663	NCT05281471	Map
CA	Sutter Cancer Research Consortium	Novato94945	NCT06580314	Map
CA	Kaiser Permanente Oakland-Broadway	Oakland94611	NCT06580314	Map
CA	Kaiser Permanente-Oakland	Oakland94611	NCT06580314	Map
CA	Kaiser Permanente-Oakland	Oakland94611	NCT04181060	Map
CA	Children's Hospital Orange County	Orange92868	NCT02446431	Map
CA	Clinical Study Site	Orange92868	NCT07228832	Map
CA	UC Irvine /ID# 255673	Orange92868	NCT06109272	Map
CA	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange92868	NCT07166406	Map
CA	UCI Health Chao Family Comprehensive Cancer Center	Orange92868	NCT05281471	Map
CA	University of California Irvine Medical Center	Orange92868	NCT05440708	Map
CA	University of California Irvine Medical Center	Orange92868-3201	NCT06703073	Map
CA	University of California Irvine Medical Center	Orange92868-3201	NCT06701656	Map
CA	University of California, Irvine (UCI) Health - UC Irvine Medical Center	Orange92868	NCT07221357	Map
CA	Corcept Therapeutics Investigator Site #150	Palo Alto94304	NCT06906341	Map
CA	Palo Alto Medical Foundation	Palo Alto94301	NCT06819007	Map
CA	Palo Alto Medical Foundation Health Care	Palo Alto94301	NCT06580314	Map
CA	Palo Alto Medical Foundation Health Care	Palo Alto94301	NCT07166406	Map
CA	Research Site	Palo Alto94304	NCT06921785	Map
CA	Stanford Cancer Institute Palo Alto	Palo Alto94304	NCT07198074	Map
CA	Stanford Cancer Institute Palo Alto	Palo Alto94304	NCT06580314	Map
CA	Stanford Cancer Institute Palo Alto	Palo Alto94304	NCT04181060	Map
CA	Stanford Cancer Institute, Stanford University	Palo Alto94304	NCT05919264	Map
CA	Kaiser Permanente - Panorama City	Panorama City91402	NCT06580314	Map
CA	Clinical Study Site	Pasadena91030	NCT07228832	Map
CA	Huntington Memorial Hospital	Pasadena91105	NCT06580314	Map
CA	Los Angeles Hematology Oncology Medical Group	Pasadena91105	NCT05253651	Map
CA	Kaiser Permanente-Rancho Cordova Cancer Center	Rancho Cordova95670	NCT06580314	Map
CA	Eisenhower Medical Center	Rancho Mirage92270	NCT07198074	Map
CA	Kaiser Permanente- Marshall Medical Offices	Redwood City94063	NCT06580314	Map
CA	Kaiser Permanente-Richmond	Richmond94801	NCT06580314	Map
CA	Kaiser Permanente-Richmond	Richmond94801	NCT04181060	Map
CA	Kaiser Permanente-Riverside	Riverside92505	NCT06580314	Map
CA	Mercy Cancer Center - Rocklin	Rocklin95765	NCT07198074	Map
CA	Mercy Cancer Center - Rocklin	Rocklin95765	NCT06580314	Map
CA	Rohnert Park Cancer Center	Rohnert Park94928	NCT06580314	Map
CA	Kaiser Permanente-Roseville	Roseville95661	NCT06580314	Map
CA	Kaiser Permanente-Roseville	Roseville95661	NCT04181060	Map
CA	Sutter Cancer Centers Radiation Oncology Services-Roseville	Roseville95661	NCT06580314	Map
CA	Sutter Cancer Centers Radiation Oncology Services-Roseville	Roseville95661	NCT07166406	Map
CA	Sutter Roseville Medical Center	Roseville95661	NCT06580314	Map
CA	Sutter Roseville Medical Center	Roseville95661	NCT07166406	Map
CA	The Permanente Medical Group-Roseville Radiation Oncology	Roseville95678	NCT06580314	Map
CA	Kaiser Permanente Downtown Commons	Sacramento95814	NCT06580314	Map
CA	Kaiser Permanente Downtown Commons	Sacramento95814	NCT04181060	Map
CA	Kaiser Permanente-South Sacramento	Sacramento95823	NCT06580314	Map
CA	Kaiser Permanente-South Sacramento	Sacramento95823	NCT04181060	Map
CA	Mercy Cancer Center - Sacramento	Sacramento95816	NCT07198074	Map
CA	Mercy Cancer Center - Sacramento	Sacramento95816	NCT06580314	Map
CA	South Sacramento Cancer Center	Sacramento95823	NCT06580314	Map
CA	Sutter Medical Center Sacramento	Sacramento95816	NCT06580314	Map
CA	Sutter Medical Center Sacramento	Sacramento95816	NCT07166406	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT07198074	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT04181060	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT07166406	Map
CA	University of California Davis Medical Center - Pulmonary Medicine	Sacramento95816-4300	NCT06703073	Map
CA	University of California Davis Medical Center - Pulmonary Medicine	Sacramento95816-4300	NCT06701656	Map
CA	Kaiser Permanente-San Diego Zion	San Diego92120	NCT06580314	Map
CA	Scripps Md Anderson - Prebys Cancer Center /ID# 276891	San Diego92103	NCT06890338	Map
CA	University of California San Diego Medical Center	San Diego92103	NCT04524871	Map
CA	University of California San Diego Moores Cancer Center	San Diego92093	NCT06625775	Map
CA	University of California, San Diego; Moores Cancer Center	San Diego92093	NCT05579366	Map
CA	Corcept Therapeutics Investigator Site #014	San Francisco94143	NCT06906341	Map
CA	California Pacific Medical Center /ID# 275329	San Francisco94109	NCT06890338	Map
CA	California Pacific Medical Center-Pacific Campus	San Francisco94115	NCT06580314	Map
CA	California Pacific Medical Center-Pacific Campus	San Francisco94115	NCT07166406	Map
CA	Kaiser Permanente-San Francisco	San Francisco94115	NCT06580314	Map
CA	Kaiser Permanente-San Francisco	San Francisco94115	NCT04181060	Map
CA	UCSF at China Basin	San Francisco94107	NCT07222800	Map
CA	UCSF at Mount Zion	San Francisco94115	NCT07222800	Map
CA	UCSF at Parnassus	San Francisco94143	NCT07222800	Map
CA	UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco94158	NCT06625775	Map
CA	UCSF Medical Center	San Francisco94158	NCT07222800	Map
CA	UCSF Medical Center at Mission Bay ( Site 0013)	San Francisco94158	NCT06824467	Map
CA	University of California San Francisco Cancer Center	San Francisco94115	NCT04524871	Map
CA	University of California San Francisco, Helen Diller Family Comprehensive Cancer Center	San Francisco94158	NCT05919264	Map
CA	Kaiser Permanente-Santa Teresa-San Jose	San Jose95119	NCT06580314	Map
CA	Kaiser Permanente-Santa Teresa-San Jose	San Jose95119	NCT04181060	Map
CA	Stanford Cancer Center South Bay	San Jose95124	NCT06580314	Map
CA	Kaiser Permanente San Leandro	San Leandro94577	NCT06580314	Map
CA	Kaiser Permanente San Leandro	San Leandro94577	NCT04181060	Map
CA	Pacific Central Coast Health Center-San Luis Obispo	San Luis Obispo93401	NCT06580314	Map
CA	Kaiser Permanente-San Marcos	San Marcos92078	NCT06580314	Map
CA	Mills Health Center	San Mateo94401	NCT06580314	Map
CA	Kaiser San Rafael-Gallinas	San Rafael94903	NCT06580314	Map
CA	Kaiser San Rafael-Gallinas	San Rafael94903	NCT04181060	Map
CA	Ridley-Tree Cancer Center	Santa Barbara93105	NCT06580314	Map
CA	Sansum Clinic	Santa Barbara93105	NCT07213804	Map
CA	USOR Sansum Clinic	Santa Barbara93105	NCT05579366	Map
CA	Kaiser Permanente Medical Center - Santa Clara	Santa Clara95051	NCT06580314	Map
CA	Kaiser Permanente Medical Center - Santa Clara	Santa Clara95051	NCT04181060	Map
CA	Palo Alto Medical Foundation-Santa Cruz	Santa Cruz95065	NCT06580314	Map
CA	Santa Cruz Radiation Oncology Medical Group	Santa Cruz95065	NCT06580314	Map
CA	Mission Hope Medical Oncology - Santa Maria	Santa Maria93444	NCT06580314	Map
CA	Sarcoma Oncology Center	Santa Monica90403	NCT05919264	Map
CA	UCLA	Santa Monica90404	NCT06750094	Map
CA	UCLA - Santa Monica /ID# 270621	Santa Monica90404	NCT06820463	Map
CA	UCLA Center for East	Santa Monica90404	NCT04524871	Map
CA	UCLA Hematology/Oncology-Santa Monica	Santa Monica90404	NCT06607458	Map
CA	Kaiser Permanente-Santa Rosa	Santa Rosa95403	NCT06580314	Map
CA	Kaiser Permanente-Santa Rosa	Santa Rosa95403	NCT04181060	Map
CA	Providence Medical Foundation	Santa Rosa95403	NCT06750094	Map
CA	Providence Medical Foundation	Santa Rosa95403	NCT05579366	Map
CA	Providence Medical Foundation - Santa Rosa	Santa Rosa95403	NCT06580314	Map
CA	Providence Santa Rosa Memorial Hospital	Santa Rosa95405	NCT06580314	Map
CA	Research Site	Santa Rosa95403	NCT05489211	Map
CA	Sutter Pacific Medical Foundation	Santa Rosa95403	NCT06580314	Map
CA	Sutter Pacific Medical Foundation	Santa Rosa95403	NCT07166406	Map
CA	City of Hope South Pasadena	South Pasadena91030	NCT07288034	Map
CA	Kaiser Permanente Cancer Treatment Center	South San Francisco94080	NCT06580314	Map
CA	Kaiser Permanente-South San Francisco	South San Francisco94080	NCT06580314	Map
CA	Kaiser Permanente-South San Francisco	South San Francisco94080	NCT04181060	Map
CA	GSK Investigational Site	Stanford94063	NCT06551142	Map
CA	Kaiser Permanente-Stockton	Stockton95210	NCT06580314	Map
CA	Kaiser Permanente-Stockton	Stockton95210	NCT04181060	Map
CA	Saint Joseph's Medical Center	Stockton95204	NCT06580314	Map
CA	Palo Alto Medical Foundation-Sunnyvale	Sunnyvale94086	NCT06580314	Map
CA	Palo Alto Medical Foundation-Sunnyvale	Sunnyvale94086	NCT07166406	Map
CA	City of Hope South Bay	Torrance90503	NCT07288034	Map
CA	Clinical Study Site	Torrance90503	NCT07228832	Map
CA	Torrance Memorial Physician Network - Cancer Care	Torrance90505	NCT06580314	Map
CA	Torrance Memorial Physicians Network	Torrance90505	NCT06750094	Map
CA	City of Hope Upland	Upland91786	NCT07288034	Map
CA	Clinical Study Site	Upland91786	NCT07228832	Map
CA	Kaiser Permanente Medical Center-Vacaville	Vacaville95688	NCT06580314	Map
CA	Kaiser Permanente Medical Center-Vacaville	Vacaville95688	NCT04181060	Map
CA	Kaiser Permanente-Vallejo	Vallejo94589	NCT06580314	Map
CA	Kaiser Permanente-Vallejo	Vallejo94589	NCT04181060	Map
CA	Sutter Solano Medical Center/Cancer Center	Vallejo94589	NCT06580314	Map
CA	Los Angeles Hematology Oncology Medical Group	Van Nuys91405	NCT05253651	Map
CA	John Muir Medical Center-Walnut Creek	Walnut Creek94598	NCT06580314	Map
CA	Kaiser Permanente-Walnut Creek	Walnut Creek94596	NCT06580314	Map
CA	Kaiser Permanente-Walnut Creek	Walnut Creek94596	NCT04181060	Map
CA	Clinical Study Site	West Hollywood90048	NCT07228832	Map
CA	Woodland Memorial Hospital	Woodland95695	NCT07198074	Map
CA	Woodland Memorial Hospital	Woodland95695	NCT06580314	Map
CA	Kaiser Permanente-Woodland Hills	Woodland Hills91367	NCT06580314	Map
CO	Cherry Creek Medical Center	Aurora80045	NCT04524871	Map
CO	GSK Investigational Site	Aurora80045	NCT06796907	Map
CO	Research Site	Aurora80045	NCT05797168	Map
CO	Rocky Mountain Cancer Centers-Aurora	Aurora80012	NCT04181060	Map
CO	Rocky Mountain Cancer Centers, LLP	Aurora80012	NCT07222800	Map
CO	Rocky Mountain Cancer Centers, LLP	Aurora80012	NCT05253651	Map
CO	Sarah Cannon Research Institute Scri Oncology Partners	Aurora80012	NCT07284849	Map
CO	Site 0264	Aurora80045	NCT04516447	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT06580314	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT05863195	Map
CO	University of Colorado	Aurora80045	NCT05919264	Map
CO	University of Colorado Cancer Center	Aurora80045-2517	NCT06233942	Map
CO	University of Colorado Cancer Center	Aurora80045	NCT04929223	Map
CO	University of Colorado Denver Anschultz Medical Campus	Aurora80045	NCT06663319	Map
CO	University of Colorado Denver Anschultz Medical Campus	Aurora80045	NCT06750094	Map
CO	University of Colorado Hospital	Aurora80045	NCT06131840	Map
CO	University of Colorado Hospital - Anschutz Cancer Pavilion	Aurora80045	NCT04524871	Map
CO	University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)	Aurora80045	NCT06131840	Map
CO	University of Colorado Hospital - Anschutz Medical Campus	Aurora80045	NCT05440708	Map
CO	University of Colorado Hospital-Anschutz Cancer Pavilion	Aurora88045	NCT06445062	Map
CO	Rocky Mountain Cancer Centers - Boulder	Boulder80303	NCT07222800	Map
CO	Rocky Mountain Cancer Centers-Boulder	Boulder80304	NCT04181060	Map
CO	Rocky Mountain Cancer Centers, LLP	Boulder80303	NCT05253651	Map
CO	Rocky Mountain Cancer Centers, LLP	Centennial80112	NCT07222800	Map
CO	Memorial Hospital North	Colorado Springs80920	NCT07198074	Map
CO	Memorial Hospital North	Colorado Springs80920	NCT06580314	Map
CO	Memorial Hospital North	Colorado Springs80920	NCT07166406	Map
CO	Penrose-Saint Francis Healthcare	Colorado Springs80907	NCT06580314	Map
CO	Rocky Mountain Cancer Centers-Penrose	Colorado Springs80907	NCT06580314	Map
CO	Rocky Mountain Cancer Centers-Penrose	Colorado Springs80907	NCT07166406	Map
CO	Rocky Mountain Cancer Centers, LLP	Colorado Springs80907	NCT07222800	Map
CO	Rocky Mountain Cancer Centers, LLP	Colorado Springs80923	NCT07222800	Map
CO	Rocky Mountain Cancer Centers, LLP	Colorado Springs80907	NCT05253651	Map
CO	Saint Francis Cancer Center	Colorado Springs80923	NCT06580314	Map
CO	UCHealth Memorial Hospital Central	Colorado Springs80909	NCT07198074	Map
CO	UCHealth Memorial Hospital Central	Colorado Springs80909	NCT06580314	Map
CO	UCHealth Memorial Hospital Central	Colorado Springs80909	NCT07166406	Map
CO	Denver Health Hospital and Authority	Denver80204-4532	NCT06701656	Map
CO	GSK Investigational Site	Denver80218	NCT06551142	Map
CO	Intermountain Health Cancer Center Saint Joseph	Denver80218	NCT07222800	Map
CO	Intermountain Health Saint Joseph Hospital	Denver80218	NCT07222800	Map
CO	Intermountain Health Saint Joseph Hospital - Research Office	Denver80218	NCT07222800	Map
CO	Kaiser Permanente-Franklin	Denver80205	NCT04181060	Map
CO	Rocky Mountain Cancer Centers	Denver80218	NCT06750094	Map
CO	Rocky Mountain Cancer Centers, LLP	Denver80218	NCT07222800	Map
CO	Rocky Mountain Cancer Centers, LLP	Denver80220	NCT07222800	Map
CO	Rocky Mountain Cancer Centers, LLP	Denver80218	NCT05253651	Map
CO	Rocky Mountain Cancer Centers, LLP	Denver80220	NCT05253651	Map
CO	Sarah Cannon Research Institute - CO	Denver80218	NCT05848739	Map
CO	Sarah Cannon Research Institute at HealthONE	Denver80218	NCT06265688	Map
CO	Sarah Cannon Research Institute at HealthONE /ID# 278785	Denver80218	NCT07278336	Map
CO	UCHealth - Cherry Creek	Denver80206	NCT06580314	Map
CO	CommonSpirit Cancer Center Mercy	Durango81301	NCT06580314	Map
CO	Mercy Medical Center	Durango81301	NCT06580314	Map
CO	Rocky Mountain Cancer Centers - Swedish	Englewood80113	NCT04181060	Map
CO	Rocky Mountain Cancer Centers, LLP	Englewood80113	NCT07222800	Map
CO	Cancer Care and Hematology-Fort Collins	Fort Collins80528	NCT07198074	Map
CO	Cancer Care and Hematology-Fort Collins	Fort Collins80528	NCT06580314	Map
CO	Cancer Care and Hematology-Fort Collins	Fort Collins80528	NCT07166406	Map
CO	Poudre Valley Hospital	Fort Collins80524	NCT07198074	Map
CO	Poudre Valley Hospital	Fort Collins80524	NCT06580314	Map
CO	Poudre Valley Hospital	Fort Collins80524	NCT07166406	Map
CO	University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0087)	Fort Collins80528	NCT06997497	Map
CO	Saint Mary's Hospital and Regional Medical Center	Grand Junction81501	NCT07166406	Map
CO	UCHealth Greeley Hospital	Greeley80631	NCT07198074	Map
CO	UCHealth Greeley Hospital	Greeley80631	NCT06580314	Map
CO	UCHealth Greeley Hospital	Greeley80631	NCT07166406	Map
CO	UCHealth Cancer Center Pharmacy - Highlands Ranch Hospital	Highlands Ranch80129-6694	NCT04524871	Map
CO	UCHealth Highlands Ranch Hospital	Highlands Ranch80129	NCT06580314	Map
CO	Kaiser Permanente-Rock Creek	Lafayette80026	NCT04181060	Map
CO	Rocky Mountain Cancer Centers, LLP	Lakewood80228	NCT07222800	Map
CO	Rocky Mountain Cancer Centers, LLP	Lakewood80228	NCT05253651	Map
CO	Saint Anthony Hospital	Lakewood80228	NCT06580314	Map
CO	Rocky Mountain Cancer Centers, LLP	Littleton80120	NCT07222800	Map
CO	Rocky Mountain Cancer Centers, LLP	Littleton80120	NCT05253651	Map
CO	Kaiser Permanente-Lone Tree	Lone Tree80124	NCT04181060	Map
CO	Rocky Mountain Cancer Centers (RMCC) ( Site 8000)	Lone Tree80124	NCT06997497	Map
CO	Rocky Mountain Cancer Centers-Sky Ridge	Lone Tree80124	NCT05238922	Map
CO	Rocky Mountain Cancer Centers, LLP	Lone Tree80124	NCT06948448	Map
CO	Rocky Mountain Cancer Centers, LLP	Lone Tree80124	NCT07222800	Map
CO	Rocky Mountain Cancer Centers, LLP	Lone Tree80124	NCT05253651	Map
CO	Rocky Mountain Cancer Centers, LLP	Lone Tree80124	NCT04929223	Map
CO	Longmont United Hospital	Longmont80501	NCT06580314	Map
CO	Rocky Mountain Cancer Centers, LLP	Longmont80504	NCT07222800	Map
CO	Rocky Mountain Cancer Centers, LLP	Longmont80504	NCT05253651	Map
CO	Medical Center of the Rockies	Loveland80538	NCT07198074	Map
CO	Medical Center of the Rockies	Loveland80538	NCT06580314	Map
CO	Medical Center of the Rockies	Loveland80538	NCT07166406	Map
CO	Rocky Mountain Cancer Centers, LLP	Pueblo81003	NCT07222800	Map
CO	Rocky Mountain Cancer Centers, LLP	Pueblo81003	NCT05253651	Map
CO	Saint Mary Corwin Medical Center	Pueblo81004	NCT06580314	Map
CO	Rocky Mountain Cancer Centers, LLP	Thornton80260	NCT07222800	Map
CO	Rocky Mountain Cancer Centers, LLP	Thornton80260	NCT05253651	Map
CO	Saint Anthony North Hospital	Westminster80023	NCT06580314	Map
CT	Danbury Hospital	Danbury06810	NCT06580314	Map
CT	Danbury Hospital, Western Connecticut Health Network /ID# 274783	Danbury06810	NCT06890338	Map
CT	Smilow Cancer Hospital-Derby Care Center	Derby06418	NCT04181060	Map
CT	Smilow Cancer Hospital-Derby Care Center	Derby06418	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center-Fairfield	Fairfield06824	NCT06580314	Map
CT	Smilow Cancer Hospital Care Center-Fairfield	Fairfield06824	NCT04181060	Map
CT	Smilow Cancer Hospital Care Center-Fairfield	Fairfield06824	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center at Glastonbury	Glastonbury06033	NCT04181060	Map
CT	Smilow Cancer Hospital Care Center at Glastonbury	Glastonbury06033	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center at Greenwich	Greenwich06830	NCT06580314	Map
CT	Smilow Cancer Hospital Care Center at Greenwich	Greenwich06830	NCT04181060	Map
CT	Smilow Cancer Hospital Care Center at Greenwich	Greenwich06830	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT04181060	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT07166406	Map
CT	Smilow Cancer Hospital-Hamden Care Center	Hamden06518	NCT07166406	Map
CT	Clinical Study Site	Hartford06106	NCT07228832	Map
CT	Hartford Hospital	Hartford06102	NCT07198074	Map
CT	Hartford Hospital	Hartford06102	NCT04181060	Map
CT	Smilow Cancer Hospital Care Center at Saint Francis	Hartford06105	NCT06580314	Map
CT	Smilow Cancer Hospital Care Center at Saint Francis	Hartford06105	NCT04181060	Map
CT	Smilow Cancer Hospital Care Center at Saint Francis	Hartford06105	NCT07166406	Map
CT	Hartford HealthCare - Manchester	Manchester06042	NCT07198074	Map
CT	Midstate Medical Center	Meriden06451	NCT04181060	Map
CT	The Hospital of Central Connecticut	New Britain06050	NCT07198074	Map
CT	The Hospital of Central Connecticut	New Britain06050	NCT04181060	Map
CT	Clinical Study Site	New Haven06520-8028	NCT07228832	Map
CT	GSK Investigational Site	New Haven06511	NCT06551142	Map
CT	Research Site	New Haven06520	NCT06921785	Map
CT	Smilow Cancer Center/Yale-New Haven Hospital	New Haven06510	NCT06580314	Map
CT	Smilow Cancer Center/Yale-New Haven Hospital	New Haven06510	NCT07166406	Map
CT	Smilow Cancer Hospital at Yale New Haven	New Haven06510	NCT04524871	Map
CT	Yale Cancer Center	New Haven06520	NCT04929223	Map
CT	Yale New Haven Hospital /ID# 270565	New Haven06510	NCT06820463	Map
CT	Yale University	New Haven06520	NCT06580314	Map
CT	Yale University	New Haven06520	NCT04181060	Map
CT	Yale University	New Haven06520	NCT07166406	Map
CT	Yale University	New Haven06511	NCT07079631	Map
CT	Yale University School of Medicine	New Haven06520	NCT05919264	Map
CT	Yale University School of Medicine /ID# 275794	New Haven06510	NCT06890338	Map
CT	Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001)	New Haven06510	NCT06824467	Map
CT	Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)	New Haven06510	NCT06843447	Map
CT	Yale-New Haven Hospital-Yale Cancer Center	New Haven06520	NCT06445062	Map
CT	Yale-New Haven Hospital - Yale Cancer Center	North Haven06473 2195	NCT07527858	Map
CT	Yale-New Haven Hospital North Haven Medical Center	North Haven06473	NCT04181060	Map
CT	Yale-New Haven Hospital North Haven Medical Center	North Haven06473	NCT07166406	Map
CT	Norwalk Hospital	Norwalk06856	NCT06580314	Map
CT	Norwalk Hospital /ID# 274561	Norwalk06856	NCT06890338	Map
CT	Clinical Study Site	Norwich06360	NCT07228832	Map
CT	Eastern Connecticut Hematology & Oncology Assoc.	Norwich06360	NCT06750094	Map
CT	Smilow Cancer Hospital Care Center at Long Ridge	Stamford06902	NCT06580314	Map
CT	Smilow Cancer Hospital Care Center at Long Ridge	Stamford06902	NCT04181060	Map
CT	Smilow Cancer Hospital Care Center at Long Ridge	Stamford06902	NCT07166406	Map
CT	Stamford Hospital/Bennett Cancer Center	Stamford06904	NCT04181060	Map
CT	Smilow Cancer Hospital-Torrington Care Center	Torrington06790	NCT04181060	Map
CT	Smilow Cancer Hospital-Torrington Care Center	Torrington06790	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT06580314	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT04181060	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT07166406	Map
CT	Smilow Cancer Hospital-Waterbury Care Center	Waterbury06708	NCT06580314	Map
CT	Smilow Cancer Hospital-Waterbury Care Center	Waterbury06708	NCT04181060	Map
CT	Smilow Cancer Hospital-Waterbury Care Center	Waterbury06708	NCT07166406	Map
CT	Smilow Cancer Hospital Care Center - Waterford	Waterford06385	NCT06580314	Map
CT	Smilow Cancer Hospital Care Center - Waterford	Waterford06385	NCT04181060	Map
CT	Smilow Cancer Hospital Care Center - Waterford	Waterford06385	NCT07166406	Map
DE	Beebe Medical Center	Lewes19958	NCT06580314	Map
DE	Beebe South Coastal Health Campus	Millville19967	NCT07198074	Map
DE	Beebe South Coastal Health Campus	Millville19967	NCT06580314	Map
DE	Christiana Care Health System - Newark- Site Number : 8400011	Newark19718	NCT05584670	Map
DE	Christiana Care Health System-Christiana Hospital	Newark19718	NCT06580314	Map
DE	Christiana Care Health System-Christiana Hospital	Newark19718	NCT07166406	Map
DE	Clinical Study Site	Newark19713	NCT07228832	Map
DE	Helen F Graham Cancer Center	Newark19713	NCT07198074	Map
DE	Helen F Graham Cancer Center	Newark19713	NCT06580314	Map
DE	Helen F Graham Cancer Center	Newark19713	NCT07166406	Map
DE	Medical Oncology Hematology Consultants PA	Newark19713	NCT07198074	Map
DE	Medical Oncology Hematology Consultants PA	Newark19713	NCT06580314	Map
DE	Medical Oncology Hematology Consultants PA	Newark19713	NCT07166406	Map
DE	Research Site	Newark19713	NCT06921785	Map
DE	Beebe Health Campus	Rehoboth Beach19971	NCT07198074	Map
DE	Beebe Health Campus	Rehoboth Beach19971	NCT06580314	Map
DE	Christiana Care Health System-Wilmington Hospital	Wilmington19801	NCT06580314	Map
DE	Christiana Care Health System-Wilmington Hospital	Wilmington19801	NCT07166406	Map
DC	George Washington University Medical Center	Washington D.C.20037	NCT04181060	Map
DC	Georgetown Lombardi Comprehensive Cancer Center	Washington D.C.20007	NCT05482516	Map
DC	Georgetown University Medical Center	Washington D.C.20007	NCT04524871	Map
DC	Johns Hopkins University, Sibley Memorial Hospital	Washington D.C.20016	NCT05919264	Map
DC	Medstar Washington Hospital Center	Washington D.C.20010	NCT05482516	Map
DC	MedStar Washington Hospital Center	Washington D.C.20010-3017	NCT06703073	Map
DC	MedStar Washington Hospital Center	Washington D.C.20010-3017	NCT06701656	Map
DC	Research Site	Washington D.C.20007	NCT06792695	Map
FL	Mount Sinai Medical Center Aventura ER	Aventura33180	NCT05253651	Map
FL	UM Sylvester Comprehensive Cancer Center at Aventura	Aventura33180	NCT05863195	Map
FL	Florida Cancer Specialists	Bonita Springs34135	NCT07222800	Map
FL	MDR Core Network	Boynton Beach33426	NCT06047379	Map
FL	Florida Cancer Specialists	Bradenton34211	NCT07222800	Map
FL	Nova Clinical Research	Bradenton34209-4617	NCT06703073	Map
FL	Nova Clinical Research	Bradenton34209-4617	NCT06701656	Map
FL	Comprehensive Hematology Oncology	Brandon33511	NCT07222800	Map
FL	Florida Cancer Specialists	Cape Coral33909	NCT07222800	Map
FL	Florida Cancer Specialists - East	Cape Coral33990	NCT07221357	Map
FL	UM Sylvester Comprehensive Cancer Center at Coral Gables	Coral Gables33146	NCT05863195	Map
FL	BRCR Global - Coral Springs	Coral Springs33065	NCT07222800	Map
FL	UM Sylvester Comprehensive Cancer Center at Deerfield Beach	Deerfield Beach33442	NCT05863195	Map
FL	Broward Health Medical Center	Fort Lauderdale33316	NCT06580314	Map
FL	Broward Health Medical Center	Fort Lauderdale33316	NCT06819007	Map
FL	Holy Cross Hospital	Fort Lauderdale33308	NCT06580314	Map
FL	Holy Cross Hospital	Fort Lauderdale33308	NCT04181060	Map
FL	Corcept Therapeutics Investigator Site #544	Fort Myers33901	NCT06906341	Map
FL	Florida Cancer Specialist- South	Fort Myers33901	NCT07213804	Map
FL	Florida Cancer Specialists	Fort Myers33905	NCT07222800	Map
FL	Florida Cancer Specialists	Fort Myers33908	NCT07222800	Map
FL	Florida Cancer Specialists - South ( Site 7002)	Fort Myers33901	NCT06997497	Map
FL	Florida Cancer Specialists South	Fort Myers33901	NCT06750094	Map
FL	Florida Oncology & Hematology	Fort Myers33912	NCT07284849	Map
FL	USOR Florida Cancer Specialists South	Fort Myers33908	NCT05579366	Map
FL	North Florida / South Georgia Veterans Health System	Gainesville32608-1135	NCT06703073	Map
FL	North Florida / South Georgia Veterans Health System	Gainesville32608-1135	NCT06701656	Map
FL	UF Health Cancer Institute - Gainesville	Gainesville32610	NCT06580314	Map
FL	UF Health Cancer Institute - Gainesville	Gainesville32610	NCT06696768	Map
FL	University of Florida College of Medicine /ID# 278348	Gainesville32610	NCT07059845	Map
FL	University of Florida Health	Gainesville32610	NCT05101070	Map
FL	Clinical Study Site	Hialeah33013	NCT07228832	Map
FL	UM Sylvester Comprehensive Cancer Center at Hollywood	Hollywood33021	NCT05863195	Map
FL	Baptist MD Anderson Cancer Center	Jacksonville32207	NCT07213804	Map
FL	Cancer Specialists of North Florida - Southpoint	Jacksonville32256	NCT06252649	Map
FL	Mayo Clinic	Jacksonville32224	NCT05919264	Map
FL	Mayo Clinic Cancer Center	Jacksonville32224	NCT06445062	Map
FL	Mayo Clinic Florida	Jacksonville32224	NCT06948448	Map
FL	Mayo Clinic in Florida	Jacksonville32224	NCT05824975	Map
FL	Mayo Clinic Jacksonville	Jacksonville32224	NCT06787612	Map
FL	Research Site	Jacksonville32224	NCT06921785	Map
FL	Jupiter Medical Center	Jupiter33458	NCT06819007	Map
FL	Jupiter Medical Center /ID# 276616	Jupiter33458	NCT06890338	Map
FL	Orlando Health Cancer Institute - Lake Mary	Lake Mary32746	NCT06580314	Map
FL	Comprehensive Hematology Oncology	Largo33770	NCT07222800	Map
FL	Cancer Care Centers of Brevard, Inc.	Melbourne32935	NCT07222800	Map
FL	Clinical Study Site	Miami33176	NCT07228832	Map
FL	Jackson Memorial Hospital	Miami33136	NCT05956821	Map
FL	Mt. Sinai Comprehensive Cancer Center	Miami33140	NCT07225270	Map
FL	Sylvester Comprehensive Cancer Center	Miami33136	NCT07284849	Map
FL	Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics)	Miami33136	NCT05733598	Map
FL	UM Sylvester Comprehensive Cancer Center at Kendall	Miami33176	NCT05863195	Map
FL	University of Miami	Miami33136	NCT05284643	Map
FL	University of Miami	Miami33136	NCT04374305	Map
FL	University of Miami Miller School of Medicine-Sylvester Cancer Center	Miami33136	NCT05863195	Map
FL	University of Miami Sylvester Comprehensive Cancer Center	Miami33136	NCT06787612	Map
FL	Corcept Therapeutics Investigator Site #335	Miami Beach33140	NCT06906341	Map
FL	Mount Sinai Cancer Center ( Site 0029)	Miami Beach33140	NCT07318558	Map
FL	Mount Sinai Cancer Center ( Site 0078)	Miami Beach33140	NCT06824467	Map
FL	Mount Sinai Comprehensive Cancer Center	Miami Beach33140	NCT05253651	Map
FL	Mount Sinai Comprehensive Cancer Center ( Site 5043)	Miami Beach33140	NCT07216703	Map
FL	Mount Sinai Comprehensive Cancer Center ( Site 6000)	Miami Beach33140	NCT07216703	Map
FL	Mount Sinai Medical Center	Miami Beach33140	NCT05253651	Map
FL	Mount Sinai Medical Center	Miami Beach33140	NCT06819007	Map
FL	Mount Sinai Medical Center /ID# 274868	Miami Beach33140	NCT06890338	Map
FL	Mount Sinai Medical Center Comprehensive Cancer Center	Miami Beach33140	NCT05238922	Map
FL	Florida Cancer Specialists	N. Venice34275	NCT07222800	—
FL	Florida Cancer Specialists	Naples34102	NCT07222800	Map
FL	Health Central	Ocoee34761	NCT06580314	Map
FL	Mid Florida Hematology and Oncology Center	Orange City32763	NCT07222800	Map
FL	Advent Health	Orlando32803	NCT06948448	Map
FL	Advent Health Cancer Institute	Orlando32804	NCT06787612	Map
FL	AdventHealth Cancer Institute	Orlando32804	NCT06750094	Map
FL	AdventHealth Cancer Institute	Orlando32804	NCT05281471	Map
FL	AdventHealth Cancer Institute	Orlando32804	NCT06819007	Map
FL	Clinical Study Site	Orlando32806	NCT07228832	Map
FL	Florida Cancer Specialist Research Institute Lake Nona	Orlando32827-7400	NCT06233942	Map
FL	Florida Cancer Specialists	Orlando32827	NCT06131840	Map
FL	Orlando Health Cancer Institute	Orlando32806	NCT06580314	Map
FL	Orlando Health Cancer Institute ( Site 0065)	Orlando32806	NCT06997497	Map
FL	Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623	Orlando32806	NCT07059845	Map
FL	Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085)	Orlando32806	NCT07318558	Map
FL	Sarah Cannon Research Institute at Florida Cancer Specialists	Orlando32827	NCT06131840	Map
FL	Cancer Care Centers of Brevard, Inc.	Palm Bay32909	NCT07222800	Map
FL	Comprehensive Hematology Oncology	Palm Harbor34683	NCT07222800	Map
FL	Sacred Heart Hospital	Pensacola32504	NCT06580314	Map
FL	Clinical Study Site	Plantation33322	NCT07228832	Map
FL	UM Sylvester Comprehensive Cancer Center at Plantation	Plantation33324	NCT05863195	Map
FL	Florida Cancer Specialists	Port Charlotte33980	NCT07222800	Map
FL	Clinical Study Site	Port Saint Lucie34952	NCT07228832	Map
FL	Cancer Care Centers of Brevard, Inc.	Rockledge32955	NCT07222800	Map
FL	Florida Cancer Specialists	Sarasota34236	NCT07222800	Map
FL	Florida Cancer Specialists	Sarasota34232	NCT06663319	Map
FL	Sarasota Memorial Health Care System	Sarasota34239	NCT07225270	Map
FL	Sarasota Memorial Healthcare System	Sarasota34239	NCT05281471	Map
FL	Sarasota Memorial Hospital	Sarasota34239	NCT06703073	Map
FL	Sarasota Memorial Hospital	Sarasota34239	NCT06701656	Map
FL	Sarasota Memorial Hospital ( Site 0075)	Sarasota34239	NCT06824467	Map
FL	Clinical Study Site	St. Petersburg33705	NCT07228832	Map
FL	Comprehensive Hematology Oncology	St. Petersburg33701	NCT07222800	Map
FL	Comprehensive Hematology Oncology	St. Petersburg33709	NCT07222800	Map
FL	Florida Cancer Specialists - North	St. Petersburg33705	NCT07221357	Map
FL	Florida Cancer Specialists - North ( Site 7001)	St. Petersburg33705	NCT06997497	Map
FL	Florida Cancer Specialists - North /ID# 278626	St. Petersburg33705	NCT07059845	Map
FL	Florida Cancer Specialists North Region	St. Petersburg33701-4553	NCT06750094	Map
FL	USOR Florida Cancer Specialists North	St. Petersburg33709	NCT05579366	Map
FL	Woman's Care FL	St. Petersburg33713	NCT06819007	Map
FL	Women's Cancer Associates with Women's Care Florida	St. Petersburg33713	NCT05281471	Map
FL	Clinical Study Site	Tamarac33321	NCT07228832	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05440708	Map
FL	Moffitt Cancer Center	Tampa33612	NCT07221357	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06625775	Map
FL	Moffitt Cancer Center	Tampa33612	NCT04929223	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06607458	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06445062	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05733598	Map
FL	Tampa General Hospital Cancer Institute	Tampa33606	NCT06787612	Map
FL	Comprehensive Hematology Oncology	Trinity34655	NCT07222800	Map
FL	Corcept Therapeutics Investigator Site #543	West Palm Beach33041	NCT06906341	Map
FL	Florida Cancer Specialist- East	West Palm Beach33401	NCT07213804	Map
FL	Florida Cancer Specialists - East ( Site 7000)	West Palm Beach33401	NCT07216703	Map
FL	Florida Cancer Specialists - East ( Site 7000)	West Palm Beach33401	NCT06997497	Map
FL	Florida Cancer Specialists - East /ID# 278605	West Palm Beach33401	NCT07059845	Map
FL	Florida Cancer Specialists East	West Palm Beach33401-3406	NCT06750094	Map
FL	Florida Cancer Specialists East ( Site 7000)	West Palm Beach33401	NCT06824467	Map
FL	USOR Florida Cancer Specialists East	West Palm Beach33401	NCT05579366	Map
GA	University Cancer & Blood Center, LLC	Athens30607	NCT07222800	Map
GA	University Cancer and Blood Center LLC	Athens30607	NCT06580314	Map
GA	University Cancer And Blood Center LLC	Athens30607	NCT06750094	Map
GA	Clinical Study Site	Atlanta30303	NCT07228832	Map
GA	Clinical Study Site	Atlanta30322	NCT07228832	Map
GA	Emory Proton Therapy Center	Atlanta30308	NCT07166406	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT06580314	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT04981509	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT07166406	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT05863195	Map
GA	Emory University	Atlanta30322	NCT05281471	Map
GA	Emory University Hospital	Atlanta30322	NCT05253651	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT07198074	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06580314	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT05253651	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT04181060	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT04981509	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT07166406	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT07198074	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT06580314	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT04181060	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT04981509	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT07166406	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT05863195	Map
GA	Emory University School of Medicine	Atlanta30322	NCT06004245	Map
GA	Emory Winship Cancer Institute	Atlanta30302	NCT07446322	Map
GA	Grady Health System	Atlanta30303	NCT06580314	Map
GA	Grady Health System	Atlanta30303	NCT05253651	Map
GA	Grady Health System	Atlanta30303	NCT07166406	Map
GA	Grady Memorial Hospital	Atlanta30303	NCT06750094	Map
GA	Northside Hospital	Atlanta30342	NCT06580314	Map
GA	Northside Hospital	Atlanta30342	NCT07221357	Map
GA	Piedmont Cancer Institute	Atlanta30318	NCT06750094	Map
GA	Research Site	Atlanta30318	NCT06921785	Map
GA	Winship Cancer Institute	Atlanta30322	NCT05253651	Map
GA	Winship Cancer Institute Emory University	Atlanta30322	NCT06750094	Map
GA	Winship Cancer Institute of Emory University ( Site 0037)	Atlanta30308	NCT07318558	Map
GA	Winship Cancer Institute of Emory University ( Site 0086)	Atlanta30322	NCT06824467	Map
GA	Winship Cancer Institute of Emory University ( Site 5005)	Atlanta30308	NCT07216703	Map
GA	Augusta University - Georgia Cancer Center ( Site 0066)	Augusta30912	NCT06824467	Map
GA	Augusta University Georgia Cancer Center	Augusta30912	NCT05579366	Map
GA	Augusta University Medical Center	Augusta30912	NCT06580314	Map
GA	Emory Decatur Hospital	Decatur30033	NCT07198074	Map
GA	Emory Decatur Hospital	Decatur30033	NCT06580314	Map
GA	Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital	Marietta30060	NCT07221357	Map
GA	City of Hope Atlanta Cancer Center	Newnan30265	NCT07288034	Map
GA	Clinical Study Site	Newnan30265	NCT07228832	Map
GA	Lewis Cancer and Research Pavilion at Saint Joseph's/Candler	Savannah31405	NCT04181060	Map
GA	Nancy N. & J.C Lewis Cancer & Research Pavillion- St. Josephs/ Candler Health System	Savannah31405	NCT06819007	Map
GA	Nancy N. & J.C. Lewis Cancer and Research Pavillion - Research Department ( Site 6005)	Savannah31405	NCT07216703	Map
HI	Hawaii Cancer Care - Westridge	‘Aiea96701	NCT06580314	Map
HI	Pali Momi Medical Center	‘Aiea96701	NCT06580314	Map
HI	Queen's Cancer Center - Pearlridge	‘Aiea96701	NCT06580314	Map
HI	The Cancer Center of Hawaii-Pali Momi	‘Aiea96701	NCT06580314	Map
HI	The Queen's Medical Center - West Oahu	‘Ewa Beach96706	NCT06580314	Map
HI	Hawaii Cancer Care Inc - Waterfront Plaza	Honolulu96813	NCT06580314	Map
HI	Kaiser Permanente Moanalua Medical Center	Honolulu96819	NCT06580314	Map
HI	Kaiser Permanente Moanalua Medical Center	Honolulu96819	NCT04181060	Map
HI	Kapiolani Medical Center for Women and Children	Honolulu96826	NCT06580314	Map
HI	Kuakini Medical Center	Honolulu96817	NCT06580314	Map
HI	Queen's Cancer Cenrer - POB I	Honolulu96813	NCT06580314	Map
HI	Queen's Cancer Center - Kuakini	Honolulu96817	NCT06580314	Map
HI	Queen's Medical Center	Honolulu96813	NCT06580314	Map
HI	Straub Clinic and Hospital	Honolulu96813	NCT06580314	Map
HI	The Cancer Center of Hawaii-Liliha	Honolulu96817	NCT06580314	Map
HI	University of Hawaii Cancer Center	Honolulu96813	NCT06580314	Map
HI	Wilcox Memorial Hospital and Kauai Medical Clinic	Lihue96766	NCT06580314	Map
ID	Saint Alphonsus Cancer Care Center-Boise	Boise83706	NCT04181060	Map
ID	Saint Alphonsus Regional Medical Center	Boise83706	NCT07222800	Map
ID	Saint Alphonsus Regional Medical Center ( Site 0085)	Boise83706	NCT06997497	Map
ID	Saint Luke's Cancer Institute - Boise	Boise83712	NCT06580314	Map
ID	Saint Luke's Cancer Institute - Boise	Boise83712	NCT04181060	Map
ID	St. Luke's Boise Medical Center	Boise83712-6241	NCT06703073	Map
ID	St. Luke's Boise Medical Center	Boise83712-6241	NCT06701656	Map
ID	Saint Alphonsus Cancer Care Center-Caldwell	Caldwell83605	NCT04181060	Map
ID	Kootenai Health - Coeur d'Alene	Coeur d'Alene83814	NCT07198074	Map
ID	Kootenai Health - Coeur d'Alene	Coeur d'Alene83814	NCT06580314	Map
ID	Kootenai Health - Coeur d'Alene	Coeur d'Alene83814	NCT04181060	Map
ID	Saint Luke's Cancer Institute - Fruitland	Fruitland83619	NCT06580314	Map
ID	Saint Luke's Cancer Institute - Fruitland	Fruitland83619	NCT04181060	Map
ID	Saint Luke's Cancer Institute - Meridian	Meridian83642	NCT06580314	Map
ID	Saint Luke's Cancer Institute - Meridian	Meridian83642	NCT04181060	Map
ID	Saint Alphonsus Cancer Care Center-Nampa	Nampa83687	NCT04181060	Map
ID	Saint Alphonsus Nampa Cancer Care Center	Nampa83687	NCT07222800	Map
ID	Saint Luke's Cancer Institute - Nampa	Nampa83687	NCT06580314	Map
ID	Saint Luke's Cancer Institute - Nampa	Nampa83687	NCT04181060	Map
ID	Kootenai Clinic Cancer Services - Post Falls	Post Falls83854	NCT07198074	Map
ID	Kootenai Clinic Cancer Services - Post Falls	Post Falls83854	NCT06580314	Map
ID	Kootenai Clinic Cancer Services - Post Falls	Post Falls83854	NCT04181060	Map
ID	Kootenai Clinic Cancer Services - Sandpoint	Sandpoint83864	NCT07198074	Map
ID	Kootenai Clinic Cancer Services - Sandpoint	Sandpoint83864	NCT06580314	Map
ID	Kootenai Clinic Cancer Services - Sandpoint	Sandpoint83864	NCT04181060	Map
ID	Saint Luke's Cancer Institute - Twin Falls	Twin Falls83301	NCT06580314	Map
ID	Saint Luke's Cancer Institute - Twin Falls	Twin Falls83301	NCT04181060	Map
IL	OSF Saint Anthony's Health Center	Alton62002	NCT06580314	Map
IL	Illinois Cancer Specialists	Arlington Heights60005	NCT07222800	Map
IL	Illinois Cancer Specialists	Arlington Heights60005	NCT06750094	Map
IL	Illinois Cancer Specialists	Arlington Heights60005	NCT07213804	Map
IL	Illinois Cancer Specialists	Arlington Heights60005	NCT04929223	Map
IL	Advocate Outpatient Center - Aurora	Aurora60506	NCT06580314	Map
IL	Rush-Copley Medical Center	Aurora60504	NCT06580314	Map
IL	Rush-Copley Medical Center	Aurora60504	NCT04181060	Map
IL	Advocate Good Shepherd Hospital	Barrington60010	NCT06580314	Map
IL	Carle BroMenn Outpatient Center	Bloomington61704	NCT06580314	Map
IL	Illinois CancerCare - Bloomington	Bloomington61704	NCT07222800	Map
IL	Illinois CancerCare-Bloomington	Bloomington61704	NCT06580314	Map
IL	Illinois CancerCare-Bloomington	Bloomington61704	NCT04181060	Map
IL	Illinois CancerCare-Canton	Canton61520	NCT06580314	Map
IL	Illinois CancerCare-Canton	Canton61520	NCT04181060	Map
IL	Memorial Hospital of Carbondale	Carbondale62902	NCT06580314	Map
IL	SIH Cancer Institute	Carterville62918	NCT06580314	Map
IL	Illinois CancerCare-Carthage	Carthage62321	NCT06580314	Map
IL	Illinois CancerCare-Carthage	Carthage62321	NCT04181060	Map
IL	Centralia Oncology Clinic	Centralia62801	NCT06580314	Map
IL	Centralia Oncology Clinic	Centralia62801	NCT04181060	Map
IL	Advocate Illinois Masonic Medical Center	Chicago60657	NCT06580314	Map
IL	Alliance for Clinical Trials in Oncology	Chicago60606	NCT05001880	Map
IL	Clinical Study Site	Chicago60611	NCT07228832	Map
IL	Illinois Cancer Specialists	Chicago60631	NCT07222800	Map
IL	Insight Research Institute	Chicago60616	NCT06252649	Map
IL	John H Stroger Jr Hospital of Cook County	Chicago60612	NCT06580314	Map
IL	Northwestern University	Chicago60611	NCT07198074	Map
IL	Northwestern University	Chicago60611	NCT04181060	Map
IL	Northwestern University	Chicago60611	NCT05620771	Map
IL	Northwestern University	Chicago60611	NCT05863195	Map
IL	Northwestern University	Chicago60611	NCT02847559	Map
IL	Rush MD Anderson Cancer Center	Chicago60612	NCT07198074	Map
IL	Rush Md Anderson Cancer Center /ID# 274926	Chicago60607	NCT06890338	Map
IL	The University of Chicago Medical Center /ID# 255674	Chicago60637-1443	NCT06109272	Map
IL	University of Chicago	Chicago60637	NCT06787612	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT05001880	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT06580314	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT07166406	Map
IL	University of Chicago Comprehensive Cancer Center	Chicago60637	NCT05863195	Map
IL	University of Chicago Medical Center /ID# 271688	Chicago60637	NCT06820463	Map
IL	University of Chicago Medical Center /ID# 276271	Chicago60637	NCT05005403	Map
IL	University of Chicago Medical Center /ID# 278295	Chicago60637	NCT07278336	Map
IL	University of Illinois	Chicago60612	NCT06580314	Map
IL	University of Illinois	Chicago60612	NCT04181060	Map
IL	University of Illinois	Chicago60612	NCT07166406	Map
IL	University of Illinois Hospital and Health Sciences System /ID# 251750	Chicago60607	NCT05005403	Map
IL	AMG Crystal Lake - Oncology	Crystal Lake60014	NCT06580314	Map
IL	Carle at The Riverfront	Danville61832	NCT05001880	Map
IL	Carle at The Riverfront	Danville61832	NCT06580314	Map
IL	Carle at The Riverfront	Danville61832	NCT04181060	Map
IL	Carle at The Riverfront	Danville61832	NCT07166406	Map
IL	Cancer Care Specialists of Illinois - Decatur	Decatur62526	NCT07198074	Map
IL	Cancer Care Specialists of Illinois - Decatur	Decatur62526	NCT06580314	Map
IL	Cancer Care Specialists of Illinois - Decatur	Decatur62526	NCT04181060	Map
IL	Decatur Memorial Hospital	Decatur62526	NCT07198074	Map
IL	Decatur Memorial Hospital	Decatur62526	NCT06580314	Map
IL	Northwestern Medicine Cancer Center Kishwaukee	DeKalb60115	NCT07198074	Map
IL	Northwestern Medicine Cancer Center Kishwaukee	DeKalb60115	NCT04181060	Map
IL	Northwestern Medicine Kishwaukee Hospital	DeKalb60115	NCT05620771	Map
IL	Illinois CancerCare-Dixon	Dixon61021	NCT06580314	Map
IL	Illinois CancerCare-Dixon	Dixon61021	NCT04181060	Map
IL	Advocate Good Samaritan Hospital	Downers Grove60515	NCT06580314	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT05001880	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT06580314	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT04181060	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT07166406	Map
IL	Crossroads Cancer Center	Effingham62401	NCT06580314	Map
IL	Crossroads Cancer Center	Effingham62401	NCT04181060	Map
IL	Advocate Sherman Hospital	Elgin60123	NCT06580314	Map
IL	Clinical Study Site	Elmhurst60540	NCT07228832	Map
IL	Elmhurst Memorial Hospital	Elmhurst60126	NCT06580314	Map
IL	Illinois CancerCare-Eureka	Eureka61530	NCT06580314	Map
IL	Illinois CancerCare-Eureka	Eureka61530	NCT04181060	Map
IL	Endeavor Health Evanston Kellogg Cancer Care Center	Evanston60201	NCT06819007	Map
IL	Illinois CancerCare - Galesburg	Galesburg61401	NCT07222800	Map
IL	Illinois CancerCare-Galesburg	Galesburg61401	NCT06580314	Map
IL	Illinois CancerCare-Galesburg	Galesburg61401	NCT04181060	Map
IL	Northwestern Medicine Cancer Center Delnor	Geneva60134	NCT07198074	Map
IL	Northwestern Medicine Cancer Center Delnor	Geneva60134	NCT04181060	Map
IL	Northwestern Medicine Delnor Hospital	Geneva60134	NCT05620771	Map
IL	Northwestern Medicine Glenview Outpatient Center	Glenview60026	NCT04181060	Map
IL	Northwestern Medicine Grayslake Outpatient Center	Grayslake60030	NCT04181060	Map
IL	Northwestern Medicine Grayslake Outpatient Center	Grayslake60030	NCT05620771	Map
IL	Ingalls Memorial Hospital	Harvey60426	NCT04181060	Map
IL	Advocate South Suburban Hospital	Hazel Crest60429	NCT06580314	Map
IL	Hope and Healing Cancer Services	Hinsdale60521	NCT07222800	Map
IL	Hope And Healing Cancer Services /ID# 271562	Hinsdale60521	NCT06820463	Map
IL	UChicago Medicine AdventHealth Cancer Institute Hinsdale	Hinsdale60521	NCT06580314	Map
IL	Illinois CancerCare-Kewanee Clinic	Kewanee61443	NCT06580314	Map
IL	Illinois CancerCare-Kewanee Clinic	Kewanee61443	NCT04181060	Map
IL	Northwestern Medicine Lake Forest Hospital	Lake Forest60045	NCT04181060	Map
IL	Northwestern Medicine Lake Forest Hospital	Lake Forest60045	NCT05620771	Map
IL	AMG Libertyville - Oncology	Libertyville60048	NCT06580314	Map
IL	Condell Memorial Hospital	Libertyville60048	NCT06580314	Map
IL	Accellacare of Duly ( Site 2015)	Lisle60532	NCT06997497	Map
IL	Illinois CancerCare-Macomb	Macomb61455	NCT06580314	Map
IL	Illinois CancerCare-Macomb	Macomb61455	NCT04181060	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT05001880	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT06580314	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT04181060	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT07166406	Map
IL	SSM Health Good Samaritan	Mount Vernon62864	NCT06580314	Map
IL	Edward Hospital/Cancer Center	Naperville60540	NCT06580314	Map
IL	Hope and Healing Cancer Services	New Lenox60451	NCT07222800	Map
IL	UC Comprehensive Cancer Center at Silver Cross	New Lenox60451	NCT06580314	Map
IL	UC Comprehensive Cancer Center at Silver Cross	New Lenox60451	NCT07166406	Map
IL	Illinois Cancer Specialists	Niles60714	NCT07222800	Map
IL	Carle BroMenn Medical Center	Normal61761	NCT06580314	Map
IL	Carle Cancer Institute Normal	Normal61761	NCT06580314	Map
IL	Cancer Care Center of O'Fallon	O'Fallon62269	NCT07198074	Map
IL	Cancer Care Center of O'Fallon	O'Fallon62269	NCT06580314	Map
IL	Cancer Care Center of O'Fallon	O'Fallon62269	NCT04181060	Map
IL	Clinical Study Site	O'Fallon62269	NCT07228832	Map
IL	HSHS Saint Elizabeth's Hospital	O'Fallon62269	NCT07198074	Map
IL	HSHS Saint Elizabeth's Hospital	O'Fallon62269	NCT06580314	Map
IL	Northwestern Medicine Oak Brook	Oak Brook60523	NCT07198074	Map
IL	Northwestern Medicine Oak Brook	Oak Brook60523	NCT04181060	Map
IL	Advocate Christ Medical Center	Oak Lawn60453-2699	NCT06580314	Map
IL	Advocate Outpatient Center - Oak Lawn	Oak Lawn60453	NCT06580314	Map
IL	Rush MD Anderson Cancer Center at Rush Oak Park	Oak Park60304	NCT07198074	Map
IL	Northwestern Medicine Orland Park	Orland Park60462	NCT07198074	Map
IL	Northwestern Medicine Orland Park	Orland Park60462	NCT04181060	Map
IL	Northwestern Medicine Orland Park	Orland Park60462	NCT05620771	Map
IL	University of Chicago Medicine-Orland Park	Orland Park60462	NCT06580314	Map
IL	University of Chicago Medicine-Orland Park	Orland Park60462	NCT07166406	Map
IL	Illinois CancerCare-Ottawa Clinic	Ottawa61350	NCT06580314	Map
IL	Illinois CancerCare-Ottawa Clinic	Ottawa61350	NCT04181060	Map
IL	Illinois CancerCare-Ottawa-Fox River Cancer Center	Ottawa61350	NCT07222800	Map
IL	Advocate High Tech Medical Park	Palos Heights60463	NCT06580314	Map
IL	Advocate Lutheran General Hospital	Park Ridge60068	NCT06580314	Map
IL	Illinois CancerCare-Pekin	Pekin61554	NCT07222800	Map
IL	Illinois CancerCare-Pekin	Pekin61554	NCT06580314	Map
IL	Illinois CancerCare-Pekin	Pekin61554	NCT04181060	Map
IL	Illinois Cancer Care	Peoria61615	NCT07222800	Map
IL	Illinois CancerCare	Peoria61615	NCT06750094	Map
IL	Illinois CancerCare PC	Peoria61615-7822	NCT07549412	Map
IL	Illinois CancerCare-Peoria	Peoria61615	NCT06580314	Map
IL	Illinois CancerCare-Peoria	Peoria61615	NCT04181060	Map
IL	Methodist Medical Center of Illinois	Peoria61636	NCT06580314	Map
IL	OSF Saint Francis Medical Center	Peoria61637	NCT07198074	Map
IL	OSF Saint Francis Medical Center-	Peoria61637-0001	NCT06703073	Map
IL	OSF Saint Francis Medical Center-	Peoria61637-0001	NCT06701656	Map
IL	OSF St. Francis Medical Center /ID# 274752	Peoria61637-0001	NCT06890338	Map
IL	Illinois CancerCare-Peru	Peru61354	NCT06580314	Map
IL	Illinois CancerCare-Peru	Peru61354	NCT04181060	Map
IL	Illinois CancerCare-Peru - Valley Regional Cancer Center	Peru61354	NCT07222800	Map
IL	Valley Radiation Oncology	Peru61354	NCT06580314	Map
IL	Edward Hospital/Cancer Center?Plainfield	Plainfield60585	NCT06580314	Map
IL	Illinois CancerCare-Princeton	Princeton61356	NCT06580314	Map
IL	Illinois CancerCare-Princeton	Princeton61356	NCT04181060	Map
IL	UW Health Carbone Cancer Center Rockford	Rockford61114	NCT06580314	Map
IL	Memorial Hospital East	Shiloh62269	NCT07166406	Map
IL	Memorial Hospital East	Shiloh62269	NCT06696768	Map
IL	Memorial Hospital East	Shiloh62269	NCT05863195	Map
IL	Southern Illinois University School of Medicine	Springfield62702	NCT07198074	Map
IL	Southern Illinois University School of Medicine	Springfield62702	NCT06580314	Map
IL	Southern Illinois University School of Medicine	Springfield62702	NCT04181060	Map
IL	Springfield Clinic	Springfield62702	NCT07198074	Map
IL	Springfield Clinic	Springfield62702	NCT06580314	Map
IL	Springfield Clinic	Springfield62702	NCT04181060	Map
IL	Springfield Memorial Hospital	Springfield62781	NCT07198074	Map
IL	Springfield Memorial Hospital	Springfield62781	NCT06580314	Map
IL	Springfield Memorial Hospital	Springfield62781	NCT04181060	Map
IL	Carle Cancer Center	Urbana61801	NCT05001880	Map
IL	Carle Cancer Center	Urbana61801	NCT06580314	Map
IL	Carle Cancer Center	Urbana61801	NCT04181060	Map
IL	Carle Cancer Center	Urbana61801	NCT07166406	Map
IL	Carle Foundation Hospital /ID# 276470	Urbana61801	NCT06890338	Map
IL	The Carle Foundation Hospital	Urbana61801	NCT05001880	Map
IL	Northwestern Medicine Cancer Center Warrenville	Warrenville60555	NCT07198074	Map
IL	Northwestern Medicine Cancer Center Warrenville	Warrenville60555	NCT04181060	Map
IL	Northwestern Medicine Warrenville	Warrenville60555	NCT05620771	Map
IL	Illinois CancerCare - Washington	Washington61571	NCT06580314	Map
IL	Illinois CancerCare - Washington	Washington61571	NCT04181060	Map
IL	Illinois CancerCare-Washington	Washington61571	NCT07222800	Map
IL	Northwestern Medicine/ Cadence Health - CDH	Winfield60190	NCT02847559	Map
IL	Rush-Copley Healthcare Center	Yorkville60560	NCT06580314	Map
IL	City of Hope at Chicago	Zion60099	NCT07288034	Map
IL	City of Hope Chicago Cancer Center	Zion60099	NCT06427941	Map
IN	IU Health North Hospital	Carmel46032	NCT06580314	Map
IN	IU Health North Hospital	Carmel46032	NCT05863195	Map
IN	Northwest Cancer Center - Crown Point	Crown Point46307	NCT04181060	Map
IN	Northwest Cancer Center - Main Campus	Crown Point46307	NCT06580314	Map
IN	UChicago Medicine Northwest Indiana	Crown Point46307	NCT06580314	Map
IN	UChicago Medicine Northwest Indiana	Crown Point46307	NCT07166406	Map
IN	Northwest Oncology LLC	Dyer46311	NCT06580314	Map
IN	Northwest Oncology LLC	Dyer46311	NCT04181060	Map
IN	Clinical Study Site	Fort Wayne46804	NCT07228832	Map
IN	Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593	Fort Wayne46804	NCT05005403	Map
IN	GSK Investigational Site	Fort Wayne46804	NCT06551142	Map
IN	Parkview Regional Medical Center	Fort Wayne46845	NCT06580314	Map
IN	Parkview Research Center /ID# 274338	Fort Wayne46845	NCT06890338	Map
IN	Parkview Research Center at Parkview Regional Medical Center ( Site 0003)	Fort Wayne46845	NCT06824467	Map
IN	Parkview Research Center at Parkview Regional Medical Center ( Site 0055)	Fort Wayne46845	NCT07318558	Map
IN	Goshen Center for Cancer Care	Goshen46526	NCT07198074	Map
IN	Goshen Center for Cancer Care	Goshen46526	NCT06580314	Map
IN	Northwest Cancer Center - Hobart	Hobart46342	NCT06580314	Map
IN	Saint Mary Medical Center	Hobart46342	NCT06580314	Map
IN	Saint Mary Medical Center	Hobart46342	NCT04181060	Map
IN	Ascension Saint Vincent Indianapolis Hospital	Indianapolis46260	NCT07198074	Map
IN	Ascension Saint Vincent Indianapolis Hospital	Indianapolis46260	NCT06580314	Map
IN	Clinical Study Site	Indianapolis46202	NCT07228832	Map
IN	Community Health Network	Indianapolis46256	NCT06663319	Map
IN	Community Health Network, Inc.	Indianapolis46250	NCT07284849	Map
IN	Community Health Network, Inc. /ID# 243011	Indianapolis46250-2042	NCT05005403	Map
IN	Franciscan Health	Indianapolis46237	NCT07222800	Map
IN	Franciscan Health	Indianapolis46237	NCT06750094	Map
IN	Franciscan Health	Indianapolis46237	NCT07213804	Map
IN	Hematology Oncology of Indiana	Indianapolis46260	NCT07284849	Map
IN	Indiana University	Indianapolis46202	NCT06819007	Map
IN	Indiana University Melvin and Bren Simon Cancer Center /ID# 275492	Indianapolis46202	NCT06890338	Map
IN	Indiana University Simon Comprehensive Cancer Center	Indianapolis46202	NCT05281471	Map
IN	Indiana University Simon Comprehensive Cancer Center	Indianapolis46202	NCT06625775	Map
IN	Indiana University/Melvin and Bren Simon Cancer Center	Indianapolis46202	NCT06580314	Map
IN	Indiana University/Melvin and Bren Simon Cancer Center	Indianapolis46202	NCT05863195	Map
IN	Saint Catherine Hospital	Indianapolis46312	NCT06580314	Map
IN	Saint Catherine Hospital	Indianapolis46312	NCT04181060	Map
IN	Sidney and Lois Eskenazi Hospital	Indianapolis46202	NCT06580314	Map
IN	Franciscan Health Mooresville	Mooresville46158	NCT07222800	Map
IN	The Community Hospital	Munster46321	NCT06580314	Map
IN	The Community Hospital	Munster46321	NCT04181060	Map
IN	Women's Diagnostic Center - Munster	Munster46321	NCT06580314	Map
IN	Women's Diagnostic Center - Munster	Munster46321	NCT04181060	Map
IN	Memorial Hospital of South Bend	South Bend46601	NCT07198074	Map
IN	Memorial Hospital of South Bend	South Bend46601	NCT06580314	Map
IN	Northwest Cancer Center - Valparaiso	Valparaiso46383	NCT06580314	Map
IN	Northwest Cancer Center - Valparaiso	Valparaiso46383	NCT04181060	Map
IA	Mary Greeley Medical Center	Ames50010	NCT06580314	Map
IA	Mary Greeley Medical Center	Ames50010	NCT04181060	Map
IA	McFarland Clinic - Ames	Ames50010	NCT06580314	Map
IA	McFarland Clinic - Ames	Ames50010	NCT04181060	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT07198074	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT04181060	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT07166406	Map
IA	Saint Anthony Regional Hospital	Carroll51401	NCT07198074	Map
IA	Saint Anthony Regional Hospital	Carroll51401	NCT04181060	Map
IA	Mercy Hospital	Cedar Rapids52403	NCT07198074	Map
IA	Mercy Hospital	Cedar Rapids52403	NCT06580314	Map
IA	Oncology Associates at Mercy Medical Center	Cedar Rapids52403	NCT07198074	Map
IA	Oncology Associates at Mercy Medical Center	Cedar Rapids52403	NCT06580314	Map
IA	Mercy Cancer Center-West Lakes	Clive50325	NCT07166406	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT07198074	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT04181060	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT07166406	Map
IA	Methodist Jennie Edmundson Hospital	Council Bluffs51503	NCT06580314	Map
IA	Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ	Council Bluffs51503	NCT06580314	Map
IA	Greater Regional Medical Center	Creston50801	NCT07166406	Map
IA	Broadlawns Medical Center	Des Moines50314	NCT07198074	Map
IA	Broadlawns Medical Center	Des Moines50314	NCT04181060	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT07198074	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT04181060	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT07166406	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT07198074	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT07166406	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT07198074	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT04181060	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT07166406	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT07198074	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT04181060	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT07166406	Map
IA	McFarland Clinic - Trinity Cancer Center	Fort Dodge50501	NCT06580314	Map
IA	McFarland Clinic - Trinity Cancer Center	Fort Dodge50501	NCT04181060	Map
IA	UI Healthcare Mission Cancer and Blood - Fort Dodge	Fort Dodge50501	NCT07198074	Map
IA	UI Healthcare Mission Cancer and Blood - Fort Dodge	Fort Dodge50501	NCT04181060	Map
IA	University of Iowa ( Site 0074)	Iowa City52242	NCT06997497	Map
IA	University of Iowa Health Care	Iowa City52242	NCT07541781	Map
IA	University of Iowa Hospitals and Clinics	Iowa City52242	NCT06750094	Map
IA	University of Iowa- Site Number : 8400014	Iowa City52242	NCT05584670	Map
IA	University of Iowa/Holden Comprehensive Cancer Center	Iowa City52242	NCT07198074	Map
IA	University of Iowa/Holden Comprehensive Cancer Center	Iowa City52242	NCT06580314	Map
IA	McFarland Clinic - Marshalltown	Marshalltown50158	NCT06580314	Map
IA	McFarland Clinic - Marshalltown	Marshalltown50158	NCT04181060	Map
IA	Mission Cancer Blood	Waukee50263	NCT06750094	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT07198074	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT04181060	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT07166406	Map
IA	Mercy Medical Center-West Lakes	West Des Moines50266	NCT07166406	Map
IA	The Iowa Clinic PC	West Des Moines50266	NCT07166406	Map
KS	The University of Kansas Clinical Research Center	Fairway66205	NCT06607458	Map
KS	University of Kansas Clinical Research Center	Fairway66205	NCT06696768	Map
KS	Central Care Cancer Center - Garden City	Garden City67846	NCT06580314	Map
KS	Central Care Cancer Center - Great Bend	Great Bend67530	NCT06580314	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT06696768	Map
KS	University of Kansas Hospital-Indian Creek Campus	Overland Park66211	NCT06696768	Map
KS	Mercy Hospital Pittsburg	Pittsburg66762	NCT06580314	Map
KS	Clinical Study Site	Westwood66205	NCT07228832	Map
KS	The University of Kansas Cancer Center	Westwood66205	NCT06787612	Map
KS	The University of Kansas Cancer Center - Westwood- Site Number : 8400008	Westwood66205	NCT05584670	Map
KS	The University of Kansas Clinical Research Center	Westwood66205	NCT06445062	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT06696768	Map
KS	University of Kansas Medical Center (KUMC)	Westwood66205	NCT05579366	Map
KS	Ascension Via Christi Hospitals Wichita	Wichita67214	NCT04181060	Map
KS	Cancer Center of Kansas	Wichita67214	NCT06750094	Map
KS	Cancer Center of Kansas - Wichita	Wichita67214	NCT04181060	Map
KS	Cancer Center of Kansas-Wichita Medical Arts Tower	Wichita67208	NCT04181060	Map
KY	Flaget Memorial Hospital	Bardstown40004	NCT06580314	Map
KY	Baptist Health Corbin	Corbin40701	NCT06580314	Map
KY	Commonwealth Cancer Center-Corbin	Corbin40701	NCT06580314	Map
KY	Clinical Study Site	Edgewood41017	NCT07228832	Map
KY	Baptist Health Lexington	Lexington40503	NCT06580314	Map
KY	Baptist Health Lexington	Lexington40503	NCT05253651	Map
KY	Baptist Health Lexington	Lexington40503	NCT07213804	Map
KY	Baptist Health Lexington /ID# 275218	Lexington40503	NCT06890338	Map
KY	Saint Joseph Hospital	Lexington40504	NCT06580314	Map
KY	Saint Joseph Hospital East	Lexington40509	NCT06580314	Map
KY	Saint Joseph Radiation Oncology Resource Center	Lexington40504	NCT06580314	Map
KY	University of Kentucky - Markey Cancer Center	Lexington40536-7001	NCT04524871	Map
KY	University of Kentucky ( Site 0055)	Lexington40536	NCT06997497	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT07198074	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT07166406	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT05863195	Map
KY	Saint Joseph London	London40741	NCT06580314	Map
KY	Baptist Health Louisville	Louisville40207	NCT06580314	Map
KY	Norton Audubon Hospital	Louisville40217	NCT05253651	Map
KY	Norton Brownsboro Hospital	Louisville40241	NCT05253651	Map
KY	Norton Cancer Institute - Downtown	Louisville40202	NCT05253651	Map
KY	Norton Cancer Institute - MDC	Louisville40202	NCT06004245	Map
KY	Norton Cancer Institute - St. Matthews /ID# 276173	Louisville40207	NCT06890338	Map
KY	Norton Cancer Institute /ID# 248903	Louisville40241-2832	NCT05005403	Map
KY	Norton Cancer Institute /ID# 260775	Louisville40217-1395	NCT06109272	Map
KY	Norton Cancer Institute, Audubon Hospital Campus	Louisville40217	NCT05253651	Map
KY	Norton Cancer Institute, Audubon Hospital Campus ( Site 0054)	Louisville40217	NCT06997497	Map
KY	Norton Cancer Institute, Brownsboro Hospital Campus	Louisville40241	NCT05253651	Map
KY	Norton Cancer Institute, Downtown	Louisville40202	NCT05253651	Map
KY	Norton Cancer Institute, St. Matthews Clinic	Louisville40207	NCT06787612	Map
KY	Norton Hospital	Louisville40202	NCT05253651	Map
KY	Norton Women's and Children's Hospital	Louisville40207	NCT07213804	Map
KY	The James Graham Brown Cancer Center at University of Louisville	Louisville40202	NCT06580314	Map
KY	The University of Louisville, James Graham Brown Cancer Center ( Site 0009)	Louisville40202	NCT06843447	Map
KY	University of Louisville-James Graham Brown Cancer Center	Louisville40202	NCT03899155	Map
KY	UofL Health Medical Center Northeast	Louisville40245	NCT06580314	Map
KY	Saint Joseph Mount Sterling	Mount Sterling40353	NCT06580314	Map
KY	Baptist Health Paducah	Paducah42003	NCT06580314	Map
KY	Pikeville Medical Center	Pikeville41501	NCT06252649	Map
LA	LSU Health Baton Rouge-North Clinic	Baton Rouge70805	NCT06580314	Map
LA	Mary Bird Perkins Cancer Center	Baton Rouge70809	NCT06750094	Map
LA	Mary Bird Perkins Cancer Ctr	Baton Rouge70809	NCT04929223	Map
LA	Our Lady of The Lake	Baton Rouge70808	NCT06580314	Map
LA	Our Lady of the Lake Medical Oncology	Baton Rouge70817	NCT06580314	Map
LA	Our Lady of the Lake Physician Group	Baton Rouge70808	NCT06580314	Map
LA	Our Lady of the Lake Physician Group - Medical Oncology /ID# 277440	Baton Rouge70817	NCT07059845	Map
LA	Women's Cancer Care ( Site 0018)	Covington70433	NCT07318558	Map
LA	Women's Cancer Care ( Site 0067)	Covington70433	NCT06824467	Map
LA	Women'S Cancer Care /ID# 276469	Covington70433	NCT06890338	Map
LA	West Jefferson Medical Center	Marrero70072	NCT07198074	Map
LA	West Jefferson Medical Center	Marrero70072	NCT06580314	Map
LA	East Jefferson General Hospital	Metairie70006	NCT07198074	Map
LA	East Jefferson General Hospital	Metairie70006	NCT06580314	Map
LA	LSU Healthcare Network / Metairie Multi-Specialty Clinic	Metairie70006	NCT07198074	Map
LA	LSU Healthcare Network / Metairie Multi-Specialty Clinic	Metairie70006	NCT06580314	Map
LA	Clinical Study Site	New Orleans70121	NCT07228832	Map
LA	Ochsner Baptist Medical Center	New Orleans70115	NCT06580314	Map
LA	Ochsner Clinic Foundation	New Orleans70123	NCT05848739	Map
LA	Ochsner Clinic Foundation	New Orleans70121	NCT06607458	Map
LA	Ochsner Medical Center Jefferson	New Orleans70121	NCT06580314	Map
LA	University Medical Center New Orleans	New Orleans70112	NCT07198074	Map
LA	University Medical Center New Orleans	New Orleans70112	NCT06580314	Map
LA	University Medical Center New Orleans /ID# 274755	New Orleans70112	NCT06890338	Map
LA	Trials 365	Shreveport71103	NCT07213804	Map
LA	TRIALS 365 ( Site 6008)	Shreveport71103	NCT07216703	Map
LA	Trials 365 /ID# 274310	Shreveport71103	NCT06890338	Map
LA	Trials365 LLC	Shreveport71103	NCT06819007	Map
ME	Lafayette Family Cancer Center-EMMC	Brewer04412	NCT07198074	Map
ME	Maine Medical Center - Scarborough Campus	Scarborough04074	NCT07213804	Map
ME	Maine Medical Center - Scarborough Campus /ID# 277205	Scarborough04074	NCT07059845	Map
ME	Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0008)	Scarborough04074	NCT06824467	Map
ME	MaineHealth Maine Medical Center- Scarborough	Scarborough04074	NCT07198074	Map
ME	MaineHealth Maine Medical Center- Scarborough	Scarborough04074	NCT06580314	Map
MD	Clinical Study Site	Baltimore21201	NCT07228832	Map
MD	Greater Baltimore Medical Center	Baltimore21204	NCT07222800	Map
MD	Greater Baltimore Medical Center	Baltimore21204	NCT07213804	Map
MD	Greater Baltimore Medical Center ( Site 0068)	Baltimore21204	NCT06997497	Map
MD	Johns Hopkins Hospital	Baltimore21287	NCT04374305	Map
MD	Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center	Baltimore21287	NCT05919264	Map
MD	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore21287	NCT07198074	Map
MD	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore21287	NCT06580314	Map
MD	MedStar Franklin Square Medical Center	Baltimore21237	NCT06750094	Map
MD	Research Site	Baltimore21224	NCT06792695	Map
MD	Sidney Kimmel Comprehensive Cancer at Johns Hopkins	Baltimore21287	NCT06131840	Map
MD	Sidney Kimmel Comprehensive Cancer At Johns Hopkins	Baltimore21287	NCT06233942	Map
MD	Sinai Hospital Of Baltimore	Baltimore21215	NCT07213804	Map
MD	The Sidney Kimmel Comprehensive Cancer Center	Baltimore21231	NCT05440708	Map
MD	The Sidney Kimmel Comprehensive Cancer Center at John Hopkins	Baltimore21287	NCT06445062	Map
MD	University of Maryland Medical Center	Baltimore21201	NCT05733598	Map
MD	University of Maryland, Baltimore /ID# 275308	Baltimore21201	NCT06890338	Map
MD	Cancer Center For Blood Disorders A Division of American Oncology Partners P.A	Bethesda20817	NCT07284849	Map
MD	NCI - Center for Cancer Research	Bethesda20892	NCT04981509	Map
MD	Walter Reed National Military Medical Center	Bethesda20889-5600	NCT06580314	Map
MD	Sarah Cannon Research Institute Scri Oncology Partners	Brandywine20613	NCT07284849	Map
MD	Christiana Care - Union Hospital	Elkton21921	NCT06580314	Map
MD	Frederick Health Hospital - James M Stockman Cancer Institute	Frederick21702	NCT06750094	Map
MD	USOR Maryland Oncology Hematology	Rockville20850	NCT05579366	Map
MD	Holy Cross Hospital	Silver Spring20910	NCT05281471	Map
MD	Holy Cross Hospital /ID# 275872	Silver Spring20910	NCT06890338	Map
MD	Maryland Oncology Hematology - Silver Spring	Silver Spring20904	NCT07221357	Map
MD	Greater Baltimore Medical Center	Towson21204	NCT06819007	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT06131840	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT07527858	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT05848739	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT05919264	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT05579366	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT05836324	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT06445062	Map
MA	Dana_Farber Cancer Institute (DFCI)	Boston02215	NCT03899155	Map
MA	Dana-Farber Cancer Insitute	Boston02215	NCT06625775	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05096715	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06265688	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT07198074	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06819007	Map
MA	Dana-Farber Cancer Institute ( Site 0015)	Boston02215	NCT06843447	Map
MA	Dana-Farber Cancer Institute /ID# 270624	Boston02215	NCT06820463	Map
MA	GSK Investigational Site	Boston02114	NCT06551142	Map
MA	Massachusetts General Hospital	Boston02114	NCT05919264	Map
MA	Massachusetts General Hospital	Boston02114	NCT05579366	Map
MA	Massachusetts General Hospital	Boston02114	NCT06625775	Map
MA	Massachusetts General Hospital	Boston02114	NCT06787612	Map
MA	Massachusetts General Hospital	Boston02114	NCT06819007	Map
MA	Massachusetts General Hospital	Boston02114	NCT06445062	Map
MA	Massachusetts General Hospital	Boston02115	NCT04374305	Map
MA	Massachusetts General Hospital	Boston02114	NCT06469281	Map
MA	Massachusetts General Hospital Cancer Center	Boston02114	NCT05096715	Map
MA	Massachusetts General Hospital Cancer Center	Boston02114	NCT07166406	Map
MA	Research Site	Boston02114	NCT05797168	Map
MA	Site 0104	Boston02215	NCT04516447	Map
MA	Lahey Hospital and Medical Center	Burlington01805-0001	NCT06703073	Map
MA	Lahey Hospital and Medical Center	Burlington01805-0001	NCT06701656	Map
MA	Baystate Medical Center	Springfield01199	NCT06580314	Map
MA	UMass Memorial Medical Center - University Campus	Worcester01655	NCT04181060	Map
MI	MyMichigan Medical Center Gratiot	Alma48801	NCT06580314	Map
MI	MyMichigan Medical Center Alpena	Alpena49707	NCT06580314	Map
MI	Trinity Health Saint Joseph Mercy Hospital Ann Arbor	Ann Arbor48106	NCT06580314	Map
MI	Trinity Health Saint Joseph Mercy Hospital Ann Arbor	Ann Arbor48106	NCT04181060	Map
MI	Trinity Health St. Joseph Mercy Ann Arbor	Ann Arbor48106	NCT06819007	Map
MI	University of Michigan	Ann Arbor48109	NCT05281471	Map
MI	University of Michigan	Ann Arbor48109	NCT05588388	Map
MI	University of Michigan Hospital	Ann Arbor48109-5000	NCT06703073	Map
MI	University of Michigan Hospital	Ann Arbor48109-5000	NCT06701656	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT07198074	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT06750094	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT06580314	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT05440708	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT05863195	Map
MI	V.A. Ann Arbor Healthcare System	Ann Arbor48105	NCT05588388	Map
MI	Bronson Battle Creek	Battle Creek49017	NCT07198074	Map
MI	Bronson Battle Creek	Battle Creek49017	NCT06580314	Map
MI	The Cancer & Hematology Centers	Big Rapids49307	NCT07222800	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT07198074	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT06580314	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT04181060	Map
MI	Trinity Health Medical Center - Brighton	Brighton48114	NCT06580314	Map
MI	Trinity Health Medical Center - Brighton	Brighton48114	NCT04181060	Map
MI	University of Michigan - Brighton Center for Specialty Care	Brighton48116	NCT07198074	Map
MI	University of Michigan - Brighton Center for Specialty Care	Brighton48116	NCT06580314	Map
MI	Henry Ford Cancer Institute-Downriver	Brownstown48183	NCT07166406	—
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT07198074	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT06580314	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT04181060	Map
MI	Trinity Health Medical Center - Canton	Canton48188	NCT06580314	Map
MI	Trinity Health Medical Center - Canton	Canton48188	NCT04181060	Map
MI	Chelsea Hospital	Chelsea48118	NCT06580314	Map
MI	Chelsea Hospital	Chelsea48118	NCT04181060	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT07198074	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT06580314	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT04181060	Map
MI	Hematology Oncology Consultants-Clarkston	Clarkston48346	NCT06580314	Map
MI	Hematology Oncology Consultants-Clarkston	Clarkston48346	NCT04181060	Map
MI	Newland Medical Associates-Clarkston	Clarkston48346	NCT06580314	Map
MI	Corewell Health Dearborn Hospital	Dearborn48124	NCT04181060	Map
MI	Henry Ford Medical Center-Fairlane	Dearborn48126	NCT07166406	Map
MI	Barbara Ann Karmanos Cancer Institute	Detroit48201	NCT05440708	Map
MI	Clinical Study Site	Detroit48201	NCT07228832	Map
MI	GSK Investigational Site	Detroit48201	NCT06551142	Map
MI	Henry Ford Health Hospital	Detroit48202-2608	NCT06703073	Map
MI	Henry Ford Health Hospital	Detroit48202-2608	NCT06701656	Map
MI	Henry Ford Health Saint John Hospital	Detroit48236	NCT06580314	Map
MI	Henry Ford Health Saint John Hospital	Detroit48236	NCT04181060	Map
MI	Henry Ford Health System	Detroit48202	NCT06252649	Map
MI	Henry Ford Hospital	Detroit48202	NCT06750094	Map
MI	Henry Ford Hospital	Detroit48202	NCT07166406	Map
MI	Henry Ford Hospital /ID# 255803	Detroit48202	NCT06109272	Map
MI	Karmanos Cancer Institute	Detroit48085	NCT05579366	Map
MI	Karmanos Cancer Institute	Detroit48201	NCT05281471	Map
MI	Karmanos Cancer Institute	Detroit48201	NCT06787612	Map
MI	Karmanos Cancer Institute - Detroit /ID# 277085	Detroit48201	NCT07059845	Map
MI	Karmanos Cancer Institute - Detroit- Site Number : 8400006	Detroit48201	NCT05584670	Map
MI	Research Site	Detroit48201	NCT05797168	Map
MI	Henry Ford River District Hospital	East China Township48054	NCT06580314	—
MI	Henry Ford River District Hospital	East China Township48054	NCT04181060	—
MI	OSF Saint Francis Hospital and Medical Group	Escanaba49829	NCT07198074	Map
MI	OSF Saint Francis Hospital and Medical Group	Escanaba49829	NCT06580314	Map
MI	Cancer Hematology Centers - Flint	Flint48503	NCT06580314	Map
MI	Cancer Hematology Centers - Flint	Flint48503	NCT04181060	Map
MI	Genesee Hematology Oncology PC	Flint48503	NCT06580314	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT07198074	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT06580314	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT04181060	Map
MI	Hurley Medical Center	Flint48503	NCT07198074	Map
MI	Hurley Medical Center	Flint48503	NCT06580314	Map
MI	Hurley Medical Center	Flint48503	NCT04181060	Map
MI	MyMichigan Medical Center Gladwin	Gladwin48624	NCT06580314	Map
MI	Cancer and Hematology Centers of Western Michigan	Grand Rapids49503	NCT06252649	Map
MI	Cancer And Hematology Centers of Western Michigan PC	Grand Rapids49503	NCT06750094	Map
MI	Cancer and Hematology Centers of Western Michigan-Start Midwest	Grand Rapids49546	NCT05836324	Map
MI	Corewell Health	Grand Rapids49503	NCT06819007	Map
MI	Corewell Health Grand Rapids Hospitals - Butterworth Hospital	Grand Rapids49503	NCT07198074	Map
MI	Corewell Health Grand Rapids Hospitals - Butterworth Hospital	Grand Rapids49503	NCT06580314	Map
MI	Corewell Health Grand Rapids Hospitals - Butterworth Hospital	Grand Rapids49503	NCT05863195	Map
MI	Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital	Grand Rapids49503	NCT06580314	Map
MI	Helen DeVos Children's Hospital	Grand Rapids48503	NCT01356290	Map
MI	Research Site	Grand Rapids49503	NCT06921785	Map
MI	Research Site	Grand Rapids49503	NCT05489211	Map
MI	South Texas Accelerated Research Therapeutics (START) Midwest	Grand Rapids49546	NCT06400472	Map
MI	Start Midwest	Grand Rapids49546	NCT06663319	Map
MI	START Midwest	Grand Rapids49546	NCT06131840	Map
MI	START Midwest	Grand Rapids49503	NCT05579366	Map
MI	START Midwest	Grand Rapids49546	NCT07079631	Map
MI	START Midwest /ID# 248685	Grand Rapids49546-7062	NCT05005403	Map
MI	START Midwest, LLC	Grand Rapids49546	NCT07318805	Map
MI	The Cancer & Hematology Centers	Grand Rapids49503	NCT07222800	Map
MI	The Cancer & Hematology Centers	Grand Rapids49546	NCT07222800	Map
MI	Trinity Health Grand Rapids Hospital	Grand Rapids49503	NCT07198074	Map
MI	Trinity Health Grand Rapids Hospital	Grand Rapids49503	NCT06580314	Map
MI	Henry Ford Saint John Hospital - Academic	Grosse Pointe Woods48236	NCT06580314	Map
MI	Henry Ford Saint John Hospital - Academic	Grosse Pointe Woods48236	NCT04181060	Map
MI	Henry Ford Saint John Hospital - Breast	Grosse Pointe Woods48236	NCT06580314	Map
MI	Henry Ford Saint John Hospital - Van Elslander	Grosse Pointe Woods48236	NCT06580314	Map
MI	Henry Ford Saint John Hospital - Van Elslander	Grosse Pointe Woods48236	NCT04181060	Map
MI	The Cancer & Hematology Centers	Holland49424	NCT07222800	Map
MI	Allegiance Health	Jackson49201	NCT07166406	Map
MI	Beacon Kalamazoo	Kalamazoo49048	NCT06580314	Map
MI	Beacon Kalamazoo Cancer Center	Kalamazoo49009	NCT07198074	Map
MI	Beacon Kalamazoo Cancer Center	Kalamazoo49009	NCT06580314	Map
MI	Bronson Methodist Hospital	Kalamazoo49007	NCT07198074	Map
MI	Bronson Methodist Hospital	Kalamazoo49007	NCT06580314	Map
MI	West Michigan Cancer Center	Kalamazoo49007	NCT07198074	Map
MI	West Michigan Cancer Center	Kalamazoo49007	NCT06580314	Map
MI	West Michigan Cancer Center	Kalamazoo49007	NCT07213804	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT07198074	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT06580314	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT04181060	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT07198074	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT06580314	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT04181060	Map
MI	Henry Ford Saint John Hospital - Macomb Medical	Macomb48044	NCT06580314	Map
MI	Henry Ford Saint John Hospital - Macomb Medical	Macomb48044	NCT04181060	Map
MI	Henry Ford Warren Hospital - Breast Macomb	Macomb48044	NCT06580314	Map
MI	MyMichigan Medical Center Midland	Midland48670	NCT06580314	Map
MI	MyMichigan Medical Center Mount Pleasant	Mount Pleasant48858	NCT06580314	Map
MI	Trinity Health Muskegon Hospital	Muskegon49444	NCT07198074	Map
MI	Trinity Health Muskegon Hospital	Muskegon49444	NCT06580314	Map
MI	Corewell Health Lakeland Hospitals - Niles Hospital	Niles49120	NCT07198074	Map
MI	Corewell Health Lakeland Hospitals - Niles Hospital	Niles49120	NCT06580314	Map
MI	Cancer and Hematology Centers of Western Michigan - Norton Shores	Norton Shores49444	NCT07198074	Map
MI	Cancer and Hematology Centers of Western Michigan - Norton Shores	Norton Shores49444	NCT06580314	Map
MI	The Cancer & Hematology Centers	Norton Shores49444	NCT07222800	Map
MI	Henry Ford Medical Center-Columbus	Novi48377	NCT07166406	Map
MI	Hope Cancer Center	Pontiac48341	NCT06580314	Map
MI	Michigan Healthcare Professionals Pontiac	Pontiac48341	NCT06580314	Map
MI	Michigan Healthcare Professionals Pontiac	Pontiac48341	NCT04181060	Map
MI	Newland Medical Associates-Pontiac	Pontiac48341	NCT06580314	Map
MI	Newland Medical Associates-Pontiac	Pontiac48341	NCT04181060	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT07198074	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT06580314	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT04181060	Map
MI	Corewell Health Reed City Hospital	Reed City49677	NCT07198074	Map
MI	Corewell Health Reed City Hospital	Reed City49677	NCT06580314	Map
MI	Corewell Health William Beaumont University Hospital	Royal Oak48073	NCT04181060	Map
MI	MyMichigan Medical Center Saginaw	Saginaw48601	NCT06580314	Map
MI	MyMichigan Medical Center Saginaw	Saginaw48601	NCT04181060	Map
MI	Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center	Saint Joseph49085	NCT07198074	Map
MI	Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center	Saint Joseph49085	NCT06580314	Map
MI	Corewell Health Lakeland Hospitals - Saint Joseph Hospital	Saint Joseph49085	NCT07198074	Map
MI	Corewell Health Lakeland Hospitals - Saint Joseph Hospital	Saint Joseph49085	NCT06580314	Map
MI	Profound Research LLC at Cancer and Leukemia Center	Sterling Heights48098	NCT07549412	Map
MI	MyMichigan Medical Center Tawas	Tawas City48764	NCT06580314	Map
MI	MyMichigan Medical Center Tawas	Tawas City48764	NCT04181060	Map
MI	Munson Medical Center	Traverse City49684	NCT07198074	Map
MI	Munson Medical Center	Traverse City49684	NCT06580314	Map
MI	Corewell Health Beaumont Troy Hospital	Troy48085	NCT04181060	Map
MI	Henry Ford Health Warren Hospital	Warren48093	NCT06580314	Map
MI	Henry Ford Health Warren Hospital	Warren48093	NCT04181060	Map
MI	Henry Ford Madison Heights Hospital - Breast	Warren48093	NCT06580314	Map
MI	Henry Ford Warren Hospital - GLCMS	Warren48093	NCT06580314	Map
MI	Henry Ford Warren Hospital - GLCMS	Warren48093	NCT04181060	Map
MI	Henry Ford West Bloomfield Hospital	West Bloomfield48322	NCT07166406	Map
MI	Henry Ford Wyandotte Hospital	Wyandotte48192	NCT07166406	Map
MI	University of Michigan Health - West	Wyoming49519	NCT07198074	Map
MI	University of Michigan Health - West	Wyoming49519	NCT06580314	Map
MI	Huron Gastroenterology PC	Ypsilanti48106	NCT06580314	Map
MI	Huron Gastroenterology PC	Ypsilanti48106	NCT04181060	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT07198074	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT06580314	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT04181060	Map
MN	Riverwood Healthcare Center	Aitkin56431	NCT06580314	Map
MN	Essentia Health - Baxter Clinic	Baxter56425	NCT06580314	Map
MN	Sanford Joe Lueken Cancer Center	Bemidji56601	NCT05001880	Map
MN	Sanford Joe Lueken Cancer Center	Bemidji56601	NCT06580314	Map
MN	Essentia Health Saint Joseph's Medical Center	Brainerd56401	NCT07198074	Map
MN	Essentia Health Saint Joseph's Medical Center	Brainerd56401	NCT06580314	Map
MN	Essentia Health Saint Joseph's Medical Center	Brainerd56401	NCT07166406	Map
MN	Minnesota Oncology - Burnsville	Burnsville55337	NCT06580314	Map
MN	Minnesota Oncology - Burnsville	Burnsville55337	NCT04181060	Map
MN	Minnesota Oncology Hematology, PA	Burnsville55337	NCT05253651	Map
MN	Cambridge Medical Center	Cambridge55008	NCT06580314	Map
MN	Allina Health Cancer institute	Coon Rapids55433	NCT05253651	Map
MN	Mercy Hospital	Coon Rapids55433	NCT05001880	Map
MN	Mercy Hospital	Coon Rapids55433	NCT07198074	Map
MN	Mercy Hospital	Coon Rapids55433	NCT06580314	Map
MN	Mercy Hospital	Coon Rapids55433	NCT04181060	Map
MN	Minnesota Oncology Hematology, PA	Coon Rapids55433	NCT05253651	Map
MN	Essentia Health - Saint Joseph's Crosslake Clinic	Crosslake56442	NCT06580314	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT07198074	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT06580314	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT07166406	Map
MN	Essentia Health Saint Mary's - Detroit Lakes Clinic	Detroit Lakes56501	NCT06580314	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT07198074	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT06580314	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT07166406	Map
MN	Essentia Health Saint Mary's Medical Center	Duluth55805	NCT06580314	Map
MN	Essentia Health Saint Mary's Medical Center	Duluth55805	NCT07166406	Map
MN	Miller-Dwan Hospital	Duluth55805	NCT06580314	Map
MN	Miller-Dwan Hospital	Duluth55805	NCT07166406	Map
MN	Fairview Southdale Hospital	Edina55435	NCT05001880	Map
MN	Fairview Southdale Hospital	Edina55435	NCT07198074	Map
MN	Fairview Southdale Hospital	Edina55435	NCT06580314	Map
MN	Fairview Southdale Hospital	Edina55435	NCT04181060	Map
MN	M Health Fairview Cancer Clinic-Edina	Edina55435	NCT05253651	Map
MN	Minnesota Oncology Hematology, PA	Edina55435	NCT05253651	Map
MN	Minnesota Oncology Hematology, PA ( Site 8003)	Edina55435	NCT07216703	Map
MN	Essentia Health - Ely Clinic	Ely55731	NCT06580314	Map
MN	Essentia Health - Fosston	Fosston56542	NCT06580314	Map
MN	Minnesota Oncology Hematology, PA	Fridley55432	NCT05253651	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT07198074	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT06580314	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT07166406	Map
MN	Essentia Health - International Falls Clinic	International Falls56649	NCT06580314	Map
MN	Fairview Clinics and Surgery Center Maple Grove	Maple Grove55369	NCT06580314	Map
MN	Fairview Clinics and Surgery Center Maple Grove	Maple Grove55369	NCT04181060	Map
MN	Minnesota Oncology	Maple Grove55369	NCT07221357	Map
MN	Minnesota Oncology Hematology, PA	Maple Grove55369	NCT05253651	Map
MN	M Health Fairview St. John's Hospital	Maplewood55109	NCT05253651	Map
MN	Minnesota Oncology Hematology PA-Maplewood	Maplewood55109	NCT06580314	Map
MN	Minnesota Oncology Hematology PA-Maplewood	Maplewood55109	NCT04181060	Map
MN	Minnesota Oncology Hematology, PA	Maplewood55109	NCT05253651	Map
MN	Saint John's Hospital - Healtheast	Maplewood55109	NCT06580314	Map
MN	Saint John's Hospital - Healtheast	Maplewood55109	NCT04181060	Map
MN	USOR Minnesota Oncology Hematology	Maplewood55109	NCT05579366	Map
MN	Avera Cancer Institute at Marshall	Marshall56258	NCT06580314	Map
MN	Avera Cancer Institute- Marshall	Marshall56258	NCT07222800	Map
MN	Corcept Therapeutics Investigator Site #518	Minneapolis55404	NCT06906341	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT05001880	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT07198074	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT06580314	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT04181060	Map
MN	Allina Health Cancer Institute (Virginia Piper Cancer Institute)	Minneapolis55404	NCT05253651	Map
MN	Health Partners Inc	Minneapolis55454	NCT06580314	Map
MN	Hennepin County Medical Center	Minneapolis55415	NCT06580314	Map
MN	Hennepin County Medical Center	Minneapolis55415	NCT05253651	Map
MN	Hennepin County Medical Center	Minneapolis55415	NCT04181060	Map
MN	M Health Fairview University of Minnesota Medical Center	Minneapolis55455	NCT05919264	Map
MN	M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200	Minneapolis55455	NCT05005403	Map
MN	Minnesota Oncology Hematology PA	Minneapolis55404	NCT06819007	Map
MN	Minnesota Oncology Hematology, PA	Minneapolis55404	NCT05253651	Map
MN	University of Minnesota - Minneapolis /ID# 275718	Minneapolis55455-0341	NCT06890338	Map
MN	University of Minnesota/Masonic Cancer Center	Minneapolis55455	NCT06580314	Map
MN	Monticello Cancer Center	Monticello55362	NCT06580314	Map
MN	Essentia Health - Moose Lake Clinic	Moose Lake55767	NCT06580314	Map
MN	New Ulm Medical Center	New Ulm56073	NCT06580314	Map
MN	Essentia Health - Park Rapids	Park Rapids56470	NCT06580314	Map
MN	Essentia Health - Saint Joseph's Pequot Lakes Clinic	Pequot Lakes56472	NCT06580314	Map
MN	Essentia Health - Saint Joseph's Pine River Clinic	Pine River56474	NCT06580314	Map
MN	Fairview Northland Medical Center	Princeton55371	NCT06580314	Map
MN	North Memorial Health Cancer Center	Robbinsdale55422	NCT05253651	Map
MN	North Memorial Medical Health Center	Robbinsdale55422	NCT06580314	Map
MN	May Clinic Rochester	Rochester55905	NCT06948448	Map
MN	Mayo Clinic	Rochester55905	NCT06131840	Map
MN	Mayo Clinic	Rochester55905	NCT05919264	Map
MN	Mayo Clinic	Rochester55905	NCT06160206	Map
MN	Mayo Clinic	Rochester55905-0001	NCT06703073	Map
MN	Mayo Clinic	Rochester55905-0001	NCT06701656	Map
MN	Mayo Clinic	Rochester55905	NCT06445062	Map
MN	Mayo Clinic Cancer Center	Rochester55905	NCT06131840	Map
MN	Mayo Clinic Cancer Center Outpatient Pharmacy	Rochester55905	NCT05253651	Map
MN	Mayo Clinic in Minnesota	Rochester55905	NCT05824975	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT05001880	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT06580314	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT03942328	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT05863195	Map
MN	Mayo Clinic Rochester	Rochester55902	NCT04929223	Map
MN	Research Site	Rochester55905	NCT06792695	Map
MN	Research Site	Rochester55905	NCT06921785	Map
MN	Clinical Study Site	Saint Louis Park55426	NCT07228832	Map
MN	Metro Minnesota Community Oncology Research Consortium	Saint Louis Park55416	NCT05253651	Map
MN	Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 256041	Saint Louis Park55416	NCT06109272	Map
MN	Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780	Saint Louis Park55416	NCT06890338	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT05001880	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT07198074	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT06580314	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT04181060	Map
MN	Park Nicollet Frauenshuh Cancer Center	Saint Louis Park55426	NCT05253651	Map
MN	Regulatory Location: MMCORC	Saint Louis Park55426	NCT05253651	Map
MN	Allina Health Cancer Institute-United(VPCI)	Saint Paul55102	NCT05253651	Map
MN	Metro-Minnesota Community Oncology Research Consortium	Saint Paul55101-2502	NCT03424005	Map
MN	Regions Hospital	Saint Paul55101	NCT05001880	Map
MN	Regions Hospital	Saint Paul55101	NCT07198074	Map
MN	Regions Hospital	Saint Paul55101	NCT06580314	Map
MN	Regions Hospital	Saint Paul55101	NCT05253651	Map
MN	Regions Hospital	Saint Paul55101	NCT04181060	Map
MN	United Hospital	Saint Paul55102	NCT05001880	Map
MN	United Hospital	Saint Paul55102	NCT07198074	Map
MN	United Hospital	Saint Paul55102	NCT06580314	Map
MN	United Hospital	Saint Paul55102	NCT04181060	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT07198074	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT06580314	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT07166406	Map
MN	Saint Francis Regional Medical Center	Shakopee55379	NCT06580314	Map
MN	Saint Francis Regional Medical Center	Shakopee55379	NCT04181060	Map
MN	Essentia Health - Saint Joseph's Staples Clinic	Staples56479	NCT06580314	Map
MN	Lakeview Hospital	Stillwater55082	NCT06580314	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT07198074	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT06580314	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT07166406	Map
MN	Ridgeview Medical Center	Waconia55387	NCT06580314	Map
MN	Ridgeview Medical Center	Waconia55387	NCT04181060	Map
MN	Rice Memorial Hospital	Willmar56201	NCT05001880	Map
MN	Rice Memorial Hospital	Willmar56201	NCT06580314	Map
MN	Minnesota Oncology Hematology PA-Woodbury	Woodbury55125	NCT07198074	Map
MN	Minnesota Oncology Hematology PA-Woodbury	Woodbury55125	NCT06580314	Map
MN	Minnesota Oncology Hematology, PA Cornerstone Medical Specialty Center	Woodbury55125	NCT05253651	Map
MN	Sanford Cancer Center Worthington	Worthington56187	NCT05001880	Map
MN	Fairview Lakes Medical Center	Wyoming55092	NCT06580314	Map
MS	Baptist Memorial Hospital and Cancer Center-Golden Triangle	Columbus39705	NCT04181060	Map
MS	Baptist Cancer Center-Grenada	Grenada38901	NCT04181060	Map
MS	Hattiesburg Clinic	Hattiesburg39401	NCT06750094	Map
MS	Hattiesburg Clinic ( Site 0064)	Hattiesburg39401	NCT06997497	Map
MS	University Of Mississippi Medical Center /ID# 276342	Jackson39216	NCT06890338	Map
MS	Baptist Memorial Hospital and Cancer Center-Union County	New Albany38652	NCT04181060	Map
MS	Baptist Memorial Hospital and Cancer Center-Oxford	Oxford38655	NCT04181060	Map
MS	Baptist Memorial Hospital and Cancer Center-Desoto	Southhaven38671	NCT04181060	Map
MO	Mercy Oncology and Hematology - Clayton-Clarkson	Ballwin63011	NCT06580314	Map
MO	Central Care Cancer Center - Bolivar	Bolivar65613	NCT06580314	Map
MO	Cox Cancer Center Branson	Branson65616	NCT06580314	Map
MO	Mercy Cancer Center - Cape Girardeau	Cape Girardeau63703	NCT06580314	Map
MO	Saint Francis Medical Center	Cape Girardeau63703	NCT06580314	Map
MO	Saint Francis Medical Center	Cape Girardeau63703	NCT04181060	Map
MO	Saint Luke's Hospital	Chesterfield63017	NCT04181060	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT07166406	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT06696768	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT05863195	Map
MO	Missouri Cancer Associates	Columbia65201	NCT07284849	Map
MO	Missouri Cancer Associates - 150518964	Columbia65201	NCT07549412	Map
MO	MU Health - University Hospital/Ellis Fischel Cancer Center	Columbia65212	NCT07198074	Map
MO	MU Health - University Hospital/Ellis Fischel Cancer Center	Columbia65212	NCT06580314	Map
MO	University of Missouri Hospital	Columbia65212	NCT07213804	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT07166406	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT06696768	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT05863195	Map
MO	Parkland Health Center - Farmington	Farmington63640	NCT06580314	Map
MO	Parkland Health Center - Farmington	Farmington63640	NCT04181060	Map
MO	Freeman Health System	Joplin64804	NCT06580314	Map
MO	Mercy Hospital Joplin	Joplin64804	NCT06580314	Map
MO	Corcept Therapeutics Investigator Site #334	Kansas City64132	NCT06906341	Map
MO	Midamerica Cancer Care	Kansas City64121	NCT07284849	Map
MO	Saint Lukes Hospital of Kansas City /ID# 270633	Kansas City64111	NCT06820463	Map
MO	St. Lukes Hospital of Kansas City	Kansas City64111	NCT06625775	Map
MO	Lake Regional Hospital	Osage Beach65065	NCT06580314	Map
MO	Mercy Clinic-Rolla-Cancer and Hematology	Rolla65401	NCT06580314	Map
MO	Phelps Health Delbert Day Cancer Institute	Rolla65401	NCT06580314	Map
MO	Heartland Regional Medical Center	Saint Joseph64506	NCT06580314	Map
MO	Sainte Genevieve County Memorial Hospital	Sainte Genevieve63670	NCT06580314	Map
MO	Sainte Genevieve County Memorial Hospital	Sainte Genevieve63670	NCT04181060	Map
MO	Clinical Study Site	Springfield65804	NCT07228832	Map
MO	Cox Medical Center South /ID# 274826	Springfield65807	NCT06890338	Map
MO	CoxHealth South Hospital	Springfield65807	NCT07198074	Map
MO	CoxHealth South Hospital	Springfield65807	NCT06580314	Map
MO	Mercy Hospital Springfield	Springfield65804	NCT07198074	Map
MO	Mercy Hospital Springfield	Springfield65804	NCT06580314	Map
MO	Oncology Hematology Associates	Springfield65807	NCT07284849	Map
MO	Corcept Therapeutics Investigator Site #521	St Louis63110	NCT06906341	Map
MO	Mercy Hospital Saint Louis	St Louis63141	NCT06580314	Map
MO	Mercy Hospital Saint Louis	St Louis63141	NCT04181060	Map
MO	Mercy Hospital South	St Louis63128	NCT06580314	Map
MO	Mercy Hospital South	St Louis63128	NCT04181060	Map
MO	Mercy Hospital St. Louis	St Louis63141	NCT05281471	Map
MO	Mercy Hospital St. Louis /ID# 275655	St Louis63141	NCT06890338	Map
MO	Mercy Infusion Center - Chippewa	St Louis63109	NCT06580314	Map
MO	Missouri Baptist Medical Center	St Louis63131	NCT06580314	Map
MO	Missouri Baptist Medical Center	St Louis63131	NCT04181060	Map
MO	Site 0111	St Louis53110	NCT04516447	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT07166406	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT06696768	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT05863195	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT07166406	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT06696768	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT05863195	Map
MO	Washington University in St. Louis	St Louis63129	NCT05440708	Map
MO	Washington University School of Medicine	St Louis63110	NCT07284849	Map
MO	Washington University School of Medicine	St Louis63110	NCT06580314	Map
MO	Washington University School of Medicine	St Louis63110	NCT05919264	Map
MO	Washington University School of Medicine	St Louis63110	NCT05281471	Map
MO	Washington University School of Medicine	St Louis63110	NCT06625775	Map
MO	Washington University School of Medicine	St Louis63110	NCT07166406	Map
MO	Washington University School of Medicine	St Louis63110	NCT06696768	Map
MO	Washington University School of Medicine	St Louis63110	NCT05863195	Map
MO	Washington University School Of Medicine	St Louis63110	NCT06750094	Map
MO	Washington University School of Medicine ( Site 0052)	St Louis63110	NCT06824467	Map
MO	Washington University School OF Medicine-Siteman Cancer Center	St Louis63110	NCT07221357	Map
MO	Washington University-School of Medicine /ID# 255720	St Louis63110	NCT06109272	Map
MO	Missouri Baptist Sullivan Hospital	Sullivan63080	NCT06580314	Map
MO	Missouri Baptist Sullivan Hospital	Sullivan63080	NCT04181060	Map
MO	BJC Outpatient Center at Sunset Hills	Sunset Hills63127	NCT06580314	Map
MO	BJC Outpatient Center at Sunset Hills	Sunset Hills63127	NCT04181060	Map
MO	Mercy Hospital Washington	Washington63090	NCT06580314	Map
MT	Community Hospital of Anaconda	Anaconda59711	NCT07198074	Map
MT	Community Hospital of Anaconda	Anaconda59711	NCT06580314	Map
MT	Community Hospital of Anaconda	Anaconda59711	NCT04181060	Map
MT	Billings Clinic Cancer Center	Billings59101	NCT07198074	Map
MT	Billings Clinic Cancer Center	Billings59101	NCT06580314	Map
MT	Billings Clinic Cancer Center	Billings59101	NCT04181060	Map
MT	Clinical Study Site	Billings59102	NCT07228832	Map
MT	Intermountain Health - Intermountain Health West End Clinic /ID# 278470	Billings59106	NCT07059845	Map
MT	Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 2000)	Billings59102	NCT06997497	Map
MT	Intermountain Health West End Clinic	Billings59106	NCT06580314	Map
MT	Saint Vincent Frontier Cancer Center	Billings59102	NCT06580314	Map
MT	Saint Vincent Healthcare	Billings59101	NCT06580314	Map
MT	St. Vincent Gynecologic Oncology	Billings59102	NCT06819007	Map
MT	Bozeman Health Deaconess Hospital	Bozeman59715	NCT07198074	Map
MT	Bozeman Health Deaconess Hospital	Bozeman59715	NCT06580314	Map
MT	Bozeman Health Deaconess Hospital	Bozeman59715	NCT04181060	Map
MT	Saint James Community Hospital and Cancer Treatment Center	Butte59701	NCT06580314	Map
MT	Benefis Sletten Cancer Institute	Great Falls59405	NCT07198074	Map
MT	Benefis Sletten Cancer Institute	Great Falls59405	NCT06580314	Map
MT	Benefis Sletten Cancer Institute	Great Falls59405	NCT04181060	Map
MT	Great Falls Clinic	Great Falls59405	NCT06580314	Map
MT	Hi-Line Sletten Cancer Center	Havre59501	NCT06580314	Map
MT	Benefis Helena Specialty Center	Helena59601	NCT06580314	Map
MT	Logan Health Medical Center	Kalispell59901	NCT07198074	Map
MT	Logan Health Medical Center	Kalispell59901	NCT06580314	Map
MT	Logan Health Medical Center	Kalispell59901	NCT04181060	Map
MT	Community Medical Center	Missoula59804	NCT07198074	Map
MT	Community Medical Center	Missoula59804	NCT06580314	Map
MT	Community Medical Center	Missoula59804	NCT04181060	Map
MT	Saint Patrick Hospital - Community Hospital	Missoula59802	NCT06580314	Map
NE	Nebraska Medicine-Bellevue	Bellevue68123	NCT07198074	Map
NE	Nebraska Medicine-Bellevue	Bellevue68123	NCT07166406	Map
NE	CHI Health Saint Francis	Grand Island68803	NCT06580314	Map
NE	CHI Health Good Samaritan	Kearney68847	NCT06580314	Map
NE	Fred and Pamela Buffett Cancer Center - Kearney	Kearney68845	NCT07198074	Map
NE	Cancer Partners of Nebraska	Lincoln68516	NCT07222800	Map
NE	Cancer Partners of Nebraska	Lincoln68516	NCT04181060	Map
NE	Clinical Study Site	Lincoln68506	NCT07228832	Map
NE	Alegent Health Bergan Mercy Medical Center	Omaha68124	NCT06580314	Map
NE	Alegent Health Immanuel Medical Center	Omaha68122	NCT06580314	Map
NE	Alegent Health Lakeside Hospital	Omaha68130	NCT06580314	Map
NE	Creighton University Medical Center	Omaha68131	NCT06580314	Map
NE	Nebraska Cancer Specialists	Omaha68130	NCT06750094	Map
NE	Nebraska Cancer Specialists	Omaha68130	NCT06445062	Map
NE	Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399	Omaha68130	NCT05005403	Map
NE	Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646	Omaha68130	NCT06820463	Map
NE	Nebraska Cancer Specialists/Oncology Hematology West PC - MECC	Omaha68114	NCT06580314	Map
NE	Nebraska Medicine-Village Pointe	Omaha68118	NCT07198074	Map
NE	Nebraska Medicine-Village Pointe	Omaha68118	NCT07166406	Map
NE	Nebraska Methodist Hospital	Omaha68114	NCT07198074	Map
NE	Nebraska Methodist Hospital	Omaha68114	NCT06580314	Map
NE	Nebraska Methodist Hospital ( Site 0004)	Omaha68114	NCT07318558	Map
NE	Nebraska Methodist Hospital ( Site 0053)	Omaha68114	NCT06824467	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT07198074	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT07166406	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT06445062	Map
NE	University Of Nebraska Medical Center	Omaha68198	NCT07221357	Map
NE	University Of Nebraska Medical Center ( Site 0035)	Omaha68198	NCT07318558	Map
NE	University Of Nebraska Medical Center ( Site 0078)	Omaha68198	NCT06997497	Map
NV	Women's Cancer Center of Nevada	Las Vegas89106	NCT07198074	Map
NV	Women's Cancer Center of Nevada	Las Vegas89106	NCT05281471	Map
NV	Women's Cancer Center of Nevada ( Site 6011)	Las Vegas89106	NCT07216703	Map
NV	Center of Hope	Reno89511	NCT05281471	Map
NV	Renown Health Medical Oncology	Reno89502	NCT07222800	Map
NV	Renown Regional Medical Center	Reno89502	NCT07222800	Map
NV	Renown Regional Medical Center	Reno89502-1576	NCT03424005	Map
NV	Renown Regional Medical Center ( Site 0056)	Reno89502	NCT06997497	Map
NV	The Center of Hope	Reno89511	NCT07213804	Map
NV	The Center Of Hope /ID# 274313	Reno89511	NCT06890338	Map
NH	Clinical Study Site	Lebanon03766	NCT07228832	Map
NH	Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center	Lebanon03756	NCT07166406	Map
NH	Dartmouth-Hitchcock Medical Center /ID# 274676	Lebanon03756	NCT06890338	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT07198074	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT06580314	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT04181060	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT05863195	Map
NJ	MSK Basking Ridge	Basking Ridge07920	NCT05253651	Map
NJ	Summit Medical Group	Berkeley Heights07922	NCT06580314	Map
NJ	Cooper Hospital University Medical Center	Camden08103	NCT06580314	Map
NJ	Cooper University Health Care	Camden08103	NCT06510582	Map
NJ	Md Anderson Cancer Center At Cooper /ID# 278390	Camden08103	NCT07059845	Map
NJ	MD Anderson Cancer Center at Cooper- Two Cooper Plaza	Camden08103	NCT05579366	Map
NJ	Astera Cancer Care	East Brunswick08816	NCT06750094	Map
NJ	Astera Cancer Care /ID# 279532	East Brunswick08816-4096	NCT07525206	Map
NJ	Research Site	East Brunswick08816	NCT05489211	Map
NJ	Trinitas Hospital and Comprehensive Cancer Center	Elizabeth07202	NCT05806931	Map
NJ	Englewood Hospital and Medical Center	Englewood07631	NCT04181060	Map
NJ	Summit Health - Florham Park Campus	Florham Park07932	NCT06580314	Map
NJ	Summit Health Cancer Center	Florham Park07932	NCT07446322	Map
NJ	Hackensack University Medical Center	Hackensack07601	NCT05836324	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center	Hackensack07601	NCT06697197	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center	Hackensack07601	NCT05482516	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center	Hackensack07601-2191	NCT07291076	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center ( Site 0060)	Hackensack07601	NCT06997497	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center ( Site 0081)	Hackensack07601	NCT06824467	Map
NJ	John Theurer Cancer Center Hackensack University Medical Center	Hackensack07601	NCT06469281	Map
NJ	John Theurer Cancer Center- Site Number : 8400001	Hackensack07601	NCT05584670	Map
NJ	The Cancer Institute of New Jersey Hamilton	Hamilton08690	NCT06580314	Map
NJ	Jersey City Medical Center	Jersey City07302	NCT06580314	Map
NJ	Jersey City Medical Center	Jersey City07302	NCT04181060	Map
NJ	RWJBarnabas Health Jersey City Medical Center	Jersey City07302	NCT05806931	Map
NJ	Monmouth Medical Center Southern Campus	Lakewood08701	NCT04181060	Map
NJ	RWJBarnabas Health - Monmouth Medical Center Southern Campus	Lakewood08701	NCT05806931	Map
NJ	Cooperman Barnabas Medical Center (Saint Barnabas Medical Center)	Livingston07039	NCT05806931	Map
NJ	Saint Barnabas Medical Center	Livingston07039	NCT04181060	Map
NJ	Monmouth Medical Center	Long Branch07740	NCT04181060	Map
NJ	RWJBarnabas Health - Monmouth Medical Center	Long Branch07740	NCT05806931	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT07198074	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT06580314	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT04181060	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT05863195	Map
NJ	MSK Monmouth	Middletown07748	NCT05253651	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT07198074	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT06580314	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT04181060	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT05863195	Map
NJ	MSK Bergen	Montvale07645	NCT05253651	Map
NJ	Atlantic Health System	Morristown07960	NCT06445062	Map
NJ	Clinical Study Site	New Brunswick08901	NCT07228832	Map
NJ	GSK Investigational Site	New Brunswick08903	NCT06551142	Map
NJ	Research Site	New Brunswick08901	NCT06921785	Map
NJ	Robert Wood Johnson Medical School	New Brunswick08901-1928	NCT06703073	Map
NJ	Robert Wood Johnson Medical School	New Brunswick08901-1928	NCT06701656	Map
NJ	Rutgers Cancer Institute	New Brunswick08901	NCT07446322	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT07198074	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT06580314	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT04181060	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT05806931	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08901	NCT06004245	Map
NJ	Rutgers Cancer Institute of New Jersey ( Site 0071)	New Brunswick08901	NCT06824467	Map
NJ	Rutgers Cancer Institute of New Jersey /ID# 274358	New Brunswick08901	NCT06890338	Map
NJ	RWJBarnabas Health - Robert Wood Johnson University Hospital	New Brunswick08903	NCT05806931	Map
NJ	Rutgers New Jersey Medical School	Newark07101	NCT07198074	Map
NJ	The Valley Hospital - Luckow Pavilion	Paramus07652	NCT07198074	Map
NJ	The Valley Hospital - Luckow Pavilion	Paramus07652	NCT04181060	Map
NJ	Valley Health System	Paramus07652	NCT06819007	Map
NJ	Valley Health System Ridgewood Campus	Ridgewood07450	NCT07198074	Map
NJ	Valley Health System Ridgewood Campus	Ridgewood07450	NCT04181060	Map
NJ	Sidney Kimmel Cancer Center Washington Township	Sewell08080	NCT07198074	Map
NJ	Sidney Kimmel Cancer Center Washington Township	Sewell08080	NCT06580314	Map
NJ	RWJBarnabas Health - Robert Wood Johnson University Hospital	Somerset08873	NCT05806931	Map
NJ	Robert Wood Johnson University Hospital Somerset	Somerville08876	NCT06580314	Map
NJ	Atlantic Health System ( Site 0093)	Summit07901	NCT06997497	Map
NJ	Holy Name Medical Center /ID# 276240	Teaneck07666	NCT06890338	Map
NJ	Holy Name Medical Center /ID# 279017	Teaneck07666	NCT07024784	Map
NJ	RWJBarnabas Health - Community Medical Center	Toms River08755	NCT05806931	Map
NJ	Research Site	Trenton08690	NCT06792695	Map
NM	Corcept Therapeutics Investigator Site #292	Albuquerque97102	NCT06906341	Map
NM	Optimum Clinical Research Group /ID# 274583	Albuquerque87109	NCT06890338	Map
NM	Research Site	Albuquerque87109	NCT05489211	Map
NM	University of New Mexico Cancer Center	Albuquerque87106	NCT07198074	Map
NM	University of New Mexico Cancer Center	Albuquerque87106	NCT06580314	Map
NM	University of New Mexico Cancer Center	Albuquerque87106	NCT04181060	Map
NM	University of New Mexico Cancer Center	Albuquerque87106	NCT07166406	Map
NM	University of New Mexico Comprehensive Cancer Center ( Site 0055)	Albuquerque87131	NCT06824467	Map
NM	San Juan Oncology Associates, P.C ( Site 2011)	Farmington87401	NCT06997497	Map
NM	Presbyterian Rust Medical Center	Rio Rancho87124	NCT07284849	Map
NY	NYOH Albany Cancer Center	Albany12206	NCT07222800	Map
NY	Hematology-Oncology Associates of Central New York, PC	Auburn13021	NCT07222800	Map
NY	North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists	Babylon11702	NCT07222800	Map
NY	Imbert Cancer Center /ID# 275634	Bay Shore11706	NCT06890338	Map
NY	Northwell Health Imbert Cancer Center	Bay Shore11706	NCT07198074	Map
NY	North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists	Brooklyn11210	NCT07222800	Map
NY	NYU Langone Hospital - Brooklyn	Brooklyn11220	NCT06580314	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT06580314	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT04919629	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT04181060	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT05863195	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT05231122	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT03899155	Map
NY	Roswell Park Cancer Institute	Buffalo14203	NCT06469281	Map
NY	Roswell Park Comprehensive Cancer Center	Buffalo14236	NCT05733598	Map
NY	Hematology-Oncology Associates of Central New York, PC	Camillus13031	NCT07222800	Map
NY	New York Oncology Hematology - Clifton Park Cancer Center	Clifton Park12065	NCT07222800	Map
NY	Memorial Sloan Kettering Commack	Commack11725	NCT07198074	Map
NY	Memorial Sloan Kettering Commack	Commack11725	NCT06580314	Map
NY	Memorial Sloan Kettering Commack	Commack11725	NCT04181060	Map
NY	Memorial Sloan Kettering Commack	Commack11725	NCT05863195	Map
NY	MSK Commack	Commack11725	NCT05253651	Map
NY	Research Site	Commack11725	NCT05489211	Map
NY	The Cancer Institute at Saint Francis Hospital	East Hills11548	NCT04181060	Map
NY	Hematology-Oncology Associates of Central New York, PC	East Syracuse13057	NCT07222800	Map
NY	Memorial Sloan Kettering Westchester	East White Plains10604	NCT05863195	Map
NY	Northwell Health Physician Partners at Flushing	Flushing11354	NCT07198074	Map
NY	Glens Falls Hospital	Glens Falls12801	NCT06580314	Map
NY	Glens Falls Hospital	Glens Falls12801	NCT04181060	Map
NY	Northwell Health Cancer Institute at Huntington	Greenlawn11740	NCT07198074	Map
NY	Northwell Health Cancer Institute At Huntington /ID# 276814	Greenlawn11740	NCT06890338	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT07198074	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT06580314	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT04181060	Map
NY	MSK Westchester	Harrison10604	NCT05253651	Map
NY	GSK Investigational Site	Lake Success11042	NCT07277270	Map
NY	Northwell Health / RJ Zuckerberg Cancer Center	Lake Success11042	NCT06445062	Map
NY	Northwell Health Center for Advanced Medicine. /ID# 275641	Lake Success11042	NCT06890338	Map
NY	Northwell Health Center for Advanced Medicine. /ID# 279590	Lake Success11042	NCT07525206	Map
NY	Northwell Health/ RJ Zuckerberg Cancer Center	Lake Success11042	NCT06697197	Map
NY	Northwell Health/ RJ Zuckerberg Cancer Center	Lake Success11042	NCT07221357	Map
NY	Northwell Health/Center for Advanced Medicine	Lake Success11042	NCT07198074	Map
NY	Northwell Health/Center for Advanced Medicine	Lake Success11042	NCT07166406	Map
NY	RJ Zuckerberg	Lake Success11042	NCT07193862	Map
NY	Start - Ny	Lake Success11042	NCT07470853	Map
NY	Clinical Study Site	Mineola11501	NCT07228832	Map
NY	Laura and Isaac Perlmutter Cancer Center at NYU Langone	Mineola11501	NCT07221357	Map
NY	NYU Langone Health - Long Island	Mineola11501	NCT06400472	Map
NY	Nyu Langone Health - Long Island Hospital	Mineola11501	NCT05836324	Map
NY	NYU Langone Hematology Oncology Associates-Mineola	Mineola11501	NCT03899155	Map
NY	NYU Langone Hospital - Long Island	Mineola11501	NCT06580314	Map
NY	NYU Langone Hospital - Long Island ( Site 0015)	Mineola11501	NCT06824467	Map
NY	Perlmutter Cancer Center at NYU Langone Hospital - Long Island	Mineola11501	NCT07213804	Map
NY	Perlmutter Cancer Center at NYU Long Island	Mineola11501	NCT06750094	Map
NY	Long Island Jewish Medical Center	New Hyde Park11040	NCT07193862	Map
NY	New York Cancer & Blood Specialists - New Hyde Park	New Hyde Park11042-1116	NCT04929223	Map
NY	North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists	New Hyde Park11042	NCT07222800	Map
NY	Bellevue Hospital Center	New York10016	NCT06580314	Map
NY	Clinical Study Site	New York10016	NCT07228832	Map
NY	Columbia University	New York10032	NCT06819007	Map
NY	Columbia University Irving Medical Center	New York10032	NCT05867420	Map
NY	Columbia University Irving Medical Center	New York10032	NCT06625775	Map
NY	Columbia University Medical Center	New York10032	NCT06445062	Map
NY	David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center	New York10065	NCT06400472	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT07059494	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT06819007	Map
NY	Laura and Isaac Perlmutter Cancer Center	New York10016	NCT05836324	Map
NY	Laura and Isaac Perlmutter Cancer Center	New York10016	NCT07213804	Map
NY	Laura and Isaac Perlmutter Cancer Center ( Site 0076)	New York10016	NCT06824467	Map
NY	Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York10016	NCT06580314	Map
NY	Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York10016	NCT06819007	Map
NY	Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009)	New York10016	NCT07216703	Map
NY	Lenox Hill Brain Tumor Center	New York10075	NCT05271240	Map
NY	Lenox Hill Brain Tumor Center	New York10065	NCT01269853	Map
NY	Lenox Hill Hospital	New York10075	NCT07198074	Map
NY	Manhattan Eye Ear and Throat Hospital	New York10065	NCT07198074	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT07198074	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06580314	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05919264	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT04181060	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT07213804	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06625775	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05863195	Map
NY	Memorial Sloan Kettering Cancer Center - New York	New York10065	NCT05440708	Map
NY	Memorial Sloan Kettering Cancer Center ( Site 0003)	New York10065	NCT06843447	Map
NY	Memorial Sloan Kettering Cancer Center Main Campus	New York10065	NCT06445062	Map
NY	Memorial Sloan Kettering Cancer Center Mskcc	New York10065-6800	NCT06427941	Map
NY	Memorial Sloan-Kettering Cancer Center	New York10065	NCT05824975	Map
NY	Memorial Solan Kettering Cancer Center- Main Campus	New York10065	NCT05253651	Map
NY	Mount Sinai Chelsea	New York10011	NCT06580314	Map
NY	Mount Sinai Chelsea	New York10011	NCT04181060	Map
NY	Mount Sinai Hospital	New York10029	NCT06580314	Map
NY	Mount Sinai Hospital	New York10029	NCT04181060	Map
NY	Mount Sinai Hospital	New York10029	NCT07166406	Map
NY	Mount Sinai Hospital	New York10029	NCT05863195	Map
NY	Mount Sinai West	New York10019	NCT06580314	Map
NY	New York Cancer and Blood Specialists-Central Park Hematology & Oncology	New York10028	NCT04929223	Map
NY	New York University (NYU) Clinical Cancer Center	New York10016	NCT06400472	Map
NY	New York University Langone Medical Center	New York10016	NCT04374305	Map
NY	North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists	New York10028	NCT07222800	Map
NY	NYU Langone Medical Center NYU Hematology Associates	New York10016	NCT06750094	Map
NY	NYU Langone Medical Center- Site Number : 8400013	New York10016	NCT05584670	Map
NY	Research Site	New York10029	NCT06921785	Map
NY	Rockefeller Outpatient Pavilion (53rd Street)	New York10022	NCT05253651	Map
NY	Site 0173	New York10029	NCT04516447	Map
NY	Hematology Oncology Associates of Rockland	Nyack10960	NCT07222800	Map
NY	Upstate Cancer Center at Oswego	Oswego13126	NCT04181060	Map
NY	North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists	Patchogue11772	NCT07222800	Map
NY	New York Cancer & Blood Specialists	Port Jefferson Station11776	NCT04929223	Map
NY	North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists	Port Jefferson Station11776	NCT07222800	Map
NY	Northwell Health Queens Cancer Center /ID# 274850	Rego Park11374	NCT06890338	Map
NY	Queens Cancer Center	Rego Park11374	NCT07198074	Map
NY	North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists	Riverhead11901	NCT07222800	Map
NY	Clinical Study Site	Rochester14642	NCT07228832	Map
NY	GSK Investigational Site	Rochester55905-0001	NCT06796907	Map
NY	Research Site	Rochester14618	NCT06792695	Map
NY	University of Rochester	Rochester14642	NCT07198074	Map
NY	University of Rochester	Rochester14642	NCT06580314	Map
NY	Ellis Hospital ( Site 0098)	Schenectady12308	NCT06997497	Map
NY	New York Cancer and Blood Specialists	Shirley11967	NCT06750094	Map
NY	New York Cancer and Blood Specialists	Shirley11967	NCT07221357	Map
NY	North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists	Shirley11967	NCT07222800	Map
NY	Phelps Memorial Hospital Center	Sleepy Hollow10591	NCT07198074	Map
NY	Staten Island University Hospital	Staten Island10305	NCT07198074	Map
NY	Stony Brook Cancer Center	Stony Brook11794	NCT05281471	Map
NY	Stony Brook University Medical Center	Stony Brook11794	NCT07198074	Map
NY	Clinical Study Site	Syracuse13210	NCT07228832	Map
NY	State University of New York Upstate Medical University	Syracuse13210	NCT07198074	Map
NY	State University of New York Upstate Medical University	Syracuse13210	NCT06580314	Map
NY	State University of New York Upstate Medical University	Syracuse13210	NCT04181060	Map
NY	SUNY Upstate Medical University - Syracuse /ID# 277245	Syracuse13210	NCT07059845	Map
NY	Clinical Study Site	The Bronx10461	NCT07228832	Map
NY	Montefiore Einstein Comprehensive Cancer Center	The Bronx10461	NCT06750094	Map
NY	Montefiore Hospital - Moses Campus	The Bronx10467	NCT06703073	Map
NY	Montefiore Hospital - Moses Campus	The Bronx10467	NCT06701656	Map
NY	Montefiore Medical Center	The Bronx10461	NCT06265688	Map
NY	Montefiore Medical Center - Moses Campus	The Bronx10467	NCT07198074	Map
NY	Montefiore Medical Center - Moses Campus	The Bronx10467	NCT04181060	Map
NY	Montefiore Medical Center - Moses Campus	The Bronx10467	NCT07166406	Map
NY	Montefiore Medical Center-Einstein Campus	The Bronx10461	NCT07198074	Map
NY	Montefiore Medical Center-Einstein Campus	The Bronx10461	NCT04181060	Map
NY	Montefiore Medical Center-Einstein Campus	The Bronx10461	NCT07166406	Map
NY	Montefiore Medical Center-Weiler Hospital	The Bronx10461	NCT07198074	Map
NY	Montefiore Medical CenterMontefiore Medical Park	The Bronx10461	NCT05733598	Map
NY	New York Cancer & Blood Specialists - Bronx	The Bronx10469-5930	NCT04929223	Map
NY	North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists	The Bronx10469	NCT07222800	Map
NY	Memorial Sloan Kettering Nassau	Uniondale11553	NCT07198074	Map
NY	Memorial Sloan Kettering Nassau	Uniondale11553	NCT06580314	Map
NY	Memorial Sloan Kettering Nassau	Uniondale11553	NCT04181060	Map
NY	Memorial Sloan Kettering Nassau	Uniondale11553	NCT05863195	Map
NY	MSK Nassau	Uniondale11553	NCT05253651	Map
NY	Westchester Medical Center	Valhalla10595	NCT05848739	Map
NY	Upstate Cancer Center at Verona	Verona13478	NCT04181060	Map
NY	Wilmot Cancer Institute at Webster	Webster14580	NCT06580314	Map
NY	Good Samaritan University Hospital	West Islip11795	NCT04181060	Map
NY	Clinical Study Site	White Plains10601-5000	NCT07228832	Map
NY	Dickstein Cancer Treatment Center	White Plains10601	NCT04181060	Map
NC	Messino Cancer Center	Asheville28806	NCT07284849	Map
NC	UNC Hospital	Chapel Hill27599	NCT06819007	Map
NC	UNC Lineberger Comprehensive Cancer Center	Chapel Hill27599	NCT07198074	Map
NC	UNC Lineberger Comprehensive Cancer Center	Chapel Hill27599	NCT06580314	Map
NC	University of North Carolina at Chapel Hill	Chapel Hill27599-0001	NCT06703073	Map
NC	University of North Carolina at Chapel Hill	Chapel Hill27599-0001	NCT06701656	Map
NC	University of North Carolina Medical Center /ID# 267786	Chapel Hill27514	NCT06820463	Map
NC	University of North Carolina Medical Center /ID# 275307	Chapel Hill27514	NCT06890338	Map
NC	Atrium Health Levine Cancer Institute /ID# 274557	Charlotte28204	NCT06890338	Map
NC	Levine Cancer Institute	Charlotte28204	NCT05281471	Map
NC	Levine Cancer Institute	Charlotte28204	NCT06697197	Map
NC	Novant Health Presbyterian Medical Center	Charlotte28204	NCT04181060	Map
NC	Southeastern Medical Oncology Center-Clinton	Clinton28328	NCT07198074	Map
NC	Southeastern Medical Oncology Center-Clinton	Clinton28328	NCT04181060	Map
NC	Duke Cancer Center	Durham27710	NCT06252649	Map
NC	Duke Cancer Institute /ID# 276267	Durham27710	NCT05005403	Map
NC	Duke University	Durham27705	NCT05919264	Map
NC	Duke University Hospital	Durham27710	NCT05253651	Map
NC	Duke University Medical Center	Durham27710	NCT06580314	Map
NC	Duke University Medical Center	Durham27710	NCT05253651	Map
NC	Duke University Medical Center	Durham27710	NCT07166406	Map
NC	Duke University Medical Center	Durham27710	NCT05863195	Map
NC	Duke University Medical Center	Durham27710	NCT06445062	Map
NC	Duke University Medical Center, Duke Cancer Center	Durham27710	NCT05253651	Map
NC	Duke Universtiy	Durham27708	NCT05848739	Map
NC	Durham VA Medical Center	Durham27705-3875	NCT06703073	Map
NC	Durham VA Medical Center	Durham27705-3875	NCT06701656	Map
NC	GSK Investigational Site	Durham27710	NCT06796907	Map
NC	Site 0259	Durham27710	NCT04516447	Map
NC	Southeastern Medical Oncology Center-Goldsboro	Goldsboro27534	NCT07198074	Map
NC	Southeastern Medical Oncology Center-Goldsboro	Goldsboro27534	NCT04181060	Map
NC	East Carolina University	Greenville27834	NCT05281471	Map
NC	East Carolina University - Brody School of Medicine /ID# 275770	Greenville27834	NCT06890338	Map
NC	Carolina BioOncology Institute /ID# 232597	Huntersville28078	NCT05005403	Map
NC	Carolina BioOncology Institute, PLLC	Huntersville28078	NCT06265688	Map
NC	Novant Health Cancer Institute - Huntersville	Huntersville28078	NCT04181060	Map
NC	Southeastern Medical Oncology Center-Jacksonville	Jacksonville28546	NCT07198074	Map
NC	Southeastern Medical Oncology Center-Jacksonville	Jacksonville28546	NCT04181060	Map
NC	Novant Health Cancer Institute - Kernersville	Kernersville27284	NCT04181060	Map
NC	Novant Health Cancer Institute - Matthews	Matthews28105	NCT04181060	Map
NC	Novant Health Cancer Institute - Mooresville	Mooresville28117	NCT04181060	Map
NC	Novant Health Cancer Institute - Mount Airy	Mount Airy27030	NCT04181060	Map
NC	FirstHealth Cancer Center	Pinehurst28374	NCT06252649	Map
NC	FirstHealth Cancer Center	Pinehurst28374	NCT05253651	Map
NC	FirstHealth Cancer Center ( Site 0079)	Pinehurst28374	NCT06824467	Map
NC	FirstHealth Moore Regional Hospital	Pinehurst28374	NCT05253651	Map
NC	FirstHealth of the Carolinas- Speciality Center /ID# 278636	Pinehurst28374	NCT07059845	Map
NC	Duke Cancer Center Raleigh	Raleigh27609	NCT07166406	Map
NC	Duke Cancer Center Raleigh	Raleigh27609	NCT05863195	Map
NC	Duke Women's Cancer Care Raleigh	Raleigh27607	NCT07198074	Map
NC	Duke Women's Cancer Care Raleigh	Raleigh27607	NCT06580314	Map
NC	Atrium Health Wake Forest Baptist Medical Center /ID# 276952	Winston-Salem27157	NCT06890338	Map
NC	Novant Health Forsyth Medical Center	Winston-Salem27103	NCT04181060	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT05863195	Map
ND	Sanford Bismarck Medical Center	Bismarck58501	NCT05001880	Map
ND	Sanford Bismarck Medical Center	Bismarck58501	NCT06580314	Map
ND	Essentia Health Cancer Center-South University Clinic	Fargo58103	NCT07198074	Map
ND	Essentia Health Cancer Center-South University Clinic	Fargo58103	NCT06580314	Map
ND	Sanford Broadway Medical Center	Fargo58122	NCT05001880	Map
ND	Sanford Broadway Medical Center	Fargo58122	NCT06580314	Map
ND	Sanford Fargo Medical Center	Fargo58102	NCT07221357	Map
ND	Sanford Fargo Medical Center - Fargo /ID# 275489	Fargo58102	NCT06890338	Map
ND	Sanford Roger Maris Cancer Center	Fargo58122	NCT05001880	Map
ND	Sanford Roger Maris Cancer Center	Fargo58122	NCT06580314	Map
ND	Essentia Health - Jamestown Clinic	Jamestown58401	NCT06580314	Map
OH	Clinical Study Site	Akron44032	NCT07228832	Map
OH	OhioHealth O'Bleness Hospital	Athens45701	NCT07198074	Map
OH	OhioHealth O'Bleness Hospital	Athens45701	NCT06580314	Map
OH	UH Seidman Cancer Center at UH Avon Health Center	Avon44011	NCT04181060	Map
OH	UH Seidman Cancer Center at UH Avon Health Center	Avon44011	NCT07166406	Map
OH	UHHS-Chagrin Highlands Medical Center	Beachwood44122	NCT07198074	Map
OH	UHHS-Chagrin Highlands Medical Center	Beachwood44122	NCT06580314	Map
OH	UHHS-Chagrin Highlands Medical Center	Beachwood44122	NCT04181060	Map
OH	UHHS-Chagrin Highlands Medical Center	Beachwood44122	NCT07166406	Map
OH	Strecker Cancer Center-Belpre	Belpre45714	NCT04181060	Map
OH	Aultman Health Foundation	Canton44710	NCT07198074	Map
OH	Clinical Study Site	Canton44703	NCT07228832	Map
OH	Gabrail Cancer Center	Canton44718	NCT06750094	Map
OH	Gabrail Cancer Center	Canton44718	NCT07446322	Map
OH	Corcept Therapeutics Investigator Site #304	Centerville45459	NCT06906341	Map
OH	Miami Valley Hospital South	Centerville45459	NCT07225270	Map
OH	Miami Valley Hospital South	Centerville45459	NCT04181060	Map
OH	Miami Valley Hospital South	Centerville45459	NCT07213804	Map
OH	Miami Valley Hospital South	Centerville45459	NCT06819007	Map
OH	Miami Valley Hospital South ( Site 0075)	Centerville45459	NCT06997497	Map
OH	Geauga Hospital	Chardon44024	NCT07198074	Map
OH	Geauga Hospital	Chardon44024	NCT06580314	Map
OH	Adena Regional Medical Center	Chillicothe45601	NCT04181060	Map
OH	Bethesda North Hospital	Cincinnati45242	NCT06580314	Map
OH	Clinical Study Site	Cincinnati45219	NCT07228832	Map
OH	Clinical Study Site	Cincinnati45220	NCT07228832	Map
OH	Good Samaritan Hospital - Cincinnati	Cincinnati45220	NCT06580314	Map
OH	Oncology Hematology Care	Cincinnati45242	NCT03899155	Map
OH	Oncology Hematology Care - Eastgate	Cincinnati45245	NCT07222800	Map
OH	Oncology Hematology Care - Eastgate /ID# 271493	Cincinnati45245	NCT06820463	Map
OH	Oncology Hematology Care Inc	Cincinnati45242	NCT07213804	Map
OH	Research Site	Cincinnati45219	NCT05489211	Map
OH	TriHealth Cancer Institute-Anderson	Cincinnati45255	NCT06580314	Map
OH	TriHealth Cancer Institute-Westside	Cincinnati45247	NCT06580314	Map
OH	University of Cincinnati Cancer Center-UC Medical Center	Cincinnati45219	NCT04181060	Map
OH	University of Cincinnati Medical Center	Cincinnati45267	NCT06445062	Map
OH	University of Cincinnati Medical Center ( Site 0090)	Cincinnati45219	NCT06824467	Map
OH	University of Cincinnati Medical Center. /ID# 278925	Cincinnati45219	NCT07024784	Map
OH	Case Western Reserve University	Cleveland44106	NCT07198074	Map
OH	Case Western Reserve University	Cleveland44106	NCT06580314	Map
OH	Case Western Reserve University	Cleveland44106	NCT04181060	Map
OH	Case Western Reserve University	Cleveland44106	NCT07166406	Map
OH	Cleveland Clinic	Cleveland44195	NCT05919264	Map
OH	Cleveland Clinic	Cleveland44195	NCT05281471	Map
OH	Cleveland Clinic	Cleveland44195	NCT05824975	Map
OH	Cleveland Clinic - Cleveland /ID# 276133	Cleveland44195	NCT06890338	Map
OH	Cleveland Clinic - Cleveland /ID# 278273	Cleveland44195	NCT06890338	Map
OH	Cleveland Clinic - Cleveland /ID# 278274	Cleveland44195	NCT06890338	Map
OH	Cleveland Clinic Cancer Center/Fairview Hospital	Cleveland44111	NCT06580314	Map
OH	Cleveland Clinic Foundation	Cleveland44195	NCT06580314	Map
OH	Cleveland Clinic Foundation	Cleveland44195	NCT04181060	Map
OH	Cleveland Clinic Lerner College of Medicine	Cleveland44195	NCT05440708	Map
OH	Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center	Cleveland44195	NCT07079631	Map
OH	Clinical Study Site	Cleveland44111	NCT07228832	Map
OH	Clinical Study Site	Cleveland44195	NCT07228832	Map
OH	The Cleveland Clinic	Cleveland44195-0001	NCT05405595	Map
OH	University Hospital of Cleveland	Cleveland44106	NCT06750094	Map
OH	University Hospitals Cleveland Medical Center, Seidman Cancer Center	Cleveland44106	NCT05919264	Map
OH	Columbus Oncology and Hematology Associates Inc	Columbus43214	NCT06580314	Map
OH	Doctors Hospital	Columbus43228	NCT07198074	Map
OH	Doctors Hospital	Columbus43228	NCT06580314	Map
OH	Doctors Hospital	Columbus43228	NCT04181060	Map
OH	Grant Medical Center	Columbus43215	NCT07198074	Map
OH	Grant Medical Center	Columbus43215	NCT06580314	Map
OH	Grant Medical Center	Columbus43215	NCT04181060	Map
OH	GSK Investigational Site	Columbus43210	NCT06796907	Map
OH	James Cancer Hospital and Solove Research Institute	Columbus43210-1240	NCT06233942	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT05001880	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT07198074	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06580314	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT07166406	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT05863195	Map
OH	Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute	Columbus43210	NCT05579366	Map
OH	OhioHealth Research Institute	Columbus43214	NCT05281471	Map
OH	Research Site	Columbus43219	NCT05489211	Map
OH	Research Site	Columbus43201	NCT05797168	Map
OH	Riverside Methodist Hospital	Columbus43214	NCT07198074	Map
OH	Riverside Methodist Hospital	Columbus43214	NCT06580314	Map
OH	The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054)	Columbus43210	NCT06824467	Map
OH	The Mark H Zangmeister Center	Columbus43219	NCT04181060	Map
OH	The Mark H Zangmeister Center	Columbus43219	NCT07213804	Map
OH	The Mark H Zangmeister Center /ID# 275106	Columbus43219	NCT06890338	Map
OH	The Ohio State University (OSU) Wexner Medical Center	Columbus43210	NCT06400472	Map
OH	The Ohio State University Comprehensive Cancer Center	Columbus43221	NCT06948448	Map
OH	The Ohio University	Columbus43210	NCT03899155	Map
OH	Zangmeister Cancer Center	Columbus43219	NCT07225270	Map
OH	Miami Valley Hospital	Dayton45409	NCT04181060	Map
OH	Miami Valley Hospital North	Dayton45415	NCT04181060	Map
OH	Premier Blood and Cancer Center	Dayton45409	NCT04181060	Map
OH	Delaware Health Center-Grady Cancer Center	Delaware43015	NCT07198074	Map
OH	Delaware Health Center-Grady Cancer Center	Delaware43015	NCT06580314	Map
OH	Delaware Health Center-Grady Cancer Center	Delaware43015	NCT04181060	Map
OH	Grady Memorial Hospital	Delaware43015	NCT07198074	Map
OH	Grady Memorial Hospital	Delaware43015	NCT06580314	Map
OH	Columbus Oncology and Hematology Associates	Dublin43016	NCT06580314	Map
OH	Dublin Methodist Hospital	Dublin43016	NCT07198074	Map
OH	Dublin Methodist Hospital	Dublin43016	NCT06580314	Map
OH	Oncology Hematology Care Clinical Trials, LLC	Fairfield45014	NCT07222800	Map
OH	Atrium Medical Center-Middletown Regional Hospital	Franklin45005-1066	NCT04181060	Map
OH	Dayton Physicians LLC-Atrium	Franklin45005	NCT04181060	Map
OH	Miami Valley Cancer Care and Infusion	Greenville45331	NCT04181060	Map
OH	Jamescare Gynecologic Oncology At Mill Run /ID# 277951	Hilliard43026	NCT07059845	Map
OH	The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T	Hilliard43026	NCT07213804	Map
OH	The Ohio State University Comprehensive Cancer Center	Hilliard43026	NCT06787612	Map
OH	Kettering Health	Kettering45429	NCT05281471	Map
OH	Kettering Medical Center /ID# 274365	Kettering45429	NCT06890338	Map
OH	OhioHealth Mansfield Hospital	Mansfield44903	NCT07198074	Map
OH	OhioHealth Mansfield Hospital	Mansfield44903	NCT06580314	Map
OH	Marietta Memorial Hospital	Marietta45750	NCT04181060	Map
OH	OhioHealth Marion General Hospital	Marion43302	NCT07198074	Map
OH	OhioHealth Marion General Hospital	Marion43302	NCT06580314	Map
OH	OhioHealth Marion General Hospital	Marion43302	NCT04181060	Map
OH	Memorial Hospital	Marysville43040	NCT04181060	Map
OH	Clinical Study Site	Mayfield Heights44124	NCT07228832	Map
OH	Hillcrest Hospital Cancer Center	Mayfield Heights44124	NCT06580314	Map
OH	Hillcrest Hospital Cancer Center	Mayfield Heights44124	NCT04181060	Map
OH	UH Seidman Cancer Center at Lake Health Mentor Campus	Mentor44060	NCT07198074	Map
OH	UH Seidman Cancer Center at Lake Health Mentor Campus	Mentor44060	NCT06580314	Map
OH	UH Seidman Cancer Center at Lake Health Mentor Campus	Mentor44060	NCT04181060	Map
OH	UH Seidman Cancer Center at Lake Health Mentor Campus	Mentor44060	NCT07166406	Map
OH	UH Seidman Cancer Center at Southwest General Hospital	Middleburg Heights44130	NCT04181060	Map
OH	Knox Community Hospital	Mount Vernon43050	NCT04181060	Map
OH	Licking Memorial Hospital	Newark43055	NCT04181060	Map
OH	University Hospitals Parma Medical Center	Parma44129	NCT07198074	Map
OH	OhioHealth Pickerington Methodist Hospital	Pickerington43147	NCT07198074	Map
OH	OhioHealth Pickerington Methodist Hospital	Pickerington43147	NCT06580314	Map
OH	Southern Ohio Medical Center	Portsmouth45662	NCT04181060	Map
OH	Springfield Regional Cancer Center	Springfield45504	NCT04181060	Map
OH	ProMedica Flower Hospital	Sylvania43560	NCT07198074	Map
OH	ProMedica Flower Hospital	Sylvania43560	NCT06580314	Map
OH	ProMedica Flower Hospital	Sylvania43560	NCT05281471	Map
OH	Mercy Health - St. Vincent Medical Center	Toledo43608-2603	NCT06703073	Map
OH	Mercy Health - St. Vincent Medical Center	Toledo43608-2603	NCT06701656	Map
OH	ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital	Toledo43606	NCT06580314	Map
OH	Upper Valley Medical Center	Troy45373	NCT04181060	Map
OH	University of Cincinnati Cancer Center-West Chester	West Chester45069	NCT04181060	Map
OH	OhioHealth Westerville Medical Campus/Westerville Cancer Center	Westerville43082	NCT07198074	Map
OH	OhioHealth Westerville Medical Campus/Westerville Cancer Center	Westerville43082	NCT06580314	Map
OH	UH Seidman Cancer Center at Saint John Medical Center	Westlake44145	NCT07198074	Map
OH	UH Seidman Cancer Center at Saint John Medical Center	Westlake44145	NCT06580314	Map
OH	Saint Elizabeth Youngstown Hospital	Youngstown44501	NCT05863195	Map
OH	Genesis Healthcare System Cancer Care Center	Zanesville43701	NCT04181060	Map
OK	Clinical Study Site	Oklahoma City73120	NCT07228832	Map
OK	Integris Cancer Institute of Oklahoma	Oklahoma City73142	NCT04181060	Map
OK	Integris Southwest Medical Center	Oklahoma City73109	NCT04181060	Map
OK	Mercy Hospital Oklahoma City	Oklahoma City73120	NCT06580314	Map
OK	Oklahoma University Health Sciences Center	Oklahoma City73170	NCT06004245	Map
OK	Oklahoma University Health Stephenson Cancer Center	Oklahoma City73104	NCT05281471	Map
OK	OU Health - Stephenson Cancer Center /ID# 277656	Oklahoma City73104	NCT07024784	Map
OK	OU Health Stephenson Cancer Center	Oklahoma City73104	NCT05848739	Map
OK	OU Health University of Oklahoma Medical Center ( Site 7000)	Oklahoma City73104	NCT06843447	Map
OK	OU Health, Stephenson Cancer Center	Oklahoma City73104	NCT05739981	Map
OK	Stephenson Cancer Center	Oklahoma City73104	NCT06445062	Map
OK	The University of Oklahoma Health Sciences Center	Oklahoma City73104-3609	NCT06703073	Map
OK	The University of Oklahoma Health Sciences Center	Oklahoma City73104-3609	NCT06701656	Map
OK	University of Oklahoma - Health Sciences Center	Oklahoma City73104	NCT05579366	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT05001880	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT07198074	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06580314	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT04181060	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT05440708	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06696768	Map
OK	University of Oklahoma Health Stephenson Cancer Center	Oklahoma City73104	NCT04486352	Map
OK	Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007)	Tulsa74146	NCT07318558	Map
OK	Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056)	Tulsa74146	NCT06824467	Map
OK	Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6001)	Tulsa74146	NCT07216703	Map
OR	Oncology Associates of Oregon, P.C.	Albany97321	NCT07222800	Map
OR	Saint Charles Health System	Bend97701	NCT06580314	Map
OR	Saint Charles Health System	Bend97701	NCT04181060	Map
OR	Clackamas Radiation Oncology Center	Clackamas97015	NCT06580314	Map
OR	Clackamas Radiation Oncology Center	Clackamas97015	NCT07166406	Map
OR	Kaiser Permanente Sunnyside Medical Center	Clackamas97015	NCT07222800	Map
OR	Bay Area Hospital	Coos Bay97420	NCT06580314	Map
OR	Oncology Associates of Oregon, P.C.	Corvallis97330	NCT07222800	Map
OR	Corcept Therapeutics Investigator Site #517	Eugene97401	NCT06906341	Map
OR	Oncology Associates of Oregon, P.C.	Eugene97401	NCT07222800	Map
OR	Oncology Associates of Oregon, P.C. /ID# 275006	Eugene97401	NCT06890338	Map
OR	Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007)	Eugene97401	NCT07216703	Map
OR	Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010)	Eugene97401	NCT06824467	Map
OR	USO - Oncology Associates of Oregon, P. C.	Eugene97401	NCT07213804	Map
OR	USOR Oncology Associates of Oregon, P.C.	Eugene97401	NCT05579366	Map
OR	Willamette Valley Cancer Institute and Research Center /ID# 277714	Eugene97401	NCT07059845	Map
OR	Kaiser Permanente Westside Medical Center	Hillsboro97124	NCT07222800	Map
OR	Providence Hood River Memorial Hospital	Hood River97031	NCT06580314	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT06580314	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT04181060	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT07166406	Map
OR	Saint Alphonsus Cancer Care Center-Ontario	Ontario97914	NCT04181060	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT06580314	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT04181060	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT07166406	Map
OR	Compass Oncology - Rose Quarter	Portland97227	NCT05579366	Map
OR	Kaiser Permanente Interstate Medical Office Central	Portland97227	NCT07222800	Map
OR	Kaiser Permanente Interstate Medical Office Central	Portland97227	NCT07213804	Map
OR	Legacy Good Samaritan Hospital and Medical Center	Portland97210	NCT07198074	Map
OR	Legacy Good Samaritan Hospital and Medical Center	Portland97210	NCT06580314	Map
OR	Legacy Medical Group Gynecologic Oncology	Portland97210	NCT06819007	Map
OR	Northwest Cancer Specialists, P.C.	Portland97213	NCT05253651	Map
OR	Northwest Cancer Specialists, P.C.	Portland97227	NCT05253651	Map
OR	Oregon Health & Science University	Portland97239	NCT04524871	Map
OR	Oregon Health and Science University	Portland97239	NCT06580314	Map
OR	Oregon Health and Science University	Portland97239	NCT05919264	Map
OR	Oregon Health and Science University	Portland97239	NCT07213804	Map
OR	Oregon Health and Science University	Portland97239	NCT05863195	Map
OR	Oregon Health and Science University	Portland97239-3011	NCT06703073	Map
OR	Oregon Health and Science University	Portland97239-3011	NCT06701656	Map
OR	Oregon Health And Science University	Portland97239	NCT06750094	Map
OR	Providence Cancer Center Oncology	Portland97213	NCT06819007	Map
OR	Providence Cancer Institute	Portland97213	NCT06787612	Map
OR	Providence Cancer Institute Franz Clinic	Portland97213	NCT05253651	Map
OR	Providence Oncology and Hematology Care Clinic - Westside	Portland97225	NCT05253651	Map
OR	Providence Portland Medical Center	Portland97213	NCT07198074	Map
OR	Providence Portland Medical Center	Portland97213	NCT06580314	Map
OR	Providence Portland Medical Center	Portland97213	NCT05253651	Map
OR	Providence Portland Medical Center	Portland97213	NCT04181060	Map
OR	Providence Portland Medical Center	Portland97213	NCT07213804	Map
OR	Providence Portland Medical Center	Portland97213	NCT07166406	Map
OR	Providence Portland Medical Center	Portland97213	NCT07291076	Map
OR	Providence Portland Medical Center /ID# 277727	Portland97213	NCT07024784	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT07198074	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT06580314	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT04181060	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT07166406	Map
OR	Providence St. Vincent Medical Center	Portland97225	NCT05253651	Map
OR	Providence St. Vincent Medical Center	Portland97225	NCT07291076	Map
OR	Research Site	Portland97239	NCT05797168	Map
OR	Saint Charles Health System-Redmond	Redmond97756	NCT06580314	Map
OR	Hematology Oncology Salem	Salem97301	NCT04929223	Map
OR	Oncology Associates of Oregon, P.C.	Springfield97477	NCT07222800	Map
OR	Compass Oncology - West - Tigard /ID# 275101	Tigard97223	NCT06890338	Map
OR	Northwest Cancer Specialists, P.C.	Tigard97223	NCT05253651	Map
OR	Legacy Meridian Park Hospital	Tualatin97062	NCT07198074	Map
OR	Legacy Meridian Park Hospital	Tualatin97062	NCT06580314	Map
PA	Lehigh Valley Health Network	Allentown18103	NCT07221357	Map
PA	Lehigh Valley Hospital-Cedar Crest	Allentown18103	NCT06580314	Map
PA	Lehigh Valley Hospital-Cedar Crest	Allentown18103	NCT04181060	Map
PA	Lehigh Valley Hospital-Cedar Crest	Allentown18103	NCT05863195	Map
PA	Saint Luke's Cancer Center - Allentown	Allentown18104	NCT06580314	Map
PA	UPMC Hillman Cancer Center - Beaver	Beaver15009	NCT05253651	Map
PA	Lehigh Valley Hospital - Muhlenberg	Bethlehem18017	NCT06580314	Map
PA	Lehigh Valley Hospital - Muhlenberg	Bethlehem18017	NCT04181060	Map
PA	Saint Luke's University Hospital-Bethlehem Campus	Bethlehem18015	NCT06580314	Map
PA	St. Lukes University Health Network	Bethlehem18015	NCT06819007	Map
PA	St. Lukes University Hospital /ID# 274362	Bethlehem18015	NCT06890338	Map
PA	UPMC Hillman Cancer Center at Butler Health System	Butler16001	NCT05253651	Map
PA	Christiana Care Health System-Concord Health Center	Chadds Ford19317	NCT06580314	Map
PA	Christiana Care Health System-Concord Health Center	Chadds Ford19317	NCT07166406	Map
PA	Chambersburg Hospital	Chambersburg17201	NCT06580314	Map
PA	WellSpan Medical Oncology and Hematology	Chambersburg17201	NCT04181060	Map
PA	Geisinger Medical Center	Danville17822	NCT07166406	Map
PA	Geisinger Cancer Center Dickson City	Dickson City18519	NCT07166406	Map
PA	Alliance Cancer Specialists	Doylestown18901	NCT07284849	Map
PA	USOR Alliance Cancer Specialist	Doylestown18901	NCT05579366	Map
PA	Pocono Medical Center	East Stroudsburg18301	NCT06580314	Map
PA	Saint Luke's Hospital-Anderson Campus	Easton18045	NCT06580314	Map
PA	Ephrata Cancer Center	Ephrata17522	NCT06580314	Map
PA	Ephrata Cancer Center	Ephrata17522	NCT04181060	Map
PA	Saint Vincent Hospital	Erie16544	NCT05863195	Map
PA	UPMC Hillman Cancer Center Erie	Erie16505	NCT07198074	Map
PA	UPMC Hillman Cancer Center Erie	Erie16505	NCT05253651	Map
PA	Adams Cancer Center	Gettysburg17325	NCT06580314	Map
PA	Adams Cancer Center	Gettysburg17325	NCT04181060	Map
PA	UPMC Cancer Centers - Arnold Palmer Pavilion	Greensburg15601	NCT07198074	Map
PA	UPMC Hillman Cancer Center at Arnold Palmer Pavilion, In Partnership with Excela Health	Greensburg15601	NCT05253651	Map
PA	WellSpan Medical Oncology and Hematology	Hanover17331	NCT06580314	Map
PA	WellSpan Medical Oncology and Hematology	Hanover17331	NCT04181060	Map
PA	UPMC Hillman Cancer Center - Pinnacle (Community Osteopathic / Medical Sciences Pavillion)	Harrisburg17109	NCT05253651	Map
PA	Lehigh Valley Hospital-Hazleton	Hazleton18201	NCT06580314	Map
PA	Penn State Milton S Hershey Medical Center	Hershey17033-0850	NCT06580314	Map
PA	UPMC Hillman Cancer Center at Arnold Palmer Pavilion, In Partnership with Excela Health	Irwin15642	NCT05253651	Map
PA	Jefferson Hospital	Jefferson Hills15025	NCT05863195	Map
PA	Ann B Barshinger Cancer Institute	Lancaster17601	NCT06819007	Map
PA	Lancaster General Health	Lancaster17601	NCT03899155	Map
PA	Clinical Study Site	Lebanon17042	NCT07228832	Map
PA	Sechler Family Cancer Center	Lebanon17042	NCT06580314	Map
PA	Sechler Family Cancer Center	Lebanon17042	NCT04181060	Map
PA	Geisinger Medical Oncology-Lewisburg	Lewisburg17837	NCT07166406	Map
PA	UPMC Hillman Cancer Center - Pinnacle (Ortenzio)	Mechanicsburg17050	NCT05253651	Map
PA	UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion	Mechanicsburg17050	NCT07198074	Map
PA	Riddle Memorial Hospital	Media19063	NCT04181060	Map
PA	Forbes Hospital	Monroeville15146	NCT05863195	Map
PA	UPMC Hillman Cancer Center - Monroeville	Monroeville15146	NCT05253651	Map
PA	Paoli Memorial Hospital	Paoli19301	NCT04181060	Map
PA	Alliance Cancer Specialists at Main Line	Penn Wynne19096	NCT06750094	Map
PA	Abramson Cancer Center of the University of Pennsylvania	Philadelphia19104-4283	NCT05488522	Map
PA	Clinical Study Site	Philadelphia19111	NCT07228832	Map
PA	Clinical Study Site	Philadelphia19140	NCT07228832	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT05101070	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT06750094	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT04181060	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT05863195	Map
PA	Hospital of the University of Pennsylvania	Philadelphia19104	NCT06445062	Map
PA	Jefferson Health Honickman Center	Philadelphia19107	NCT07213804	Map
PA	Jefferson Torresdale Hospital	Philadelphia19114	NCT07198074	Map
PA	Jefferson Torresdale Hospital	Philadelphia19114	NCT06580314	Map
PA	Penn Medicine University of Pennsylvania Health System /ID# 277963	Philadelphia19104	NCT07059845	Map
PA	Pennsylvania Hospital	Philadelphia19107	NCT06580314	Map
PA	Thomas Jefferson University	Philadelphia19107	NCT06750094	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT07198074	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT06580314	Map
PA	Thomas Jefferson University, Sidney Kimmel Cancer Center	Philadelphia19107	NCT06948448	Map
PA	University of Pennsylvania	Philadelphia19104	NCT05836324	Map
PA	University of Pennsylvania /ID# 275612	Philadelphia19104	NCT06890338	Map
PA	University of Pennsylvania Abramson Cancer Center	Philadelphia19104	NCT05238922	Map
PA	University of Pennsylvania Hospital	Philadelphia19104	NCT07213804	Map
PA	University of Pennsylvania, Abramson Cancer Center	Philadelphia19104	NCT05733598	Map
PA	University of Pennsylvania, Perelman School of Medicine	Philadelphia19104	NCT05919264	Map
PA	University of Pennsylvania/Abramson Cancer Center	Philadelphia19104	NCT06580314	Map
PA	Corcept Therapeutics Investigator Site #127	Pittsburgh15213	NCT06906341	Map
PA	AHN West Penn Hospital	Pittsburgh15224	NCT05281471	Map
PA	Allegheny General Hospital	Pittsburgh15212	NCT05863195	Map
PA	Allegheny Health Network	Pittsburgh15224	NCT05579366	Map
PA	Allegheny Health Network West Penn Hospital ( Site 0099)	Pittsburgh15224	NCT06824467	Map
PA	Clinical Study Site	Pittsburgh15212	NCT07228832	Map
PA	Research Site	Pittsburgh15232	NCT06921785	Map
PA	St. Clair Cancer Center Medical Oncology	Pittsburgh15243	NCT05253651	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT05001880	Map
PA	University Of Pittsburgh Medical Center UPMC Hillman Cancer Center	Pittsburgh15232 1301	NCT06750094	Map
PA	University of Pittsburgh Medical Center, Hillman Cancer Center	Pittsburgh15232	NCT05919264	Map
PA	University of Pittsburgh Medical Center, Magee-Womens Hospital	Pittsburgh15213	NCT06787612	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT05867420	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT05253651	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT05733598	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT06469281	Map
PA	UPMC Hillman Cancer Center - Passavant (HOA)	Pittsburgh15237	NCT05253651	Map
PA	UPMC Hillman Cancer Center - St Margarets	Pittsburgh15215	NCT05253651	Map
PA	Upmc Hillman Cancer Center(Univ of Pittsburgh)	Pittsburgh15232-1309	NCT06427941	Map
PA	UPMC-Magee Womens Hospital	Pittsburgh15213	NCT07198074	Map
PA	UPMC-Passavant Hospital	Pittsburgh15237	NCT07198074	Map
PA	West Penn Hospital	Pittsburgh15224	NCT05863195	Map
PA	West Penn Hospital of Allegheny Health Network	Pittsburgh15224	NCT06787612	Map
PA	Saint Luke's Hospital - Upper Bucks Campus	Quakertown18951	NCT06580314	Map
PA	Guthrie Medical Group PC-Robert Packer Hospital	Sayre18840	NCT04181060	Map
PA	Saint Luke's Hospital - Monroe Campus	Stroudsburg18360	NCT06580314	Map
PA	UPMC Cancer Center-Washington	Washington15301	NCT07198074	Map
PA	UPMC Hillman Cancer Center - Washington	Washington15301	NCT05253651	Map
PA	Chester County Hospital	West Chester19380	NCT06580314	Map
PA	Wexford Health and Wellness Pavilion	Wexford15090	NCT05863195	Map
PA	Geisinger Wyoming Valley/Henry Cancer Center	Wilkes-Barre18711	NCT07166406	Map
PA	Asplundh Cancer Pavilion	Willow Grove19090	NCT07198074	Map
PA	Asplundh Cancer Pavilion	Willow Grove19090	NCT06580314	Map
PA	Asplundh Cancer Pavilion	Willow Grove19090	NCT07213804	Map
PA	Lankenau Medical Center	Wynnewood19096	NCT04181060	Map
PA	Cancer Care Associates of York	York17403	NCT07284849	Map
PA	WellSpan Health-York Cancer Center	York17403	NCT06580314	Map
PA	WellSpan Health-York Cancer Center	York17403	NCT04181060	Map
PA	WellSpan Health-York Hospital	York17403	NCT06580314	Map
PA	WellSpan Health-York Hospital	York17403	NCT04181060	Map
RI	Clinical Study Site	Providence02903	NCT07228832	Map
RI	Lifespan Cancer Research Institute	Providence02903	NCT05836324	Map
RI	Research Site	Providence02903	NCT05797168	Map
RI	Research Site	Providence02905	NCT05797168	Map
RI	Rhode Island Hospital	Providence02903	NCT05464030	Map
RI	Rhode Island Hospital - Providence - Eddy Street- Site Number : 8400004	Providence02905	NCT05584670	Map
RI	Site 0191	Providence02905	NCT04516447	Map
RI	Women & Infants Hospital ( Site 0001)	Providence02905	NCT07318558	Map
RI	Women & Infants Hospital ( Site 0050)	Providence02905	NCT06824467	Map
RI	Women & Infants Hospital ( Site 6003)	Providence02905	NCT07216703	Map
RI	Women & Infants Hospital /ID# 274716	Providence02905	NCT06890338	Map
RI	Women & Infants Hospital /ID# 277930	Providence02905	NCT07024784	Map
RI	Women and Infants Hospital	Providence02905	NCT07198074	Map
RI	Women and Infants Hospital	Providence02905	NCT06580314	Map
RI	Women and Infants Hospital of Rhode Island	Providence02905	NCT05579366	Map
SC	Hollings Cancer Center	Charleston29425	NCT05281471	Map
SC	Medical University of South Carolina	Charleston29425	NCT06971744	Map
SC	Medical University of South Carolina (MUSC)	Charleston29425-8908	NCT06703073	Map
SC	Medical University of South Carolina (MUSC)	Charleston29425-8908	NCT06701656	Map
SC	Gibbs Cancer Center-Gaffney	Gaffney29341	NCT06580314	Map
SC	Clinical Study Site	Greenville29605	NCT07228832	Map
SC	Gibbs Cancer Center-Pelham	Greer29651	NCT06580314	Map
SC	GSK Investigational Site	Myrtle Beach29572	NCT06551142	Map
SC	Spartanburg Medical Center	Spartanburg29303	NCT06580314	Map
SC	SMC Center for Hematology Oncology Union	Union29379	NCT06580314	Map
SD	Avera Cancer Institute- Aberdeen	Aberdeen57401	NCT07222800	Map
SD	Avera Cancer Institute-Aberdeen	Aberdeen57401	NCT06580314	Map
SD	Avera Cancer Institute - Mitchell	Mitchell57301	NCT06580314	Map
SD	Avera Cancer Institute- Mitchell	Mitchell57301	NCT07222800	Map
SD	Avera Cancer Institute at Pierre	Pierre57501	NCT06580314	Map
SD	Avera Cancer Institute- Pierre	Pierre57501	NCT07222800	Map
SD	Avera Cancer Institute	Sioux Falls57105	NCT07284849	Map
SD	Avera Cancer Institute	Sioux Falls57105	NCT07222800	Map
SD	Avera Cancer Institute	Sioux Falls57105	NCT06580314	Map
SD	Avera Cancer Institute	Sioux Falls57105	NCT05253651	Map
SD	Avera Cancer Institute	Sioux Falls57105	NCT07527858	Map
SD	Avera Cancer Institute - Sioux Falls /ID# 276226	Sioux Falls57105	NCT06890338	Map
SD	Avera Cancer Institute - Sioux Falls /ID# 278627	Sioux Falls57105	NCT07059845	Map
SD	Avera Cancer Institute Sioux Falls	Sioux Falls57105	NCT06787612	Map
SD	Avera Medical Group Gynecologic	Sioux Falls57105	NCT06819007	Map
SD	Sanford Cancer Center	Sioux Falls57104	NCT07221357	Map
SD	Sanford Cancer Center	Sioux Falls57104	NCT05848739	Map
SD	Sanford Cancer Center /ID# 274901	Sioux Falls57104	NCT06890338	Map
SD	Sanford Cancer Center Oncology Clinic	Sioux Falls57104	NCT05001880	Map
SD	Sanford Cancer Center Oncology Clinic	Sioux Falls57104	NCT06580314	Map
SD	Sanford Cancer Center Oncology Clinic	Sioux Falls57104	NCT04181060	Map
SD	Sanford USD Medical Center - Sioux Falls	Sioux Falls57117-5134	NCT05001880	Map
SD	Sanford USD Medical Center - Sioux Falls	Sioux Falls57117-5134	NCT06580314	Map
SD	Sanford USD Medical Center - Sioux Falls	Sioux Falls57117-5134	NCT04181060	Map
SD	AMG Oncology & Hematology -Yankton	Yankton57078	NCT07222800	Map
SD	Avera Cancer Institute at Yankton	Yankton57078	NCT06580314	Map
TN	Erlanger Health, Inc.	Chattanooga37403	NCT05281471	Map
TN	Tennessee Oncology - Chattanooga Oncology & Hematology Associates	Chattanooga37404	NCT03424005	Map
TN	Tennessee Oncology Chattanooga	Chattanooga37404	NCT06750094	Map
TN	Baptist Memorial Hospital and Cancer Center-Collierville	Collierville38017	NCT04181060	Map
TN	Vanderbilt-Ingram Cancer Center at Franklin	Franklin37067	NCT06580314	Map
TN	Vanderbilt-Ingram Cancer Center Cool Springs	Franklin37067	NCT07198074	Map
TN	Vanderbilt-Ingram Cancer Center Cool Springs	Franklin37067	NCT06580314	Map
TN	The West Clinic	Germantown38138	NCT03424005	Map
TN	The West Clinic	Germantown38138	NCT05733598	Map
TN	West Cancer Center and Research Institute ( Site 0013)	Germantown38138	NCT07318558	Map
TN	Clinical Study Site	Hermitage37129	NCT07228832	Map
TN	Provision Center For Biomedical Research	Knoxville37909	NCT07284849	Map
TN	University of Tennessee Medical Center	Knoxville37920	NCT05733598	Map
TN	University of Tennessee Medical Center ( Site 0087)	Knoxville37920	NCT07318558	Map
TN	University of Tennessee Medical Center ( Site 6012)	Knoxville37920	NCT07216703	Map
TN	University Of Tennessee Medical Center /ID# 278225	Knoxville37920	NCT07059845	Map
TN	Baptist Memorial Hospital and Cancer Center-Memphis	Memphis38120	NCT04181060	Map
TN	St. Jude Children's Research Hospital	Memphis38105	NCT05468359	Map
TN	GSK Investigational Site	Nashville37203	NCT06551142	Map
TN	Henry-Joyce Cancer Clinic	Nashville37232	NCT07222800	Map
TN	Henry-Joyce Cancer Clinic	Nashville37232	NCT05253651	Map
TN	Henry-Joyce Cancer Clinic ( Site 0060)	Nashville37232	NCT06824467	Map
TN	Research Site	Nashville37203	NCT05489211	Map
TN	Sarah Cannon Research Institute	Nashville37203	NCT05919264	Map
TN	Sarah Cannon Research Institute - Pharmacy	Nashville37203	NCT06131840	Map
TN	Sarah Cannon Research Institute (Oncology Associates of Oregon PC)	Nashville37203	NCT06819007	Map
TN	Sarah Cannon Research Institute at Tennessee Oncology	Nashville37203	NCT05579366	Map
TN	Sarah Cannon Research Institute, LLC	Nashville37203	NCT06265688	Map
TN	Scri Oncology Partners	Nashville37203-1503	NCT06427941	Map
TN	SCRI Oncology Partners	Nashville37203	NCT06750094	Map
TN	SCRI Oncology Partners	Nashville37203	NCT06131840	Map
TN	SCRI Oncology Partners	Nashville37203	NCT07549412	Map
TN	SCRI Oncology Partners	Nashville37203	NCT06004245	Map
TN	SCRI Oncology Partners	Nashville37203	NCT07221357	Map
TN	SCRI Oncology Partners	Nashville37203	NCT06625775	Map
TN	SCRI Oncology Partners	Nashville37203	NCT04929223	Map
TN	SCRI Oncology Partners	Nashville37203	NCT06445062	Map
TN	SCRI Oncology Partners /ID# 279733	Nashville37203	NCT07024784	Map
TN	Tennesse Oncology	Nashville37203	NCT03899155	Map
TN	Tennessee Oncology	Nashville37203	NCT06750094	Map
TN	Tennessee Oncology	Nashville37203	NCT05579366	Map
TN	Tennessee Oncology	Nashville37203	NCT07291076	Map
TN	Tennessee Oncology PLLC	Nashville37203	NCT03424005	Map
TN	Tennessee Oncology PLLC - Chattanooga	Nashville37203	NCT06252649	Map
TN	Tennessee Oncology, PLLC	Nashville37203	NCT06252649	Map
TN	Vanderbilt Breast Center at One Hundred Oaks	Nashville37204	NCT07198074	Map
TN	Vanderbilt Breast Center at One Hundred Oaks	Nashville37204	NCT06580314	Map
TN	Vanderbilt Ingram Cancer Center	Nashville37232	NCT05919264	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT06750094	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT06252649	Map
TN	Vanderbilt University Medical Center	Nashville37212	NCT03424005	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT06047379	Map
TN	Vanderbilt University Medical Center	Nashville37232-0004	NCT06703073	Map
TN	Vanderbilt University Medical Center	Nashville37232-0004	NCT06701656	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT07291076	Map
TN	Vanderbilt University/Ingram Cancer Center	Nashville37232	NCT07198074	Map
TN	Vanderbilt University/Ingram Cancer Center	Nashville37232	NCT06580314	Map
TN	Vanderbilt University/Ingram Cancer Center	Nashville37232	NCT06696768	Map
TN	Vanderbilt University/Ingram Cancer Center	Nashville37232	NCT05863195	Map
TX	Texas Oncology - Abilene - Antilley Road /ID# 265820	Abilene79606	NCT06109272	Map
TX	Texas Oncology - Abilene - Antilley Road /ID# 277739	Abilene79606	NCT07059845	Map
TX	Texas Oncology - West Texas	Abilene79606	NCT07222800	Map
TX	Texas Oncology West Texas	Abilene79606	NCT06750094	Map
TX	USOR Texas Oncology	Abilene79606	NCT05579366	Map
TX	Research Site	Amarillo79124	NCT06921785	Map
TX	Texas Oncology - West Texas	Amarillo79124	NCT07222800	Map
TX	Texas Oncology Dallas Fort Worth West (DFWW) - Arlington Cancer Center North	Arlington76012	NCT07221357	Map
TX	Dell Children's Medical Group SFC-HEM/ONC	Austin78723	NCT01356290	Map
TX	GSK Investigational Site	Austin78705	NCT06551142	Map
TX	NEXT Oncology Austin /ID# 243005	Austin78705-1171	NCT05005403	Map
TX	Research Site	Austin78705	NCT06921785	Map
TX	Texas Oncology	Austin78745	NCT07284849	Map
TX	Texas Oncology - Austin Central /ID# 275046	Austin78731	NCT06890338	Map
TX	Texas Oncology - Austin Midtown /ID# 271354	Austin78705	NCT06820463	Map
TX	Texas Oncology - Central / South Texas	Austin78758	NCT05579366	Map
TX	Texas Oncology - Central/South Texas ( Site 8009)	Austin78758	NCT06824467	Map
TX	Texas Oncology-Austin North /ID# 279958	Austin78758	NCT07024784	Map
TX	Texas Oncology, PA	Austin78705	NCT07221357	Map
TX	USO-Texas Oncology-Central/South Texas	Austin78731	NCT07213804	Map
TX	Houston Methodist San Jacinto Hospital	Baytown77521	NCT04181060	Map
TX	Texas Oncology - Gulf Coast	Beaumont77702	NCT07222800	Map
TX	Texas Oncology DFW	Bedford75246	NCT07549412	Map
TX	The University of Texas MD Anderson Cancer Center - Conroe	Conroe77384	NCT07318805	Map
TX	UT MD Anderson - The Woodlands	Conroe77384	NCT05001880	Map
TX	Houston Methodist Cypress Hospital	Cypress77429	NCT04181060	Map
TX	Baylor Scott and White Research Institute /ID# 260853	Dallas76508-0001	NCT06109272	Map
TX	Baylor, Scott and White Research Institute	Dallas75246	NCT06047379	Map
TX	Clinical Study Site	Dallas75235	NCT07228832	Map
TX	Clinical Study Site	Dallas75390	NCT07228832	Map
TX	GSK Investigational Site	Dallas75230	NCT06551142	Map
TX	Harold C. Simmons Comprehensive Cancer Center	Dallas75390	NCT05440708	Map
TX	Mary Crowley Cancer Research	Dallas75521	NCT05579366	Map
TX	Mary Crowley Cancer Research	Dallas75230	NCT05464030	Map
TX	Parkland Health & Hospital System	Dallas75235	NCT04524871	Map
TX	Parkland Health and Hospital System	Dallas75235	NCT06750094	Map
TX	Parkland Memorial Hospital	Dallas75235	NCT06580314	Map
TX	Parkland Memorial Hospital	Dallas75235	NCT04181060	Map
TX	Parkland Memorial Hospital	Dallas75235	NCT05863195	Map
TX	SCRI at Mary Crowley	Dallas75230	NCT06625775	Map
TX	Texas Oncology - Dallas - Worth Street /ID# 265806	Dallas75246	NCT06109272	Map
TX	Texas Oncology - DFW	Dallas75246	NCT05253651	Map
TX	Texas Oncology - DFW ( Site 8002)	Dallas75246	NCT06997497	Map
TX	Texas Oncology DFW	Dallas75246	NCT06750094	Map
TX	The University of Texas Southwestern Medical Center at Dallas	Dallas75390	NCT04524871	Map
TX	University of Texas Southwestern Medical Center	Dallas75390	NCT06625775	Map
TX	UT Southwestern Medical Center	Dallas75390	NCT06750094	Map
TX	UT Southwestern Medical Center	Dallas75390	NCT06787612	Map
TX	UT Southwestern Medical Center ( Site 0059)	Dallas75390	NCT06997497	Map
TX	UT Southwestern Simmons Cancer Center - RedBird	Dallas75237	NCT05863195	Map
TX	UT Southwestern/Simmons Cancer Center-Dallas	Dallas75390	NCT06580314	Map
TX	UT Southwestern/Simmons Cancer Center-Dallas	Dallas75390	NCT04181060	Map
TX	UT Southwestern/Simmons Cancer Center-Dallas	Dallas75390	NCT05863195	Map
TX	Texas Oncology - Northeast Texas	Denison75020	NCT07222800	Map
TX	Texas Oncology - Northeast Texas ( Site 8001)	Denison75020	NCT06997497	Map
TX	Texas Oncology - Northeast Texas	Denton76201	NCT07222800	Map
TX	Texas Oncology - Northeast Texas	Denton76201	NCT04929223	Map
TX	Texas Oncology - West Texas	El Paso79902	NCT07222800	Map
TX	Texas Oncology - West Texas	El Paso79915	NCT07222800	Map
TX	Texas Oncology - West Texas	El Paso79938	NCT07222800	Map
TX	Texas Oncology - Northeast Texas	Flower Mound75028	NCT07222800	Map
TX	Baylor All Saints Medical Center	Fort Worth76104-4110	NCT06703073	Map
TX	Baylor All Saints Medical Center	Fort Worth76104-4110	NCT06701656	Map
TX	Clinical Study Site	Fort Worth76104	NCT07228832	Map
TX	START - Dallas/Fort Worth	Fort Worth76104	NCT06265688	Map
TX	Texas Oncology - DFW ( Site 8000)	Fort Worth76104	NCT06843447	Map
TX	Texas Oncology - DFW ( Site 8001)	Fort Worth76104	NCT06824467	Map
TX	Texas Oncology - DFW ( Site 8005)	Fort Worth76104	NCT07216703	Map
TX	Texas Oncology - Fort Worth Cancer Center /ID# 275043	Fort Worth76104	NCT06890338	Map
TX	Texas Oncology - Fort Worth Cancer Center /ID# 277989	Fort Worth76104	NCT07059845	Map
TX	USOR Texas Oncology	Fort Worth76104	NCT05579366	Map
TX	UT Southwestern/Simmons Cancer Center-Fort Worth	Fort Worth76104	NCT06580314	Map
TX	UT Southwestern/Simmons Cancer Center-Fort Worth	Fort Worth76104	NCT05863195	Map
TX	Baylor College of Medicine	Houston77030	NCT05281471	Map
TX	Baylor College of Medicine	Houston77030	NCT06445062	Map
TX	Baylor College of Medicine Medical Center	Houston77030	NCT07221357	Map
TX	Houston Methodist Hospital	Houston77030	NCT06580314	Map
TX	Houston Methodist Hospital	Houston77030	NCT04181060	Map
TX	Houston Methodist Hospital /ID# 274568	Houston77030	NCT06890338	Map
TX	Houston Methodist Hospital Cancer Center	Houston77030	NCT05733598	Map
TX	Houston Methodist Neal Cancer Center	Houston77030	NCT06887218	Map
TX	Houston Methodist Research Institute	Houston77030	NCT05185505	Map
TX	Houston Methodist West Hospital	Houston77094	NCT06580314	Map
TX	Houston Methodist West Hospital	Houston77094	NCT04181060	Map
TX	M D Anderson Cancer Center	Houston77030	NCT05062317	Map
TX	M D Anderson Cancer Center	Houston77030	NCT05636111	Map
TX	M D Anderson Cancer Center	Houston77030	NCT05231122	Map
TX	M D Anderson Cancer Center	Houston77030	NCT05039801	Map
TX	Md Anderson Cancer Center	Houston77030	NCT07284849	Map
TX	MD Anderson Cancer Center	Houston77030	NCT05101070	Map
TX	MD Anderson Cancer Center	Houston77030	NCT05405595	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06439485	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06576037	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06750094	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06004245	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06083844	Map
TX	MD Anderson Cancer Center	Houston77030	NCT07500298	Map
TX	MD Anderson Cancer Center - Oncology	Houston77030	NCT05464030	Map
TX	Memorial Hermann Texas Medical Center	Houston77030	NCT06580314	Map
TX	Methodist Willowbrook Hospital	Houston77070	NCT06580314	Map
TX	Methodist Willowbrook Hospital	Houston77070	NCT04181060	Map
TX	Oncology Consultants P.A.	Houston77008	NCT07222800	Map
TX	Oncology Consultants P.A.	Houston77024	NCT07222800	Map
TX	Oncology Consultants P.A.	Houston77030	NCT07222800	Map
TX	Radnet/Houston Medical Imaging	Houston77098	NCT07222800	Map
TX	Research Site	Houston77030	NCT06792695	Map
TX	Research Site	Houston77030	NCT06921785	Map
TX	Research Site	Houston77030	NCT05489211	Map
TX	Research Site	Houston77030	NCT05797168	Map
TX	Site 0103	Houston77030	NCT04516447	Map
TX	Texas Oncology - Gulf Coast	Houston77024	NCT07222800	Map
TX	Texas Oncology - Gulf Coast	Houston77054	NCT07222800	Map
TX	Texas Oncology - Gulf Coast	Houston77070	NCT07222800	Map
TX	The University of Texas - M.D. Anderson Cancer Center	Houston77030	NCT07318805	Map
TX	The University of Texas - MD Anderson Cancer Center	Houston77030-4000	NCT06400472	Map
TX	The University of Texas Md Anderson Cancer Center	Houston77030-4009	NCT06427941	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT06131840	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT05919264	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT05253651	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT06625775	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT06445062	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT07079631	Map
TX	The University of Texas MD Anderson Cancer Center /ID# 270059	Houston77030	NCT05005403	Map
TX	The University of Texas MD Anderson Cancer Center- Site Number : 8400005	Houston77030	NCT05584670	Map
TX	The University of Texas, MD Anderson Cancer Center - West Houston	Houston77079	NCT07318805	Map
TX	University of Texas Md Anderson Cancer Center	Houston77030	NCT05836324	Map
TX	University of Texas MD Anderson Cancer Center	Houston77030	NCT05739981	Map
TX	University of Texas MD Anderson Cancer Center	Houston77030-4000	NCT05440708	Map
TX	University of Texas Science Center at Houston, McGovern Medical School	Houston77030	NCT05281471	Map
TX	UT MD Anderson - West Houston	Houston77079	NCT05001880	Map
TX	UT MD Anderson Cancer Center	Houston77030	NCT05001880	Map
TX	Texas Oncology - Gulf Coast	Humble77338	NCT07222800	Map
TX	NEXT Oncology Dallas	Irving75039	NCT06445062	Map
TX	Next Oncology Dallas /ID# 276254	Irving75039	NCT05005403	Map
TX	US Oncology Investigational Product Center (IPC)	Irving75063	NCT05253651	Map
TX	US Oncology Investigational Products Center	Irving75063	NCT07222800	Map
TX	US Oncology Investigational Products Center (IPC)	Irving75063	NCT07222800	Map
TX	US Oncology Investigational Products Center (IPC)	Irving75063	NCT05253651	Map
TX	The University of Texas, MD Anderson Cancer Center - League City	League City77573	NCT07318805	Map
TX	UT MD Anderson - League City	League City77573	NCT05001880	Map
TX	Texas Oncology - Northeast Texas	Longview75601	NCT07222800	Map
TX	DHR Health Institute for Research and Development	McAllen78504	NCT05440708	Map
TX	Texas Oncology - West Texas	Midland79701	NCT07222800	Map
TX	Houston Methodist Saint John Hospital	Nassau Bay77058	NCT06580314	Map
TX	Houston Methodist Saint John Hospital	Nassau Bay77058	NCT04181060	Map
TX	Texas Oncology - West Texas	Odessa79761	NCT07222800	Map
TX	Texas Oncology - Gulf Coast	Pearland77584	NCT07222800	Map
TX	UT Southwestern Clinical Center at Richardson/Plano	Richardson75080	NCT06580314	Map
TX	UT Southwestern Clinical Center at Richardson/Plano	Richardson75080	NCT05863195	Map
TX	Baylor Scott & White Medical Center	Round Rock77845	NCT06750094	Map
TX	GSK Investigational Site	San Antonio78229	NCT06551142	Map
TX	NEXT Oncology	San Antonio78229	NCT05464030	Map
TX	NEXT Oncology - San Antonio /ID# 278606	San Antonio78229	NCT07278336	Map
TX	NEXT Oncology /ID# 243007	San Antonio78229	NCT05005403	Map
TX	Research Site	San Antonio78240	NCT06921785	Map
TX	South Texas Accelerated Research Therapeutics	San Antonio78229	NCT05836324	Map
TX	South Texas Accelerated Research Therapeutics (START) /ID# 276268	San Antonio78229	NCT05005403	Map
TX	South Texas Accelerated Research Therapeutics, LLC	San Antonio78229	NCT06131840	Map
TX	South Texas Accelerated Research Therapeutics, LLC	San Antonio78229	NCT05919264	Map
TX	START San Antonio	San Antonio78229	NCT07318805	Map
TX	START San Antonio LLC	San Antonio78229	NCT06265688	Map
TX	Texas Oncology - San Antonio	San Antonio78240	NCT06750094	Map
TX	Texas Oncology - San Antonio	San Antonio78240	NCT07221357	Map
TX	Texas Oncology - San Antonio ( Site 8004)	San Antonio78240	NCT06997497	Map
TX	Texas Oncology - San Antonio ( Site 8005)	San Antonio78240	NCT06824467	Map
TX	Texas Oncology - San Antonio Medical Center - Research Drive /ID# 275090	San Antonio78240	NCT06890338	Map
TX	Texas Oncology - San Antonio Medical Center - Research Drive /ID# 277735	San Antonio78240	NCT07059845	Map
TX	Texas Oncology- San Antonio	San Antonio78240	NCT07549412	Map
TX	University of Texas Health Science Center - San Antonio	San Antonio78229	NCT05440708	Map
TX	University of Texas San Antonio (UTSA)	San Antonio78229	NCT06625775	Map
TX	Houston Methodist Sugar Land Hospital	Sugar Land77479	NCT04181060	Map
TX	Texas Oncology - Gulf Coast	Sugar Land77479	NCT07222800	Map
TX	The University of Texas, MD Anderson Cancer Center - Sugar Land	Sugar Land77478	NCT07318805	Map
TX	UT MD Anderson - Sugar Land	Sugar Land77478	NCT05001880	Map
TX	Baylor Scott & White Medical Center	Temple76508	NCT06948448	Map
TX	Scott And White Memorial Hospital	Temple76508	NCT06750094	Map
TX	Houston Methodist The Woodlands Hospital	The Woodlands77385	NCT06580314	Map
TX	Houston Methodist The Woodlands Hospital	The Woodlands77385	NCT04181060	Map
TX	Texas Oncology - Gulf Coast	The Woodlands77380	NCT07222800	Map
TX	Texas Oncology - The Woodlands /ID# 275015	The Woodlands77380	NCT06890338	Map
TX	Texas Oncology - The Woodlands /ID# 277926	The Woodlands77380	NCT07059845	Map
TX	Texas Oncology-The Woodlands ( Site 8000)	The Woodlands77380	NCT07216703	Map
TX	US Oncology	The Woodlands77380	NCT07213804	Map
TX	Clinical Study Site	Tyler75701	NCT07228832	Map
TX	GSK Investigational Site	Tyler75702	NCT06551142	Map
TX	Research Site	Tyler75702	NCT06921785	Map
TX	Texas Oncology - Northeast Texas	Tyler75702	NCT07222800	Map
TX	Texas Oncology - Northeast Texas ( Site 8002)	Tyler75702	NCT07216703	Map
TX	Texas Oncology - Northeast Texas /ID# 275057	Tyler75702	NCT06890338	Map
TX	Texas Oncology - Northeast Texas /ID# 277737	Tyler75702	NCT07059845	Map
TX	Texas Oncology - Northeast TX	Tyler75702	NCT05579366	Map
TX	UT Health East Texas HOPE Cancer Center	Tyler75701	NCT06750094	Map
TX	Texas Oncology - Deke Slayton Cancer Center /ID# 271355	Webster77598	NCT06820463	Map
TX	Texas Oncology - Gulf Coast	Webster77598-4420	NCT04929223	Map
TX	Texas Oncology - Gulf Coast ( Site 8003)	Webster77598	NCT06824467	Map
TX	USO - Texas Oncology Gulf Coast	Webster77598-4420	NCT07213804	Map
TX	Texas Oncology - West Texas	Wichita Falls76310	NCT07222800	Map
TX	USOR Texas Oncology Gulf Coast	Woodland77380	NCT05579366	Map
UT	Intermountain Medical Center	Murray84107-5701	NCT06703073	Map
UT	Intermountain Medical Center	Murray84107-5701	NCT06701656	Map
UT	Community Cancer Trials of Utah ( Site 0086)	Ogden84405	NCT06997497	Map
UT	Clinical Study Site	Salt Lake City84106	NCT07228832	Map
UT	Huntsman Cancer Institute	Salt Lake City84112	NCT07213804	Map
UT	Huntsman Cancer Institute, University of Utah	Salt Lake City84112	NCT06607458	Map
UT	Huntsman Cancer Institute, University of Utah	Salt Lake City84112	NCT06445062	Map
UT	Huntsman Cancer Institute/University of Utah	Salt Lake City84112	NCT07198074	Map
UT	Huntsman Cancer Institute/University of Utah	Salt Lake City84112	NCT06580314	Map
UT	LDS Hospital	Salt Lake City84143	NCT06469281	Map
UT	START Mountain	Salt Lake City84119	NCT07470853	Map
UT	START Mountain Region	Salt Lake City84119	NCT06131840	Map
UT	University of Utah Sugarhouse Health Center	Salt Lake City84106	NCT07198074	Map
UT	University of Utah Sugarhouse Health Center	Salt Lake City84106	NCT06580314	Map
UT	Utah Cancer Specialists Network	Salt Lake City84106	NCT06819007	Map
UT	South Jordan Health Center	South Jordan84009	NCT07198074	Map
UT	South Jordan Health Center	South Jordan84009	NCT06580314	Map
UT	GSK Investigational Site	West Valley City84119	NCT06551142	Map
UT	South Texas Accelerated Research Therapeutics Mountain Region	West Valley City84119	NCT06131840	Map
UT	START Mountain Region	West Valley City84119	NCT05579366	Map
UT	START Mountain Region	West Valley City84119	NCT06400472	Map
UT	START Mountain Region	West Valley City84119	NCT07318805	Map
UT	START Mountain Region ( Site 0008)	West Valley City84119	NCT06843447	Map
UT	Start Mountain Region /ID# 276270	West Valley City84119	NCT05005403	Map
UT	Start Mountain Region /ID# 278609	West Valley City84119	NCT07278336	Map
VA	Inova Alexandria Hospital	Alexandria22304	NCT07166406	Map
VA	Research Site	Arlington22201	NCT06921785	Map
VA	Virginia Cancer Specialists	Arlington22201	NCT06750094	Map
VA	Virginia Cancer Specialists, PC	Arlington22201	NCT07222800	Map
VA	Oncology & Hematology Associates of Southwest Virginia, Inc. D.B.A Blue Ridge Cancer Care	Blacksburg24060	NCT05253651	Map
VA	Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care	Blacksburg24060	NCT07222800	Map
VA	Clinical Study Site	Charlottesville22908	NCT07228832	Map
VA	University of Virginia	Charlottesville22908	NCT05919264	Map
VA	University of Virginia	Charlottesville22903	NCT06329570	Map
VA	University of Virginia ( Site 0080)	Charlottesville22908	NCT06997497	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT07198074	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT06580314	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT04181060	Map
VA	University of Virginia Cancer Center ( Site 5044)	Charlottesville22908	NCT07216703	Map
VA	University of Virginia Cancer Center ( Site 6014)	Charlottesville22908	NCT07216703	Map
VA	University of Virginia Health System ( Site 0011)	Charlottesville22908	NCT06843447	Map
VA	University of Virginia,	Charlottesville22908	NCT07527858	Map
VA	UVA Health University Hospital /ID# 275309	Charlottesville22903	NCT06890338	Map
VA	Corcept Therapeutics Investigator Site #522	Fairfax22031	NCT06906341	Map
VA	Clinical Study Site	Fairfax22031	NCT07228832	Map
VA	Inova Fair Oaks Hospital	Fairfax22033	NCT07166406	Map
VA	Inova Schar Cancer Institute	Fairfax22031	NCT07166406	Map
VA	Inova Schar Cancer Institute - Fair Oaks	Fairfax22033	NCT06789757	Map
VA	Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456	Fairfax22031	NCT06890338	Map
VA	NEXT Virginia	Fairfax22031	NCT06265688	Map
VA	Next Virginia /ID# 278607	Fairfax22031	NCT07278336	Map
VA	Next Virginia /ID# 279684	Fairfax22031	NCT07024784	Map
VA	Research Site	Fairfax22031	NCT05797168	Map
VA	USOR Virginia Cancer Specialists	Fairfax22031	NCT05579366	Map
VA	Virginia Cancer Institute	Fairfax22031	NCT05238922	Map
VA	Virginia Cancer Specialists	Fairfax22314	NCT06445062	Map
VA	Virginia Cancer Specialists - Fairfax /ID# 232592	Fairfax22031	NCT05005403	Map
VA	Virginia Cancer Specialists - Fairfax /ID# 271351	Fairfax22031	NCT06820463	Map
VA	Virginia Cancer Specialists (VCS) ( Site 8011)	Fairfax22031	NCT06824467	Map
VA	Virginia Cancer Specialists, PC	Fairfax22031	NCT07222800	Map
VA	Virginia Cancer Specialists, PC ( Site 0069)	Fairfax22031	NCT06997497	Map
VA	Inova Fairfax Hospital	Falls Church22042	NCT07166406	Map
VA	Inova Health Care Service	Falls Church22042	NCT06789757	Map
VA	Inova Loudoun Hospital	Leesburg20176	NCT07166406	Map
VA	Oncology & Hematology Associates of Southwest Virginia	Low Moor24457	NCT05253651	Map
VA	Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care	Low Moor24457	NCT07222800	Map
VA	Virginia Cancer Specialists, PC	Manassas20110	NCT07222800	Map
VA	Virginia Cancer Institute	Mechanicsville23116	NCT07222800	Map
VA	Virginia Cancer Institute	Midlothian23112	NCT07222800	Map
VA	Corcept Therapeutics Investigator Site #300	Norfolk23502	NCT06906341	Map
VA	GSK Investigational Site	Norfolk23502	NCT06551142	Map
VA	USOR Virginia Oncology Associates	Norfolk23502	NCT05579366	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT06948448	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT07221357	Map
VA	Virginia Oncology Associates- Norfolk (Brock) /ID# 275227	Norfolk23502-2800	NCT06890338	Map
VA	Virginia Cancer Institute	Petersburg23805	NCT07222800	Map
VA	Virginia Cancer Specialists, PC	Reston20190	NCT07222800	Map
VA	Richmond VA Medical Center	Richmond23249	NCT06750094	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT07198074	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT06750094	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT06580314	Map
VA	Virginia Cancer Institute	Richmond23229	NCT07222800	Map
VA	Virginia Cancer Institute	Richmond23235	NCT07222800	Map
VA	Carilion Roanoke Memorial Hospital /ID# 274684	Roanoke24014	NCT06890338	Map
VA	Oncology & Hematology Associates of Southwest Virginia Inc dba Blue Ridge Cancer Care	Roanoke24014	NCT05253651	Map
VA	Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care	Roanoke24014	NCT07222800	Map
VA	Oncology and Hematology Associates of Southwest Virginia /ID# 265834	Roanoke98684	NCT06109272	Map
VA	Blue Ridge Cancer Care	Salem24153	NCT06948448	Map
VA	Oncology & Hematology Associates of Southwest Virginia, Inc. D.B.A Blue Ridge Cancer Care	Salem24153	NCT05253651	Map
VA	Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care	Salem24153	NCT07222800	Map
VA	Research Site	Salem24153	NCT06921785	Map
VA	Shenandoah Oncology	Winchester22601	NCT07284849	Map
VA	Virginia Cancer Specialists, PC	Woodbridge22191	NCT07222800	Map
VA	Oncology & Hematology Associates of Southwest Virginia	Wytheville24382	NCT05253651	Map
VA	Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care	Wytheville24382	NCT07222800	Map
WA	Providence Regional Cancer System-Aberdeen	Aberdeen98520	NCT06580314	Map
WA	PeaceHealth Saint Joseph Medical Center	Bellingham98225	NCT06580314	Map
WA	Northwest Medical Specialties, PLLC	Bonney Lake98391	NCT07222800	Map
WA	Providence Regional Cancer System-Centralia	Centralia98531	NCT06580314	Map
WA	Swedish Cancer Institute-Edmonds	Edmonds98026	NCT07198074	Map
WA	Swedish Cancer Institute-Edmonds	Edmonds98026	NCT06580314	Map
WA	Providence Regional Cancer Partnership	Everett98201	NCT06580314	Map
WA	Providence Regional Cancer Partnership	Everett98201	NCT05253651	Map
WA	Providence Regional Medical Center Everett	Everett98201	NCT05253651	Map
WA	Northwest Medical Specialties, PLLC	Federal Way98003	NCT07222800	Map
WA	Northwest Medical Specialties, PLLC	Gig Harbor98332	NCT07222800	Map
WA	Swedish Cancer Institute-Issaquah	Issaquah98029	NCT07198074	Map
WA	Swedish Cancer Institute-Issaquah	Issaquah98029	NCT06580314	Map
WA	Kadlec Clinic Hematology and Oncology	Kennewick99336	NCT06580314	Map
WA	Kadlec Clinic Hematology and Oncology	Kennewick99336	NCT04181060	Map
WA	Providence Regional Cancer System	Lacey98503	NCT06750094	Map
WA	Providence Regional Cancer System-Lacey	Lacey98503	NCT06580314	Map
WA	PeaceHealth Saint John Medical Center	Longview98632	NCT06580314	Map
WA	Skagit Regional Health Cancer Care Center	Mount Vernon98274	NCT06580314	Map
WA	Northwest Medical Specialties, PLLC	Puyallup98373	NCT07222800	Map
WA	Fred Hutch Cancer Center	Seattle98109	NCT05848739	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT05405595	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT06580314	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT06697197	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT06625775	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT06445062	Map
WA	Fred Hutchinson Cancer Center ( Site 0076)	Seattle98109	NCT06997497	Map
WA	Fred Hutchinson Cancer Center- Site Number : 8400010	Seattle98109	NCT05584670	Map
WA	Fred Hutchinson Cancer Research Center	Seattle98109	NCT06750094	Map
WA	Swedish Cancer Institute	Seattle98104	NCT06663319	Map
WA	Swedish Cancer Institute	Seattle98104	NCT05579366	Map
WA	Swedish Cancer Institute	Seattle98104	NCT06787612	Map
WA	Swedish Medical Center	Seattle98122-4379	NCT06703073	Map
WA	Swedish Medical Center	Seattle98122-4379	NCT06701656	Map
WA	Swedish Medical Center-Ballard Campus	Seattle98107	NCT06580314	Map
WA	Swedish Medical Center-Cherry Hill	Seattle98122-5711	NCT06580314	Map
WA	Swedish Medical Center-First Hill	Seattle98122	NCT07198074	Map
WA	Swedish Medical Center-First Hill	Seattle98122	NCT06580314	Map
WA	University of Washington Medical Center - Montlake	Seattle98195	NCT06580314	Map
WA	University of Washington Medical Center - Northwest	Seattle98133	NCT06580314	Map
WA	University Of Washington-Fred Hutchinson Cancer Center - Seattle /ID# 271298	Seattle98109	NCT06820463	Map
WA	University Of Washington-Fred Hutchinson Cancer Center - Seattle /ID# 281451	Seattle98109	NCT07525206	Map
WA	Virginia Mason Hospital and Medical Center /ID# 277259	Seattle98101	NCT07059845	Map
WA	Virginia Mason Medical Center	Seattle98101	NCT05440708	Map
WA	PeaceHealth United General Medical Center	Sedro-Woolley98284	NCT06580314	Map
WA	Saint Michael Cancer Center	Silverdale98383	NCT06580314	Map
WA	Cancer Care Northwest - Spokane South	Spokane99202	NCT06580314	Map
WA	Cancer Care Northwest-North Spokane	Spokane99218	NCT06580314	Map
WA	Cancer Care Northwest-Valley	Spokane99216	NCT06580314	Map
WA	Clinical Study Site	Spokane99208	NCT07228832	Map
WA	Providence Sacred Heart Medical Center & Children's Hospital	Spokane99204	NCT05281471	Map
WA	Providence Sacred Heart Medical Center & Children'S Hospital /ID# 274585	Spokane99204	NCT06890338	Map
WA	Summit Cancer Centers - North Spokane	Spokane99208	NCT05440708	Map
WA	Clinical Study Site	Tacoma98405	NCT07228832	Map
WA	Northwest Medical Specialties	Tacoma98405	NCT06047379	Map
WA	Northwest Medical Specialties, PLLC	Tacoma98405	NCT07222800	Map
WA	Legacy Salmon Creek Hospital	Vancouver98686	NCT07198074	Map
WA	Legacy Salmon Creek Hospital	Vancouver98686	NCT06580314	Map
WA	Northwest Cancer Specialists, P.C.	Vancouver98684	NCT05253651	Map
WA	Northwest Cancer Specialists, P.C.	Vancouver98684	NCT07221357	Map
WA	Providence Saint Mary Regional Cancer Center	Walla Walla99362	NCT06580314	Map
WV	United Hospital Center	Bridgeport26330	NCT07198074	Map
WV	United Hospital Center	Bridgeport26330	NCT06580314	Map
WV	Clinical Study Site	Charleston25304	NCT07228832	Map
WV	West Virginia University Charleston Division	Charleston25304	NCT07198074	Map
WV	West Virginia University Charleston Division	Charleston25304	NCT04181060	Map
WV	WVUH-Berkely Medical Center	Martinsburg25401	NCT07198074	Map
WV	WVUH-Berkely Medical Center	Martinsburg25401	NCT06580314	Map
WV	West Virginia University ( Site 2017)	Morgantown26506	NCT06997497	Map
WV	West Virginia University Cancer Institute	Morgantown26506	NCT07284849	Map
WV	West Virginia University Healthcare	Morgantown26506	NCT07198074	Map
WV	West Virginia University Healthcare	Morgantown26506	NCT06580314	Map
WV	West Virginia University Hospitals /ID# 278965	Morgantown26506	NCT07059845	Map
WV	West Virginia University School of Medicine /ID# 274556	Morgantown26506	NCT06890338	Map
WV	Camden Clark Medical Center	Parkersburg26101	NCT07198074	Map
WV	Camden Clark Medical Center	Parkersburg26101	NCT06580314	Map
WV	Princeton Community Hospital	Princeton24740	NCT06580314	Map
WV	Wheeling Hospital/Schiffler Cancer Center	Wheeling26003	NCT06580314	Map
WI	ThedaCare Regional Cancer Center	Appleton54911	NCT05001880	Map
WI	ThedaCare Regional Cancer Center	Appleton54911	NCT04181060	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT07198074	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT06580314	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT07166406	Map
WI	Northwest Wisconsin Cancer Center	Ashland54806	NCT06580314	Map
WI	Northwest Wisconsin Cancer Center	Ashland54806	NCT07166406	Map
WI	ThedaCare Cancer Care - Berlin	Berlin54923	NCT04181060	Map
WI	Aurora Cancer Care-Southern Lakes VLCC	Burlington53105	NCT06580314	Map
WI	Aurora Saint Luke's South Shore	Cudahy53110	NCT06580314	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT05001880	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT04181060	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT07166406	Map
WI	Aurora Health Care Germantown Health Center	Germantown53022	NCT06580314	Map
WI	Aurora Cancer Care-Grafton	Grafton53024	NCT06580314	Map
WI	Aurora BayCare Medical Center	Green Bay54311	NCT06580314	Map
WI	Saint Vincent Hospital Cancer Center at Saint Mary's	Green Bay54303	NCT07198074	Map
WI	Saint Vincent Hospital Cancer Center at Saint Mary's	Green Bay54303	NCT06580314	Map
WI	Saint Vincent Hospital Cancer Center Green Bay	Green Bay54301	NCT07198074	Map
WI	Saint Vincent Hospital Cancer Center Green Bay	Green Bay54301	NCT06580314	Map
WI	Essentia Health-Hayward Clinic	Hayward54843	NCT06580314	Map
WI	Essentia Health-Hayward Clinic	Hayward54843	NCT07166406	Map
WI	Tamarack Health Hayward Medical Center	Hayward54843	NCT06580314	Map
WI	Mercyhealth Hospital and Cancer Center - Janesville	Janesville53548	NCT04181060	Map
WI	Aurora Cancer Care-Kenosha South	Kenosha53142	NCT06580314	Map
WI	Gundersen Lutheran Medical Center	La Crosse54601	NCT07198074	Map
WI	Gundersen Lutheran Medical Center	La Crosse54601	NCT06580314	Map
WI	Gundersen Lutheran Medical Center	La Crosse54601	NCT04181060	Map
WI	Clinical Study Site	Madison53792	NCT07228832	Map
WI	Research Site	Madison53792	NCT05489211	Map
WI	University of Wisconsin	Madison53792	NCT06787612	Map
WI	University of Wisconsin Carbone Cancer Center	Madison52792	NCT05854498	Map
WI	University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	Madison53718	NCT05863195	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT07213804	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT05863195	Map
WI	University of Wisconsin, Carbone Cancer Center	Madison53705	NCT05919264	Map
WI	Wisconsin Institute for Medical Research	Madison53792	NCT06625775	Map
WI	Aurora Bay Area Medical Group-Marinette	Marinette54143	NCT06580314	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT05001880	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT04181060	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT07166406	Map
WI	Froedtert Menomonee Falls Hospital	Menomonee Falls53051	NCT07166406	Map
WI	Corcept Therapeutics Investigator Site #121	Milwaukee53226	NCT06906341	Map
WI	Aurora Cancer Care-Milwaukee	Milwaukee53209	NCT06580314	Map
WI	Aurora Saint Luke's Medical Center	Milwaukee53215	NCT06580314	Map
WI	Aurora Sinai Medical Center	Milwaukee53233	NCT06580314	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06580314	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT04181060	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT07166406	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06787612	Map
WI	Medical College Of Wisconsin	Milwaukee53226	NCT06750094	Map
WI	Research Site	Milwaukee53226	NCT06921785	Map
WI	Marshfield Medical Center - Minocqua	Minocqua54548	NCT05001880	Map
WI	Marshfield Medical Center - Minocqua	Minocqua54548	NCT04181060	Map
WI	ProHealth D N Greenwald Center	Mukwonago53149	NCT06580314	Map
WI	ProHealth D N Greenwald Center	Mukwonago53149	NCT04181060	Map
WI	ProHealth D N Greenwald Center	Mukwonago53149	NCT07166406	Map
WI	ThedaCare Regional Medical Center - Neenah	Neenah54956	NCT04181060	Map
WI	Froedtert and MCW Moorland Reserve Health Center	New Berlin53151	NCT07166406	Map
WI	ThedaCare Cancer Care - New London	New London54961	NCT04181060	Map
WI	Cancer Center of Western Wisconsin	New Richmond54017	NCT06580314	Map
WI	Drexel Town Square Health Center	Oak Creek53154	NCT07166406	Map
WI	ProHealth Oconomowoc Memorial Hospital	Oconomowoc53066	NCT06580314	Map
WI	ProHealth Oconomowoc Memorial Hospital	Oconomowoc53066	NCT04181060	Map
WI	ProHealth Oconomowoc Memorial Hospital	Oconomowoc53066	NCT07166406	Map
WI	Saint Vincent Hospital Cancer Center at Oconto Falls	Oconto Falls54154	NCT07198074	Map
WI	Saint Vincent Hospital Cancer Center at Oconto Falls	Oconto Falls54154	NCT06580314	Map
WI	ThedaCare Cancer Care - Oshkosh	Oshkosh54904	NCT04181060	Map
WI	Vince Lombardi Cancer Clinic - Oshkosh	Oshkosh54904	NCT06580314	Map
WI	Aurora Cancer Care-Racine	Racine53406	NCT06580314	Map
WI	Marshfield Medical Center-Rice Lake	Rice Lake54868	NCT05001880	Map
WI	Marshfield Medical Center-Rice Lake	Rice Lake54868	NCT04181060	Map
WI	Marshfield Medical Center-Rice Lake	Rice Lake54868	NCT07166406	Map
WI	ThedaCare Cancer Care - Shawano	Shawano54166	NCT04181060	Map
WI	Saint Vincent Hospital Cancer Center at Sheboygan	Sheboygan53081	NCT07198074	Map
WI	Saint Vincent Hospital Cancer Center at Sheboygan	Sheboygan53081	NCT06580314	Map
WI	Sheboygan Physicians Group	Sheboygan53081	NCT07198074	Map
WI	Sheboygan Physicians Group	Sheboygan53081	NCT06580314	Map
WI	Vince Lombardi Cancer Clinic-Sheboygan	Sheboygan53081	NCT06580314	Map
WI	Essentia Health-Spooner Clinic	Spooner54801	NCT07198074	Map
WI	Essentia Health-Spooner Clinic	Spooner54801	NCT06580314	Map
WI	Essentia Health-Spooner Clinic	Spooner54801	NCT07166406	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT05001880	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT04181060	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT07166406	Map
WI	Saint Vincent Hospital Cancer Center at Sturgeon Bay	Sturgeon Bay54235-1495	NCT07198074	Map
WI	Saint Vincent Hospital Cancer Center at Sturgeon Bay	Sturgeon Bay54235-1495	NCT06580314	Map
WI	Aurora Medical Center in Summit	Summit53066	NCT06580314	—
WI	Essentia Health Saint Mary's Hospital - Superior	Superior54880	NCT07198074	Map
WI	Essentia Health Saint Mary's Hospital - Superior	Superior54880	NCT06580314	Map
WI	Essentia Health Saint Mary's Hospital - Superior	Superior54880	NCT07166406	Map
WI	Vince Lombardi Cancer Clinic-Two Rivers	Two Rivers54241	NCT06580314	Map
WI	ProHealth Waukesha Memorial Hospital	Waukesha53188	NCT06580314	Map
WI	ProHealth Waukesha Memorial Hospital	Waukesha53188	NCT04181060	Map
WI	UW Cancer Center at ProHealth Care	Waukesha53188	NCT06580314	Map
WI	UW Cancer Center at ProHealth Care	Waukesha53188	NCT04181060	Map
WI	UW Cancer Center at ProHealth Care	Waukesha53188	NCT07166406	Map
WI	ThedaCare Cancer Care - Waupaca	Waupaca54981	NCT04181060	Map
WI	Aurora Cancer Care-Milwaukee West	Wauwatosa53226	NCT06580314	Map
WI	Aurora West Allis Medical Center	West Allis53227	NCT06580314	Map
WI	Froedtert West Bend Hospital/Kraemer Cancer Center	West Bend53095	NCT07166406	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT05001880	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT04181060	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT07166406	Map
WY	Memorial Hospital of Laramie County	Cheyenne82001	NCT06580314	Map
WY	Billings Clinic-Cody	Cody82414	NCT06580314	Map

Bevacizumab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	suspended	not yet recruiting	unknown	no longer available	Total
Early P1	2	4		8	2	4		3	2		25
P1	42	21		183	35	9	1	3	17		311
P1/P2	59	16	1	70	30	16	2	10	24		228
P2	170	60	3	624	148	42	2	71	189		1,309
P2/P3	12	6	1	21	5	4		4	16		69
P3	54	34		158	28	13		6	43		336
P4	6	2		39	5	7		3	11		73
N/A	14	11	3	93	8	8	1	12	44	3	197

Recruiting Bevacizumab clinical trials (479)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT05620771	Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk	P2	Hepatocellular Carcinoma	200	Nov 2022
NCT05468359	Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients	P1/P2	Refractory Solid Tumor	64	Nov 2022
NCT06492421	Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.	P2	Lung Cancer	90	Jul 2024
NCT06482801	Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT	P2	Liver Cancer	90	Jun 2024
NCT06990516	SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer	P1/P2	Ovarian Cancer	90	Jun 2025
NCT06580314	Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer	P3	Fallopian Tube Endometrioid Adenocarcinoma	880	Mar 2025
NCT07293468	BIIRTHComparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)	P2/P3	Hepatocellular Carcinoma (HCC)	106	Apr 2024
NCT06725121	MacroTransUsing Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant	P1/P2	Hepatocellular Carcinoma (HCC)	48	Dec 2024
NCT05863195	Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial	P3	Metastatic Colorectal Carcinoma	408	Oct 2023
NCT07221357	A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer	P2/P3	Untreated, Unresectable, or Metastatic Colorectal Cancer	990	Dec 2025
NCT06492408	Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.	P2	Hepatic Cancer	90	Jul 2024
NCT06483347	Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT	P2	Lung Cancer	90	Apr 2024
NCT07359456	COLIBRI-GITesting Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases	P2	Metastatic Colorectal Cancer	130	Aug 2026
NCT07472153	PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer	P2/P3	Metastatic Cervical Cancer	120	Jul 2025
NCT07472140	PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer	P2/P3	Ovarian Cancer	120	Jul 2025
NCT05797467	Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients	P3	Colorectal Cancer	366	Apr 2023
NCT05862285	UmbrellaMAXA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study	P3	Cancer	100	Jun 2023
NCT07318558	TroFuse-021A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)	P3	Ovarian Neoplasms	900	Feb 2026
NCT07079631	BNT327A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer	P1/P2	Metastatic Colorectal Cancer	482	Jul 2025
NCT05007132	Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer	P2	Metastatic Colorectal Cancer	153	Dec 2021
NCT07500298	Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer	P1	Phase 1	41	May 2026
NCT06824467	MK-2870A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)	P3	Ovarian Cancer	770	Apr 2025
NCT07001618	IMMUNOLIFE2Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer	P2	NSCLC (Advanced Non-small Cell Lung Cancer)	162	Nov 2025
NCT06252649	CodeBreaK 301Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation	P3	Metastatic Colorectal Cancer	450	Jul 2024
NCT06954584	Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer	P3	Ovarian Cancer	424	May 2025
NCT07585279	A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer	P2/P3	Metastatic Colorectal Cancer (CRC)	408	May 2026
NCT05183984	NIRVANA-1Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer	P2	Ovarian Cancer	390	Feb 2022
NCT06543576	External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer	P1/P2	Cervical Adenocarcinoma	35	Jul 2025
NCT06819007	DO-01Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)	P3	Ovarian Cancer	582	Mar 2025
NCT05096715	Atezolizumab+Bevacizumab+SBRT in Unresectable HCC	P1	Unresectable Hepatocellular Carcinoma	20	Aug 2022
NCT07370818	To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer	P2	Ovarian Cancer	81	Feb 2026
NCT06791512	BASKETⅢmFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC	P3	Colorectal Cancer (CRC)	166	Jan 2025
NCT05009082	Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer	P3	Ovarian Cancer	970	Sep 2022
NCT07564141	RAINFOL™-07Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer	P3	Platinum-Sensitive Ovarian Cancer	688	Jul 2026
NCT07071714	A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer	P2	Colorectal Cancer	200	Jul 2025
NCT07216703	MK-2870A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)	P3	Cervical Cancer	1,023	Jan 2026
NCT07291076	HCCA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)	P1/P2	Hepatocellular Carcinoma (HCC)	198	Mar 2026
NCT07213804	FRAmework-01A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer	P3	Ovarian Neoplasms	1,630	Oct 2025
NCT07222800	Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer	P3	Intestinal Neoplasms	800	Dec 2025
NCT07018947	ASPIREStudy to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC	P2	Resectable Hepatocellular Carcinoma	90	Jun 2026
NCT07346157	PNOC044Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease	P1/P2	Medulloblastoma	69	Jul 2026
NCT07381764	ROMANCE - GOIMROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"	P2	Metastatic Colorectal Cancer (CRC)	150	Mar 2026
NCT06339424	PhotonABAtezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma	45	Mar 2024
NCT07271355	Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial	P3	Metastatic Appendix Carcinoma	129	Jul 2026
NCT03942328	Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer	P1/P2	Stage III Hepatocellular Carcinoma AJCC v8	85	Sep 2019
NCT07490262	A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.	P2/P3	Hepatocellular Carcinoma (HCC)	680	Mar 2026
NCT07340164	TROYTrastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy	P2	Ovarian Cancer	116	Feb 2026
NCT07239596	Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom	P1/P2	Advanced Renal Cell Carcinoma	139	Jan 2026
NCT07263438	PhenixEfficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial	P2	Glioblastoma	59	Nov 2025
NCT07012954	ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC	P1/P2	Colorectal Cancer Metastatic	64	Jun 2025
NCT07334301	BEACON2A Multi-Arm, Platform Trial For Relapsed Neuroblastoma	P1/P2	Relapsed Neuroblastoma	160	Nov 2024
NCT06618664	A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma	P3	Advanced Hepatocellular Carcinoma	590	Oct 2024
NCT06988852	FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis	P2	Colorectal Liver Metastasis (CRLM)	300	May 2023
NCT07317414	β-alanine in the Treatment of Advanced Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma	158	Dec 2025
NCT07347951	A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer	P2	Locally Advanced Rectal Cancer (LARC)	30	Dec 2025
NCT04374305	INTUITT-NF2Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)	P2	Neurofibromatosis Type 2	109	Jun 2020
NCT06160206	Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma	P2	Recurrent Glioblastoma	134	Oct 2024
NCT05462613	REPROGRAM-02Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer	P2/P3	Metastatic Colorectal Cancer	446	May 2023
NCT07239245	ATTACHStudy to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo	P2	Resectable Hepatocellular Carcinoma With High Risk of Recurrence	30	Nov 2025
NCT07389265	CAPRI-3 GOIMContinuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer	P3	Metastatic Colorectal Cancer (mCRC)	480	Oct 2025
NCT06997497	MK-1084A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)	P3	Colon Adenocarcinoma	477	Jul 2025
NCT07361991	IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer	P1/P2	Advan'ce'd	50	Mar 2026
NCT06109272	LIVIGNO-2A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)	P2/P3	Hepatocellular Carcinoma	660	Jan 2024
NCT06133062	ProtonABAtezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma Non-resectable	45	Nov 2023
NCT03424005	Morpheus-panBCA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer	P1/P2	Metastatic Breast Cancer	1,132	Mar 2018
NCT07351487	NEOTORCH-BREAST07Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)	P2	TNBC - Triple-Negative Breast Cancer	37	Sep 2025
NCT06131840	A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors	P1	Colorectal Neoplasms	914	Nov 2023
NCT07134101	SMARTi-RC01Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)	P2	Colorectal Cancer (Diagnosis)	138	Sep 2025
NCT06471465	BRADICorticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases	P3	Radionecrosis of Brain	84	Apr 2025
NCT04929223	INTRINSICA Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)	P1	Metastatic Colorectal Cancer	542	Oct 2021
NCT06540729	DABRC48 in Combination With AK104 and Bevacizumab in OCCC	P2	Ovary Cancer	39	Sep 2024
NCT06680258	A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy	P3	Hepatocellular Carcinoma (HCC)	740	Dec 2025
NCT06888817	BRAINSBevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases	P3	Radiation Necrosis	408	Jun 2025
NCT05253651	MOUNTAINEER-03A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer	P3	Colorectal Neoplasms	400	Oct 2022
NCT07182708	HOFIBRENHigh-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC	P2	NSCLC (Non-small Cell Lung Cancer)	62	Oct 2025
NCT07541781	Sitagliptin in Recurrent/Progressive Grade 4 Glioma	P1	Glioma	45	Jun 2026
NCT07225270	RAINFOL-04Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy	P3	Ovarian Cancer	544	Apr 2026
NCT06469281	MUC16A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers	P1	Epithelial Ovarian Cancer	90	Aug 2024
NCT07446322	FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer	P2	Ras-mutated Metastatic Colorectal Cancer	60	Apr 2026
NCT06917092	QLPPEC/GOG-003QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer	P2	Endometrial Adenocarcinoma	30	May 2025
NCT01356290	MEMMATAntiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors	P2	Medulloblastoma Recurrent	232	Apr 2014
NCT07318805	A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors	P1	Advanced Breast Cancer	260	Dec 2025
NCT07525206	AndroMETa-CRCA Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer	P3	Colorectal Cancer	700	May 2026
NCT07094893	ARIEL-ENGICAnti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status	P4	Colorectal Cancer	280	Apr 2026
NCT06921785	ARTEMIDE-HCC01Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma	P3	Hepatocellular Carcinoma	1,220	May 2025
NCT06928584	Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer	P2	Locally Recurrent Rectal Cancer	221	Mar 2025
NCT07183865	NOVELTY-RHypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)	P2	Locally Recurrent Rectal Cancer	44	Mar 2025
NCT07392866	A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma	P2/P3	Hepatocellular Carcinoma (HCC)	120	Mar 2026
NCT07472647	SYS6090 Combination Therapy in Advanced Lung Cancer	P1/P2	Non-Small Cell Lung Cancer	596	Feb 2026
NCT06890338	IVA Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.	P2	Epithelial Ovarian Cancer	140	Nov 2025
NCT05528952	TERTIOEvaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma	105	Sep 2022
NCT06439485	Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion	P1/P2	Advanced Cholangiocarcinoma	25	Nov 2024
NCT07324824	Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma	37	Jan 2026
NCT07362836	FRU-RASFruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)	P3	Colorectal Cancer	224	Jan 2026
NCT07383285	CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer	P2	Rectal Neoplasms Malignant	106	Feb 2026
NCT07281664	Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma	N/A	Hepatocellular Carcinoma	30	Jan 2026
NCT07286695	Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer	P2	Metastatic Colorectal Cancer (CRC)	292	Dec 2025
NCT07283367	A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.	P1/P2	CRC	502	Dec 2025
NCT06856837	- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases	P2	Metastatic Colorectal Cancer	140	Oct 2025
NCT07071844	BETWEENBETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients	P2	Metastatic Colorectal Cancer	162	Sep 2025
NCT06887218	5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer	P2	Metastatic Colorectal Cancer (CRC)	57	May 2025
NCT06922383	A Clinical Study of Arfolitixorin in Patients With mCRC	P1/P2	Metastatic Colorectal Cancer (mCRC)	90	Apr 2025
NCT06775275	A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC	P2	Resectable Lung Non-Small Cell Carcinoma	60	Sep 2024
NCT06280495	Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients	P2/P3	Colorectal Cancer	156	Feb 2024
NCT06023862	DOVEA Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)	P2	Ovarian Neoplasms	198	Jan 2024
NCT05441475	A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients	P2	Hepatocellular Carcinoma	118	Dec 2021
NCT04250064	LoBULarDIPGA Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma	P2	DIPG	40	Feb 2020
NCT03872661	NIBCUNNeoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC	P2	Lung Cancer Stage III	36	Mar 2019
NCT07119931	A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)	P2	HCC	34	Sep 2025
NCT07128251	TACEA Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)	P2	Hepatocellular Carcinoma (HCC)	47	Aug 2025
NCT06953323	A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors	P1/P2	Advanced Solid Tumor	86	Jul 2025
NCT06730750	A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors	P1/P2	Advanced Solid Tumors	360	Feb 2025
NCT07274787	Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma	N/A	GBM	10	Dec 2026
NCT05956821	Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age	P1/P2	Glioblastoma Multiforme	20	Jun 2025
NCT07228832	HARMONi-GI3Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer	P3	Metastatic Colorectal Cancer (CRC)	600	Nov 2025
NCT07318389	ASCEND-CRCASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer	Early P1	Dynamic Tumor Resistance	100	Jun 2026
NCT01269853	Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA	P1/P2	Glioblastoma Multiforme	54	Oct 2010
NCT07549412	PROCEADE-CRC-03A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)	P3	Metastatic Colorectal Cancer	1,020	May 2026
NCT06976944	PRELUDEPembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer	P2	Recurrent Triple-Negative Breast Cancer	24	Jun 2025
NCT05284643	Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma	N/A	Recurrent Glioblastoma	96	Sep 2022
NCT07284849	A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer	P3	CRC (Colorectal Cancer)	700	Mar 2026
NCT07481786	Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases	P3	Lung Adenocarcinoma	220	Mar 2026
NCT07543510	Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma	N/A	Hepatocellular Carcinoma	38	May 2026
NCT07543783	TACE-HAICEfficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial	P2	Adebrelimab (SHR-1316)	38	Apr 2026
NCT05551208	Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi	P2	Ovarian Cancer	42	Aug 2022
NCT03899155	Pan Tumor Rollover Study	P2	Cancer	1,500	Aug 2019
NCT05984511	TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT	N/A	Hepatocellular Carcinoma	234	Aug 2023
NCT07297212	BNT327A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma	P2	Recurrent Glioblastoma	75	Jan 2026
NCT07134413	QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC	P2	NSCLC	77	Aug 2025
NCT07025239	QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer	P3	Metastatic Colorectal Cancer	430	Jul 2025
NCT02446431	MetronomicMetronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence	Early P1	Solid Tumor	20	Jul 2014
NCT07235930	Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer	P3	Non-Resectable Pancreas Carcinoma	292	Nov 2025
NCT07397819	Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy	P1/P2	Malignant Ascites	48	Nov 2025
NCT05769010	Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases	P2	Metastatic Breast Cancer	150	Mar 2023
NCT06971744	AUTOMAINAutophagy Maintenance (AUTOMAIN)	P2	Ovarian Cancer	38	Dec 2025
NCT06551142	PanTumor-101A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)	P1	Neoplasms	845	Sep 2024
NCT07002346	INVIGORATEINVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma	P3	Ovarian Clear Cell Carcinoma	226	Nov 2025
NCT06576037	Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin	P1	Solid Tumor	128	Oct 2024
NCT04215731	FOBEARNeoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer	P3	Rectal Cancer	582	Mar 2020
NCT07559760	New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer	P2	Metastatic Colorectal Cancer	30	Nov 2025
NCT07014215	PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy	P2	NSCLC (Advanced Non-small Cell Lung Cancer)	52	Jun 2025
NCT06411600	BRAVECombination Therapy for BRAF-V600E Metastatic CRCm	P2	Metastatic Colorectal Cancer	94	May 2024
NCT07551778	Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors	P1/P2	NSCLC (Advanced Non-small Cell Lung Cancer)	20	May 2026
NCT07514793	Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma	P2	Mesothelioma	37	Apr 2026
NCT07549399	CRITⅡSCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC	P3	Rectal Adenocarcinoma	204	May 2026
NCT06750094	OrigAMI-3A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy	P3	Colorectal Neoplasms	700	Dec 2024
NCT07504588	Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy	P2	Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma	87	Sep 2026
NCT07515625	Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma	P2	Gastric Cancer (GC)	46	Apr 2026
NCT06733038	AtezoTRIBE2FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.	P3	Colorectal Cancer	238	Nov 2024
NCT07466238	HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer	N/A	Biliary Tract Cancer (BTC)	40	Mar 2026
NCT07331883	CLEAR-2Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)	P2	Hepatocellular Carcinoma (HCC)	35	Nov 2025
NCT06265688	First In Human Study of CX-2051 in Advanced Solid Tumors	P1	Solid Tumor, Adult	160	Apr 2024
NCT06843447	MK-5909-003A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)	P1/P2	Ovarian Cancer Recurrent	460	Apr 2025
NCT07166406	Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial	P3	Advanced Hepatocellular Carcinoma	226	Feb 2026
NCT07453394	QLS5132 Combination Therapy in Advanced Solid Tumors	P1/P2	Gastric Cancer (GC)	626	Apr 2026
NCT07395063	A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.	P2	Metastatic Colorectal Cancer (CRC)	68	Feb 2026
NCT07278336	IVA Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer	P1	Ovarian Cancer	219	Nov 2025
NCT07059845	FLORENZAA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer	P2	Ovarian Cancer	400	Nov 2025
NCT07004335	LEfficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study	P4	PD-(L)1	40	Jul 2025
NCT06264531	BevacizuMAVEfficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations	P2/P3	Cerebral AV Malformation	54	Jan 2026
NCT06951503	AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer	P3	Colorectal Adenocarcinoma	560	May 2025
NCT06697197	A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors	P1/P2	Advanced Solid Tumors	413	Feb 2025
NCT07276100	Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab	P2	Hepato Cellular Carcinoma (HCC)	15	Jan 2026
NCT07557251	A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma	P1	Advanced HBV-Related Hepatocellular Carcinoma	21	May 2026
NCT07527858	GS-1811Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer	P2	Advanced Microsatellite Stable Colorectal Cancer	170	May 2026
NCT07391566	LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation	P1/P2	Metastatic Colorectal Cancer (mCRC)	99	Mar 2026
NCT07116577	Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC	P2	mCRC	37	Aug 2025
NCT07021950	AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer	P2	Colorectal Cancer	130	Aug 2025
NCT06895928	A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors	P2	Advanced Solid Tumors	400	Mar 2025
NCT06878196	ctDNA-guided First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervical Cancer	N/A	Uterine Cervical Neoplasm	20	Mar 2025
NCT06737913	HAIBrave-001HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma	P2	Advanced Hepatocellular Carcinoma (HCC)	76	Jan 2025
NCT06755684	Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer	P2	EGFR	60	Nov 2024
NCT06786026	QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC	P2	TNBC, Triple Negative Breast Cancer	60	Oct 2024
NCT06031233	MINUTEEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie	P4	Oncology	776	Sep 2023
NCT05482516	MRD-GIEvaluating Novel Therapies in ctDNA Positive GI Cancers	P3	Colon Adenocarcinoma	20	Mar 2023
NCT05525767	Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer	P4	Solid Tumor	75	Mar 2022
NCT05503667	Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma	P2	Lung Adenocarcinoma Stage III	96	Feb 2022
NCT07311577	Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study	P2	Ovarian Cancer Metastatic	43	Jan 2026
NCT07327788	QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT	P2	Hepatecellular Carcinoma	38	Dec 2025
NCT07197008	Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis	P2	Lung Cancer	50	Oct 2025
NCT06982924	LIBRAA Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.	P2	EGFR Mutation Positive Advanced Non Small Cell Lung Cancer	136	Jun 2025
NCT07058428	FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma	P3	Multiple Brain Metastases in Lung Adenocarcinoma	258	Jun 2025
NCT06625775	Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors	P1	Solid Tumor, Adult	392	Oct 2024
NCT07420439	Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease	P2	Non Small Cell Lung Cancer Metastatic	108	May 2026
NCT07075757	BLITZIn Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment	P1	Brain Arteriovenous Malformations	20	Oct 2025
NCT06650709	NEOCATSNEoadjuvant Olaparib Combination OvArian Cancer Targeted Study	P2	Ovarian Cancer Stage IV	40	Nov 2024
NCT07179900	Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma	60	Dec 2025
NCT07150403	Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer	P2	Metastatic Colorectal Carcinoma (mCRC)	74	Dec 2025
NCT07120451	Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker	P2	Advanced Ovarian Cancer	37	Oct 2025
NCT06787612	Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer	P2	Ovarian Cancer	220	May 2025
NCT06245356	TRIFLUOX-DPSafety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer	P2	Metastatic Colorectal Cancer	73	Mar 2025
NCT06796907	BEHOLD-2A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)	P1/P2	Tumours, Gynecological	305	Mar 2025
NCT07288034	LImmunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial	P2	Lung Non-Small Cell Carcinoma	535	Apr 2026
NCT06948448	A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer	P2	Colorectal Cancer	144	Nov 2025
NCT06735326	Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer	P2	Ovarian Cancer	105	Nov 2024
NCT07448922	A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors	P2	Advanced Gynecological Malignancies	280	Apr 2026
NCT07328802	Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma	P2	ORR,OS,PFS	25	Jan 2026
NCT06701656	JUST BREATHEJUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab	P2	Acute Respiratory Distress Syndrome (ARDS)	200	Oct 2025
NCT07150208	THUMBT-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis	P2	Breast Cancer With Brain Metastasis	140	Sep 2025
NCT06703073	JUST BREATHEJUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)	P2	Acute Respiratory Distress Syndrome (ARDS)	600	Jun 2025
NCT06497985	A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients	P3	Colorectal Cancer	430	Dec 2024
NCT06755515	A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer	P2/P3	Cervical Cancer	510	Sep 2024
NCT06530251	HCCA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)	P1/P2	Hepatocellular Carcinoma	280	Sep 2024
NCT02885753	OSCARSystemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver	P3	Colorectal Neoplasms	348	Dec 2016
NCT07277270	A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors	P1	Neoplasms	84	Dec 2025
NCT06792695	CANTORA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer	P2	Metastatic Colorectal Cancer	80	Mar 2025
NCT07518602	Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma	P2	Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)	34	Mar 2026
NCT07123441	IIA Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer	P2	Colorectal Cancer	300	Sep 2025
NCT07147101	HCC-IM-1Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment	—	Advanced Hepatocellular Carcinoma (HCC)	150	Sep 2025
NCT06459687	Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer	P3	Cervical Cancer	440	Nov 2024
NCT07178717	REFISHA Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations	P2	Colo-rectal Cancer	25	Oct 2025
NCT07070713	Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC	P2	Metastatic Colorectal Cancer With Left-sided Primary Tumor	44	Jul 2025
NCT05739981	MRDPhase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer	P1/P2	Ovarian Cancer	30	Feb 2023
NCT06294548	A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC	P1/P2	Hepatocellular Carcinoma	45	Jul 2025
NCT06809946	DEFLECT IFeasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy	P2	Lung Neoplasms	20	Aug 2026
NCT07059494	Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant	P4	Hepatocellular Carcinoma	40	Jun 2026
NCT07085169	Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC	P2	Colo-rectal Cancer	50	Aug 2025
NCT07244705	A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC	P1/P2	Colorectal Cancer (Diagnosis)	66	Nov 2025
NCT07106034	ONTOPStandard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial	P2	Advanced Colorectal Cancer	32	Aug 2025
NCT06867822	Trial of ProAgio in Advanced/Metastatic Colorectal Cancer	P1	Advanced Colorectal Cancer	27	Jul 2025
NCT06823375	SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis	P2	HCC	40	Jul 2025
NCT06557096	CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC	Early P1	Non Small Cell Lung Cancer	100	Aug 2024
NCT05854498	Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer	P2	Metastatic Colorectal Cancer	50	Oct 2023
NCT06936527	XS-03-II201XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation	P1/P2	Colorectal Cancer	102	May 2025
NCT06663319	A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers	P1	Colorectal Neoplasms	260	Oct 2024
NCT07051785	ARKFruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer	P2	Colorectal Cancer (CRC)	68	Jul 2025
NCT07198074	Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer	P3	Advanced Endometrial Carcinoma	255	Jan 2026
NCT05733598	Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC	P2	Hepatocellular Carcinoma	60	Aug 2024
NCT05354674	Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis	—	Colorectal Cancer	302	Sep 2023
NCT07497074	JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer	P2	Cervical Cancer	78	Apr 2026
NCT07244926	Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer	P2	Lung Cancer	31	Dec 2025
NCT07093762	Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC	—	Non Small Cell Lung Cancer	35	Aug 2025
NCT07150247	Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer	P2	BRAF V600 Colorectal Cancer	20	Jun 2025
NCT06446206	Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer	P2	Platinum-sensitive Relapsed Ovarian Cancer	22	Jun 2024
NCT06563986	STARLIGHTFTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer	P2	Metastatic Colorectal Cancer	40	Jun 2024
NCT06510582	CHAIChronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection	P1/P2	Chronic Subdural Hematoma	140	Jun 2024
NCT06881537	CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer	P2	Locally Recurrent Colorectal Cancer	15	Jun 2024
NCT05867420	A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.	P1/P2	Advanced Solid Tumors	594	Aug 2023
NCT05039801	IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	P1	Advanced Endometrial Carcinoma	54	Sep 2021
NCT04516447	MUIRA Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer	P1	Solid Tumor	172	Oct 2020
NCT05584670	A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors	P1/P2	Solid Tumor	542	Nov 2022
NCT07535632	BESTSBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer	P2	Colorectal Neoplasms	58	Jun 2026
NCT06478693	A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC	P1	Hepatocellular Carcinoma	70	Jul 2024
NCT05101070	aCCeleR8-001S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors	P1/P2	Solid Tumors	282	May 2022
NCT06427941	A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors	P1	Metastatic Hepatocellular Carcinoma	392	Jul 2024
NCT06233942	Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors	P1	Advanced Solid Tumor	308	Apr 2024
NCT07089719	BASECOVIDBevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)	P2	Dyspnea Caused by 2019-nCoV	21	Oct 2025
NCT07003022	Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC	P2	Colo-rectal Cancer	40	Jun 2025
NCT05585814	COBPCapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer	P2	Locally Advanced Colorectal Cancer	30	May 2023
NCT07560488	Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma	P2	HCC - Hepatocellular Carcinoma	43	Mar 2026
NCT06820463	AndroMETa-CRCA Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer	P2	Metastatic Colorectal Cancer	390	Apr 2025
NCT06839105	A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies	P1	Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor	214	Feb 2025
NCT04919629	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	P2	Fallopian Tube Carcinosarcoma	60	Apr 2023
NCT07193862	Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis	Early P1	Colorectal Cancer Metastatic	10	Dec 2025
NCT06336707	HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors	P1	Advanced Solid Tumors	1,048	Apr 2024
NCT06995105	Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma	P1/P2	Advanced Hepatocellular Carcinoma (HCC)	30	Apr 2025
NCT06872606	SCRIPBOTShort-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer	P2	Rectal Adenocarcinoma	33	Apr 2025
NCT05271240	SIACIRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM	P3	Glioblastoma	432	Apr 2022
NCT07045805	Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer	P2	Gastric Cancer (GC)	66	Jul 2025
NCT05690048	FLORAFecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)	P2	Immunotherapy	48	Jul 2025
NCT06329570	Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)	P1/P2	Glioblastoma Multiforme	10	Oct 2024
NCT06360042	Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC	P2	Unresectable Hepatocellular Carcinoma	111	Jan 2024
NCT05742425	Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases	P2	Unresectable Colon Cancer Peritoneal Metastases	30	Mar 2023
NCT07503756	JS212 Combination Therapies in Metastatic Colorectal Cancer	P2	Metastatic Colorectal Cancer	80	Apr 2026
NCT07261709	Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial	P2	Refractory Metastatic Colorectal Cancer	236	Dec 2025
NCT06893887	ICT-HCCIndividualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma	N/A	Hepatocellular Carcinoma(HCC)	300	May 2025
NCT06860490	TASK-03HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)	P2	Hepatocellular Carcinoma (HCC)	164	Mar 2025
NCT07470853	A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.	P1	PROC	265	Mar 2026
NCT07229846	QL1706A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation	P2	Colorectal Cancer	30	Feb 2026
NCT07024784	A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies	P2	Gynecologic Cancers	377	Jul 2025
NCT06844474	A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC	P2	NSCLC	300	Mar 2025
NCT05334277	FOCUS-CFurmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA	P2	Non-small Cell Lung Cancer	280	May 2022
NCT07474727	A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer	P2	Colorectal Cancer	180	Apr 2026
NCT07337551	Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive	P2	Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment	20	Feb 2026
NCT06728865	Better BrainEvaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study	P2	Non-small Cell Lung Cancer (NSCLC)	70	Sep 2024
NCT07355764	MA-CRC-II-016 SHR-1811	P2	mCRC	80	Dec 2025
NCT05377034	STRATUMMultinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients	P2	Locally Advanced Hepatocellular Carcinoma	100	Oct 2022
NCT07358520	Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients	P4	Proteinuria	40	Jan 2026
NCT06789757	(HCC)The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)	P2	Hepatocellular Carcinoma	19	Feb 2025
NCT05797168	FONTANAPhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors	P1/P2	Ovarian Cancer	506	Jun 2023
NCT07478302	A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma	P1	Advanced Unresectable Hepatocellular Carcinoma	36	Apr 2026
NCT07233850	A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers	P2	Gastric/Gastroesophageal Junction Adenocarcinoma	300	Nov 2025
NCT07080216	Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer	P1/P2	Cervical Cancer	120	Sep 2025
NCT07054567	A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer	P2	Cervical Cancer	96	Aug 2025
NCT06953843	NSCLCStudy on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases	P2	NSCLC Stage IV Without EGFR/ALK Mutation	366	Jul 2025
NCT07009145	QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC	P2	Unresectable Colorectal Cancer	22	Jun 2025
NCT06958484	QL1706Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence	P2	HCC - Hepatocellular Carcinoma	60	May 2025
NCT07562490	CLEAR-04A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer	P2	ctDNA	100	Apr 2025
NCT06992648	REGTAS-2Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer	P3	Colorectal Cancer Metastatic	302	Apr 2025
NCT06584071	A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC	P1/P2	HCC	140	Dec 2024
NCT06590259	A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM	P2	Colorectal Cancer Liver Metastasis	20	Mar 2024
NCT06307249	PTST_PALBEVAPrecision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA	P1	Cancer	50	Feb 2023
NCT05502991	Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma	P2	Glioblastoma	60	Dec 2022
NCT05518994	Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma	P2	Astrocytoma of Brain	70	Dec 2022
NCT05281471	PRROCEfficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)	P3	Platinum-resistant Ovarian Cancer	186	Aug 2022
NCT04981509	Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer	P2	Hereditary Leiomyomatosis and Renal Cell Carcinoma	65	Jun 2022
NCT02925234	DRUPThe Drug Rediscovery Protocol (DRUP Trial)	P2	Cancer	1,550	Aug 2016
NCT07398599	Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study	N/A	Leptomeningeal Metastasis	30	Feb 2026
NCT07314619	Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer	P2	Platinum-resistant Recurrent Ovarian Cancer (PROC)	30	Dec 2025
NCT07186868	LQL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer	—	Recurrent Cervical Cancer	25	Oct 2025
NCT07007767	Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）	P2	Colorectal Cancer Metastatic	32	Jun 2025
NCT06663306	Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC	P1	Lung Cancer (NSCLC)	19	Dec 2024
NCT05588388	BELIEVEStudy of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases	P2	Extensive-stage Small-cell Lung Cancer	39	Aug 2024
NCT07111546	A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]	P2	Advanced Solid Tumour	140	Oct 2025
NCT06683703	Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases	P2	Non-small Cell Lung Cancer Patients with Brain Metastases	118	Dec 2024
NCT06711471	TAS-102Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer	P2	Gastric Cancer Adenocarcinoma Metastatic	31	Nov 2024
NCT06035133	Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy	N/A	Rectal Cancer	213	Nov 2023
NCT07134218	Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer	P2/P3	Rectal Cancer	180	Oct 2025
NCT06607458	DEL-LIVEREvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease	P2	Refractory Metastatic Colorectal Cancer	90	Aug 2025
NCT06540326	Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab	P2	Colorectal Cancer Metastatic	100	Nov 2024
NCT05185505	Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria	P4	Hepatocellular Carcinoma	24	Jan 2023
NCT05579366	RAINFOL-01Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)	P1/P2	High Grade Epithelial Ovarian Cancer	884	Dec 2022
NCT04486352	EndoMAPA Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer	P1/P2	Endometrial Cancer	148	Oct 2021
NCT06063070	First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer	P2	Ovarian Cancer	44	Oct 2023
NCT07407465	CHIMERAUpfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.	P2	Colorectal Cancer	42	Oct 2025
NCT06092242	The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer	P2	Colorectal Cancer	50	Oct 2023
NCT05284539	AwesomeEfficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer	P2	Non Small Cell Lung Cancer	760	Apr 2022
NCT05489211	Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)	P2	Endometrial Cancer	454	Sep 2022
NCT06976671	A Study to Determine the Safety and Efficacy of Bevacizumab Administered Via Injection Into the Shoulder Joint of Participants With Adhesive Capsulitis (Frozen Shoulder)	P2	Adhesive Capsulitis	28	Sep 2024
NCT06083844	Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy	P2	Ovarian Cancer	20	Dec 2023
NCT04687631	Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases	P3	Colorectal Cancer	508	Jan 2021
NCT04524871	MORPHEUS-LIVERA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	P1/P2	Advanced Liver Cancers	518	Nov 2020
NCT06420973	RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression	P2	Ovarian Carcinoma	54	May 2024
NCT05976568	A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma	P2/P3	Hepatocellular Carcinoma	668	Sep 2023
NCT07117877	Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer	P2	Platinum Resistant Ovarian Cancer	33	Sep 2025
NCT06047379	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	P1/P2	Diffuse Astrocytoma, IDH-Mutant	134	Nov 2023
NCT05919264	FOG-001 in Locally Advanced or Metastatic Solid Tumors	P1/P2	Cancer	595	May 2023
NCT05238922	Study of INCB123667 in Subjects With Advanced Solid Tumors	P1	Solid Tumors	604	Jul 2022
NCT07047560	IILiposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study	P2	Colorectal Cancer (CRC)	46	Sep 2024
NCT07044908	TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer	P1/P2	RAS/BRAF Wild Type Colorectal Cancer	72	Jul 2025
NCT07044921	IIClinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.	P2	Colorectal Cancer Metastatic	30	Sep 2024
NCT05828459	First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors	P1	Hematological Malignancy	150	Jul 2023
NCT05005403	Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan	P1	Non-Small Cell Lung Cancer	694	Nov 2021
NCT04803994	TACEThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma	P3	Hepatocellular Carcinoma	434	Jul 2021
NCT06742424	PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC	P2	Hepato Cellular Carcinoma (HCC)	36	Oct 2024
NCT06445062	ONStudy of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors	P1/P2	Colorectal Cancer	1,130	May 2024
NCT06703177	A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors	P1/P2	Advanced Solid Tumors	876	Feb 2025
NCT07059949	Union-mRCShort Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer	P2	Unresectable Metastatic Rectal Cancer	80	Jun 2025
NCT07157969	ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC	P2	HCC - Hepatocellular Carcinoma	300	Feb 2025
NCT06493760	A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients	P2	Metastatic Colorectal Cancer	130	Sep 2024
NCT05200260	Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer	P2	Ovarian Cancer	220	Jul 2022
NCT05364489	Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer	P2	Advanced Colorectal Cancer	20	Jun 2022
NCT06749860	Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression	P2	Lung Cancer	58	Feb 2024
NCT07083375	QL1706A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.	P2	Extensive Small Cell Lung Cancer	56	Aug 2025
NCT06753721	An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.	P1/P2	Advanced Colorectal Adenocarcinoma	13	Dec 2024
NCT06835179	SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.	P2	Unresectable Metastatic Colorectal Cancer	28	Feb 2025
NCT06004245	A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors	P1	Advanced Solid Tumors	280	Jan 2024
NCT05848739	A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors	P1	Colon Cancer	130	Jun 2023
NCT05398861	Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer	P2	HER-2 Negative Breast Cancer	79	Aug 2022
NCT07090525	Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions	P2	Overall Response Rate	60	Jul 2025
NCT06882915	TAS-102Efficacy and Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study	P1	Colorectal Cancer (CRC)	20	Jun 2026
NCT05806931	SCOTISequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer	P2	Colon Cancer	50	May 2023
NCT06856187	TASBELSecond-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer	P2	Metastatic Colorectal Cancer (CRC)	119	Feb 2025
NCT06400472	A Study of LY4170156 in Participants With Selected Advanced Solid Tumors	P1	Ovarian Neoplasms	495	May 2024
NCT05405595	ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors	P1/P2	Advanced/Metastatic Solid Tumors	186	Jun 2022
NCT05824975	KEYNOTE-G08A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)	P1/P2	Advanced Solid Tumor	358	May 2023
NCT06513221	A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab	P2	Metastatic Colorectal Cancer	100	Jul 2024
NCT06401824	Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases	P2	NSCLC Stage IV	25	Apr 2025
NCT06908031	CRITSCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer(CRIT)	P2	Rectal Adenocarcinoma	49	Apr 2025
NCT06876701	The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults	Early P1	Acute Leukemia	10	Apr 2025
NCT06873763	Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer	P1/P2	Metastatic Colorectal Cancer (CRC)	52	Jun 2025
NCT06496971	BEVA Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients	P3	Glioblastoma Multiforme	32	Nov 2024
NCT06782685	Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV	P1/P2	Advanced Pancreatic Cancer (Part 1)	138	Jun 2024
NCT05654454	A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer	P3	Non-Small Cell Lung Cancer	620	May 2023
NCT05516628	EMPHASISDeep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma	30	Feb 2023
NCT05525858	KOSMOSIIKPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II	—	Solid Tumor	1,000	Sep 2022
NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	P2	Ovarian Clear Cell Adenocarcinoma	80	Mar 2024
NCT05440708	A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma	P1/P2	Hepatocellular Carcinoma	193	Mar 2023
NCT07192185	Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab	P2	Hepatocellular Carcinoma (HCC)	30	Sep 2025
NCT06867432	Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma	20	Mar 2025
NCT06184698	Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer	P2	Colorectal Cancer	173	Jan 2024
NCT06718933	Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis	P1/P2	Breast Cancer Metastatic	74	Jan 2025
NCT05062317	ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases	P2	Liver Metastases	120	Apr 2022
NCT06801665	FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis	P2	Colon Cancer Liver Metastases	30	Apr 2025
NCT06566755	AK104Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer	P3	Colorectal Cancer	30	Feb 2024
NCT06859775	SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer	P1/P2	Recurrent or Metastatic Cervical Cancer	100	Apr 2025
NCT06543069	Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM	P2	Malignant Peritoneal Mesothelioma, Advanced	28	Jan 2024
NCT06123884	BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer	P2/P3	Cervical Cancer	526	Dec 2023
NCT06041490	Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation	P2	Liver Transplant; Complications	88	Sep 2023
NCT04689347	5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.	P1/P2	Metastatic Colorectal Cancer	27	Jan 2021
NCT06265350	Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases	N/A	Hepatocellular Carcinoma	80	Feb 2024
NCT05836324	A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors	P1	Solid Tumors	408	Jul 2023
NCT07253896	Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab	P2	Safety	40	Jan 2024
NCT07446452	Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study	P2	HER2-low Breast Cancer	37	Jan 2024
NCT07012798	MEDI4736FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma (HCC)	30	Sep 2025
NCT06696768	Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer	P1	Metastatic Colorectal Adenocarcinoma	24	Jun 2025
NCT07007728	Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis	P2	Colorectal Neoplasms	54	Jun 2025
NCT03401294	CONVERSIONConversion From Unresectable To Resectable Metastatic Colorectal Cancer.	P2	Metastatic Colorectal Cancer	32	May 2025
NCT06906341	Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers	P2	Ovarian Cancer	270	Apr 2025
NCT06764680	Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer	P2	Colorectal Cancer Metastatic	57	Dec 2024
NCT06643793	IIEvaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC	P2	Colorectal Neoplasms Malignant	30	Nov 2024
NCT06825624	ARTEMIS-102ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer	P1	Metastatic Colorectal Cancer (CRC)	560	Oct 2024
NCT06603376	Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer	P2	Colorectal Carcinoma	75	Sep 2024
NCT06341296	Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer	P2	Metastatic Colorectal Cancer	86	Jun 2024
NCT07359404	Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC	P2	Advanced Breast Cancer	60	Apr 2024
NCT06218810	Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer	P2	Metastatic Colorectal Cancer	53	Jan 2024
NCT06433869	The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites	P2	Malignant Ascites	60	Dec 2023
NCT06292286	SCENICSecondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer	N/A	Recurrent Ovarian Carcinoma	18	Nov 2023
NCT05540275	Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma	P2	Recurrent Glioblastoma	30	Oct 2023
NCT06156527	A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker	P2	Lazertinib	120	Sep 2023
NCT05636111	Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer	P1	Ovarian Cancer	34	Jul 2023
NCT05844046	MONTBLANCSequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients	P2	Hepatocellular Carcinoma	83	Apr 2023
NCT05640830	TREAZURETrastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy	P1/P2	HER2-positive Advanced Gastric Cancer	47	Jan 2023
NCT05512351	Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma	P2	Oligodendroglioma	80	Dec 2022
NCT05512325	Study on Gene Evolution in Glioma Under Stress Therapy	—	Genetic Change	100	Dec 2022
NCT05488522	SBRT With Atezo/Bev for HCC	P1	Hepatocellular Carcinoma	18	Sep 2022
NCT05727163	FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients	P2	Colorectal Cancer Metastatic	194	Jul 2022
NCT04181060	Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer	P3	Advanced Lung Non-Squamous Non-Small Cell Carcinoma	300	Dec 2020
NCT04566380	ONO-4538-98ONO-4538 Phase II Rollover Study (ONO-4538-98)	P2	Pan-tumor	59	Sep 2020
NCT02847559	Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma	P2	Anaplastic (Malignant) Meningioma	27	Aug 2016
NCT03303495	A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC	P3	Colorectal Neoplasms	280	Nov 2011
NCT06793813	NSCLCCadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)	P2	Stage IVB Lung Cancer	44	Jan 2024
NCT05305131	GPPBRandomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer	P2	Nasopharyngeal Cancer	50	Mar 2022
NCT06783647	NSCLCA Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]	P2	Advanced Solid Tumour	230	Jun 2025
NCT06008119	Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer	P3	Colorectal Cancer Metastatic	165	Oct 2023
NCT05757336	Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer	P2	Gallbladder Cancer	50	Dec 2022
NCT06801730	NALIRIBVRGIrinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma	P2	Glioma	38	Jan 2025
NCT06788171	PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM	P2	Colorectal Cancer Liver Metastasis	35	Mar 2025
NCT05798819	A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer	P3	Persistent, Recurrent, or Metastatic Cervical Cancer	424	May 2023
NCT05594095	SNF Platform Study of HR+/ HER2-advanced Breast Cancer	P2	Breast Neoplasm	620	Dec 2022
NCT07445347	BevaHHearTEfficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network	—	Hereditary Hemorrhagic Telangiectasia (HHT)	111	Oct 2025
NCT06293014	TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer	P2	Colorectal Cancer	224	Feb 2024
NCT05970666	Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma	P2	Adebrelimab	71	Nov 2023
NCT05640609	Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer	P1/P2	Stomach Neoplasm	57	Mar 2023
NCT06558227	Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma	P2	Hepatocellular Carcinoma	90	Oct 2024
NCT06512051	A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer	P1/P2	Advanced or Metastatic Non-small Cell Lung Cancer	248	Jul 2024
NCT06313970	First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients	P2	Pancreatic Cancer	58	Jun 2024
NCT06125080	UTILIZABLEThe Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study	P2	TNBC - Triple-Negative Breast Cancer	78	Oct 2023
NCT05464030	PROCEADE-CRC-01Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)	P1	Colorectal Cancer	200	Aug 2022
NCT06229340	NТО-RASLeflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations	P2	RAS Mutation	20	Oct 2023
NCT06192680	Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer	P2	Colorectal Cancer	63	Apr 2024
NCT06202001	Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients	P1/P2	Metastatic Colorectal Cancer	70	Oct 2022
NCT06769425	HS-10502HS-10502 Combination Treatment in Patients With Advanced Solid Tumors	P1	Recurrent Ovarian Cancer	157	May 2025
NCT04361370	OPEB-01Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer	P2	Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer	44	Oct 2020
NCT07285850	ABATE-MASLDThe Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD	P2/P3	HCC - Hepatocellular Carcinoma	20	Oct 2025
NCT05001880	Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma	P2	Peritoneal Malignant Mesothelioma	66	Mar 2022
NCT06341309	Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer	P1/P2	Metastatic Colorectal Cancer	20	Aug 2024
NCT06539559	Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer	P2	Breast Neoplasms	60	Aug 2024
NCT06840002	A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer	P1/P2	Ovarian Cancer	150	Mar 2025
NCT05930665	Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma	P2	Pleural Mesothelioma	38	Nov 2023
NCT05975463	Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy	P2	Hepatocellular Carcinoma	30	Sep 2023
NCT06717880	A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer	P1	Advanced Malignancies	260	Jul 2023
NCT05970302	XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC	P2	Tislelizumab	52	Jul 2023
NCT06952452	AMDPharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)	P3	Wet Age-related Macular Degeneration	630	Nov 2022
NCT06971237	IMSIRTSIRT and Peri-immunotherapy : a New Concept	—	Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy	60	Jun 2025
NCT07117435	Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases	P1	Colorectal Liver Metastases	7	May 2025
NCT06747728	Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain	N/A	Brain Glioma	20	Mar 2024
NCT06858956	LReal-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer	—	Colorectal Cancer	200	Mar 2025
NCT06530784	Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma	P2	Carcinoma, Hepatocellular	36	Jul 2024
NCT04999761	AB122 Platform Study	P1	Advanced or Metastatic Solid Tumor	917	Jun 2021
NCT04776655	LIBImAbStudy in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB	P3	Colorectal Cancer	280	Apr 2021
NCT06311851	TACETransarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases	P1/P2	Cancer	40	Jun 2025
NCT06537297	Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases	P2	Non-small Cell Lung Cancer	30	Sep 2024
NCT06282445	MSSEfficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer	P2	Colorectal Cancer Metastatic	36	Mar 2024
NCT05992220	ALERT-HCCAtezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion	P2	Hepatocellular Carcinoma	138	Oct 2022
NCT06276283	WU-KONG29DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)	P2	Non-small Cell Lung Cancer	60	Feb 2023
NCT07338097	Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema	N/A	Diabetic Macular Edema (DME)	116	Sep 2025
NCT06163820	BETTERBevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases	P1/P2	Melanoma Brain Metastases	46	May 2025
NCT06139211	A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors	P1/P2	Advanced Solid Tumor	186	Jan 2024
NCT06550453	Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer	P4	Locally Advanced Colorectal Cancer	20	Sep 2024
NCT07065435	RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study	P2	HER2 + Breast Cancer	74	Jan 2024
NCT07204574	The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer	P1/P2	CRC	40	May 2025
NCT06682247	A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer	—	Colorectal Cancer Metastatic	200	Nov 2024
NCT06016062	A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors	P1/P2	Solid Tumor	221	Sep 2023
NCT04973293	Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer	N/A	Lung Neoplasm Malignant	20	Oct 2022
NCT05751343	Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial	P2	Hepatocellular Carcinoma	55	Mar 2023
NCT06323382	Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma	—	Advanced Hepatocellular Carcinoma	240	Jan 2021
NCT05713994	CCGLC-001Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma	—	Hepatocellular Carcinoma Non-resectable	300	May 2020
NCT06850571	Aflibercept and Bevacizumab for Diabetic Maculopathies	P4	Diabetic Maculopathy	102	Feb 2025
NCT05628038	TORCH-RThe Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer	P2	Recurrent Rectal Cancer	93	Nov 2022
NCT05192798	Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC	P2	Triple-negative Breast Cancer	128	Jan 2022
NCT06827353	OVNI-BNiraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency	—	Ovarian Carcinoma	300	Oct 2020
NCT06595355	Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin	P2/P3	Diabetic Macular Edema	52	Oct 2021
NCT06090656	BESTBevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)	P2	Hepatocellular Carcinoma	88	Mar 2023
NCT06808412	To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer	P2	Rcctal Cancer	118	Jul 2024
NCT04303988	A Phase II Study of Triple-negative Breast Cancer Brain Metastases.	P2	Breast Cancer	35	Mar 2020
NCT06849362	Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer	—	Metastatic Colorectal Cancer (CRC)	200	Dec 2019
NCT04787289	A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer	P2	Ovarian Cancer	244	Sep 2021
NCT05468242	Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy	P2	Stage III Non-small Cell Lung Cancer	116	Jan 2022

Bevacizumab clinical trials by indication

Colorectal Cancer (189)

NCT	Acronym	Phase	Status	Title
NCT05797467	—	P3	recruiting	Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
NCT07071714	—	P2	recruiting	A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT07323576	INAVO-CRC	P2	withdrawn	A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer
NCT07525206	AndroMETa-CRC	P3	recruiting	A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07094893	ARIEL-ENGIC	P4	not yet recruiting	Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
NCT07362836	FRU-RAS	P3	not yet recruiting	Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)
NCT06280495	—	P2/P3	recruiting	Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
NCT04230187	TRIBE-C	P3	active not recruiting	Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer
+ 181 more, see All trials below.

Metastatic Colorectal Cancer (116)

NCT	Acronym	Phase	Status	Title
NCT05375708	SIRIUS	P2	suspended	Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites
NCT07359456	COLIBRI-GI	P2	not yet recruiting	Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
NCT07079631	BNT327	P1/P2	recruiting	A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
NCT05007132	—	P2	recruiting	Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
NCT06252649	CodeBreaK 301	P3	recruiting	Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT05462613	REPROGRAM-02	P2/P3	recruiting	Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
NCT04929223	INTRINSIC	P1	recruiting	A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT06856837	—	P2	recruiting	- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
+ 108 more, see All trials below.

Breast Cancer (113)

NCT	Acronym	Phase	Status	Title
NCT04158258	—	N/A	active not recruiting	A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
NCT04732598	AMBITION	P3	completed	A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
NCT04303988	—	P2	recruiting	A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
NCT05386524	—	P2	unknown	Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC
NCT05180006	BIS-Program	P2	terminated	Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
NCT05357417	—	P2	unknown	Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases
NCT03961698	MARIO-3	P2	unknown	Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
NCT03395899	ECLIPSE	P2	completed	Pre-operative Immunotherapy Combination Strategies in Breast Cancer
+ 105 more, see All trials below.

Hepatocellular Carcinoma (78)

NCT	Acronym	Phase	Status	Title
NCT05620771	—	P2	recruiting	Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
NCT06339424	PhotonAB	P2	recruiting	Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
NCT04727307	AB-LATE02	P2	active not recruiting	Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
NCT07317414	—	P2	recruiting	β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
NCT06109272	LIVIGNO-2	P2/P3	recruiting	A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
NCT06921785	ARTEMIDE-HCC01	P3	recruiting	Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT05528952	TERTIO	P2	recruiting	Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT07324824	—	P2	recruiting	Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
+ 70 more, see All trials below.

Ovarian Cancer (78)

NCT	Acronym	Phase	Status	Title
NCT06990516	—	P1/P2	not yet recruiting	SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
NCT07472140	—	P2/P3	recruiting	PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
NCT06824467	MK-2870	P3	recruiting	A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT05445778	GLORIOSA	P3	active not recruiting	Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT06954584	—	P3	recruiting	Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
NCT05183984	NIRVANA-1	P2	recruiting	Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
NCT06819007	DO-01	P3	recruiting	Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT07370818	—	P2	not yet recruiting	To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer
+ 70 more, see All trials below.

Lung Cancer (50)

NCT	Acronym	Phase	Status	Title
NCT06492421	—	P2	recruiting	Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
NCT06483347	—	P2	recruiting	Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
NCT07197008	—	P2	not yet recruiting	Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis
NCT07244926	—	P2	not yet recruiting	Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT06749860	—	P2	recruiting	Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
NCT03390686	—	P3	active not recruiting	A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
NCT04988607	—	P2	unknown	Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
NCT04939662	SUKSES-B2	P2	completed	Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects
+ 42 more, see All trials below.

Glioblastoma (47)

NCT	Acronym	Phase	Status	Title
NCT07263438	Phenix	P2	recruiting	Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
NCT06061809	—	P2	active not recruiting	N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
NCT04121455	GLORIA	P1/P2	active not recruiting	Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
NCT05271240	SIACI	P3	recruiting	Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
NCT05502991	—	P2	not yet recruiting	Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
NCT03743662	—	P2	active not recruiting	Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
NCT05410301	—	N/A	withdrawn	Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
NCT01903330	—	P2	unknown	ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
+ 39 more, see All trials below.

Non-Small Cell Lung Cancer (40)

NCT	Acronym	Phase	Status	Title
NCT07472647	—	P1/P2	not yet recruiting	SYS6090 Combination Therapy in Advanced Lung Cancer
NCT04449874	—	P1	active not recruiting	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT05029882	IV	P1	active not recruiting	Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
NCT05005403	—	P1	recruiting	Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
NCT05654454	—	P3	recruiting	A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
NCT05491811	EAGLE	P2	active not recruiting	Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
NCT03178552	B-FAST	P2/P3	active not recruiting	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT05273814	—	P1	unknown	Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer
+ 32 more, see All trials below.

Glioblastoma Multiforme (39)

NCT	Acronym	Phase	Status	Title
NCT05956821	—	P1/P2	recruiting	Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
NCT01269853	—	P1/P2	recruiting	Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
NCT06329570	—	P1/P2	recruiting	Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NCT01386710	—	P1/P2	suspended	Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
NCT06496971	BEV	P3	recruiting	A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NCT02285959	—	P1	unknown	Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
NCT01933815	—	P1/P2	suspended	Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
NCT02386826	—	P1	completed	INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
+ 31 more, see All trials below.

Colorectal Neoplasms (37)

NCT	Acronym	Phase	Status	Title
NCT06131840	—	P1	recruiting	A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT05253651	MOUNTAINEER-03	P3	recruiting	A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT06750094	OrigAMI-3	P3	recruiting	A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT02885753	OSCAR	P3	recruiting	Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
NCT05239741	MK-3475	P3	active not recruiting	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
NCT06663319	—	P1	recruiting	A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT07535632	BEST	P2	not yet recruiting	SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer
NCT05141721	—	P2/P3	active not recruiting	A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
+ 29 more, see All trials below.

Diabetic Macular Edema (35)

NCT	Acronym	Phase	Status	Title
NCT02229175	—	P2/P3	withdrawn	Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema
NCT05217680	PRO-169	P3	completed	Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
NCT06595355	—	P2/P3	recruiting	Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin
NCT03832179	STAMP	P4	completed	Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
NCT05582577	—	P2/P3	unknown	Additional Effect of Subthreshold Micropulse Laser to Intravitreous Injection of Bevacizumab on Diabetic Macular Edema
NCT04991350	REBEL	P4	terminated	Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema
NCT05080803	—	N/A	completed	Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome
NCT05083689	—	P2/P3	unknown	Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema
+ 27 more, see All trials below.

Non-small Cell Lung Cancer (29)

NCT	Acronym	Phase	Status	Title
NCT05334277	FOCUS-C	P2	recruiting	Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
NCT06537297	—	P2	not yet recruiting	Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases
NCT06276283	WU-KONG29	P2	recruiting	DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
NCT06182800	—	P2	unknown	Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy
NCT05754736	—	P2	unknown	Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.
NCT05738317	—	P2	unknown	Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment
NCT03991403	—	P3	unknown	Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
NCT04997382	CLASSIC5	P2	completed	Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC
+ 21 more, see All trials below.

Pancreatic Cancer (26)

NCT	Acronym	Phase	Status	Title
NCT03351296	BETTER2	P2	active not recruiting	Two Chemotherapy Regimens Plus or Minus Bevacizumab
NCT06313970	—	P2	recruiting	First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
NCT03329248	—	P1/P2	terminated	QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03136406	—	P1/P2	terminated	QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03586869	—	P1/P2	terminated	QUILT-3.080: NANT Pancreatic Cancer Vaccine
NCT01803282	—	P1	completed	Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
NCT03387098	—	P1/P2	terminated	QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT02574663	—	P1	completed	TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
+ 18 more, see All trials below.

Colorectal Cancer Metastatic (25)

NCT	Acronym	Phase	Status	Title
NCT07012954	—	P1/P2	recruiting	ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
NCT07193862	—	Early P1	recruiting	Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
NCT06992648	REGTAS-2	P3	recruiting	Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer
NCT07007767	—	P2	not yet recruiting	Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）
NCT06540326	—	P2	recruiting	Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
NCT07044921	II	P2	recruiting	Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
NCT06764680	—	P2	recruiting	Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
NCT05727163	—	P2	recruiting	FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
+ 17 more, see All trials below.

Metastatic Breast Cancer (25)

NCT	Acronym	Phase	Status	Title
NCT03424005	Morpheus-panBC	P1/P2	recruiting	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT05769010	—	P2	recruiting	Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
NCT02299999	SAFIR02_Breast	P2	active not recruiting	SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
NCT04389073	—	P2	unknown	Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
NCT04408118	ATRACTIB	P2	completed	First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
NCT02829008	—	P2	unknown	Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
NCT02802098	—	Early P1	completed	Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer
NCT01989780	BOOSTER	P2	completed	Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
+ 17 more, see All trials below.

Cervical Cancer (23)

NCT	Acronym	Phase	Status	Title
NCT07216703	MK-2870	P3	recruiting	A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT06755515	—	P2/P3	enrolling by invitation	A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
NCT06459687	—	P3	recruiting	Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
NCT07497074	—	P2	not yet recruiting	JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
NCT07080216	—	P1/P2	recruiting	Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
NCT07054567	—	P2	recruiting	A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
NCT06123884	—	P2/P3	recruiting	BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
NCT03786081	—	P1/P2	terminated	Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
+ 15 more, see All trials below.

Non Small Cell Lung Cancer (23)

NCT	Acronym	Phase	Status	Title
NCT06557096	—	Early P1	not yet recruiting	CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC
NCT07093762	—	N/A	not yet recruiting	Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC
NCT05284539	Awesome	P2	recruiting	Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
NCT05781308	ADAPTABLE	P2	active not recruiting	Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
NCT05296278	—	P2	unknown	Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC
NCT03647592	—	N/A	unknown	Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer
NCT03520686	—	P3	terminated	Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT04405674	—	P2	unknown	Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC
+ 15 more, see All trials below.

Rectal Cancer (21)

NCT	Acronym	Phase	Status	Title
NCT04215731	FOBEAR	P3	recruiting	Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer
NCT06035133	—	N/A	not yet recruiting	Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy
NCT07134218	—	P2/P3	not yet recruiting	Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer
NCT05640726	SCRT	P2	unknown	The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
NCT04017455	TARZAN	P2	active not recruiting	Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
NCT01818973	—	P2	unknown	Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer
NCT01650428	BACCHUS	P2	completed	Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery
NCT03085992	TRUST	P2	completed	Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer
+ 13 more, see All trials below.

Cancer (21)

NCT	Acronym	Phase	Status	Title
NCT05862285	UmbrellaMAX	P3	recruiting	A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT03899155	—	P2	recruiting	Pan Tumor Rollover Study
NCT03768063	IMbrella B	P3	active not recruiting	A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT06307249	PTST_PALBEVA	P1	recruiting	Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
NCT02925234	DRUP	P2	recruiting	The Drug Rediscovery Protocol (DRUP Trial)
NCT05919264	—	P1/P2	recruiting	FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT03148418	—	P3	active not recruiting	A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT06311851	TACE	P1/P2	recruiting	Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
+ 13 more, see All trials below.

Renal Cell Carcinoma (19)

NCT	Acronym	Phase	Status	Title
NCT03693573	—	P3	withdrawn	A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
NCT02919371	CASA	P1/P2	unknown	Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)
NCT02420821	IMmotion151	P3	completed	A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
NCT03063762	RCC	P1	completed	Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
NCT01399918	RCC	P2	completed	Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
NCT01984242	IMmotion150	P2	completed	A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
NCT01625936	—	P1	completed	CRLX101 Plus Bevacizumab in Advanced RCC
NCT02835833	—	P1	completed	Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
+ 11 more, see All trials below.

Carcinoma, Non-Small-Cell Lung (17)

NCT	Acronym	Phase	Status	Title
NCT03337698	Morpheus Lung	P1/P2	terminated	A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
NCT04194203	—	P3	completed	A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
NCT05263947	—	P2	completed	Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
NCT04426825	—	P2	completed	A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
NCT02810457	AVANA	P3	completed	Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
NCT02366143	IMpower150	P3	completed	A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02655536	BRILLIANT	P2	unknown	Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
NCT01578551	—	P2	terminated	Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.
+ 9 more, see All trials below.

Advanced Solid Tumors (16)

NCT	Acronym	Phase	Status	Title
NCT06730750	—	P1/P2	recruiting	A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
NCT06697197	—	P1/P2	recruiting	A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT06895928	—	P2	recruiting	A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
NCT05867420	—	P1/P2	recruiting	A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
NCT06336707	—	P1	recruiting	HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
NCT04185883	—	P1	active not recruiting	Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT02671435	MEDI4736	P1/P2	active not recruiting	A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
NCT06703177	—	P1/P2	recruiting	A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
+ 8 more, see All trials below.

Hepatocellular Carcinoma (HCC) (15)

NCT	Acronym	Phase	Status	Title
NCT07293468	BIIRTH	P2/P3	recruiting	Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
NCT06725121	MacroTrans	P1/P2	recruiting	Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
NCT07291076	HCC	P1/P2	recruiting	A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07490262	—	P2/P3	recruiting	A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
NCT06680258	—	P3	not yet recruiting	A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
NCT07392866	—	P2/P3	not yet recruiting	A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
NCT07128251	TACE	P2	not yet recruiting	A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
NCT07331883	CLEAR-2	P2	recruiting	Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
+ 7 more, see All trials below.

Recurrent Glioblastoma (15)

NCT	Acronym	Phase	Status	Title
NCT06160206	—	P2	recruiting	Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
NCT05284643	—	N/A	recruiting	Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
NCT07297212	BNT327	P2	recruiting	A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
NCT05540275	—	P2	not yet recruiting	Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
NCT02974621	—	P2	active not recruiting	Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
NCT05118776	—	P3	active not recruiting	Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
NCT05191784	GBM	P2	unknown	GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
NCT05638451	GBM	P2	unknown	Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
+ 7 more, see All trials below.

Liver Cancer (15)

NCT	Acronym	Phase	Status	Title
NCT06482801	—	P2	recruiting	Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
NCT06408623	—	P2	unknown	Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer
NCT05717400	—	P4	terminated	Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
NCT00410956	—	P2	completed	Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
NCT01180959	HCC	P2	completed	Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
NCT00881751	—	P2	completed	Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
NCT00980239	—	P1	completed	HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
NCT00867321	—	P1/P2	completed	Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
+ 7 more, see All trials below.

Solid Tumor (14)

NCT	Acronym	Phase	Status	Title
NCT02446431	Metronomic	Early P1	recruiting	Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
NCT06576037	—	P1	recruiting	Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
NCT05525767	—	P4	recruiting	Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
NCT04516447	MUIR	P1	recruiting	A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
NCT05584670	—	P1/P2	recruiting	A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
NCT05525858	KOSMOSII	N/A	recruiting	KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
NCT03872947	—	P1	active not recruiting	A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
NCT06016062	—	P1/P2	recruiting	A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
+ 6 more, see All trials below.

Non-Squamous Non-Small Cell Lung Cancer (14)

NCT	Acronym	Phase	Status	Title
NCT06334757	—	P2	unknown	Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
NCT01995188	—	P1	completed	A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
NCT01351415	NSCLC	P3	completed	A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
NCT01496742	—	P2	completed	A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
NCT00974584	—	P1	completed	A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
NCT01077713	—	P2	completed	A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer
NCT02596958	NSLC	N/A	completed	Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants
NCT01366131	NILE	P2	completed	Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)
+ 6 more, see All trials below.

Neoplasms (13)

NCT	Acronym	Phase	Status	Title
NCT06551142	PanTumor-101	P1	recruiting	A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
NCT07277270	—	P1	recruiting	A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
NCT04607421	—	P3	active not recruiting	A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT05112965	—	P3	active not recruiting	An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
NCT03307785	—	P1	completed	Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
NCT03250832	CITRINO	P1	completed	Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors
NCT01588184	—	P4	completed	An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
NCT01514123	—	P1	completed	Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors
+ 5 more, see All trials below.

Age Related Macular Degeneration (13)

NCT	Acronym	Phase	Status	Title
NCT03609307	—	P2/P3	unknown	Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
NCT02296567	—	P2/P3	unknown	Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients
NCT00593450	—	P3	completed	Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
NCT01626339	—	N/A	unknown	Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter
NCT01014468	AxL-2009	P3	unknown	Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration
NCT01327222	LOW-VISION	P3	completed	Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)
NCT00729846	PDT	P2	completed	Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
NCT00376701	—	P2	completed	Combination Therapy for Age-Related Macular Degeneration.
+ 5 more, see All trials below.

Diabetic Retinopathy (13)

NCT	Acronym	Phase	Status	Title
NCT06559488	—	N/A	completed	IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes
NCT02590094	—	N/A	completed	Preoperative Bevacizumab and Ziv-Aflibercept Administration in PDR Subjects Undergoing PPV
NCT01298076	—	P2	completed	Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
NCT01504724	IVB	P4	completed	Effect of the Adjunctive IVB Before PRP
NCT00545870	—	P3	completed	Bevacizumab Versus Ranibizumab for Diabetic Retinopathy
NCT01487629	IBERA-DME	P2	unknown	Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema
NCT00596297	IBEVI	P1/P2	completed	Preoperative Bevacizumab for Vitreous Hemorrhage
NCT00690768	IBETRA	P2	completed	Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA)
+ 5 more, see All trials below.

Ovarian Neoplasms (12)

NCT	Acronym	Phase	Status	Title
NCT07318558	TroFuse-021	P3	recruiting	A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07213804	FRAmework-01	P3	recruiting	A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT06023862	DOVE	P2	recruiting	A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
NCT06400472	—	P1	recruiting	A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT01932125	—	P4	completed	An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT03574779	OPAL	P2	completed	A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
NCT03326193	—	P2	completed	A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT05440578	—	N/A	unknown	First-line Olaparib Combined With Bevacizumab Maintenance Therapy
+ 4 more, see All trials below.

Solid Tumors (12)

NCT	Acronym	Phase	Status	Title
NCT05101070	aCCeleR8-001	P1/P2	recruiting	S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
NCT05238922	—	P1	recruiting	Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT05836324	—	P1	recruiting	A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05904457	BRISK	P2	unknown	A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer
NCT04861948	—	P1	terminated	IBI188 Combination Therapy in Solid Tumors
NCT01197170	—	P1	completed	Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
NCT01445509	—	P1	completed	Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
NCT02648711	NLG207	P1	terminated	Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
+ 4 more, see All trials below.

Metastatic Colorectal Cancer (CRC) (11)

NCT	Acronym	Phase	Status	Title
NCT07585279	—	P2/P3	not yet recruiting	A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
NCT07381764	ROMANCE - GOIM	P2	not yet recruiting	ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"
NCT07286695	—	P2	not yet recruiting	Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer
NCT06887218	—	P2	recruiting	5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
NCT07228832	HARMONi-GI3	P3	recruiting	Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07395063	—	P2	not yet recruiting	A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.
NCT06856187	TASBEL	P2	recruiting	Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
NCT06873763	—	P1/P2	recruiting	Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer
+ 3 more, see All trials below.

Prostate Cancer (11)

NCT	Acronym	Phase	Status	Title
NCT00574769	—	P1/P2	completed	Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
NCT00776594	—	P2	completed	Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
NCT00658697	—	P2	completed	Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
NCT01083368	—	P1/P2	completed	Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
NCT00321646	—	P2	completed	Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
NCT00499694	—	N/A	completed	Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel
NCT00203424	—	P2	completed	Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
NCT00996502	—	P1/P2	terminated	Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
+ 3 more, see All trials below.

Melanoma (10)

NCT	Acronym	Phase	Status	Title
NCT04107168	—	N/A	unknown	Microbiome Immunotherapy Toxicity and Response Evaluation
NCT02681549	NSCLC	P2	completed	Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
NCT04091217	—	P2	completed	Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
NCT03167177	—	P1/P2	withdrawn	QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
NCT00790010	—	P1	completed	Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
NCT02023710	—	P2	unknown	Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma
NCT01495988	—	P2	terminated	Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
NCT01048554	MEL0107	P2	completed	Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System
+ 2 more, see All trials below.

Esophageal Cancer (10)

NCT	Acronym	Phase	Status	Title
NCT01191697	CAPOX	P2	completed	CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
NCT03558724	ORCA	P1	terminated	Fluorescence Endoscopy of Esophageal Carcinoma
NCT02129933	VICE	P1	completed	VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions
NCT00394433	TPCA	P2	completed	Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
NCT00354679	—	P2	completed	Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer
NCT00737438	—	P2	completed	Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
NCT00911820	PCA	P2	completed	Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
NCT00217581	—	P2	completed	Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
+ 2 more, see All trials below.

Clear Cell Renal Cell Carcinoma (10)

NCT	Acronym	Phase	Status	Title
NCT02210117	—	Early P1	active not recruiting	Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
NCT01684397	—	P1/P2	active not recruiting	Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
NCT01198158	—	P3	terminated	Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
NCT01727089	—	P2	completed	Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
NCT00378703	—	P2	completed	Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
NCT00112840	—	P1/P2	completed	CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00324870	—	P1/P2	completed	Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00602862	—	N/A	completed	Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
+ 2 more, see All trials below.

Glioma (9)

NCT	Acronym	Phase	Status	Title
NCT07541781	—	P1	recruiting	Sitagliptin in Recurrent/Progressive Grade 4 Glioma
NCT06801730	NALIRIBVRG	P2	recruiting	Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma
NCT05611645	—	P2	unknown	Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence
NCT03532295	—	P2	completed	Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
NCT01743950	—	P2	terminated	A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
NCT01967810	—	P2	completed	ANG1005 in Patients With Recurrent High-Grade Glioma
NCT00795665	—	P2	completed	Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
NCT01137604	—	P2	completed	A Study in Subjects With Recurrent Malignant Glioma
+ 1 more, see All trials below.

Advanced Hepatocellular Carcinoma (9)

NCT	Acronym	Phase	Status	Title
NCT06618664	—	P3	recruiting	A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
NCT07166406	—	P3	recruiting	Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT05097911	—	P1	active not recruiting	Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.
NCT05444088	—	P1/P2	unknown	Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
NCT06233994	—	N/A	unknown	A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
NCT06323382	—	N/A	recruiting	Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
NCT06370065	HCC	P2	unknown	Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients
NCT05173298	HCC	N/A	unknown	Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
+ 1 more, see All trials below.

Epithelial Ovarian Cancer (9)

NCT	Acronym	Phase	Status	Title
NCT06469281	MUC16	P1	recruiting	A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
NCT06890338	IV	P2	recruiting	A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
NCT04015739	BOLD	P2	unknown	Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse
NCT03093155	—	P2	completed	Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
NCT02606305	—	P1/P2	completed	Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
NCT02022917	—	P2	completed	Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
NCT01832415	ENCOURAGE	N/A	completed	First Line Ovarian Cancer Treatment - Cohort Study
NCT01146795	—	P2	completed	Neoadjuvant Therapy for Ovarian Cancer
+ 1 more, see All trials below.

NSCLC (9)

NCT	Acronym	Phase	Status	Title
NCT07134413	—	P2	not yet recruiting	QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
NCT06844474	—	P2	recruiting	A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC
NCT04944069	ATTRACT	N/A	unknown	Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis
NCT04575415	BELLA	N/A	unknown	Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
NCT02759614	—	P3	completed	Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations
NCT02954172	—	P3	completed	Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC
NCT02179567	—	P2	terminated	Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC
NCT01368848	NSCLC	P2	completed	Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)
+ 1 more, see All trials below.

Advanced Colorectal Cancer (9)

NCT	Acronym	Phase	Status	Title
NCT07106034	ONTOP	P2	recruiting	Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
NCT06867822	—	P1	recruiting	Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
NCT05364489	—	P2	not yet recruiting	Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer
NCT02826837	—	P1/P2	unknown	LEAC-102 for Advanced Colorectal Cancer
NCT04324476	—	P2	unknown	A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer
NCT03126071	—	P2	unknown	Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer
NCT00707889	—	P2	completed	Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
NCT00386828	—	P2	completed	Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial
+ 1 more, see All trials below.

Retinopathy of Prematurity (9)

NCT	Acronym	Phase	Status	Title
NCT04634578	ROP4	P2	active not recruiting	Bevacizumab Treatment For Type 1 ROP
NCT04634604	ROP3	P3	terminated	A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP
NCT02390531	ROP1	P1	completed	Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
NCT05712642	—	P3	completed	A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity
NCT00622726	BEAT-ROP	P2	unknown	Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
NCT01232777	BLOCK-ROP	P2	withdrawn	Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)
NCT03334513	—	N/A	completed	Refractive Error and Biometry in Retinopathy of Prematurity
NCT00702819	BLOCK-ROP	P1	terminated	Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity
+ 1 more, see All trials below.

Macular Edema (9)

NCT	Acronym	Phase	Status	Title
NCT05290948	—	P2	unknown	Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions
NCT02623673	—	N/A	completed	Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema
NCT01471054	—	P2	terminated	Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
NCT00801866	—	P4	withdrawn	Avastin for Post-photocoagulation Macular Edema
NCT00804921	IOP	P2	completed	Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab
NCT00806169	DRP	P3	completed	Combined Triple Therapy in Diabetic Retinopathy (DRP)
NCT00804206	—	P4	terminated	Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation
NCT00703235	—	P2/P3	unknown	Intravitreal Bevacizumab for Diabetic Macular Edema
+ 1 more, see All trials below.

Proliferative Diabetic Retinopathy (9)

NCT	Acronym	Phase	Status	Title
NCT04674254	PROPER	P4	completed	Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy
NCT05514925	—	P4	unknown	Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy
NCT02705274	—	P2/P3	completed	PRP vs Bevacizumab for PDR Treatment
NCT01854593	—	P4	completed	Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy
NCT00745498	IBDV	N/A	completed	Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy
NCT01025934	—	P4	completed	Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
NCT01041690	—	N/A	completed	Efficacy of PreOperative Bevacizumab for Diabetic Eye Disease
NCT00656435	—	P3	completed	Bevacizumab and Long Acting Gas in Diabetic Vitrectomy
+ 1 more, see All trials below.

Malignant Glioma (9)

NCT	Acronym	Phase	Status	Title
NCT02829931	—	P1	completed	Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
NCT01891747	—	P1	completed	A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma
NCT01004874	XRT	P2	completed	Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
NCT02313272	HFSRT	P1	completed	Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
NCT01740258	BBP	P2	completed	Bevacizumab Beyond Progression (BBP)
NCT01266031	—	P1/P2	completed	Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
NCT00859222	—	P1/P2	completed	LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
NCT00953121	MG	P2	completed	Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
+ 1 more, see All trials below.

Glaucoma (9)

NCT	Acronym	Phase	Status	Title
NCT02767219	RAFTS	P3	completed	The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery
NCT02901236	AvastinvsMMC	P2/P3	completed	Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma
NCT01229202	—	P4	withdrawn	Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery
NCT01263834	Bevacizumab	P2/P3	completed	Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome
NCT01166594	—	P4	completed	Use of Bevacizumab in Trabeculectomy Surgery
NCT01122966	bevazicumab	P2/P3	unknown	The Effect of Bevacizumab on the Trabeculectomy
NCT00853073	Avastin	P2/P3	completed	Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?
NCT00557232	—	P4	completed	Intraocular Bevacizumab (Avastin) for Rubeosis Iridis
+ 1 more, see All trials below.

Kidney Cancer (9)

NCT	Acronym	Phase	Status	Title
NCT01217931	—	P2	active not recruiting	Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
NCT01264341	—	P2	terminated	Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
NCT00193154	—	P2	completed	OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
NCT00601926	—	P2	terminated	Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00072046	—	P3	completed	Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
NCT00323739	—	P2	completed	Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
NCT00853021	—	P2	completed	Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
NCT00873236	—	P2	unknown	MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer
+ 1 more, see All trials below.

Advanced Cancer (9)

NCT	Acronym	Phase	Status	Title
NCT01187199	—	P1	active not recruiting	Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
NCT01113476	—	P1	completed	Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
NCT01015222	—	P1	completed	Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
NCT00543504	—	P1	completed	Bevacizumab in Multiple Phase I Combinations
NCT00761644	—	P1	completed	Doxil, Bevacizumab and Temsirolimus Trial
NCT00610493	—	P1	completed	Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
NCT01152203	—	P1	completed	Bendamustine and Bevacizumab for Advanced Cancers
NCT00530907	—	P1	completed	Valproic Acid and Bevacizumab in Patients With Advanced Cancer
+ 1 more, see All trials below.

Carcinoma, Hepatocellular (8)

NCT	Acronym	Phase	Status	Title
NCT04180072	—	N/A	active not recruiting	Atezolizumab Plus Bevacizumab With HCC and HBV Infection
NCT06530784	—	P2	not yet recruiting	Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
NCT04102098	IMbrave050	P3	completed	A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
NCT05337137	RELATIVITY-106	P1/P2	completed	A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
NCT05908786	—	P1/P2	completed	A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
NCT04487067	AMETHISTA	P3	completed	A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
NCT04732286	—	P3	terminated	A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
NCT03434379	IMbrave150	P3	completed	A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Sarcoma (8)

NCT	Acronym	Phase	Status	Title
NCT01746238	—	P1	active not recruiting	Bevacizumab/Doxorubicin/Radiation for Sarcoma
NCT01189643	—	Early P1	active not recruiting	Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
NCT00643565	—	P2	completed	A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.
NCT01106872	—	P1	completed	Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
NCT00288015	—	P2	completed	Bevacizumab in Treating Patients With Angiosarcoma
NCT00887809	—	P2	completed	Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
NCT00276055	—	P1	completed	Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
NCT00052390	—	P2	completed	Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma

Unspecified Adult Solid Tumor, Protocol Specific (8)

NCT	Acronym	Phase	Status	Title
NCT00276575	—	P1	completed	Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
NCT00849550	COBRA	P1	completed	Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.
NCT00550927	—	P1	completed	Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer
NCT00898794	—	N/A	unknown	Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
NCT00357318	—	P1	completed	Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
NCT00416637	—	P1	completed	Bevacizumab in Treating Patients With Advanced Solid Tumors
NCT00049088	—	P1	terminated	Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT00005061	—	P1	completed	Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors

Colorectal Carcinoma (7)

NCT	Acronym	Phase	Status	Title
NCT06603376	—	P2	recruiting	Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer
NCT04781270	—	P3	unknown	mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases
NCT05799820	—	P2	unknown	QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
NCT04988191	—	P1/P2	unknown	Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
NCT02563002	MK-3475	P3	completed	Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
NCT01126866	APRIORI	P2	terminated	Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy
NCT00735241	FAST	P2/P3	withdrawn	FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma

Breast Neoplasms (7)

NCT	Acronym	Phase	Status	Title
NCT06539559	—	P2	not yet recruiting	Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
NCT03280563	MORPHEUS HR+BC	P1/P2	completed	A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
NCT01281696	—	P2	completed	Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis
NCT00356681	—	P2	terminated	A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
NCT00373256	—	P3	completed	A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
NCT00281528	—	P2	terminated	Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
NCT00446030	—	P2	completed	Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer

Colon Cancer (7)

NCT	Acronym	Phase	Status	Title
NCT05848739	—	P1	recruiting	A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
NCT05806931	SCOTI	P2	recruiting	Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
NCT02138617	—	P2	completed	Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
NCT04213222	ROBOT	N/A	unknown	Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases
NCT00819780	KRAS	P2	completed	PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
NCT00826800	—	N/A	terminated	Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer
NCT00193219	—	P2	completed	Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

Age-Related Macular Degeneration (7)

NCT	Acronym	Phase	Status	Title
NCT05112861	NORSE SEVEN	P3	active not recruiting	A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
NCT05262244	LEAF	P1	completed	Targeted Fluorescence Imaging in AMD
NCT03668054	—	P3	completed	Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)
NCT01940887	E10030	P3	terminated	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
NCT02387957	—	P2	terminated	A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
NCT03552770	—	P4	completed	Single or Combined Protocols for NV-AMD
NCT00805649	ARMD	P4	completed	Combined Therapy in Age-Related Macular Degeneration (ARMD)

Pterygium (7)

NCT	Acronym	Phase	Status	Title
NCT05314673	—	P4	completed	Preoperative Bevacizumab Injection in Primary Pterygium in Tunisian Patients
NCT01115517	—	P2	completed	Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
NCT01311960	—	P3	completed	Topical Bevacizumab for Preventing Recurrent Pterygium
NCT01380678	bevacizumab	P3	unknown	Intralesional Bevacizumab Injection on Primary Pterygium
NCT01736449	—	P4	completed	Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management
NCT01686529	—	P1	completed	Bevacizumab for Primary Pterygium Treatment
NCT00592176	—	P2	completed	The Effect of Bevacizumab (Avastin) on Pterygium

Metastatic Renal Cell Carcinoma (7)

NCT	Acronym	Phase	Status	Title
NCT02330783	—	P2	unknown	Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
NCT02187302	NLG207	P2	completed	CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
NCT01274273	—	P2	unknown	Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
NCT01202032	PARASOL	P1	completed	Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
NCT00913913	RCC	P2	terminated	Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
NCT00619268	TORAVA	P2	completed	Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
NCT00421512	—	P1	completed	A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients

Solid Cancers (7)

NCT	Acronym	Phase	Status	Title
NCT02174172	—	P1	completed	A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
NCT01332604	—	P1	completed	GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors
NCT01301716	—	P1	completed	A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors
NCT01139723	—	P1	completed	A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors
NCT01075464	—	P1	completed	A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
NCT00954642	—	P1	completed	A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
NCT01068977	PRO143966	P1	completed	A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

Corneal Neovascularization (7)

NCT	Acronym	Phase	Status	Title
NCT01996826	—	P1/P2	completed	A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
NCT01072357	—	P1/P2	completed	Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
NCT00992849	—	P2	unknown	Bevacizumab for the Treatment of Corneal Neovascularization
NCT00512876	—	N/A	completed	Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
NCT00515684	—	N/A	withdrawn	Corneal Thinning During Topical Bevacizumab Therapy
NCT00797303	BQ-1-08-ARVO	P4	completed	The Effect of Bevacizumab on Corneal Neovascularization
NCT00555594	AVASTIN	P2/P3	completed	Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Carcinoma, Renal Cell (7)

NCT	Acronym	Phase	Status	Title
NCT01449825	—	N/A	completed	Hepatic Monitoring for Pazopanib
NCT01441388	—	P1	withdrawn	A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
NCT00992121	—	P1	completed	An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
NCT01381614	IHCIS	N/A	completed	Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
NCT01381601	—	N/A	completed	Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
NCT00523640	—	P2	terminated	A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
NCT00440973	—	P2	terminated	Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

Macular Degeneration (7)

NCT	Acronym	Phase	Status	Title
NCT00727753	AMD	N/A	completed	VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)
NCT00709657	—	N/A	terminated	The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
NCT00531336	—	P2	completed	MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen
NCT00359164	PDT	P2	completed	Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
NCT00531024	BEAT-AMD	P2/P3	completed	Systemic Avastin Therapy in Age-Related Macular Degeneration
NCT00684853	—	P2	unknown	Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD
NCT00447031	—	N/A	withdrawn	Combination Therapy for Neovascular Age Related Macular Degeneration

Head and Neck Cancer (7)

NCT	Acronym	Phase	Status	Title
NCT00423930	—	P2	completed	Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00281840	—	P2	completed	Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00392704	—	P2	completed	Treatment of Head & Neck Cancer With Chemotherapy and Radiation
NCT00409565	—	P2	completed	A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00405405	—	P1	completed	Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
NCT00140556	—	Early P1	completed	Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
NCT00203905	—	P2	completed	A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck

Mesothelioma (6)

NCT	Acronym	Phase	Status	Title
NCT07514793	—	P2	not yet recruiting	Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma
NCT00651456	MAPS	P2/P3	completed	Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
NCT00604461	MPM	P1/P2	terminated	Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
NCT00407459	—	P2	completed	Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
NCT00295503	—	P2	completed	Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
NCT00137826	—	P2	completed	Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Rectal Adenocarcinoma (6)

NCT	Acronym	Phase	Status	Title
NCT07549399	CRITⅡ	P3	recruiting	SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC
NCT06872606	SCRIPBOT	P2	not yet recruiting	Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer
NCT06908031	CRIT	P2	recruiting	SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer(CRIT)
NCT00321685	—	P2	completed	Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
NCT02314182	GRECCAR8	P3	completed	GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis
NCT01554059	New Beat	P2	completed	Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients

Lung Adenocarcinoma (6)

NCT	Acronym	Phase	Status	Title
NCT07481786	—	P3	recruiting	Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
NCT00334815	—	P2	active not recruiting	Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT05675033	—	P2	unknown	Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
NCT03904563	—	P2	completed	Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma
NCT03905317	—	P2	unknown	Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene
NCT02093000	—	N/A	completed	A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma

Colorectal Adenocarcinoma (6)

NCT	Acronym	Phase	Status	Title
NCT06951503	—	P3	recruiting	AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
NCT04094688	SOLARIS	P3	active not recruiting	Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT03708536	—	P3	withdrawn	Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma
NCT02292758	—	P2	completed	Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
NCT02413853	PRIMIER	P2	withdrawn	Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
NCT00597506	BEV/EV	P2	completed	Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus

Unresectable Hepatocellular Carcinoma (6)

NCT	Acronym	Phase	Status	Title
NCT05096715	—	P1	recruiting	Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
NCT06360042	—	P2	recruiting	Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
NCT06117891	REFINE-IO	N/A	active not recruiting	An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
NCT06503250	—	N/A	completed	A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
NCT04829383	AB7	P2	completed	A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
NCT05214339	D-TRIPLET	P2	unknown	A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

Ovarian Carcinoma (6)

NCT	Acronym	Phase	Status	Title
NCT06420973	—	P2	recruiting	RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
NCT06827353	OVNI-B	N/A	recruiting	Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency
NCT05310344	—	P2	unknown	Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
NCT01312376	—	P1	terminated	Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
NCT01936974	PGA	P2	terminated	(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
NCT00868192	—	P2	completed	Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma

Hepatocellular Carcinoma Non-resectable (6)

NCT	Acronym	Phase	Status	Title
NCT06133062	ProtonAB	P2	recruiting	Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
NCT05713994	CCGLC-001	N/A	recruiting	Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
NCT04224636	DEMAND	P2	unknown	Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab
NCT05717738	CCGLC-008	N/A	unknown	Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
NCT05530785	—	N/A	unknown	Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT
NCT04592029	—	P1	unknown	TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC

Endometrial Cancer (6)

NCT	Acronym	Phase	Status	Title
NCT04486352	EndoMAP	P1/P2	recruiting	A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT05489211	—	P2	recruiting	Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT03526432	—	P2	active not recruiting	Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
NCT03694262	EndoBARR	P2	completed	The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
NCT03836157	IMGN853	P2	withdrawn	Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
NCT00513786	—	P2	completed	Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

Age-related Macular Degeneration (6)

NCT	Acronym	Phase	Status	Title
NCT03834753	AMD	P3	completed	A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT04516278	—	P3	completed	A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
NCT03844074	AMD	P3	completed	A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT02118831	—	P1/P2	completed	Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
NCT00390026	—	P3	withdrawn	The Avastin vs Visudyne for Neovascular AMD Study
NCT01032109	—	N/A	completed	Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration

Choroidal Neovascularization (6)

NCT	Acronym	Phase	Status	Title
NCT03793400	—	N/A	completed	Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor
NCT02015351	—	N/A	completed	Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study
NCT01256580	CNV	N/A	withdrawn	Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
NCT00407719	CNV	P1	completed	Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)
NCT00370786	AMD	P3	completed	Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)
NCT00426998	—	P2	completed	Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

Retinal Vein Occlusion (6)

NCT	Acronym	Phase	Status	Title
NCT01468831	—	P1/P2	completed	Minocycline to Treat Branch Retinal Vein Occlusion
NCT03391219	—	P2/P3	unknown	Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients
NCT01428388	CRAVE	N/A	completed	Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
NCT01468844	—	P1/P2	completed	Minocycline to Treat Central Retinal Vein Occlusion
NCT01635803	BRVO	P2/P3	unknown	Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)
NCT00805064	RVO	P3	completed	Combined Triple Procedure in Retinal Vein Occlusion (RVO)

Metastatic Melanoma (6)

NCT	Acronym	Phase	Status	Title
NCT02158520	—	P2	completed	Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
NCT02065466	—	P1/P2	withdrawn	Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
NCT01743157	BBI	P1/P2	completed	Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
NCT00591734	—	P2	completed	RAD001 Plus Bevacizumab in Metastatic Melanoma
NCT00139360	—	P2	completed	Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma
NCT00308607	—	P2	completed	Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma

Brain and Central Nervous System Tumors (6)

NCT	Acronym	Phase	Status	Title
NCT00720356	—	P2	completed	Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT01013285	—	P2	completed	Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT00621686	—	P2	completed	Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00268359	—	P2	completed	Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
NCT00352521	DCE-MRI	P2	completed	Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
NCT00337207	—	P2	completed	Bevacizumab in Treating Patients With Recurrent or Progressive Glioma

Renal Cell Cancer (6)

NCT	Acronym	Phase	Status	Title
NCT00184015	RCC	P1/P2	unknown	Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
NCT02627144	—	N/A	completed	Bevacizumab in Metastatic Renal Cancer
NCT00796757	RCC	P2	completed	A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
NCT00520403	—	P2	completed	A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
NCT00738530	—	P3	completed	A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
NCT00061178	—	P3	withdrawn	Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma

Metastatic Colorectal Cancer (mCRC) (5)

NCT	Acronym	Phase	Status	Title
NCT07389265	CAPRI-3 GOIM	P3	recruiting	Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
NCT06922383	—	P1/P2	recruiting	A Clinical Study of Arfolitixorin in Patients With mCRC
NCT07391566	—	P1/P2	not yet recruiting	LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
NCT05839951	STAR-T	N/A	completed	An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
NCT02069704	BEVZ92	P1	completed	Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients

HCC - Hepatocellular Carcinoma (5)

NCT	Acronym	Phase	Status	Title
NCT07560488	—	P2	recruiting	Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
NCT06958484	QL1706	P2	not yet recruiting	Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence
NCT07157969	—	P2	recruiting	ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
NCT07285850	ABATE-MASLD	P2/P3	recruiting	The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
NCT05665348	TRIPLET	P2/P3	completed	Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Refractory Metastatic Colorectal Cancer (5)

NCT	Acronym	Phase	Status	Title
NCT07261709	—	P2	not yet recruiting	Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
NCT06607458	DEL-LIVER	P2	recruiting	Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
NCT05733611	—	P2	terminated	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
NCT04737187	SUNLIGHT	P3	completed	Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
NCT04527068	BEVTOR	P2	unknown	QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer

Malignant Ascites (5)

NCT	Acronym	Phase	Status	Title
NCT07397819	—	P1/P2	recruiting	Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
NCT06433869	—	P2	recruiting	The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites
NCT02496286	—	P1	terminated	Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites
NCT01200121	—	P2	completed	Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers
NCT00908219	—	P2	withdrawn	A Study of Bevacizumab to Prevent Malignant Ascites

Colo-rectal Cancer (5)

NCT	Acronym	Phase	Status	Title
NCT07178717	REFISH	P2	not yet recruiting	A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations
NCT07085169	—	P2	recruiting	Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
NCT07003022	—	P2	recruiting	Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
NCT06011772	—	Early P1	active not recruiting	EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
NCT06843954	—	P4	completed	Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer

HCC (5)

NCT	Acronym	Phase	Status	Title
NCT07119931	—	P2	not yet recruiting	A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)
NCT07009470	—	N/A	active not recruiting	A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence
NCT06823375	—	P2	recruiting	SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
NCT06584071	—	P1/P2	not yet recruiting	A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
NCT04682210	DaDaLi	P3	unknown	Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection

Advanced Hepatocellular Carcinoma (HCC) (5)

NCT	Acronym	Phase	Status	Title
NCT06737913	HAIBrave-001	P2	recruiting	HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
NCT07147101	HCC-IM-1	N/A	recruiting	Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
NCT06995105	—	P1/P2	recruiting	Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
NCT04723004	—	P3	completed	Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
NCT04605796	JS001	P2	completed	A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Cervical Adenocarcinoma (5)

NCT	Acronym	Phase	Status	Title
NCT06543576	—	P1/P2	recruiting	External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
NCT02020707	—	P1	completed	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
NCT02921269	—	P2	completed	Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
NCT00369122	—	P2	completed	Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer
NCT00803062	—	P3	completed	Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Advanced Solid Tumor (5)

NCT	Acronym	Phase	Status	Title
NCT06953323	—	P1/P2	recruiting	A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
NCT06233942	—	P1	recruiting	Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
NCT05824975	KEYNOTE-G08	P1/P2	recruiting	A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT06139211	—	P1/P2	recruiting	A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
NCT06509906	—	P1	terminated	M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

Colorectal Cancer (CRC) (5)

NCT	Acronym	Phase	Status	Title
NCT06791512	BASKETⅢ	P3	recruiting	mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
NCT07051785	ARK	P2	not yet recruiting	Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer
NCT07047560	II	P2	recruiting	Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study
NCT06882915	TAS-102	P1	not yet recruiting	Efficacy and Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study
NCT00851045	—	P2	completed	Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma (5)

NCT	Acronym	Phase	Status	Title
NCT02997228	—	P3	active not recruiting	Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
NCT06696768	—	P1	recruiting	Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
NCT05869097	—	N/A	completed	Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer
NCT06031376	—	N/A	completed	Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
NCT01900717	Prodige20	P2	completed	Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)

Nasopharyngeal Carcinoma (5)

NCT	Acronym	Phase	Status	Title
NCT06364826	—	P2	unknown	Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma
NCT05341193	—	P1/P2	unknown	PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT04553510	—	P2	unknown	Treatment of Bevacizumab Followed by Steroid in RN
NCT01309633	NPC	P2	completed	Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
NCT01621880	BRAIN	P2	completed	Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma

Neovascular Age-related Macular Degeneration (5)

NCT	Acronym	Phase	Status	Title
NCT04101877	SAHLVE	P2	active not recruiting	The Sahlgrenska Anti-VEGF Study
NCT06190093	AMD	P3	completed	A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT02450981	—	P1	withdrawn	Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration
NCT01027468	—	N/A	completed	Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
NCT00696592	ARMAST	P2	withdrawn	Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration

Non-small Cell Lung Cancer Metastatic (5)

NCT	Acronym	Phase	Status	Title
NCT05407155	BETTER	N/A	active not recruiting	Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer
NCT03240549	—	P2	unknown	Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease
NCT02162537	METAL2	P3	terminated	Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases
NCT01705184	BUCiL	P2	completed	Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.
NCT01966003	—	P3	completed	Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer (5)

NCT	Acronym	Phase	Status	Title
NCT02633189	BEVERLY	P3	unknown	Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
NCT05394233	—	P2	unknown	Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC
NCT01763671	Ultimate	P3	completed	Paclitaxel-bevacizumab in Advanced Lung Cancer
NCT00976456	65plus	P3	completed	Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer
NCT01057212	NSCLC	P2	terminated	Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Biliary Tract Cancer (5)

NCT	Acronym	Phase	Status	Title
NCT05052099	COMBATBIL	P1/P2	completed	Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer
NCT04677504	—	P2	completed	A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
NCT00361231	—	P2	completed	Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer
NCT00881504	—	P2	terminated	A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma
NCT00142480	—	P2	completed	Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer

Small Cell Lung Cancer (5)

NCT	Acronym	Phase	Status	Title
NCT04730999	CeLEBrATE	P2	completed	Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer
NCT00930891	CPC	P2/P3	completed	Bevacizumab in Extensive Small Cell Lung Cancer
NCT00755157	—	P2	withdrawn	Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer
NCT00403403	SALUTE	P2	completed	A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)
NCT00317200	—	P2	completed	A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer

Healthy (5)

NCT	Acronym	Phase	Status	Title
NCT05113511	—	P1	completed	PK and Safety of SCT510
NCT03882424	—	P1	completed	A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®
NCT03083990	—	P1	completed	Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male
NCT03115762	—	P1	unknown	Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects
NCT01608087	—	P1	completed	Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects

Neuroblastoma (5)

NCT	Acronym	Phase	Status	Title
NCT02308527	BEACON	P2	completed	Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
NCT00885326	N2007-02	P1	completed	N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
NCT01114555	—	P2	completed	Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
NCT01492673	CTB	P2	completed	Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
NCT00450827	—	P1	completed	Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Recurrent Melanoma (5)

NCT	Acronym	Phase	Status	Title
NCT00026221	—	P2	completed	Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
NCT00397982	Mel47	P2	completed	Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
NCT00387751	—	P2	completed	Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
NCT00074308	—	P1/P2	completed	Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
NCT00255762	—	P2	completed	Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Adenocarcinoma of the Pancreas (5)

NCT	Acronym	Phase	Status	Title
NCT00091026	—	P2	completed	Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
NCT00114179	—	P2	completed	Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
NCT00253526	—	P2	withdrawn	Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
NCT00088894	—	P3	completed	Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00028834	—	P2	completed	Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer

Colon Adenocarcinoma (4)

NCT	Acronym	Phase	Status	Title
NCT06997497	MK-1084	P3	recruiting	A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT05482516	MRD-GI	P3	recruiting	Evaluating Novel Therapies in ctDNA Positive GI Cancers
NCT00217737	—	P3	active not recruiting	Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
NCT00096278	—	P3	completed	Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer

Recurrent Ovarian Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT06769425	HS-10502	P1	recruiting	HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
NCT06308406	—	P1/P2	unknown	A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
NCT05819060	—	P2	unknown	The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab
NCT01802749	MITO16MANGO2b	P3	unknown	Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer

Non-small Cell Lung Cancer (NSCLC) (4)

NCT	Acronym	Phase	Status	Title
NCT06728865	Better Brain	P2	recruiting	Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
NCT01980472	—	P2	unknown	Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients
NCT00227019	—	P2	completed	Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
NCT00850577	—	P2	terminated	Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Metastatic Colorectal Carcinoma (4)

NCT	Acronym	Phase	Status	Title
NCT05863195	—	P3	recruiting	Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT02873195	—	P2	completed	Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
NCT04761614	—	P1	completed	Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT01937715	—	P1/P2	terminated	A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

Cholangiocarcinoma (4)

NCT	Acronym	Phase	Status	Title
NCT05510427	—	P1	withdrawn	Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
NCT01206049	GOC-B-P	P2	completed	Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations
NCT01007552	—	P2	completed	A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
NCT00350753	—	P2	completed	Avastin and Tarceva for Upper Gastrointestinal Cancers

Malignant Pleural Effusion (4)

NCT	Acronym	Phase	Status	Title
NCT05330065	—	P1/P2	unknown	A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion
NCT02942043	—	P2	unknown	Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
NCT01661790	—	P3	completed	Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
NCT02054078	—	P2	unknown	Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion

Carcinoma (4)

NCT	Acronym	Phase	Status	Title
NCT01061515	—	P1	active not recruiting	Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
NCT03952403	NSCLC	P3	unknown	A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT00719264	—	P2	completed	Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
NCT00737243	—	P2	completed	Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

Exudative Age-related Macular Degeneration (4)

NCT	Acronym	Phase	Status	Title
NCT03744806	—	N/A	completed	Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD
NCT04138420	—	N/A	completed	Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
NCT01127360	LUCAS	P4	completed	LUCAS (Lucentis Compared to Avastin Study)
NCT01306591	—	N/A	completed	Bevacizumab for Neovascular Age-related Macular Degeneration

Non-small-cell Lung Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT02930954	—	P2	unknown	Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance
NCT00741221	—	P2	completed	Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer
NCT00741195	—	P2	completed	Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer
NCT00749567	—	P2	terminated	Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Adult Anaplastic Astrocytoma (4)

NCT	Acronym	Phase	Status	Title
NCT01478321	—	P2	terminated	Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
NCT01648348	—	P1/P2	completed	Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
NCT01189240	—	P1/P2	terminated	RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
NCT00492089	—	P2	completed	Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

Recurrent Colon Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT00826540	—	P2	completed	Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT01205022	—	P1	completed	Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT00499369	—	P3	terminated	Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
NCT00077298	—	P2	completed	Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer

Advanced Cancers (4)

NCT	Acronym	Phase	Status	Title
NCT01213238	—	P1	completed	Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
NCT01183663	FOLFOX	P1	completed	Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
NCT01057264	—	P1	completed	HAI Abraxane With Gemcitabine and Bevacizumab
NCT00941499	—	P1	completed	Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

Melanoma (Skin) (4)

NCT	Acronym	Phase	Status	Title
NCT00976573	—	P2	completed	Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
NCT00626405	—	P2	completed	Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
NCT00568048	—	P2	completed	Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
NCT00538005	—	P1/P2	unknown	Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

Non-Small-Cell Lung Carcinoma (4)

NCT	Acronym	Phase	Status	Title
NCT01047059	MIMEB	P2	completed	Molecular Imaging With Erlotinib and Bevacizumab
NCT00600821	—	P2	completed	A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
NCT01090830	HCH003	P1/P2	terminated	Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer
NCT00095225	—	P2	completed	A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

NSCLC (Advanced Non-small Cell Lung Cancer) (3)

NCT	Acronym	Phase	Status	Title
NCT07001618	IMMUNOLIFE2	P2	recruiting	Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
NCT07014215	—	P2	not yet recruiting	PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy
NCT07551778	—	P1/P2	not yet recruiting	Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

Gastric Cancer (GC) (3)

NCT	Acronym	Phase	Status	Title
NCT07515625	—	P2	not yet recruiting	Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
NCT07453394	—	P1/P2	not yet recruiting	QLS5132 Combination Therapy in Advanced Solid Tumors
NCT07045805	—	P2	not yet recruiting	Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

Leptomeningeal Metastasis (3)

NCT	Acronym	Phase	Status	Title
NCT07398599	—	N/A	recruiting	Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
NCT04148898	OWONBNSCLCLM	P2	unknown	Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
NCT04425681	OWBLM	P2	unknown	Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer

Hereditary Hemorrhagic Telangiectasia (HHT) (3)

NCT	Acronym	Phase	Status	Title
NCT07445347	BevaHHearT	N/A	enrolling by invitation	Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network
NCT01397695	HHT	P2	completed	Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT01402531	HHT	P2	completed	Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Advanced Ovarian Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT07120451	—	P2	not yet recruiting	Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
NCT03737643	DUO-O	P3	active not recruiting	Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03611179	—	P2	unknown	Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

Radiation Necrosis (3)

NCT	Acronym	Phase	Status	Title
NCT06888817	BRAINS	P3	recruiting	Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
NCT02819479	LIBERTI	P2	completed	Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
NCT01201850	—	N/A	terminated	The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors

Colorectal Liver Metastases (3)

NCT	Acronym	Phase	Status	Title
NCT07117435	—	P1	recruiting	Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases
NCT00875147	—	N/A	completed	Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases
NCT00508872	—	P2	terminated	Folfox-B Study for Patients With Colorectal Liver Metastases

Endometrial Adenocarcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT06917092	QLPPEC/GOG-003	P2	recruiting	QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
NCT00977574	—	P2	active not recruiting	Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT01005329	—	P2	completed	Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

NSCLC Stage IV (3)

NCT	Acronym	Phase	Status	Title
NCT06401824	—	P2	recruiting	Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
NCT03713944	—	P2	terminated	Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
NCT04633564	—	P3	completed	MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC

Fallopian Tube Endometrioid Adenocarcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT06580314	—	P3	recruiting	Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT03587311	—	P2	active not recruiting	Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT01167712	—	P3	active not recruiting	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Unresectable Metastatic Colorectal Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT06835179	—	P2	not yet recruiting	SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
NCT06107413	IV	P2	active not recruiting	Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
NCT05068206	—	P2	unknown	A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Recurrent Ovarian Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT06292286	SCENIC	N/A	recruiting	Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
NCT03353831	—	P3	completed	Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
NCT03690739	—	P3	terminated	Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Advanced Colorectal Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT04109924	TAS-102	P2	completed	TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
NCT05648006	—	P2	terminated	First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
NCT04164069	—	P1	completed	Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Oncology (3)

NCT	Acronym	Phase	Status	Title
NCT06031233	MINUTE	P4	recruiting	Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT04813913	VASCATAQ	P4	completed	VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer
NCT04299880	—	P1	completed	Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Recurrent Endometrial Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT05523440	—	P2	terminated	Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
NCT00723255	—	P2	completed	Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00301964	—	P2	completed	Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

Tumors (3)

NCT	Acronym	Phase	Status	Title
NCT05431582	—	P1	withdrawn	Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
NCT00653939	FALCON	P2	completed	A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
NCT00395434	—	P1	completed	Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

Liver Metastases (3)

NCT	Acronym	Phase	Status	Title
NCT05062317	—	P2	recruiting	ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
NCT01320683	—	P2	terminated	Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
NCT01763450	—	P2	unknown	Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer

Liver Metastasis Colon Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT04832776	—	P2	unknown	FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
NCT04003792	CRLM	P2	unknown	Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.
NCT03732235	EMBOBEVA	N/A	unknown	TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer

Central Retinal Vein Occlusion (3)

NCT	Acronym	Phase	Status	Title
NCT04601701	CRVO	N/A	unknown	Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
NCT01969708	SCORE2	P3	completed	Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
NCT00906685	—	P3	completed	Bevacizumab for Central Retinal Vein Occlusion Study

Metastatic Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT03024437	—	P1/P2	terminated	Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
NCT04380103	—	P1/P2	unknown	A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
NCT01898130	—	P2	completed	Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy

Metastatic Pancreatic Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT03563144	—	P2	withdrawn	QUILT-3.088: NANT Pancreatic Cancer Vaccine
NCT00326911	—	P2	terminated	Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
NCT00222469	—	P2	completed	Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer

Recurrent Pterygium (3)

NCT	Acronym	Phase	Status	Title
NCT02530801	REPEAT	P4	unknown	Strategies for Management of Recurrent Pterygium
NCT02007174	—	N/A	completed	Bevacizumab Injection for Recurrent Pterygium
NCT01744756	BRP	P2/P3	completed	Subconjunctival Bevacizumab and Recurrent Pterygium

Fallopian Tube Clear Cell Adenocarcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT02853318	—	P2	completed	Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00951496	—	P3	completed	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00262847	—	P3	completed	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT02312245	—	P2	completed	Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT01305213	—	P2	completed	Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
NCT00886691	—	P2	completed	Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Retinal Detachment (3)

NCT	Acronym	Phase	Status	Title
NCT02192970	BEARRD	P2	completed	Bevacizumab Against Recurrent Retinal Detachment
NCT01860586	—	N/A	completed	Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.
NCT01270542	PDR	N/A	completed	Avastin for PDR (Proliferative Diabetic Retinopathy)

Multiple Myeloma (3)

NCT	Acronym	Phase	Status	Title
NCT01859234	—	N/A	unknown	89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
NCT00473590	AMBER	P2	completed	A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)
NCT02079519	—	P2	terminated	A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Gastric Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT00952003	—	P2	completed	Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients
NCT01962376	—	P4	unknown	Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis
NCT00887822	AVATAR	P3	completed	A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer

Central Nervous System Tumors (3)

NCT	Acronym	Phase	Status	Title
NCT01164189	TAVAREC	P2	completed	Bevacizumab in Recurrent Grade II and III Glioma
NCT00876993	CNS	P1	completed	Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
NCT01052363	—	P1	withdrawn	OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas

Adenocarcinoma of the Colon (3)

NCT	Acronym	Phase	Status	Title
NCT01270438	—	P2	withdrawn	Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
NCT00070122	—	P3	terminated	Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
NCT00025337	—	P3	completed	Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated

Brain Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT01067469	CCNU	P2	completed	Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
NCT01105702	—	P2	terminated	Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
NCT00883688	—	P2	completed	Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Neuroendocrine Tumors (3)

NCT	Acronym	Phase	Status	Title
NCT00137774	—	P2	completed	Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors
NCT00398320	—	P2	completed	Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
NCT01338090	NETPET	N/A	completed	89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors

Diffuse Diabetic Macular Edema (3)

NCT	Acronym	Phase	Status	Title
NCT00999791	—	P1	unknown	Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema
NCT00567372	—	P4	withdrawn	POSTERIOR SUB-TENON'S Avastin
NCT00600301	—	P3	withdrawn	Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study

Leukemia (3)

NCT	Acronym	Phase	Status	Title
NCT00816595	—	P2	completed	Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00022048	—	P1/P2	completed	Bevacizumab in Treating Patients With Myelodysplastic Syndrome
NCT00015951	—	P2	completed	Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers

Adenocarcinoma of the Prostate (3)

NCT	Acronym	Phase	Status	Title
NCT01656304	—	P2	completed	Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00110214	—	P3	completed	Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00016107	—	P2	completed	Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Adenocarcinoma of the Lung (3)

NCT	Acronym	Phase	Status	Title
NCT00368992	S0536	P2	completed	S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00369551	—	P1	terminated	Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
NCT00021060	—	P2/P3	completed	Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

Male Breast Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT00368875	—	P1/P2	completed	Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
NCT00119262	—	P2	completed	Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
NCT00017394	—	P2	completed	Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer

Adenocarcinoma of the Rectum (3)

NCT	Acronym	Phase	Status	Title
NCT00303628	—	P3	terminated	Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
NCT00100841	—	P2	completed	Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
NCT00052559	—	P1	completed	Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer

Non Small Cell Lung Cancer Metastatic (2)

NCT	Acronym	Phase	Status	Title
NCT07420439	—	P2	not yet recruiting	Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
NCT03133546	BOOSTER	P2	completed	Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M

Ras-mutated Metastatic Colorectal Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07446322	—	P2	recruiting	FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
NCT04310176	REVOLUTION	P2	unknown	Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

Recurrent Malignant Glioma (2)

NCT	Acronym	Phase	Status	Title
NCT07448480	GLIOTARG	N/A	active not recruiting	Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
NCT01144988	AVIRMA01-09	P2	unknown	Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma

Advanced Endometrial Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT07198074	—	P3	recruiting	Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT05039801	—	P1	recruiting	IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Advanced Renal Cell Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT07239596	—	P1/P2	recruiting	Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
NCT01664182	—	P2	completed	Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

GBM (2)

NCT	Acronym	Phase	Status	Title
NCT07274787	—	N/A	not yet recruiting	Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
NCT04074785	SCCC-06319	Early P1	terminated	Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6

Hepato Cellular Carcinoma (HCC) (2)

NCT	Acronym	Phase	Status	Title
NCT07276100	—	P2	recruiting	Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab
NCT06742424	—	P2	recruiting	PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

mCRC (2)

NCT	Acronym	Phase	Status	Title
NCT07116577	—	P2	not yet recruiting	Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
NCT07355764	—	P2	not yet recruiting	MA-CRC-II-016 SHR-1811

Advanced Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07318805	—	P1	recruiting	A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
NCT07359404	—	P2	enrolling by invitation	Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

CRC (2)

NCT	Acronym	Phase	Status	Title
NCT07283367	—	P1/P2	recruiting	A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
NCT07204574	—	P1/P2	recruiting	The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Resectable Hepatocellular Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT07018947	ASPIRE	P2	recruiting	Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
NCT04721132	—	P2	active not recruiting	Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Colorectal Cancer (Diagnosis) (2)

NCT	Acronym	Phase	Status	Title
NCT07134101	SMARTi-RC01	P2	not yet recruiting	Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)
NCT07244705	—	P1/P2	recruiting	A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Non-Resectable Pancreas Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT07235930	—	P3	recruiting	Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer
NCT06393166	—	P2	unknown	Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer

Ovarian Clear Cell Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT07002346	INVIGORATE	P3	recruiting	INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma
NCT04735861	INOVA	P2	completed	Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma

Acute Respiratory Distress Syndrome (ARDS) (2)

NCT	Acronym	Phase	Status	Title
NCT06701656	JUST BREATHE	P2	recruiting	JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
NCT06703073	JUST BREATHE	P2	recruiting	JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

Advanced Solid Tumour (2)

NCT	Acronym	Phase	Status	Title
NCT07111546	—	P2	recruiting	A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
NCT06783647	NSCLC	P2	recruiting	A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

Endometrial Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT07146919	ANGELICA	P1/P2	withdrawn	AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
NCT00879359	VEGF	P2	completed	Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer

TNBC - Triple-Negative Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07351487	NEOTORCH-BREAST07	P2	recruiting	Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
NCT06125080	UTILIZABLE	P2	recruiting	The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

Hemophilia (2)

NCT	Acronym	Phase	Status	Title
NCT07187661	—	N/A	completed	Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis
NCT02060305	—	P1	terminated	Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis

Diabetic Macular Edema (DME) (2)

NCT	Acronym	Phase	Status	Title
NCT07338097	—	N/A	enrolling by invitation	Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema
NCT06882551	—	P4	completed	Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients

Immunotherapy (2)

NCT	Acronym	Phase	Status	Title
NCT05690048	FLORA	P2	recruiting	Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
NCT05314101	—	P2	unknown	TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Unresectable Colorectal Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07009145	—	P2	not yet recruiting	QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC
NCT06540261	—	P1	active not recruiting	The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Recurrent or Metastatic Cervical Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06859775	—	P1/P2	recruiting	SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
NCT04868708	—	P2	completed	A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Ovarian Cancer Recurrent (2)

NCT	Acronym	Phase	Status	Title
NCT06843447	MK-5909-003	P1/P2	recruiting	A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
NCT04175470	—	P2	completed	Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer

Locally Recurrent Rectal Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06928584	—	P2	recruiting	Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
NCT07183865	NOVELTY-R	P2	recruiting	Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Colorectal Cancer Liver Metastasis (2)

NCT	Acronym	Phase	Status	Title
NCT06590259	—	P2	recruiting	A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
NCT06788171	—	P2	not yet recruiting	PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

Carcinoma, Pancreatic Ductal (2)

NCT	Acronym	Phase	Status	Title
NCT06447662	—	P1	active not recruiting	A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT06704724	—	P1	terminated	A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Colorectal Neoplasms Malignant (2)

NCT	Acronym	Phase	Status	Title
NCT06643793	II	P2	recruiting	Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
NCT03686254	—	P2/P3	unknown	The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM

Ovarian Cancer Stage IV (2)

NCT	Acronym	Phase	Status	Title
NCT06650709	NEOCATS	P2	not yet recruiting	NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study
NCT03275506	NEOPEMBROV	P2	completed	PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .

Solid Tumor, Adult (2)

NCT	Acronym	Phase	Status	Title
NCT06265688	—	P1	recruiting	First In Human Study of CX-2051 in Advanced Solid Tumors
NCT06625775	—	P1	recruiting	Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Gastric Adenocarcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT06667050	IBI305	P2	active not recruiting	CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
NCT04739202	IMMUNOGAST	P2	completed	Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

Locally Advanced Colorectal Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT05585814	COBP	P2	recruiting	CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer
NCT06550453	—	P4	recruiting	Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer

Metastatic Hepatocellular Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT06427941	—	P1	recruiting	A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06006286	—	P1/P2	withdrawn	A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

Carcinoma, Ovarian Epithelial (2)

NCT	Acronym	Phase	Status	Title
NCT06121401	IOLANTHE	P4	active not recruiting	First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
NCT05158062	—	P2	unknown	Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Head and Neck Squamous Cell Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT05965154	—	P2	unknown	Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma
NCT03169764	HNSCC	P1/P2	withdrawn	QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Unrescetable Hepatocellular Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT05864755	—	P2	unknown	HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma
NCT05821361	—	P2	unknown	HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma

Fallopian Tube Carcinosarcoma (2)

NCT	Acronym	Phase	Status	Title
NCT04919629	—	P2	recruiting	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
NCT02364713	—	P2	terminated	MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Wet Age-related Macular Degeneration (2)

NCT	Acronym	Phase	Status	Title
NCT06952452	AMD	P3	recruiting	Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
NCT02036723	GALATIR	P3	withdrawn	Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration

Colorectal Cancer Liver Metastases (2)

NCT	Acronym	Phase	Status	Title
NCT05588297	—	P2	unknown	Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
NCT02086656	COI-B	P2	completed	PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES

Advanced/Metastatic Solid Tumors (2)

NCT	Acronym	Phase	Status	Title
NCT05405595	—	P1/P2	recruiting	ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
NCT02665416	PK	P1	completed	Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

PFS (2)

NCT	Acronym	Phase	Status	Title
NCT05267366	—	P2	unknown	Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC
NCT04425187	—	P2	unknown	Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

Healthy Male Subjects (2)

NCT	Acronym	Phase	Status	Title
NCT05005455	—	P1	completed	Study of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects
NCT03576651	—	P1	completed	A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers

Gestational Trophoblastic Neoplasia (2)

NCT	Acronym	Phase	Status	Title
NCT04812002	—	P2	unknown	Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy
NCT02664961	GTN	P2	terminated	Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Metastatic Lung Non-Small Cell Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT04837716	—	P1	active not recruiting	Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
NCT02971501	—	P2	active not recruiting	Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Metastatic Triple Negative Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT04739670	BELLA	P2	unknown	Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
NCT03577743	—	P2	completed	Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

Pharmacokinetics (2)

NCT	Acronym	Phase	Status	Title
NCT04126044	CN	P1	withdrawn	A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS
NCT03919448	—	P1	completed	A Phase I Study Comparing Pharmacokinetics and Safety of Bevacizumab

Neuroendocrine Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT04705519	—	P2	completed	Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma
NCT01121939	—	P2	completed	Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Hereditary Hemorrhagic Telangiectasia (2)

NCT	Acronym	Phase	Status	Title
NCT04404881	TrUST-HHT	P2	active not recruiting	Bevacizumab In Hereditary Hemorrhagic Telangiectasia
NCT02106520	ALEGORI	P2/P3	terminated	Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Branch Retinal Vein Occlusion (2)

NCT	Acronym	Phase	Status	Title
NCT04601688	BRVO	N/A	unknown	Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
NCT01044329	BRVO	P2	unknown	Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion

Non-proliferative Diabetic Retinopathy (2)

NCT	Acronym	Phase	Status	Title
NCT04511715	—	P2/P3	unknown	Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
NCT02096874	—	P4	completed	Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema

Retinopathy of Prematurity Both Eyes (2)

NCT	Acronym	Phase	Status	Title
NCT05033106	—	P3	unknown	Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity
NCT03148132	—	P4	completed	VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP

Advanced Malignant Neoplasm (2)

NCT	Acronym	Phase	Status	Title
NCT03203525	P	P1	active not recruiting	Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
NCT01552434	—	P1	terminated	Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Neurofibromatosis Type 2 (2)

NCT	Acronym	Phase	Status	Title
NCT04374305	INTUITT-NF2	P2	recruiting	Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
NCT01767792	—	P2	completed	Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

Advanced Non-squamous NSCLC (2)

NCT	Acronym	Phase	Status	Title
NCT04325698	CN	P3	terminated	A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
NCT00369070	—	P2	terminated	A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

NSCLC Stage IIIB (2)

NCT	Acronym	Phase	Status	Title
NCT04042558	GFPC 06-2018	P2	completed	A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
NCT03647956	—	P2	unknown	Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Healthy Volunteers (2)

NCT	Acronym	Phase	Status	Title
NCT04238663	—	P1	completed	Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers
NCT04238650	—	P1	completed	A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers

Head and Neck Neoplasms (2)

NCT	Acronym	Phase	Status	Title
NCT03818061	ATHENA	P2	completed	Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck
NCT01262859	—	P2	withdrawn	Pilot Study for Locally Advanced Head and Neck Cancer

Myelodysplastic Syndromes (2)

NCT	Acronym	Phase	Status	Title
NCT03746041	—	P1	completed	A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
NCT00565656	IPSS	P2	terminated	A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts

Ovarian Neoplasm (2)

NCT	Acronym	Phase	Status	Title
NCT05751629	COHORT-A	P2	completed	Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
NCT00436215	—	P2	completed	Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer

Soft Tissue Sarcoma (2)

NCT	Acronym	Phase	Status	Title
NCT03913806	FLASH	P1/P2	completed	FLuoresence Image Guided Surgery With A VEGF-targeted Tracer in Soft-tissue Sarcomas in Humans Approach With Bevacizumab-IRDye 800CW
NCT00356031	—	P2	completed	Bevacizumab and Radiation Therapy for Sarcomas

Triple Negative Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT03387085	TNBC	P1/P2	terminated	QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
NCT03175666	TNBC	P1/P2	withdrawn	QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Urothelial Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT03272217	—	P2	terminated	Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
NCT03197571	—	P1/P2	withdrawn	QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Rendu Osler Disease (2)

NCT	Acronym	Phase	Status	Title
NCT03227263	BABH	P3	completed	BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
NCT01507480	ELLIPSE	P1	completed	The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia

Neuroendocrine Carcinomas (2)

NCT	Acronym	Phase	Status	Title
NCT02820857	BEVANEC	P2	completed	Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer
NCT01203306	XELBEVOCT	P2	unknown	Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors

Colorectal Neoplasm (2)

NCT	Acronym	Phase	Status	Title
NCT02758951	CAIRO6	P2/P3	active not recruiting	Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases
NCT02244632	—	P1/P2	completed	Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer

Germ Cell Tumor (2)

NCT	Acronym	Phase	Status	Title
NCT01966913	TAXIFIII	P1/P2	unknown	Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors
NCT02988843	—	P2	terminated	Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Peritoneal Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT02873962	—	P2	active not recruiting	A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
NCT00491855	—	P1	completed	Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Adult Brain Glioblastoma (2)

NCT	Acronym	Phase	Status	Title
NCT02078648	—	P1/P2	completed	Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
NCT02348255	—	P2	withdrawn	NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

Invasive Breast Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT00601900	—	P3	completed	Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT02456857	—	P2	completed	Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Non-Small Cell Lung Cancer (NSCLC) (2)

NCT	Acronym	Phase	Status	Title
NCT02521051	ALK	P1/P2	terminated	Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
NCT02316327	—	P4	completed	Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab

Breast Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT02436993	—	P2	active not recruiting	Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
NCT00520975	—	P3	terminated	Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Recurrent Respiratory Papillomatosis (2)

NCT	Acronym	Phase	Status	Title
NCT02555800	—	P2	unknown	Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
NCT01020747	RRP	P1	completed	Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)

HHT (2)

NCT	Acronym	Phase	Status	Title
NCT02389959	—	P4	completed	Intranasal Bevacizumab for HHT-Related Epistaxis
NCT01314274	HHT	P2	completed	Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Adult Glioblastoma (2)

NCT	Acronym	Phase	Status	Title
NCT02142803	—	P1	active not recruiting	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
NCT00433381	—	P2	completed	Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Adult Giant Cell Glioblastoma (2)

NCT	Acronym	Phase	Status	Title
NCT01730950	—	P2	completed	Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
NCT01894061	—	P2	completed	NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

Cystoid Macular Edema (2)

NCT	Acronym	Phase	Status	Title
NCT01774474	PREMED	P3	completed	PRevention of Macular EDema After Cataract Surgery
NCT00406172	PME	P3	withdrawn	Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)

Recurrent Glioblastoma Multiforme (2)

NCT	Acronym	Phase	Status	Title
NCT01738646	—	P2	completed	Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
NCT00883298	—	P2	completed	Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme

Brain Neoplasms (2)

NCT	Acronym	Phase	Status	Title
NCT01582152	—	P1/P2	terminated	Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
NCT00463203	—	P2	completed	Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

Giant Cell Glioblastoma (2)

NCT	Acronym	Phase	Status	Title
NCT01149850	—	P2	completed	Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT01609790	—	P2	completed	Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Vestibular Schwannoma (2)

NCT	Acronym	Phase	Status	Title
NCT01083966	—	P1	suspended	Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
NCT01207687	NF2	P2	completed	Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)

Advanced Gastric Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT01471470	—	P2	completed	Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
NCT00845884	—	P1/P2	unknown	Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer

Hypertension (2)

NCT	Acronym	Phase	Status	Title
NCT01125943	—	N/A	completed	Bevacizumab and Endothelium Dependent Vasodilation
NCT00929058	BVZ1	N/A	completed	Bevacizumab and Vasoconstriction

Fallopian Tube Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT01097746	—	P2	completed	First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT00989651	—	P1	completed	Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Locally Advanced Rectal Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT00828672	AXEBEAM	P2	completed	Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
NCT00842686	CRAB	P2	unknown	Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study

Bleb Vascularity (2)

NCT	Acronym	Phase	Status	Title
NCT00854529	—	P2	unknown	Subconjunctival Bevacizumab Effect on Bleb Vascularity
NCT00815594	—	P4	unknown	Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

B-cell Chronic Lymphocytic Leukemia (2)

NCT	Acronym	Phase	Status	Title
NCT00290810	—	P2	completed	Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00845104	—	P2	withdrawn	Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment

Neoplasm Metastasis (2)

NCT	Acronym	Phase	Status	Title
NCT00433927	FOLFIRI	P3	unknown	5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
NCT00710268	—	P1	completed	Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

Adenocarcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT00548548	AVAGAST	P3	completed	A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
NCT00127036	MACCO-A	P2	terminated	Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)

Central Serous Chorioretinopathy (2)

NCT	Acronym	Phase	Status	Title
NCT00802906	CSC	N/A	completed	Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)
NCT00418431	—	P2/P3	withdrawn	Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

Malignant Melanoma (2)

NCT	Acronym	Phase	Status	Title
NCT01164007	—	P2	completed	A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
NCT01069627	—	P2	completed	A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Neovascular Age-Related Macular Degeneration (2)

NCT	Acronym	Phase	Status	Title
NCT00370539	—	P3	unknown	Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD
NCT00370370	—	P3	unknown	Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT00217425	—	P2	completed	Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
NCT00217503	—	P2	completed	Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

Adult Primary Hepatocellular Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT00365391	—	P2	completed	Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
NCT00055692	—	P2	completed	Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

Multiple Myeloma and Plasma Cell Neoplasm (2)

NCT	Acronym	Phase	Status	Title
NCT00482495	—	P2	completed	Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00022607	—	P2	completed	Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Fallopian Tube Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT00126542	—	P2	completed	Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00483782	—	P3	completed	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Carcinoma, Small Cell Lung (2)

NCT	Acronym	Phase	Status	Title
NCT00308529	—	P2	completed	Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer
NCT00294931	—	P2	completed	Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT00118235	—	P2	completed	Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer
NCT00079040	—	P2	completed	Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer

Bladder Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT00268450	—	P2	terminated	Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
NCT00234494	—	P2	completed	Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT00101348	—	P1/P2	completed	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
NCT00023959	—	P1	completed	Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer

Brenner Tumor (2)

NCT	Acronym	Phase	Status	Title
NCT00079430	—	P1	completed	Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00085358	—	P1	completed	Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07504588	—	P2	not yet recruiting	Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Phase 1 (1)

NCT	Acronym	Phase	Status	Title
NCT07500298	—	P1	recruiting	Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Lung Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT06809946	DEFLECT I	P2	not yet recruiting	Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy

Platinum-Sensitive Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07564141	RAINFOL™-07	P3	not yet recruiting	Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

Metastatic Appendix Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07271355	—	P3	not yet recruiting	Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

Dynamic Tumor Resistance (1)

NCT	Acronym	Phase	Status	Title
NCT07318389	ASCEND-CRC	Early P1	not yet recruiting	ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Advanced HBV-Related Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07557251	—	P1	not yet recruiting	A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma

Malignant Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT07449481	—	P2	withdrawn	A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

Advanced Microsatellite Stable Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07527858	GS-1811	P2	recruiting	Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Advanced Unresectable Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07478302	—	P1	recruiting	A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

Adebrelimab (SHR-1316) (1)

NCT	Acronym	Phase	Status	Title
NCT07543783	TACE-HAIC	P2	not yet recruiting	Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial

Advanced Gynecological Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT07448922	—	P2	recruiting	A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

Lung Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07288034	L	P2	recruiting	Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Biliary Tract Cancer (BTC) (1)

NCT	Acronym	Phase	Status	Title
NCT07466238	—	N/A	recruiting	HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Advan'ce'd (1)

NCT	Acronym	Phase	Status	Title
NCT07361991	—	P1/P2	not yet recruiting	IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer

Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) (1)

NCT	Acronym	Phase	Status	Title
NCT07518602	—	P2	recruiting	Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

PROC (1)

NCT	Acronym	Phase	Status	Title
NCT07470853	—	P1	recruiting	A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

CRC (Colorectal Cancer) (1)

NCT	Acronym	Phase	Status	Title
NCT07284849	—	P3	recruiting	A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Medulloblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT07346157	PNOC044	P1/P2	not yet recruiting	Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis (1)

NCT	Acronym	Phase	Status	Title
NCT07512674	—	P2	active not recruiting	Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer

Rectal Neoplasms Malignant (1)

NCT	Acronym	Phase	Status	Title
NCT07383285	—	P2	not yet recruiting	CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment (1)

NCT	Acronym	Phase	Status	Title
NCT07337551	—	P2	not yet recruiting	Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

Proteinuria (1)

NCT	Acronym	Phase	Status	Title
NCT07358520	—	P4	not yet recruiting	Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

Cerebral AV Malformation (1)

NCT	Acronym	Phase	Status	Title
NCT06264531	BevacizuMAV	P2/P3	recruiting	Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations

ORR,OS,PFS (1)

NCT	Acronym	Phase	Status	Title
NCT07328802	—	P2	not yet recruiting	Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma

Ovarian Cancer Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT07311577	—	P2	recruiting	Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study

Untreated, Unresectable, or Metastatic Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07221357	—	P2/P3	recruiting	A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Metastatic Colorectal Carcinoma (mCRC) (1)

NCT	Acronym	Phase	Status	Title
NCT07150403	—	P2	not yet recruiting	Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

Platinum-resistant Recurrent Ovarian Cancer (PROC) (1)

NCT	Acronym	Phase	Status	Title
NCT07314619	—	P2	not yet recruiting	Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

Hepatecellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07327788	—	P2	recruiting	QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

Intestinal Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT07222800	—	P3	recruiting	Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Locally Advanced Rectal Cancer (LARC) (1)

NCT	Acronym	Phase	Status	Title
NCT07347951	—	P2	recruiting	A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

Gastric/Gastroesophageal Junction Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07233850	—	P2	not yet recruiting	A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

Resectable Hepatocellular Carcinoma With High Risk of Recurrence (1)

NCT	Acronym	Phase	Status	Title
NCT07239245	ATTACH	P2	recruiting	Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

Platinum-Refractory Fallopian Tube Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06393751	—	P1/P2	withdrawn	Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Cervical Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07186868	L	N/A	not yet recruiting	QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer

Brain Arteriovenous Malformations (1)

NCT	Acronym	Phase	Status	Title
NCT07075757	BLITZ	P1	not yet recruiting	In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment

NSCLC (Non-small Cell Lung Cancer) (1)

NCT	Acronym	Phase	Status	Title
NCT07182708	HOFIBREN	P2	not yet recruiting	High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC

Dyspnea Caused by 2019-nCoV (1)

NCT	Acronym	Phase	Status	Title
NCT07089719	BASECOVID	P2	not yet recruiting	Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)

Breast Cancer With Brain Metastasis (1)

NCT	Acronym	Phase	Status	Title
NCT07150208	THUMB	P2	not yet recruiting	T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

Platinum Resistant Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07117877	—	P2	not yet recruiting	Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Microsatellite-stable Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07011550	—	P2	suspended	Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Extensive Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07083375	QL1706	P2	not yet recruiting	A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.

Metastatic Colorectal Cancer With Left-sided Primary Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT07070713	—	P2	not yet recruiting	Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

RAS/BRAF Wild Type Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07044908	—	P1/P2	recruiting	TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer

Gynecologic Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT07024784	—	P2	recruiting	A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

NSCLC Stage IV Without EGFR/ALK Mutation (1)

NCT	Acronym	Phase	Status	Title
NCT06953843	NSCLC	P2	recruiting	Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

Metastatic Cervical Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07472153	—	P2/P3	recruiting	PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Overall Response Rate (1)

NCT	Acronym	Phase	Status	Title
NCT07090525	—	P2	recruiting	Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions

PD-(L)1 (1)

NCT	Acronym	Phase	Status	Title
NCT07004335	L	P4	not yet recruiting	Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

Unresectable Metastatic Rectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07059949	Union-mRC	P2	not yet recruiting	Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06982924	LIBRA	P2	not yet recruiting	A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Multiple Brain Metastases in Lung Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07058428	—	P3	recruiting	FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma

Recurrent Triple-Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06976944	PRELUDE	P2	recruiting	Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

BRAF V600 Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07150247	—	P2	recruiting	Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy (1)

NCT	Acronym	Phase	Status	Title
NCT06971237	IMSIRT	N/A	not yet recruiting	SIRT and Peri-immunotherapy : a New Concept

Melanoma Brain Metastases (1)

NCT	Acronym	Phase	Status	Title
NCT06163820	BETTER	P1/P2	recruiting	Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

Hepatocellular Carcinoma(HCC) (1)

NCT	Acronym	Phase	Status	Title
NCT06893887	ICT-HCC	N/A	recruiting	Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Radionecrosis of Brain (1)

NCT	Acronym	Phase	Status	Title
NCT06471465	BRADI	P3	recruiting	Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases

Colon Cancer Liver Metastases (1)

NCT	Acronym	Phase	Status	Title
NCT06801665	—	P2	recruiting	FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis

ctDNA (1)

NCT	Acronym	Phase	Status	Title
NCT07562490	CLEAR-04	P2	recruiting	A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer

Acute Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT06876701	—	Early P1	not yet recruiting	The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults

Microsatellite Stable (MSS) Colorectal Cancer (CRC) (1)

NCT	Acronym	Phase	Status	Title
NCT06784947	—	P2	active not recruiting	Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

Solid Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06771622	—	P1/P2	active not recruiting	Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Uterine Cervical Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT06878196	—	N/A	not yet recruiting	ctDNA-guided First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervical Cancer

Tumours, Gynecological (1)

NCT	Acronym	Phase	Status	Title
NCT06796907	BEHOLD-2	P1/P2	recruiting	A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT06839105	—	P1	recruiting	A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Diabetic Maculopathy (1)

NCT	Acronym	Phase	Status	Title
NCT06850571	—	P4	recruiting	Aflibercept and Bevacizumab for Diabetic Maculopathies

Breast Cancer Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT06718933	—	P1/P2	recruiting	Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis

Advanced Colorectal Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06753721	—	P1/P2	not yet recruiting	An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.

Lung Cancer (NSCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT06663306	—	P1	recruiting	Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Non-small Cell Lung Cancer Patients with Brain Metastases (1)

NCT	Acronym	Phase	Status	Title
NCT06683703	—	P2	not yet recruiting	Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases

Advanced Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06439485	—	P1/P2	recruiting	Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Gastric Cancer Adenocarcinoma Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT06711471	TAS-102	P2	recruiting	Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

Relapsed Neuroblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT07334301	BEACON2	P1/P2	recruiting	A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

EGFR (1)

NCT	Acronym	Phase	Status	Title
NCT06755684	—	P2	recruiting	Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Advanced Malignant Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT06571422	—	P1	active not recruiting	Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors

TNBC, Triple Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06786026	—	P2	recruiting	QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

Resectable Lung Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06775275	—	P2	recruiting	A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

Ovary Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06540729	DAB	P2	recruiting	RC48 in Combination With AK104 and Bevacizumab in OCCC

Adhesive Capsulitis (1)

NCT	Acronym	Phase	Status	Title
NCT06976671	—	P2	recruiting	A Study to Determine the Safety and Efficacy of Bevacizumab Administered Via Injection Into the Shoulder Joint of Participants With Adhesive Capsulitis (Frozen Shoulder)

Extensive-stage Small-cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05588388	BELIEVE	P2	recruiting	Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

Advanced or Metastatic Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06512051	—	P1/P2	recruiting	A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Rcctal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06808412	—	P2	recruiting	To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer

Hepatic Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06492408	—	P2	recruiting	Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Platinum-sensitive Relapsed Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06446206	—	P2	not yet recruiting	Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

Advanced Pancreatic Cancer (Part 1) (1)

NCT	Acronym	Phase	Status	Title
NCT06782685	—	P1/P2	recruiting	Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV

Chronic Subdural Hematoma (1)

NCT	Acronym	Phase	Status	Title
NCT06510582	CHAI	P1/P2	recruiting	Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection

Locally Recurrent Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06881537	—	P2	recruiting	CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

Breasr Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06361979	—	P2	unknown	SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

Advanced or Metastatic Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT06448364	LTbR	P1	terminated	A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

Advanced HCC (1)

NCT	Acronym	Phase	Status	Title
NCT05906524	—	P1/P2	unknown	KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Colon Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06008522	DETOUR	N/A	unknown	Safety and Feasibility of Immuno-OCT

Cervical Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06241235	—	P1/P2	unknown	Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

Ovarian Clear Cell Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05231122	—	P2	recruiting	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Brain Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT06747728	—	N/A	recruiting	Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain

Gastric Cancer Peritoneal Metastases (1)

NCT	Acronym	Phase	Status	Title
NCT06487715	—	P2	unknown	Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) (1)

NCT	Acronym	Phase	Status	Title
NCT06271837	—	P2	active not recruiting	A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

TNBC (1)

NCT	Acronym	Phase	Status	Title
NCT06210438	—	P2	unknown	SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

Malignant Peritoneal Mesothelioma, Advanced (1)

NCT	Acronym	Phase	Status	Title
NCT06543069	—	P2	recruiting	Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

Stage IVB Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06793813	NSCLC	P2	recruiting	Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)

Safety (1)

NCT	Acronym	Phase	Status	Title
NCT07253896	—	P2	recruiting	Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

HER2 + Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07065435	—	P2	recruiting	RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

HER2-low Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07446452	—	P2	recruiting	Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Recurrent Liver Cancer After Liver Transplantation (1)

NCT	Acronym	Phase	Status	Title
NCT05833126	—	P2	unknown	Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

Breast Cancer With Brain Metastases (1)

NCT	Acronym	Phase	Status	Title
NCT06152822	—	P2	unknown	Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases

Adebrelimab (1)

NCT	Acronym	Phase	Status	Title
NCT05970666	—	P2	recruiting	Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Diffuse Astrocytoma, IDH-Mutant (1)

NCT	Acronym	Phase	Status	Title
NCT06047379	—	P1/P2	recruiting	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Pleural Mesothelioma (1)

NCT	Acronym	Phase	Status	Title
NCT05930665	—	P2	recruiting	Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

RAS Mutation (1)

NCT	Acronym	Phase	Status	Title
NCT06229340	NТО-RAS	P2	recruiting	Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Liver Transplant; Complications (1)

NCT	Acronym	Phase	Status	Title
NCT06041490	—	P2	not yet recruiting	Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

Lazertinib (1)

NCT	Acronym	Phase	Status	Title
NCT06156527	—	P2	recruiting	A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Keloids (1)

NCT	Acronym	Phase	Status	Title
NCT07014280	—	P4	active not recruiting	Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.

Respiratory Tract Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT05797246	RRP	P2	active not recruiting	Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

Advanced Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT06717880	—	P1	recruiting	A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Hematological Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT05828459	—	P1	recruiting	First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Tislelizumab (1)

NCT	Acronym	Phase	Status	Title
NCT05970302	—	P2	recruiting	XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Non-squamous NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT05751187	—	P2	active not recruiting	Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Hepatocellular Carcinoma by BCLC Stage (1)

NCT	Acronym	Phase	Status	Title
NCT05883176	B-TACE	P2	unknown	TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria

Non-small Cell Lung Cancer Stage II (1)

NCT	Acronym	Phase	Status	Title
NCT05807893	SUPER BRAIN	P2/P3	completed	Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases

Metastatic Colon Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05627635	MSS	P1/P2	active not recruiting	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Persistent, Recurrent, or Metastatic Cervical Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05798819	—	P3	not yet recruiting	A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Colorectal Liver Metastasis (CRLM) (1)

NCT	Acronym	Phase	Status	Title
NCT06988852	—	P2	recruiting	FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis

HER2 Low Advanced or Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05792410	—	P1/P2	unknown	A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

Unresectable Colon Cancer Peritoneal Metastases (1)

NCT	Acronym	Phase	Status	Title
NCT05742425	—	P2	recruiting	Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

C04.588.274.476.411.307 (1)

NCT	Acronym	Phase	Status	Title
NCT05070104	—	P1	withdrawn	CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT05063552	—	P2/P3	active not recruiting	Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Stomach Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT05640609	—	P1/P2	recruiting	Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1) (1)

NCT	Acronym	Phase	Status	Title
NCT05715840	—	P3	unknown	Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Advanced Breast Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05238831	ACT	Early P1	withdrawn	SMMART Adaptive Clinical Treatment (ACT) Trial

Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05609370	LBL-007	P1/P2	active not recruiting	A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

COVID-19 Pneumonia (1)

NCT	Acronym	Phase	Status	Title
NCT04305106	BEST	P3	unknown	Bevacizumab in Patients With Severe Covid-19

HER2-positive Advanced Gastric Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05640830	TREAZURE	P1/P2	recruiting	Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

Metastatic Liver Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05643417	—	P1	unknown	Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy

Breast Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT05594095	—	P2	recruiting	SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Oligodendroglioma (1)

NCT	Acronym	Phase	Status	Title
NCT05512351	—	P2	recruiting	Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

Gallbladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05757336	—	P2	recruiting	Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

Advanced Solid Tumours (1)

NCT	Acronym	Phase	Status	Title
NCT05647122	EGRET	P1	active not recruiting	First in Human Study of AZD9592 in Solid Tumors

Genetic Change (1)

NCT	Acronym	Phase	Status	Title
NCT05512325	—	N/A	not yet recruiting	Study on Gene Evolution in Glioma Under Stress Therapy

Combined Hepatocellular Carcinoma and Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05211323	—	P2	active not recruiting	A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

High Grade Epithelial Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05579366	RAINFOL-01	P1/P2	recruiting	Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Astrocytoma of Brain (1)

NCT	Acronym	Phase	Status	Title
NCT05518994	—	P2	not yet recruiting	Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

Recurrent Rectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05628038	TORCH-R	P2	recruiting	The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

Refractory Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT05468359	—	P1/P2	recruiting	Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Neoadjuvant Treatment (1)

NCT	Acronym	Phase	Status	Title
NCT05111860	—	P1/P2	unknown	Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

Mucinous Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05665023	—	P2	unknown	Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma

Locally Advanced Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05377034	STRATUM	P2	recruiting	Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

Neurofibromatosis 2 (1)

NCT	Acronym	Phase	Status	Title
NCT05685836	—	N/A	unknown	89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Lung Neoplasm Malignant (1)

NCT	Acronym	Phase	Status	Title
NCT04973293	—	N/A	recruiting	Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Platinum-resistant Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05281471	PRROC	P3	recruiting	Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

HER-2 Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05398861	—	P2	recruiting	Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Platinum-resistant Recurrent Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05325229	—	P2	unknown	A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

Mammary Neoplasms, Human (1)

NCT	Acronym	Phase	Status	Title
NCT05781633	—	N/A	unknown	The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05163483	—	P2	unknown	Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Advanced Primary Liver Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05411757	—	Early P1	unknown	IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

Hereditary Leiomyomatosis and Renal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04981509	—	P2	recruiting	Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Childhood CNS Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT03554707	—	Early P1	withdrawn	SGT-53 in Children With Recurrent or Progressive CNS Malignancies

Metastatic Breast Cancer in the Liver (1)

NCT	Acronym	Phase	Status	Title
NCT05303038	Castle06(BC)	P2	unknown	Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy

Post-orthotopic Liver Transplantation (1)

NCT	Acronym	Phase	Status	Title
NCT05355155	—	P2	unknown	Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation

Advanced Gastroesophageal Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05299476	—	P2	completed	CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEA

Recurrent Medulloblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT04743661	—	P2	active not recruiting	131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Nasopharyngeal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05305131	GPPB	P2	recruiting	Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

Peritoneal Malignant Mesothelioma (1)

NCT	Acronym	Phase	Status	Title
NCT05001880	—	P2	recruiting	Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Colorectal Cancer Stage IV (1)

NCT	Acronym	Phase	Status	Title
NCT05171660	—	P3	active not recruiting	Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Lung Adenocarcinoma Stage III (1)

NCT	Acronym	Phase	Status	Title
NCT05503667	—	P2	recruiting	Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Triple-negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05192798	—	P2	recruiting	Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Stage III Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05468242	—	P2	recruiting	Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05132413	—	P3	unknown	A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Non-squamous Non-small-cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04958811	—	P2	active not recruiting	Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Thyroid Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06095362	TARGET-beva	P1	completed	Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW

Gastrointestinal Cancer, Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT05087992	—	P1	completed	A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

Metastatic Esophageal (1)

NCT	Acronym	Phase	Status	Title
NCT05075993	—	P1	active not recruiting	Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Advanced Metastatic Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05160896	—	P2	unknown	SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

Hepatocellular Carcinoma Recurrent (1)

NCT	Acronym	Phase	Status	Title
NCT05277675	RANT	N/A	unknown	Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)

Brain Injuries (1)

NCT	Acronym	Phase	Status	Title
NCT05303259	BRAIN	P2	unknown	Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury

Uterine Cervical Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT05007106	MK-7684A-005	P2	completed	MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Stage IVB Cervical Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04974944	—	P2	unknown	First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

Metastatic Nasopharyngeal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04872582	—	P2	unknown	Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

Ovarian Endometrioid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT04510584	—	P2	withdrawn	Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor (1)

NCT	Acronym	Phase	Status	Title
NCT04734665	NIRVANA-R	P2	unknown	Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

Advanced Liver Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05603039	—	P1/P2	unknown	A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma

Advanced or Metastatic Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT04999761	—	P1	recruiting	AB122 Platform Study

Metastatic Non-small Cell Lung Cancer (NSCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT04466917	—	P3	withdrawn	A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Venous Thrombosis (1)

NCT	Acronym	Phase	Status	Title
NCT04649489	TALENTOP	P3	active not recruiting	A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev

Pulmonary Sarcomatoid Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04725448	—	P2	unknown	Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Objective Response Rate (1)

NCT	Acronym	Phase	Status	Title
NCT04670978	—	P2	unknown	Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03462212	MITO25	P1/P2	unknown	Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination

Ovarian Cancer by FIGO Stage (1)

NCT	Acronym	Phase	Status	Title
NCT04938583	—	P1/P2	active not recruiting	Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Platinum-Resistant Fallopian Tube Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04753216	—	P2	completed	Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Hepatocellular Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03937830	TACE	P2	active not recruiting	Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Biosimilar (1)

NCT	Acronym	Phase	Status	Title
NCT05009017	—	N/A	unknown	Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients

Advanced Lung Non-Squamous Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04181060	—	P3	recruiting	Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Advanced Liver Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT04524871	MORPHEUS-LIVER	P1/P2	recruiting	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT (1)

NCT	Acronym	Phase	Status	Title
NCT04517526	—	P2	unknown	Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

Pituitary Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT04212793	DEPARTURE	P1	completed	Detection of PitNET Tissue During TSS Using Bevacizumab-800CW

Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04361370	OPEB-01	P2	enrolling by invitation	Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer

Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT02226289	BATTLE	P2	unknown	Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT04245085	ABC-lung	P2	completed	ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Pan-tumor (1)

NCT	Acronym	Phase	Status	Title
NCT04566380	ONO-4538-98	P2	recruiting	ONO-4538 Phase II Rollover Study (ONO-4538-98)

Non-Small-Cell Lung Cancer Stage IV (1)

NCT	Acronym	Phase	Status	Title
NCT04238169	—	P2	completed	Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

ARDS, Human (1)

NCT	Acronym	Phase	Status	Title
NCT04954014	BEVACOR	P2	terminated	Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients

Advanced Non-squamous Non-small-cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04416035	NSCLC	P3	unknown	A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC

Clinical Stage III Cutaneous Melanoma AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT04356729	—	P2	active not recruiting	A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Biliary Tract Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04984980	—	P2	unknown	Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

Disease Free Survival (1)

NCT	Acronym	Phase	Status	Title
NCT04138992	—	P2/P3	unknown	A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer

Advanced Biliary Tract Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04217954	—	P2	completed	HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

Unresectable Metastatic Colorectal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04508452	—	P2	unknown	A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC

Progress Free Survival (PFS) and Overall Survival (OS) (1)

NCT	Acronym	Phase	Status	Title
NCT04393220	—	P2	completed	Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma

COVID19 Pneumonia (1)

NCT	Acronym	Phase	Status	Title
NCT04344782	CORIMMUNO-BEVA	P2	unknown	Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort

NSCLC Stage IIIB~IV (1)

NCT	Acronym	Phase	Status	Title
NCT04147351	—	P2	completed	A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

ALK Gene Rearrangement Positive (1)

NCT	Acronym	Phase	Status	Title
NCT03779191	—	P2	completed	Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)

NCT	Acronym	Phase	Status	Title
NCT03878524	SMMART	P1	terminated	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Locally Advanced Lung Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04227028	—	P1	active not recruiting	Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Non-small-cell Lung Cancer Patients (1)

NCT	Acronym	Phase	Status	Title
NCT03896074	BEAT	P2	active not recruiting	Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)

Pterygium of Conjunctiva and Cornea (1)

NCT	Acronym	Phase	Status	Title
NCT03037736	OPPS	P4	withdrawn	Outpatient Performed Pterygium Surgery Study

Select Advanced Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT04262466	—	P1/P2	active not recruiting	Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Coronavirus Infections (1)

NCT	Acronym	Phase	Status	Title
NCT04275414	BEST-CP	P2	completed	Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia

DIPG (1)

NCT	Acronym	Phase	Status	Title
NCT04250064	LoBULarDIPG	P2	recruiting	A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma

Ovarian Epithelial Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03220932	HIPOVA-01	P3	unknown	Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer

Retinal Telangiectasis (1)

NCT	Acronym	Phase	Status	Title
NCT03940690	COATS-VEGF	P3	terminated	Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease

Healthy Male (1)

NCT	Acronym	Phase	Status	Title
NCT04135898	—	P1	completed	A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects

Stage III Hepatocellular Carcinoma AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT03942328	—	P1/P2	recruiting	Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Metastatic Microsatellite-stable Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04068610	COLUMBIA-1	P1/P2	active not recruiting	COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03929666	—	P2	completed	A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

End Stage Renal Disease (1)

NCT	Acronym	Phase	Status	Title
NCT02695641	—	Early P1	withdrawn	Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients

Barrett Esophagus (1)

NCT	Acronym	Phase	Status	Title
NCT03877601	ESCEND	P2	unknown	Detection of Early Esophageal Cancer by NIR-FME.

Elderly Patients (1)

NCT	Acronym	Phase	Status	Title
NCT03828227	COLAGE	P3	active not recruiting	QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.

Inverted Papilloma (1)

NCT	Acronym	Phase	Status	Title
NCT03925285	SNIPER	P1	unknown	Image Guided Surgery in Sinonasal Inverted Papilloma

Locally Recurrent Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03813394	2018/00947	P1/P2	active not recruiting	Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC

Pleural Mesothelioma Malignant Advanced (1)

NCT	Acronym	Phase	Status	Title
NCT03762018	BEAT-meso	P3	completed	BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Hilar Cholangiocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03620292	COUGAR	P1/P2	unknown	Fluorescence Image Guided Surgery in Cholangiocarcinoma

Branch Retinal Vein Occlusion With Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT03892434	—	P4	unknown	Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO

Refractory Diabetic Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT03821168	—	P2/P3	unknown	The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema

Lung Cancer Stage III (1)

NCT	Acronym	Phase	Status	Title
NCT03872661	NIBCUN	P2	recruiting	Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

Non-squamous Cell Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03792074	—	P3	unknown	To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer

Mesothelioma, Malignant (1)

NCT	Acronym	Phase	Status	Title
NCT03654833	MiST	P2	unknown	Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

Cancer of Pancreas (1)

NCT	Acronym	Phase	Status	Title
NCT03607643	—	P1/P2	unknown	A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Breast Cancer Organoids (1)

NCT	Acronym	Phase	Status	Title
NCT03925233	—	N/A	unknown	Breast Cancer Treatment Based on Organ-like Culture

MSI-H Advanced Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05035381	—	P2	unknown	PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

Punctate Inner Choroidopathy (1)

NCT	Acronym	Phase	Status	Title
NCT03897192	—	N/A	completed	Long-term Outcome of Zonal Outer Retinopathy in Punctate Inner Choroidopathy or Multifocal Choroiditis

Recurrent Adult Brain Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT03890952	—	P2	completed	Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

Carcinoma of the Cervix, Stage IVB (1)

NCT	Acronym	Phase	Status	Title
NCT03556839	BEATcc	P3	completed	Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

Colorectal Carcinomatosis (1)

NCT	Acronym	Phase	Status	Title
NCT03161041	—	P2	withdrawn	Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study

High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT03463265	—	P2	completed	Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

Cancer of Unknown Primary Site (1)

NCT	Acronym	Phase	Status	Title
NCT03498521	CUPISCO	P2	completed	A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Gastrointestinal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03597581	—	P1	completed	A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Microsatellite Stable (1)

NCT	Acronym	Phase	Status	Title
NCT03396926	—	P2	completed	Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer

Newly Diagnosed High Grade Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT03425292	—	P1	completed	A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Brain Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT02672995	—	P1	unknown	Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial

Glioblastoma Multiforme (GBM) (1)

NCT	Acronym	Phase	Status	Title
NCT01788280	—	P2	withdrawn	Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03387111	SCC	P1/P2	terminated	QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Merkel Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03167164	MCC	P1/P2	withdrawn	QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Non Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03169790	NHL	P1/P2	withdrawn	QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

MSI (1)

NCT	Acronym	Phase	Status	Title
NCT02982694	—	P2	terminated	Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Metastatic Gastric Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03990103	IP	P2	unknown	S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites

Retinal Vein Occlusion With Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT03353324	bevacizumab	P2/P3	unknown	Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein Occlusion

Elderly Metastatic Colorectal Cancer Patients (1)

NCT	Acronym	Phase	Status	Title
NCT03451370	COBRA	N/A	active not recruiting	First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer

Efficacy (1)

NCT	Acronym	Phase	Status	Title
NCT05427305	—	P3	completed	TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer

Metastatic Thyroid Gland Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03181100	—	P2	active not recruiting	Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Pancreatic Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03193190	—	P1/P2	completed	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Fallopian Tube High Grade Serous Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02839707	—	P2/P3	active not recruiting	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

BRAF V600 Wild Type (1)

NCT	Acronym	Phase	Status	Title
NCT03175432	—	P2	active not recruiting	Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Peritoneal Adhesion (1)

NCT	Acronym	Phase	Status	Title
NCT03095001	—	P2	unknown	Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion

Astrocytoma (1)

NCT	Acronym	Phase	Status	Title
NCT03032484	—	P2	completed	TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

Peritoneal Carcinosis (1)

NCT	Acronym	Phase	Status	Title
NCT02866903	IPOXA	P1/P2	unknown	Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis

Fallopian Tube Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02923739	—	P2	terminated	Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Endometriosis (1)

NCT	Acronym	Phase	Status	Title
NCT02975219	Endo-light	P1	unknown	Feasibility Study of Using Molecular Fluorescence Guided Surgery in Endometriosis

Metastatic Alveolar Soft Part Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT03141684	—	P2	active not recruiting	Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Colorectal Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT03050814	—	P2	terminated	Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

Appendix Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03074513	—	P2	active not recruiting	Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Malignant Neoplasms of Female Genital Organs (1)

NCT	Acronym	Phase	Status	Title
NCT02884648	—	P2	active not recruiting	Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

EGFR Positive Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03126799	AvaTa	P2	unknown	A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Low Grade Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT02840409	LGG	P2	active not recruiting	Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

Anaplastic (Malignant) Meningioma (1)

NCT	Acronym	Phase	Status	Title
NCT02847559	—	P2	recruiting	Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Malignant Solid Tumour (1)

NCT	Acronym	Phase	Status	Title
NCT02857920	—	P1/P2	completed	Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Lung Adenocarcinoma Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT02946359	—	P2	unknown	A+C in Metastatic Lung Adenocarcinoma Cancer

Recurrent Brain Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT02698254	—	N/A	active not recruiting	Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

Advanced Non-Clear Cell Kidney Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02724878	—	P2	completed	Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Brain Arteriovenous Malformation (1)

NCT	Acronym	Phase	Status	Title
NCT02314377	—	P1	completed	Bevacizumab Therapy for Brain Arteriovenous Malformation

Advanced/Metastatic Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT02794571	PK	P1	completed	Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Radionecrosis (1)

NCT	Acronym	Phase	Status	Title
NCT02490878	BEST	P2	terminated	Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases

Carcinoma, Non-Small Cell Lung (1)

NCT	Acronym	Phase	Status	Title
NCT02743923	—	P3	unknown	Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

Ovarian (1)

NCT	Acronym	Phase	Status	Title
NCT02734004	MEDIOLA	P1/P2	active not recruiting	A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

Non Squamous Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01951482	—	P3	completed	Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer

Metastatic Pancreas Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02620800	FABLOx	P1	completed	Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

Corneal Neovascularisation (1)

NCT	Acronym	Phase	Status	Title
NCT02594423	—	P4	unknown	Strategies for Management of Corneal Neovascularisation

Unresectable Advanced Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02640365	DOUBLIRI	P1	completed	A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer

Progression Free Survival (1)

NCT	Acronym	Phase	Status	Title
NCT02959749	—	P2/P3	completed	Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Diabetic Macula Edema (1)

NCT	Acronym	Phase	Status	Title
NCT02462304	END-DME	P4	unknown	To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema

Inflammatory Breast Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT01894451	—	Early P1	completed	Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

Recurrent High-grade Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT02416999	—	N/A	unknown	Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Clear Cell Renal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02348008	—	P1/P2	completed	Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

Choriocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02396511	—	P2	completed	TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Cancer of Brain and Nervous System (1)

NCT	Acronym	Phase	Status	Title
NCT02343549	BEV	P2	terminated	A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)

Collecting Duct Carcinoma (Kidney) (1)

NCT	Acronym	Phase	Status	Title
NCT02363751	BEVABEL	P2	completed	Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)

Pleural Effusion, Malignant (1)

NCT	Acronym	Phase	Status	Title
NCT02250118	BEVAP	P1	terminated	Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer

Untreated Metastatic Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02305758	—	P2	completed	Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Nasopharyngeal Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT02250599	—	P2	unknown	Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma

Breast Cancer Recurrent (1)

NCT	Acronym	Phase	Status	Title
NCT02248571	IMPROVE	P4	completed	Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

Advanced Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02200354	—	P2	terminated	The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab

Lung, Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02139579	—	P2	unknown	Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer

Medulloblastoma Recurrent (1)

NCT	Acronym	Phase	Status	Title
NCT01356290	MEMMAT	P2	recruiting	Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Adenomatous Polyposis Coli (1)

NCT	Acronym	Phase	Status	Title
NCT02113202	FLUOFAP	P1	completed	Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW

Primary Esophageal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02072720	—	Early P1	unknown	Angiogenic Factor Expression During Fractionated Irradiation

Non-small Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02039674	MK-3475	P1/P2	completed	A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

Advanced Gastrointestinal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02024607	—	P1/P2	completed	A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Stage IIIC Cutaneous Melanoma AJCC v7 (1)

NCT	Acronym	Phase	Status	Title
NCT01950390	—	P2	completed	Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Intraocular Pressure (1)

NCT	Acronym	Phase	Status	Title
NCT02474225	—	N/A	completed	Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent

Desmoplastic Small Round Cell Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT01946529	—	P2	active not recruiting	Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Rhabdomyosarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT01871766	—	P2	active not recruiting	Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy (1)

NCT	Acronym	Phase	Status	Title
NCT01976923	—	P3	completed	Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy

Retinal Neovascularization (1)

NCT	Acronym	Phase	Status	Title
NCT03211741	—	P4	unknown	Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema

Malignant Glioma (WHO Grade III or IV) (1)

NCT	Acronym	Phase	Status	Title
NCT01954030	—	P1	terminated	Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure

Pilomyxoid Astrocytoma (1)

NCT	Acronym	Phase	Status	Title
NCT01837862	—	P1/P2	completed	A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Advanced Gastrointestinal Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT01916447	—	P1	completed	A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

Stage II Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01959490	—	P2	completed	Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

Mucinous Adenocarcinoma of the Rectum (1)

NCT	Acronym	Phase	Status	Title
NCT01871571	—	P2	terminated	Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

Pulmonary Fibrosis (1)

NCT	Acronym	Phase	Status	Title
NCT01917877	—	P2	unknown	Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab

Ovarian Epithelial Cancer Recurrent (1)

NCT	Acronym	Phase	Status	Title
NCT01735071	—	P2	completed	Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer

Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT01787669	SwitchDMO	P2	completed	Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

Neuromyelitis Optica (1)

NCT	Acronym	Phase	Status	Title
NCT01777412	—	P1	completed	Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations

Multi-organ Metastatic Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01792934	ORCHESTRA	N/A	active not recruiting	Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases

Recurrent Platinum-sensitive Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01837251	—	P3	completed	Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Colorectal Cancer Stage II (1)

NCT	Acronym	Phase	Status	Title
NCT01853813	CENTRAL	P2	completed	First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer

Liver Metastasis (1)

NCT	Acronym	Phase	Status	Title
NCT01834014	ATOM ES	N/A	completed	Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

Refractory Malignant Ascites (1)

NCT	Acronym	Phase	Status	Title
NCT01852409	—	P1	unknown	Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites

Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01836653	ATOM	P2	completed	Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

Cancer, Ovarian (1)

NCT	Acronym	Phase	Status	Title
NCT01847677	NOVA	P2	terminated	Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin

Astrocytoma, Oligoastrocytoma, Mixed (1)

NCT	Acronym	Phase	Status	Title
NCT01999270	—	P1	completed	Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors

Ovarian Sex-cord Stromal Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT01770301	ALIENOR	P2	completed	Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)

Metastatic Malignant Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT01705392	—	P2	terminated	Bevacizumab vs Dacarbazine in Metastatic Melanoma

Gastrinoma (1)

NCT	Acronym	Phase	Status	Title
NCT01525082	—	P2	completed	Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Solid Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT01749384	—	P1	completed	Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Malignant Peripheral Nerve Sheath Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT01661283	SARC016	P2	completed	SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

Colon Cancer Liver Metastasis (1)

NCT	Acronym	Phase	Status	Title
NCT01540435	PERIMAX	P2	withdrawn	Perioperative Treatment of Resectable Liver Metastases

Vitreous Hemorrhage (1)

NCT	Acronym	Phase	Status	Title
NCT01724385	—	P4	completed	Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

Recurrent Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT01580969	RAMBO	P1/P2	completed	Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma

Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT01745757	COMET	N/A	completed	Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer

Corneal Newvessels (1)

NCT	Acronym	Phase	Status	Title
NCT01501760	BECONNEC	P3	completed	Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea

Stage III-IV or Recurrent Endometrial Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01770171	MITOBEVAEND2	P2	unknown	Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer

Stage III Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01551745	—	P2	completed	Salvage Ovarian FANG™ Vaccine + Bevacizumab

EGFR Exon 19 Deletion Mutation (1)

NCT	Acronym	Phase	Status	Title
NCT01532089	—	P2	completed	Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Keloid (1)

NCT	Acronym	Phase	Status	Title
NCT01408953	—	P2	terminated	Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue

High Grade Glioma: Glioblastoma (GBM) (1)

NCT	Acronym	Phase	Status	Title
NCT01339039	AMD3100	P1	terminated	Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Carcinoma, Squamous Cell of Head and Neck (1)

NCT	Acronym	Phase	Status	Title
NCT01588431	—	P2	completed	Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer

Genital Diseases, Female (1)

NCT	Acronym	Phase	Status	Title
NCT01462890	BOOST	P3	completed	Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer

High Grade Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT01390948	TMZ	P2	completed	A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma

Ovarian Clear Cell Cystadenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT01459380	—	P1	completed	Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Diffuse Intrinsic Pontine Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT01182350	DIPG	P2	terminated	Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Telangiectasia, Hereditary Hemorrhagic (1)

NCT	Acronym	Phase	Status	Title
NCT01408030	NOSE	P2	completed	North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Rectal Cancer Patients (1)

NCT	Acronym	Phase	Status	Title
NCT01426074	—	P2	withdrawn	DCE-MRI PET Bevacizumab Study in Rectal Cancer

Diabetes Complications (1)

NCT	Acronym	Phase	Status	Title
NCT01422018	—	N/A	unknown	Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy

Recurrent Colon Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT01383343	—	P1	completed	Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

Ovarian Cancer With Malignant Ascites (1)

NCT	Acronym	Phase	Status	Title
NCT01838538	—	P2	unknown	Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy

Ovarian Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02217956	CHIPASTIN	P1	completed	Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma

HIGH GRADE GLIOMA (1)

NCT	Acronym	Phase	Status	Title
NCT01403610	—	P2	completed	Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

Non-Ischemic Central Retinal Vein Occlusion (1)

NCT	Acronym	Phase	Status	Title
NCT01295112	—	P2/P3	completed	Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion

Ampulla of Vater Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT01208103	—	P2	completed	Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma

Adult Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT01332721	—	P1	completed	Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Ependymoma (1)

NCT	Acronym	Phase	Status	Title
NCT01295944	—	P2	completed	Carboplatin and Bevacizumab for Recurrent Ependymoma

Adenocarcinoma of the Esophagus (1)

NCT	Acronym	Phase	Status	Title
NCT01212822	—	P2	completed	Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer

Metastatic Gastric Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01359397	B-DOCT	P2	unknown	Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer

Inflammatory Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01880385	Beva	P1	unknown	Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

Infiltrating Duct and Lobular Carcinoma In Situ (1)

NCT	Acronym	Phase	Status	Title
NCT01641406	NACprotocol	P2	unknown	"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"

Nonsquamous Nonsmall Cell Neoplasm of Lung (1)

NCT	Acronym	Phase	Status	Title
NCT01814163	ANGIOMET	N/A	completed	Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab

Fallopian Tube Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT01131039	—	P2	withdrawn	Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Cognitive/Functional Effects (1)

NCT	Acronym	Phase	Status	Title
NCT01279681	—	P3	terminated	Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Brain Stem Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT01236560	—	P2/P3	completed	Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

KRAS Mutant Metastatic Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01274624	—	P1	completed	Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast (1)

NCT	Acronym	Phase	Status	Title
NCT01935492	Stop&Go	P3	completed	8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer

Locally Recurrent or Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01256762	—	P2	completed	Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Recurrent or Progressive Glioblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT05718466	—	P3	completed	Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy

Central Nervous System Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT01217437	—	P2	completed	Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Fallopian Tubes Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01223235	—	N/A	completed	Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

Adult Rhabdomyosarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT01222715	—	P2	completed	Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Advanced Pancreatic Neuroendocrine Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT01229943	—	P2	completed	Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Borderline Ovarian Mucinous Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT01081262	—	P3	active not recruiting	Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Macular Edema Caused by Retinal Vein Occlusion (1)

NCT	Acronym	Phase	Status	Title
NCT01767545	—	P4	completed	Dexamethasone-implant for the Treatment of RVO

Neoplasms, Malignant (1)

NCT	Acronym	Phase	Status	Title
NCT01193595	—	P1	completed	Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

Kaposi´s Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT01296815	—	P2	completed	Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity

Angiosarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT01303497	ANGIO-TAX+	P2	completed	Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

Stage IV Colon Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01198548	—	P2	terminated	High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer

Severe Sepsis (1)

NCT	Acronym	Phase	Status	Title
NCT01314066	VEGF-ARDS	P2	withdrawn	Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)

First Line Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01303679	—	P3	terminated	1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Metastatic Malignant Neoplasm to Brain (1)

NCT	Acronym	Phase	Status	Title
NCT01332929	—	P1	completed	Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis

Acoustic Schwannoma (1)

NCT	Acronym	Phase	Status	Title
NCT01125046	—	P2	completed	Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

HLRCC (1)

NCT	Acronym	Phase	Status	Title
NCT01130519	HLRCC	P2	completed	A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Triple Negative Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01069796	—	P2	terminated	Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Uveitis (1)

NCT	Acronym	Phase	Status	Title
NCT01095809	EBEV	P3	terminated	Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema

Advanced Non-squamous Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01063283	AVF4759	N/A	completed	Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

Large Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00955305	—	P2	terminated	Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Angiosarcomas (1)

NCT	Acronym	Phase	Status	Title
NCT01055028	—	P2	terminated	Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma

Septic Shock (1)

NCT	Acronym	Phase	Status	Title
NCT01063010	—	N/A	withdrawn	Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock

Vitreous Hemorrhage Secondary to PDR (1)

NCT	Acronym	Phase	Status	Title
NCT01091896	—	P2	unknown	Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage

Glioma Patients (1)

NCT	Acronym	Phase	Status	Title
NCT01046279	—	N/A	terminated	Hypertension Monitoring in Glioma Patients Treated With Bevacizumab

Non-squamous Nonsmall Cell Neoplasm of Lung (1)

NCT	Acronym	Phase	Status	Title
NCT01303926	ERACLE	P3	unknown	Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer

Intracranial Meningioma (1)

NCT	Acronym	Phase	Status	Title
NCT00972335	—	P2	terminated	Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Recurrent Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00976677	—	P2	terminated	Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer

Glioblastomas (1)

NCT	Acronym	Phase	Status	Title
NCT01102595	—	P2	completed	Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma

Recurrent Uterine Corpus Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT01012297	—	P3	terminated	Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Intraocular Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT01217398	—	P2	unknown	Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye

Brain Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT00939991	SAHA	P1/P2	completed	Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas

Refractory Solid Tumors in Children (1)

NCT	Acronym	Phase	Status	Title
NCT00993044	VIT-B	P1	completed	A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin

Adult Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT01010126	—	P2	completed	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Glial Cell Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT00879437	—	P2	completed	Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma

Advanced Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00948675	—	P3	completed	Study of Participants With Advanced Non-Small Cell Lung Cancer

Male Breast Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00861705	—	P2	completed	Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Metastatic Prostate Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00942578	ART-P	P2	completed	A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

Recurrent Large Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00946712	S0819	P3	terminated	S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Advanced Urothelial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00942331	—	P3	completed	Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Neoplastic Meningitis (1)

NCT	Acronym	Phase	Status	Title
NCT00924820	—	P1/P2	completed	A Pilot Study of Bevacizumab for Neoplastic Meningitis

Colon Cancer With Metastases to the Liver (1)

NCT	Acronym	Phase	Status	Title
NCT00932438	DEBIRI	P1/P2	completed	Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab

Brain Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT00906516	—	P2	unknown	Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

Newly Diagnosed High-Grade Gliomas (1)

NCT	Acronym	Phase	Status	Title
NCT00890786	—	Early P1	completed	A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas

Sarcoma, Kaposi (1)

NCT	Acronym	Phase	Status	Title
NCT00923936	—	P2	completed	Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma

Hemorrhagic Hereditary Telangiectasia (1)

NCT	Acronym	Phase	Status	Title
NCT00843440	METAFORE	P2	completed	Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study

Rectum Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00909987	—	P2	completed	Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum

Stomach Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00780494	—	P2	completed	Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Non-arteritic Anterior Ischemic Optic Neuropathy (1)

NCT	Acronym	Phase	Status	Title
NCT00813059	—	P2	unknown	Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy

Locally Advanced Gastric Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02048540	—	P1/P2	completed	Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell

Non-small Cell Lung Cancer Stage IIIB (1)

NCT	Acronym	Phase	Status	Title
NCT00766246	—	P2	terminated	Phase II Avastin Trial for Stage IIIB/IV NSCLC

Pulmonary Veno Occlusive Disease (1)

NCT	Acronym	Phase	Status	Title
NCT00891527	PVS	P1/P2	completed	Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis

Esophageal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00636298	—	P2	withdrawn	Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy

Estrogen Receptor Negative (1)

NCT	Acronym	Phase	Status	Title
NCT00785291	—	P3	completed	Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Locally Advanced Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00702975	NSCLC	P2	completed	Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy

Lymphocytic Leukemia, Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT00754650	—	P2	completed	A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia

Malignant Ovarian Epithelial Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT00748657	—	P2	completed	Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Age-Related Neovascular Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT00559715	VIBERA	P3	unknown	Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab

Kidney Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT00651482	—	P2	terminated	Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Neck Squamous Cell Carcinoma of Unknown Primary (1)

NCT	Acronym	Phase	Status	Title
NCT00588770	—	P3	active not recruiting	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Small-cell Lung Cancer (SCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT00698516	—	P2	completed	Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer

Recurrent or Refractory Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT00756340	—	P1	completed	A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors

Recurrent Renal Cell Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00684996	—	P1/P2	terminated	Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Osteosarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT00667342	—	P2	completed	A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

Non-Hodgkin's Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT00788606	—	P2	terminated	R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma

Gastroesophageal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00673673	—	P2	completed	FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer

HER2-negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00679029	HER2	P2	terminated	Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Thyroid Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT00804830	—	P2	terminated	Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer

Stage IV Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00784446	—	P1/P2	completed	First-line Therapy of Stage IV Colorectal Cancer

Gastrointestinal Stromal Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT00324987	S0502	P3	terminated	Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Estrogen Receptor-negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00733408	—	P2	completed	Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Myelofibrosis (1)

NCT	Acronym	Phase	Status	Title
NCT00667277	—	P2	terminated	Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis

Ewing Sarcoma of Bone (1)

NCT	Acronym	Phase	Status	Title
NCT00516295	—	P2	completed	Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma

Pterygium of the Conjunctiva and Cornea (1)

NCT	Acronym	Phase	Status	Title
NCT01288404	—	N/A	completed	Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium

Clear Cell Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00565851	—	P3	active not recruiting	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Colorectal Neuroendocrine Tumor G1 (1)

NCT	Acronym	Phase	Status	Title
NCT00569127	—	P3	active not recruiting	Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Untreated Mantle Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT00401817	—	P2	completed	Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma

Refractory Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT00665990	—	P1	completed	Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

Breast Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00433511	—	P3	active not recruiting	Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Oesophagogastric Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00450203	ST03	P2/P3	unknown	Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

Colorectal, Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00569335	SIRB	P2	completed	Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer

Toxicity (1)

NCT	Acronym	Phase	Status	Title
NCT00531076	—	P1	terminated	Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer

Colonic Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT00537901	—	N/A	completed	First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study

Lipid Keratopathy (1)

NCT	Acronym	Phase	Status	Title
NCT00681603	—	N/A	completed	Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization

Neovascular Age Related Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT00640640	AMD	N/A	unknown	The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)

Locally Recurrent and Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00511459	—	P2	completed	Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

B-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT00486759	—	P3	terminated	A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 (1)

NCT	Acronym	Phase	Status	Title
NCT00324805	—	P3	completed	Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Loco-regional Esophageal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00570531	—	P2	terminated	Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma

Adult Grade III Lymphomatoid Granulomatosis (1)

NCT	Acronym	Phase	Status	Title
NCT00458731	—	P1	completed	Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Unknown Primary Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT00458315	—	P2	withdrawn	Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Adrenocortical Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00469469	—	P2	withdrawn	Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma

Hormone-Sensitive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00461773	—	P2	terminated	Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Renal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00455975	—	P2	completed	High-dose Bevacizumab in Advanced Renal Carcinoma Patients

Esophageal Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT00447330	XAGastric	P2	completed	Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

Chronic Lymphocytic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT00448019	CLL	P2	completed	FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

Intravitreal Bevacizumab Injection (1)

NCT	Acronym	Phase	Status	Title
NCT00548197	—	P1	completed	Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment

Rectal Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT00557713	—	P2	unknown	XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma

Neoplasms, Breast (1)

NCT	Acronym	Phase	Status	Title
NCT00444535	—	P2	completed	Lapatinib and Bevacizumab for Metastatic Breast Cancer

Advanced Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT00428545	—	P1	completed	Bevacizumab and Bortezomib in Patients With Advanced Malignancy

Diabetic Retinopathy With Premacular Hemorrhage (1)

NCT	Acronym	Phase	Status	Title
NCT00673296	—	N/A	unknown	Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation

Vogt Koyanagi Harada Disease (1)

NCT	Acronym	Phase	Status	Title
NCT00407121	—	P3	withdrawn	Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 (1)

NCT	Acronym	Phase	Status	Title
NCT00408694	—	P2	completed	Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer

Multiple Myeloma in Relapse (1)

NCT	Acronym	Phase	Status	Title
NCT00410605	—	P2	completed	Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

Stomach Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT00390416	—	P2	completed	Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma

Neoplasms, Germ Cell and Embryonal (1)

NCT	Acronym	Phase	Status	Title
NCT00393861	—	P2	completed	Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients

Squamous Cell Carcinoma of the Head and Neck (SCCHN) (1)

NCT	Acronym	Phase	Status	Title
NCT00392665	—	P2	terminated	Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Adenosquamous Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00387374	—	P2	completed	Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

Telangiectasis (1)

NCT	Acronym	Phase	Status	Title
NCT00406380	—	P3	withdrawn	Effect of Avastin in Juxtafoveal Telangiectasias

High-Grade Gliomas (1)

NCT	Acronym	Phase	Status	Title
NCT00393094	—	P2	terminated	Bevacizumab and Irinotecan to Treat Brain Tumors

Retinal Disease (1)

NCT	Acronym	Phase	Status	Title
NCT00370851	—	P3	completed	Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial

Thymic Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00369889	—	P2	completed	A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer

Retinovascular Disease (1)

NCT	Acronym	Phase	Status	Title
NCT00370630	CRVO	P2	unknown	Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO)

Childhood Cerebral Anaplastic Astrocytoma (1)

NCT	Acronym	Phase	Status	Title
NCT00381797	—	P2	completed	Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Unspecified Adult Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT00390156	—	P1	completed	Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

Malignant Gliomas (1)

NCT	Acronym	Phase	Status	Title
NCT00463073	—	P2	completed	Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas

Wet AMD (1)

NCT	Acronym	Phase	Status	Title
NCT00403026	—	N/A	unknown	Intravitreal Bevacizumab for Retinal Disorders

Anal, Colon, and Rectal Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT00532909	—	P1	completed	Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

Neoplasm, Unknown Primary (1)

NCT	Acronym	Phase	Status	Title
NCT00360360	—	P2	completed	Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Choroidal Neovascularisation (1)

NCT	Acronym	Phase	Status	Title
NCT00344617	BEVACIZUMAB	P3	unknown	Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy

Pancreatic Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT00336648	—	P2	completed	Preop Chemoradiation Resectable Pancreas

Cholangiocarcinoma of the Extrahepatic Bile Duct (1)

NCT	Acronym	Phase	Status	Title
NCT00356889	—	P2	completed	Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

Carcinoid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT00328497	—	P2	completed	A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors

Polypoidal Choroidal Vasculopathy (1)

NCT	Acronym	Phase	Status	Title
NCT00383812	—	N/A	unknown	Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy

Myeloproliferative Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT00588666	—	P2	completed	Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma

Stage IA Pancreatic Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00305877	—	P2	completed	Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery

Retina (1)

NCT	Acronym	Phase	Status	Title
NCT00451763	—	P3	completed	Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia

Severe Nonproliferative (1)

NCT	Acronym	Phase	Status	Title
NCT00600262	—	P2/P3	terminated	Intravitreal Bevacizumab for Diabetic Retinopathy

Recurrent High-Grade Gliomas (1)

NCT	Acronym	Phase	Status	Title
NCT00271609	—	P2	completed	Bevacizumab for Recurrent Malignant Glioma

Diabetic Proliferative Retinopathy (1)

NCT	Acronym	Phase	Status	Title
NCT00417833	—	P2/P3	terminated	Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

Angioid Streaks (1)

NCT	Acronym	Phase	Status	Title
NCT00599820	—	P3	terminated	Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Diabetes Mellitus Type 2 (1)

NCT	Acronym	Phase	Status	Title
NCT00417716	—	P3	withdrawn	Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema

Lymphoma, Follicular (1)

NCT	Acronym	Phase	Status	Title
NCT00193492	—	P2	completed	A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

Contiguous Stage II Adult Diffuse Large Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT00121199	—	P2	completed	Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma

Gastrointestinal Carcinoid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT00227617	—	P2/P3	terminated	Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Chromophobe Renal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00126503	—	P1/P2	completed	Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Prostatic Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT00089609	—	P2	completed	Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

Recurrent Renal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00126490	—	P2	completed	Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Hepatic Metastases (1)

NCT	Acronym	Phase	Status	Title
NCT00200200	—	P2	completed	Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

Refractory Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT00611793	—	P1	completed	PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

Adult Acute Basophilic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT00096148	—	P2	terminated	Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Neoplasms, Unknown Primary (1)

NCT	Acronym	Phase	Status	Title
NCT00193622	—	P2	completed	Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

Adenocarcinoma of the Gastroesophageal Junction (1)

NCT	Acronym	Phase	Status	Title
NCT00084604	—	P2	completed	Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Primary Peritoneal Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00072566	—	P2	completed	Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Unspecified Childhood Solid Tumor, Protocol Specific (1)

NCT	Acronym	Phase	Status	Title
NCT00085111	—	P1	completed	Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Mucinous Adenocarcinoma of the Colon (1)

NCT	Acronym	Phase	Status	Title
NCT00060411	—	P1	completed	A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

Recurrent Squamous Cell Carcinoma of the Hypopharynx (1)

NCT	Acronym	Phase	Status	Title
NCT00055913	—	P1/P2	completed	Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Kaposi's Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT00055237	—	P2	completed	Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients

Metastatic Gastrointestinal Carcinoid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT00055809	—	P2	completed	Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Recurrent Breast Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00054132	—	P2	completed	Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Recurrent Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00055861	—	P2	completed	Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Cervical Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00025233	—	P2	completed	Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Primary Peritoneal Cavity Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00022659	—	P2	completed	Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Advanced Malignant Mesothelioma (1)

NCT	Acronym	Phase	Status	Title
NCT00027703	—	P2	completed	Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Blastic Phase Chronic Myelogenous Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT00023920	—	P2	terminated	Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia

Anaplastic Large Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT00016094	—	P2	completed	S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma

Stage IV Renal Cell Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00019539	—	P2	completed	Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

Lymphedema (1)

NCT	Acronym	Phase	Status	Title
NCT00318513	—	P1	unknown	Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema

Bevacizumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
ARIEL-ENGIC	NCT07094893	P4	not yet recruiting	Colorectal Cancer	280	—
L	NCT07004335	P4	not yet recruiting	PD-(L)1	40	—
MINUTE	NCT06031233	P4	recruiting	Oncology	776	—
IOLANTHE	NCT06121401	P4	active not recruiting	Carcinoma, Ovarian Epithelial	190	—
MITO16/MANGO-2	NCT01706120	P4	unknown	Ovarian Cancer	400	PMID 34462317
STAMP	NCT03832179	P4	completed	Diabetic Macular Edema	16	PMID 27493795
PROPER	NCT04674254	P4	completed	Proliferative Diabetic Retinopathy	43	PMID 3523356
REBEL	NCT04991350	P4	terminated	Diabetic Macular Edema	5	PMID 34189816
VASCATAQ	NCT04813913	P4	completed	Oncology	13	—
OPPS	NCT03037736	P4	withdrawn	Pterygium of Conjunctiva and Cornea	0	—
OASIS	NCT04619303	P4	completed	Diabetic Macular Edema	59	PMID 22310491
IMPACT	NCT03246152	P4	completed	Diabetic Macular Edema	31	PMID 19646547
REPEAT	NCT02530801	P4	unknown	Recurrent Pterygium	25	PMID 23807385
END-DME	NCT02462304	P4	unknown	Diabetic Macula Edema	60	—
IMPROVE	NCT02248571	P4	completed	Breast Cancer Recurrent	85	PMID 24158787
ASCENT	NCT01588990	P4	completed	Colorectal Neoplasms	128	PMID 32142532
BATMAN	NCT01094184	P4	completed	Breast Cancer	49	—
LUCAS	NCT01127360	P4	completed	Exudative Age-related Macular Degeneration	420	—
TRIASTIN	NCT00682539	P4	completed	Diabetic Macular Edema	71	PMID 29080915
ATEMD	NCT00737971	P4	completed	Diabetic Macular Edema	142	—
IVB	NCT01504724	P4	completed	Diabetic Retinopathy	30	PMID 21705686
AVATAX	NCT01156961	P4	withdrawn	Breast Cancer	0	—
BQ-1-08-ARVO	NCT00797303	P4	completed	Corneal Neovascularization	8	—
ARMD	NCT00805649	P4	completed	Age-Related Macular Degeneration	150	—
MECROV	NCT00566761	P4	terminated	Macular Edema	10	—
UmbrellaMAX	NCT05862285	P3	recruiting	Cancer	100	—
TroFuse-021	NCT07318558	P3	recruiting	Ovarian Neoplasms	900	—
MK-2870	NCT06824467	P3	recruiting	Ovarian Cancer	770	—
GLORIOSA	NCT05445778	P3	active not recruiting	Ovarian Cancer	520	PMID 39082675
CodeBreaK 301	NCT06252649	P3	recruiting	Metastatic Colorectal Cancer	450	PMID 39752885
DO-01	NCT06819007	P3	recruiting	Ovarian Cancer	582	—
BASKETⅢ	NCT06791512	P3	recruiting	Colorectal Cancer (CRC)	166	—
RAINFOL™-07	NCT07564141	P3	not yet recruiting	Platinum-Sensitive Ovarian Cancer	688	—
MK-2870	NCT07216703	P3	recruiting	Cervical Cancer	1,023	—
FRAmework-01	NCT07213804	P3	recruiting	Ovarian Neoplasms	1,630	—
CAPRI-3 GOIM	NCT07389265	P3	recruiting	Metastatic Colorectal Cancer (mCRC)	480	—
MK-1084	NCT06997497	P3	recruiting	Colon Adenocarcinoma	477	—
BRADI	NCT06471465	P3	recruiting	Radionecrosis of Brain	84	—
BRAINS	NCT06888817	P3	recruiting	Radiation Necrosis	408	—
MOUNTAINEER-03	NCT05253651	P3	recruiting	Colorectal Neoplasms	400	PMID 39723627
RAINFOL-04	NCT07225270	P3	recruiting	Ovarian Cancer	544	—
AndroMETa-CRC	NCT07525206	P3	recruiting	Colorectal Cancer	700	—
ARTEMIDE-HCC01	NCT06921785	P3	recruiting	Hepatocellular Carcinoma	1,220	—
FRU-RAS	NCT07362836	P3	not yet recruiting	Colorectal Cancer	224	—
HARMONi-GI3	NCT07228832	P3	recruiting	Metastatic Colorectal Cancer (CRC)	600	—
PROCEADE-CRC-03	NCT07549412	P3	recruiting	Metastatic Colorectal Cancer	1,020	—
BEVAMAINT	NCT04188145	P3	active not recruiting	Metastatic Colorectal Cancer	400	—
INVIGORATE	NCT07002346	P3	recruiting	Ovarian Clear Cell Carcinoma	226	—
TRIBE-C	NCT04230187	P3	active not recruiting	Colorectal Cancer	528	—
FOBEAR	NCT04215731	P3	recruiting	Rectal Cancer	582	—
CRITⅡ	NCT07549399	P3	recruiting	Rectal Adenocarcinoma	204	—
OrigAMI-3	NCT06750094	P3	recruiting	Colorectal Neoplasms	700	—
AtezoTRIBE2	NCT06733038	P3	recruiting	Colorectal Cancer	238	—
MRD-GI	NCT05482516	P3	recruiting	Colon Adenocarcinoma	20	—
OSCAR	NCT02885753	P3	recruiting	Colorectal Neoplasms	348	PMID 35027324
MK-3475	NCT05239741	P3	active not recruiting	Colorectal Neoplasms	100	—
IMbrella B	NCT03768063	P3	active not recruiting	Cancer	1,000	—
SIACI	NCT05271240	P3	recruiting	Glioblastoma	432	—
TALENTOP	NCT04649489	P3	active not recruiting	Venous Thrombosis	501	—
REGTAS-2	NCT06992648	P3	recruiting	Colorectal Cancer Metastatic	302	—
PRROC	NCT05281471	P3	recruiting	Platinum-resistant Ovarian Cancer	186	PMID 34686353
NORSE SEVEN	NCT05112861	P3	active not recruiting	Age-Related Macular Degeneration	120	—
IV	NCT06614192	P3	active not recruiting	Metastatic Colorectal Cancer	74	—
TACE	NCT04803994	P3	recruiting	Hepatocellular Carcinoma	434	—
EMERALD-2	NCT03847428	P3	active not recruiting	Hepatocellular Carcinoma	908	—
BEV	NCT06496971	P3	recruiting	Glioblastoma Multiforme	32	PMID 23527068
AK104	NCT06566755	P3	recruiting	Colorectal Cancer	30	—
SOLSTICE	NCT03869892	P3	active not recruiting	Metastatic Colorectal Cancer	856	PMID 36470291
DUO-O	NCT03737643	P3	active not recruiting	Advanced Ovarian Cancer	1,407	—
SKYSCRAPER-14	NCT05904886	P3	active not recruiting	Hepatocellular Carcinoma	687	PMID 38861301
EMERALD-1	NCT03778957	P3	active not recruiting	Hepatocellular Carcinoma	724	PMID 39798579
AMD	NCT06952452	P3	recruiting	Wet Age-related Macular Degeneration	630	—
SOLARIS	NCT04094688	P3	active not recruiting	Colorectal Adenocarcinoma	455	—
CheckMate 8HW	NCT04008030	P3	active not recruiting	Metastatic Colorectal Cancer	839	PMID 39602630
IMbrave050	NCT04102098	P3	completed	Carcinoma, Hepatocellular	668	PMID 41580093
LIBImAb	NCT04776655	P3	recruiting	Colorectal Cancer	280	—
MK-3475	NCT03740165	P3	completed	Ovarian Cancer	1,367	—
AMBITION	NCT04732598	P3	completed	Breast Cancer	281	—
COLAGE	NCT03828227	P3	active not recruiting	Elderly Patients	49	—
PRO-169	NCT05217680	P3	completed	Diabetic Macular Edema	509	PMID 37543959
RE-GEND	NCT02761070	P3	unknown	Glioblastoma	146	—
BEATcc	NCT03556839	P3	completed	Carcinoma of the Cervix, Stage IVB	410	PMID 40968753
CR-SEQUENCE	NCT03635021	P3	active not recruiting	Colorectal Cancer	419	—
CAIRO5	NCT02162563	P3	completed	Colorectal Cancer	530	PMID 38038829
AIO-KRK-0114	NCT02934529	P3	completed	Metastatic Colorectal Cancer	673	PMID 39903881
NItCHE-MITO33	NCT04679064	P3	unknown	Ovarian Cancer	427	PMID 34607820
DaDaLi	NCT04682210	P3	unknown	HCC	246	—
STRATEGIC-1	NCT01910610	P3	unknown	Colorectal Cancer Metastatic	464	PMID 26141683
AMD	NCT06190093	P3	completed	Neovascular Age-related Macular Degeneration	400	—
FERMATA	NCT03912415	P3	unknown	Cervical Cancer	316	—
BEAT-meso	NCT03762018	P3	completed	Pleural Mesothelioma Malignant Advanced	400	PMID 33358660
AMETHISTA	NCT04487067	P3	completed	Carcinoma, Hepatocellular	152	PMID 39874903
BEVERLY	NCT02633189	P3	unknown	Non-squamous Non-small Cell Lung Cancer	200	PMID 35659580
CRC	NCT05378867	P3	unknown	Metastatic Colorectal Cancer (CRC)	126	—
CheckMate 143	NCT02017717	P3	completed	Recurrent Glioblastoma	529	PMID 32691060
MK-3475	NCT03635567	P3	completed	Cervical Cancer	617	PMID 37910822
NSCLC	NCT03952403	P3	unknown	Carcinoma	643	PMID 41354044
BEST	NCT04305106	P3	unknown	COVID-19 Pneumonia	588	PMID 31986264
MITO16MANGO2b	NCT01802749	P3	unknown	Recurrent Ovarian Cancer	406	PMID 33539744
TASUKI-52	NCT03117049	P3	completed	Non-Small Cell Lung Cancer	550	PMID 41640231
MK-7339	NCT04456699	P3	completed	Metastatic Colorectal Cancer	335	PMID 38749110
COATS-VEGF	NCT03940690	P3	terminated	Retinal Telangiectasis	18	—
SUNLIGHT	NCT04737187	P3	completed	Refractory Metastatic Colorectal Cancer	492	PMID 37133585
ROP3	NCT04634604	P3	terminated	Retinopathy of Prematurity	16	—
MK-3475	NCT02563002	P3	completed	Colorectal Carcinoma	307	PMID 36369901
HIPOVA-01	NCT03220932	P3	unknown	Ovarian Epithelial Cancer	132	—
RIBBIT	NCT03462251	P3	completed	Breast Cancer	41	—
IMbrave150	NCT03434379	P3	completed	Carcinoma, Hepatocellular	558	PMID 40891895
IMagyn050	NCT03038100	P3	completed	Ovarian Cancer	1,301	PMID 37625235
S0819	NCT00946712	P3	terminated	Recurrent Large Cell Lung Carcinoma	1,333	PMID 34753703
AVANA	NCT02810457	P3	completed	Carcinoma, Non-Small-Cell Lung	731	PMID 34264503
PARADIGM	NCT02394795	P3	completed	Colorectal Cancer	823	PMID 37071094
BOOST	NCT01462890	P3	completed	Genital Diseases, Female	927	PMID 36332161
JAVELIN OVARIAN PARP 100	NCT03642132	P3	terminated	Ovarian Cancer	79	—
DRCR AC	NCT03321513	P3	completed	Diabetic Macular Edema	270	PMID 35833805
IMmotion151	NCT02420821	P3	completed	Renal Cell Carcinoma	915	PMID 31079938
NSCLC	NCT04416035	P3	unknown	Advanced Non-squamous Non-small-cell Lung Cancer	608	—
AMD	NCT03834753	P3	completed	Age-related Macular Degeneration	228	—
CanStem303C	NCT02753127	P3	completed	Colorectal Cancer	1,253	—
CN	NCT04325698	P3	terminated	Advanced Non-squamous NSCLC	8	—
SCORE2	NCT01969708	P3	completed	Central Retinal Vein Occlusion	362	PMID 28492910
TRIBE2	NCT02339116	P3	unknown	Metastatic Colorectal Cancer	654	PMID 35594613
IMpower150	NCT02366143	P3	completed	Carcinoma, Non-Small-Cell Lung	1,202	PMID 40379995
AMD	NCT03844074	P3	completed	Age-related Macular Degeneration	61	—
BABH	NCT03227263	P3	completed	Rendu Osler Disease	24	PMID 37592715
STELLA	NCT03296163	P3	completed	Non-small Cell Lung Cancer	627	PMID 33914256
OBELICS	NCT01718873	P3	completed	Colorectal Cancer	230	PMID 34309665
BECONNEC	NCT01501760	P3	completed	Corneal Newvessels	38	—
RAFTS	NCT02767219	P3	completed	Glaucoma	6	—
Protocol T	NCT01627249	P3	completed	Diabetic Macular Edema	660	PMID 25692915
Stop&Go	NCT01935492	P3	completed	Human Epidermal Growth Factor 2 Negative Carcinoma of Breast	420	—
METAL2	NCT02162537	P3	terminated	Non-small Cell Lung Cancer Metastatic	95	PMID 33948123
VISNU-1	NCT01640405	P3	completed	Metastatic Colorectal Cancer	350	PMID 32278676
GLOBE	NCT02511405	P3	completed	Glioblastoma	252	PMID 31844890
AXEPT	NCT01996306	P3	completed	Colorectal Neoplasms	650	PMID 29555258
SALTO	NCT01918852	P3	completed	Colorectal Cancer	161	PMID 30782413
GRECCAR8	NCT02314182	P3	completed	Rectal Adenocarcinoma	5	PMID 25849254
E10030	NCT01940887	P3	terminated	Age-Related Macular Degeneration	645	PMID 30957581
Ultimate	NCT01763671	P3	completed	Non-squamous Non-small Cell Lung Cancer	166	PMID 32276179
FOLFIRI	NCT00433927	P3	unknown	Neoplasm Metastasis	568	PMID 30293873
PREMED	NCT01774474	P3	completed	Cystoid Macular Edema	1,127	PMID 34417781
NSCLC	NCT01351415	P3	completed	Non-Squamous Non-Small Cell Lung Cancer	485	PMID 26828788
ITACa	NCT01878422	P3	completed	Metastatic Colorectal Cancer	376	PMID 38295317
CARIN	NCT00868634	P3	completed	Metastatic Breast Cancer	600	—
GeparQuinto	NCT00567554	P3	completed	Breast Cancer	2,600	PMID 25223482
CRC	NCT00973609	P3	completed	Colorectal Neoplasms	853	PMID 27753609
S0502	NCT00324987	P3	terminated	Gastrointestinal Stromal Tumor	12	PMID 26576593
INTORACT	NCT00631371	P3	completed	Renal Cell Carcinoma	791	PMID 24297945
TANIA	NCT01250379	P3	completed	Breast Cancer	494	PMID 27502725
VEGF	NCT00911170	P3	completed	Cancer	847	PMID 28038865
TURANDOT	NCT00600340	P3	completed	Metastatic Breast Cancer	564	PMID 23312888
ATLAS	NCT00257608	P3	completed	Non-Small Cell Lung Cancer	1,145	PMID 24101054
65plus	NCT00976456	P3	completed	Non-squamous Non-small Cell Lung Cancer	271	—
AVATAR	NCT00887822	P3	completed	Gastric Cancer	202	—
BETH	NCT00625898	P3	terminated	Breast Cancer	3,509	—
AURELIA	NCT00976911	P3	completed	Ovarian Cancer	361	PMID 24687829
BEBYP	NCT00720512	P3	terminated	Colorectal Cancer	184	PMID 25600568
GALATIR	NCT02036723	P3	withdrawn	Wet Age-related Macular Degeneration	0	—
ACT2	NCT01229813	P3	completed	Colorectal Cancer	233	PMID 26483047
ALBA	NCT01572350	P3	completed	Diabetic Macular Edema	105	PMID 33506177
CAIRO3	NCT00442637	P3	unknown	Colorectal Cancer Metastatic	635	PMID 25862517
RIBBON 1	NCT00262067	P3	unknown	Metastatic Breast Cancer	1,237	PMID 29522361
AVAGAST	NCT00548548	P3	completed	Adenocarcinoma	774	PMID 21844504
OCEANS	NCT00434642	P3	completed	Ovarian Cancer	484	PMID 26271155
EBEV	NCT01095809	P3	terminated	Uveitis	5	—
bevacizumab	NCT01380678	P3	unknown	Pterygium	206	—
RIBBON 2	NCT00281697	P3	completed	Metastatic Breast Cancer	684	—
ACT	NCT00598156	P3	completed	Metastatic Colorectal Cancer	249	PMID 23788755
ERACLE	NCT01303926	P3	unknown	Non-squamous Nonsmall Cell Neoplasm of Lung	118	PMID 25582493
AxL-2009	NCT01014468	P3	unknown	Age Related Macular Degeneration	500	—
IBeTA	NCT00997191	P3	completed	Diabetic Macular Edema	12	PMID 18997608
LOW-VISION	NCT01327222	P3	completed	Age Related Macular Degeneration	20	PMID 22776937
NSCLC	NCT00806923	P3	completed	Non-Squamous Non-Small Cell Lung Cancer	1,044	PMID 20150572
VIBERA	NCT00559715	P3	unknown	Age-Related Neovascular Macular Degeneration	366	—
PACCE	NCT00115765	P3	completed	Colorectal Cancer	1,053	PMID 30679026
DRP	NCT00806169	P3	completed	Macular Edema	40	—
RVO	NCT00805064	P3	completed	Retinal Vein Occlusion	40	—
MANTA	NCT00710229	P3	unknown	Age Related Macular Degeneration	320	PMID 23292928
TRIBE	NCT00719797	P3	completed	Colorectal Cancer	509	PMID 25337750
BEVACIZUMAB	NCT00344617	P3	unknown	Choroidal Neovascularisation	50	PMID 16156152
AMD	NCT00370786	P3	completed	Choroidal Neovascularization	31	—
PME	NCT00406172	P3	withdrawn	Cystoid Macular Edema	0	—
PDR	NCT00370721	P3	unknown	Diabetic Retinopathy	0	—
DREAM	NCT00265824	P3	completed	Colorectal Cancer	700	PMID 26474518
SIRIUS	NCT05375708	P2	suspended	Metastatic Colorectal Cancer	93	—
COLIBRI-GI	NCT07359456	P2	not yet recruiting	Metastatic Colorectal Cancer	130	—
IMMUNOLIFE2	NCT07001618	P2	recruiting	NSCLC (Advanced Non-small Cell Lung Cancer)	162	—
NIRVANA-1	NCT05183984	P2	recruiting	Ovarian Cancer	390	PMID 37650734
ASPIRE	NCT07018947	P2	recruiting	Resectable Hepatocellular Carcinoma	90	—
INAVO-CRC	NCT07323576	P2	withdrawn	Colorectal Cancer	0	—
ROMANCE - GOIM	NCT07381764	P2	not yet recruiting	Metastatic Colorectal Cancer (CRC)	150	—
PhotonAB	NCT06339424	P2	recruiting	Hepatocellular Carcinoma	45	—
AB-LATE02	NCT04727307	P2	active not recruiting	Hepatocellular Carcinoma	202	—
TROY	NCT07340164	P2	recruiting	Ovarian Cancer	116	—
Phenix	NCT07263438	P2	recruiting	Glioblastoma	59	—
INTUITT-NF2	NCT04374305	P2	recruiting	Neurofibromatosis Type 2	109	PMID 38904277
ATTACH	NCT07239245	P2	recruiting	Resectable Hepatocellular Carcinoma With High Risk of Recurrence	30	—
ProtonAB	NCT06133062	P2	recruiting	Hepatocellular Carcinoma Non-resectable	45	—
NEOTORCH-BREAST07	NCT07351487	P2	recruiting	TNBC - Triple-Negative Breast Cancer	37	—
SMARTi-RC01	NCT07134101	P2	not yet recruiting	Colorectal Cancer (Diagnosis)	138	—
DAB	NCT06540729	P2	recruiting	Ovary Cancer	39	—
HOFIBREN	NCT07182708	P2	not yet recruiting	NSCLC (Non-small Cell Lung Cancer)	62	—
QLPPEC/GOG-003	NCT06917092	P2	recruiting	Endometrial Adenocarcinoma	30	—
MEMMAT	NCT01356290	P2	recruiting	Medulloblastoma Recurrent	232	PMID 36291912
NOVELTY-R	NCT07183865	P2	recruiting	Locally Recurrent Rectal Cancer	44	—
IV	NCT06890338	P2	recruiting	Epithelial Ovarian Cancer	140	—
TERTIO	NCT05528952	P2	recruiting	Hepatocellular Carcinoma	105	PMID 37516867
BETWEEN	NCT07071844	P2	not yet recruiting	Metastatic Colorectal Cancer	162	—
DOVE	NCT06023862	P2	recruiting	Ovarian Neoplasms	198	PMID 39710508
LoBULarDIPG	NCT04250064	P2	recruiting	DIPG	40	—
NIBCUN	NCT03872661	P2	recruiting	Lung Cancer Stage III	36	—
TACE	NCT07128251	P2	not yet recruiting	Hepatocellular Carcinoma (HCC)	47	—
PRELUDE	NCT06976944	P2	recruiting	Recurrent Triple-Negative Breast Cancer	24	—
TACE-HAIC	NCT07543783	P2	not yet recruiting	Adebrelimab (SHR-1316)	38	—
BNT327	NCT07297212	P2	recruiting	Recurrent Glioblastoma	75	—
AUTOMAIN	NCT06971744	P2	recruiting	Ovarian Cancer	38	—
BRAVE	NCT06411600	P2	recruiting	Metastatic Colorectal Cancer	94	—
CLEAR-2	NCT07331883	P2	recruiting	Hepatocellular Carcinoma (HCC)	35	—
FLORENZA	NCT07059845	P2	recruiting	Ovarian Cancer	400	—
RRP	NCT05797246	P2	active not recruiting	Respiratory Tract Diseases	21	—
GS-1811	NCT07527858	P2	recruiting	Advanced Microsatellite Stable Colorectal Cancer	170	—
HAIBrave-001	NCT06737913	P2	recruiting	Advanced Hepatocellular Carcinoma (HCC)	76	—
BETTER2	NCT03351296	P2	active not recruiting	Pancreatic Cancer	140	—
LIBRA	NCT06982924	P2	not yet recruiting	EGFR Mutation Positive Advanced Non Small Cell Lung Cancer	136	—
NEOCATS	NCT06650709	P2	not yet recruiting	Ovarian Cancer Stage IV	40	—
TRIFLUOX-DP	NCT06245356	P2	recruiting	Metastatic Colorectal Cancer	73	—
L	NCT07288034	P2	recruiting	Lung Non-Small Cell Carcinoma	535	—
JUST BREATHE	NCT06701656	P2	recruiting	Acute Respiratory Distress Syndrome (ARDS)	200	—
THUMB	NCT07150208	P2	not yet recruiting	Breast Cancer With Brain Metastasis	140	—
JUST BREATHE	NCT06703073	P2	recruiting	Acute Respiratory Distress Syndrome (ARDS)	600	PMID 40028879
CANTOR	NCT06792695	P2	recruiting	Metastatic Colorectal Cancer	80	—
II	NCT07123441	P2	not yet recruiting	Colorectal Cancer	300	—
REFISH	NCT07178717	P2	not yet recruiting	Colo-rectal Cancer	25	—
DEFLECT I	NCT06809946	P2	not yet recruiting	Lung Neoplasms	20	—
ONTOP	NCT07106034	P2	recruiting	Advanced Colorectal Cancer	32	—
BBOpCo	NCT06268015	P2	active not recruiting	Colorectal Cancer	16	—
ARK	NCT07051785	P2	not yet recruiting	Colorectal Cancer (CRC)	68	—
STARLIGHT	NCT06563986	P2	recruiting	Metastatic Colorectal Cancer	40	—
BEST	NCT07535632	P2	not yet recruiting	Colorectal Neoplasms	58	—
BOUQUET	NCT04931342	P2	active not recruiting	Ovarian Cancer	176	—
BASECOVID	NCT07089719	P2	not yet recruiting	Dyspnea Caused by 2019-nCoV	21	PMID 37526809
COBP	NCT05585814	P2	recruiting	Locally Advanced Colorectal Cancer	30	—
AndroMETa-CRC	NCT06820463	P2	recruiting	Metastatic Colorectal Cancer	390	—
SCRIPBOT	NCT06872606	P2	not yet recruiting	Rectal Adenocarcinoma	33	—
FLORA	NCT05690048	P2	recruiting	Immunotherapy	48	PMID 40930564
TASK-03	NCT06860490	P2	recruiting	Hepatocellular Carcinoma (HCC)	164	—
QL1706	NCT07229846	P2	not yet recruiting	Colorectal Cancer	30	—
FOCUS-C	NCT05334277	P2	recruiting	Non-small Cell Lung Cancer	280	—
Better Brain	NCT06728865	P2	recruiting	Non-small Cell Lung Cancer (NSCLC)	70	—
STRATUM	NCT05377034	P2	recruiting	Locally Advanced Hepatocellular Carcinoma	100	—
(HCC)	NCT06789757	P2	recruiting	Hepatocellular Carcinoma	19	PMID 31954490
NSCLC	NCT06953843	P2	recruiting	NSCLC Stage IV Without EGFR/ALK Mutation	366	—
QL1706	NCT06958484	P2	not yet recruiting	HCC - Hepatocellular Carcinoma	60	—
CLEAR-04	NCT07562490	P2	recruiting	ctDNA	100	—
TACE	NCT03937830	P2	active not recruiting	Hepatocellular Cancer	27	—
DRUP	NCT02925234	P2	recruiting	Cancer	1,550	PMID 37424386
Kirros	NCT06096779	P2	active not recruiting	Hepatocellular Carcinoma	30	—
BELIEVE	NCT05588388	P2	recruiting	Extensive-stage Small-cell Lung Cancer	39	—
TAS-102	NCT06711471	P2	recruiting	Gastric Cancer Adenocarcinoma Metastatic	31	—
DEL-LIVER	NCT06607458	P2	recruiting	Refractory Metastatic Colorectal Cancer	90	—
IBI305	NCT06667050	P2	active not recruiting	Gastric Adenocarcinoma	58	—
CHIMERA	NCT07407465	P2	recruiting	Colorectal Cancer	42	—
Awesome	NCT05284539	P2	recruiting	Non Small Cell Lung Cancer	760	—
II	NCT07047560	P2	recruiting	Colorectal Cancer (CRC)	46	—
II	NCT07044921	P2	recruiting	Colorectal Cancer Metastatic	30	—
ROP4	NCT04634578	P2	active not recruiting	Retinopathy of Prematurity	77	—
Union-mRC	NCT07059949	P2	not yet recruiting	Unresectable Metastatic Rectal Cancer	80	—
QL1706	NCT07083375	P2	not yet recruiting	Extensive Small Cell Lung Cancer	56	PMID 37158938
SAHLVE	NCT04101877	P2	active not recruiting	Neovascular Age-related Macular Degeneration	402	—
BEAT	NCT03896074	P2	active not recruiting	Non-small-cell Lung Cancer Patients	206	—
SCOTI	NCT05806931	P2	recruiting	Colon Cancer	50	—
TASBEL	NCT06856187	P2	recruiting	Metastatic Colorectal Cancer (CRC)	119	—
CRIT	NCT06908031	P2	recruiting	Rectal Adenocarcinoma	49	—
EMPHASIS	NCT05516628	P2	recruiting	Hepatocellular Carcinoma	30	—
TrUST-HHT	NCT04404881	P2	active not recruiting	Hereditary Hemorrhagic Telangiectasia	33	—
MEDI4736	NCT07012798	P2	recruiting	Hepatocellular Carcinoma (HCC)	30	—
CONVERSION	NCT03401294	P2	recruiting	Metastatic Colorectal Cancer	32	—
II	NCT06643793	P2	recruiting	Colorectal Neoplasms Malignant	30	—
IV	NCT06107413	P2	active not recruiting	Unresectable Metastatic Colorectal Cancer	280	—
MONTBLANC	NCT05844046	P2	recruiting	Hepatocellular Carcinoma	83	PMID 41732658
EAGLE	NCT05491811	P2	active not recruiting	Non-Small Cell Lung Cancer	47	—
ONO-4538-98	NCT04566380	P2	recruiting	Pan-tumor	59	—
Toco-CoR	NCT04245865	P2	active not recruiting	Colorectal Cancer Metastatic	83	—
NSCLC	NCT06793813	P2	recruiting	Stage IVB Lung Cancer	44	—
GPPB	NCT05305131	P2	recruiting	Nasopharyngeal Cancer	50	PMID 31150573
NSCLC	NCT06783647	P2	recruiting	Advanced Solid Tumour	230	—
NALIRIBVRG	NCT06801730	P2	recruiting	Glioma	38	—
UTILIZABLE	NCT06125080	P2	recruiting	TNBC - Triple-Negative Breast Cancer	78	—
NТО-RAS	NCT06229340	P2	recruiting	RAS Mutation	20	—
INTEGRATE	NCT04563338	P2	active not recruiting	Hepatocellular Carcinoma	36	—
OPEB-01	NCT04361370	P2	enrolling by invitation	Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer	44	PMID 33559413
LGG	NCT02840409	P2	active not recruiting	Low Grade Glioma	109	—
EMERALD-Y90	NCT06040099	P2	active not recruiting	Hepatocellular Carcinoma (HCC)	58	PMID 41903993
ADAPTABLE	NCT05781308	P2	active not recruiting	Non Small Cell Lung Cancer	156	—
IMMUNOGAST	NCT04739202	P2	completed	Gastric Adenocarcinoma	54	—
DYNAMIC	NCT04954339	P2	completed	Hepatocellular Carcinoma	40	PMID 28130846
SCRT	NCT05640726	P2	unknown	Rectal Cancer	30	—
MSS	NCT06282445	P2	recruiting	Colorectal Cancer Metastatic	36	—
ALERT-HCC	NCT05992220	P2	recruiting	Hepatocellular Carcinoma	138	—
EndoBARR	NCT03694262	P2	completed	Endometrial Cancer	30	PMID 28403786
WU-KONG29	NCT06276283	P2	recruiting	Non-small Cell Lung Cancer	60	—
BEACON	NCT02308527	P2	completed	Neuroblastoma	225	PMID 38190578
BRISK	NCT05904457	P2	unknown	Solid Tumors	32	—
LIVERPEARL	NCT04595266	P2	active not recruiting	Colorectal Cancer Metastatic	48	—
SAFIR02_Breast	NCT02299999	P2	active not recruiting	Metastatic Breast Cancer	1,460	PMID 32067679
AXOAXI	NCT01531595	P2	active not recruiting	Metastatic Colorectal Cancer	100	—
BRAIN	NCT05303259	P2	unknown	Brain Injuries	204	—
HAITI	NCT06332079	P2	terminated	Colorectal Cancer Metastatic	4	—
TORCH-R	NCT05628038	P2	recruiting	Recurrent Rectal Cancer	93	PMID 38053659
STROBE	NCT06377267	P2	unknown	Ovarian Cancer	100	—
BELLA	NCT04739670	P2	unknown	Metastatic Triple Negative Breast Cancer	31	—
TARZAN	NCT04017455	P2	active not recruiting	Rectal Cancer	38	—
MK-7684A-005	NCT05007106	P2	completed	Uterine Cervical Neoplasms	613	—
BEST	NCT06090656	P2	recruiting	Hepatocellular Carcinoma	88	—
DeFianCe	NCT05480306	P2	completed	Colorectal Cancer	188	—
B-TACE	NCT05883176	P2	unknown	Hepatocellular Carcinoma by BCLC Stage	35	—
BEACON	NCT03363867	P2	unknown	Ovarian Cancer	30	—
LOST-B	NCT05537402	P2	terminated	Hepatocellular Carcinoma	1	—
GFPC 06-2018	NCT04042558	P2	completed	NSCLC Stage IIIB	150	PMID 36801605
OPAL	NCT03574779	P2	completed	Ovarian Neoplasms	77	PMID 38754056
NSCLC	NCT02681549	P2	completed	Melanoma	41	PMID 40048689
DEMAND	NCT04224636	P2	unknown	Hepatocellular Carcinoma Non-resectable	106	PMID 35081747
SAMCO	NCT03186326	P2	completed	Metastatic Colorectal Cancer	132	PMID 40531517
BRIGHT	NCT05044871	P2	completed	Ovarian Cancer	108	PMID 38658024
daNIS-3	NCT04952753	P2	terminated	Metastatic Colorectal Cancer	204	—
ATHENA	NCT03818061	P2	completed	Head and Neck Neoplasms	33	—
INTERACT-II	NCT06003998	P2	unknown	Colorectal Cancer	85	PMID 38238055
HCC	NCT06370065	P2	unknown	Advanced Hepatocellular Carcinoma	35	—
GBM	NCT05191784	P2	unknown	Recurrent Glioblastoma	20	—
GBM	NCT05638451	P2	unknown	Recurrent Glioblastoma	30	—
BIS-Program	NCT05180006	P2	terminated	Breast Cancer	33	—
KRAS	NCT05593328	P2	completed	Colorectal Cancer	23	—
REVOLUTION	NCT04310176	P2	unknown	Ras-mutated Metastatic Colorectal Cancer	200	PMID 32849914
CLavSyn	NCT03117972	P2	terminated	Metastatic Colorectal Cancer	54	—
CUPISCO	NCT03498521	P2	completed	Cancer of Unknown Primary Site	529	PMID 39096924
SIRTCI	NCT04659382	P2	unknown	Metastatic Colorectal Cancer	52	PMID 28781171
NIVACOR	NCT04072198	P2	completed	Colorectal Cancer	73	PMID 32867715
TELMA	NCT03836066	P2	completed	Non Small Cell Lung Cancer	41	PMID 36520426
AB7	NCT04829383	P2	completed	Unresectable Hepatocellular Carcinoma	6	—
BASKETⅡ	NCT04895137	P2	completed	Colorectal Cancer	42	PMID 33607964
POCHI	NCT04262687	P2	unknown	Colorectal Cancer Metastatic	55	PMID 23539594
TAS-102	NCT04109924	P2	completed	Advanced Colorectal Carcinoma	42	PMID 39244627
T-Double	NCT04796025	P2	unknown	Hepatocellular Carcinoma	34	—
CAPOX	NCT01191697	P2	completed	Esophageal Cancer	37	PMID 31101074
BEVANEC	NCT02820857	P2	completed	Neuroendocrine Carcinomas	153	PMID 36739879
INOVA	NCT04735861	P2	completed	Ovarian Clear Cell Carcinoma	38	PMID 39276785
ABC-lung	NCT04245085	P2	completed	EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC	95	PMID 40023017
ELEVATE CRC	NCT05330429	P2	terminated	Metastatic Colorectal Cancer	77	—
CeLEBrATE	NCT04730999	P2	completed	Small Cell Lung Cancer	54	PMID 19934295
IORT	NCT04681677	P2	terminated	Glioblastoma	12	PMID 22582564
Castle06(BC)	NCT05303038	P2	unknown	Metastatic Breast Cancer in the Liver	15	—
NIRVANA-R	NCT04734665	P2	unknown	Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor	44	PMID 34910393
NEOPEMBROV	NCT03275506	P2	completed	Ovarian Cancer Stage IV	91	PMID 40378056
ABE-LIVER	NCT05448677	P2	terminated	Hepatocellular Carcinoma	3	—
BOOSTER	NCT03133546	P2	completed	Non Small Cell Lung Cancer Metastatic	155	PMID 21135146
CLASSIC5	NCT04997382	P2	completed	Non-small Cell Lung Cancer	112	—
BOLD	NCT04015739	P2	unknown	Epithelial Ovarian Cancer	74	—
AIO-KRK-0116	NCT04034459	P2	unknown	Metastatic Colorectal Cancer	109	—
IBI308	NCT04194359	P2	unknown	Metastatic Colorectal Cancer	25	PMID 37554125
ATRACTIB	NCT04408118	P2	completed	Metastatic Breast Cancer	100	PMID 40467896
MiST	NCT03654833	P2	unknown	Mesothelioma, Malignant	186	PMID 35157829
SUKSES-B2	NCT04939662	P2	completed	Lung Cancer	25	—
CLIMB	NCT03698461	P2	completed	Colorectal Neoplasms	20	—
Clovis-001	NCT03476798	P2	completed	Cervical Cancer	49	—
MARIO-3	NCT03961698	P2	unknown	Breast Cancer	91	—
AtezoTRIBE	NCT03721653	P2	completed	Metastatic Colorectal Cancer	218	PMID 38865678
ECLIPSE	NCT03395899	P2	completed	Breast Cancer	71	—
AvaTa	NCT03126799	P2	unknown	EGFR Positive Non-small Cell Lung Cancer	128	—
HCC	NCT04541173	P2	terminated	Hepatocellular Carcinoma	6	—
D-TRIPLET	NCT05214339	P2	unknown	Unresectable Hepatocellular Carcinoma	30	—
JS001	NCT04605796	P2	completed	Advanced Hepatocellular Carcinoma (HCC)	54	—
DoT-FMI	NCT05359874	P2	withdrawn	Breast Cancer	0	—
GBM	NCT04952571	P2	terminated	Recurrent Glioblastoma	3	—
ABST-C	NCT03271255	P2	unknown	Colorectal Neoplasms	80	PMID 24933332
BEST	NCT02490878	P2	terminated	Radionecrosis	19	—
HER2	NCT00773695	P2	completed	Breast Cancer	150	PMID 41529624
HCC	NCT04741165	P2	unknown	Hepatocellular Carcinoma	72	—
AVANIRA3	NCT04556071	P2	unknown	Ovarian Neoplasms	32	—
QUATTRO-II	NCT04097444	P2	unknown	Metastatic Colorectal Cancer	112	PMID 32703200
HLRCC	NCT01130519	P2	completed	HLRCC	83	PMID 40532152
IMGN853	NCT03836157	P2	withdrawn	Endometrial Cancer	0	—
IP	NCT03990103	P2	unknown	Metastatic Gastric Adenocarcinoma	66	—
COHORT-A	NCT05751629	P2	completed	Ovarian Neoplasm	41	—
BEVTOR	NCT04527068	P2	unknown	Refractory Metastatic Colorectal Cancer	50	—
CRLM	NCT04003792	P2	unknown	Liver Metastasis Colon Cancer	49	—
SULTAN	NCT03164655	P2	completed	Colorectal Cancer Metastatic	20	PMID 32000724
XRT	NCT01004874	P2	completed	Malignant Glioma	80	—
ESCEND	NCT03877601	P2	unknown	Barrett Esophagus	60	—
BEVACOR	NCT04954014	P2	terminated	ARDS, Human	21	—
MEDI4736	NCT02336165	P2	completed	Glioblastoma	159	PMID 26327487
OWONBNSCLCLM	NCT04148898	P2	unknown	Leptomeningeal Metastasis	80	PMID 28673332
OWBLM	NCT04425681	P2	unknown	Leptomeningeal Metastasis	20	PMID 30059262
HCC	NCT01180959	P2	completed	Liver Cancer	45	PMID 26929648
ALIENOR	NCT01770301	P2	completed	Ovarian Sex-cord Stromal Tumor	60	PMID 33030515
MODUL	NCT02291289	P2	completed	Colorectal Cancer	1,044	PMID 36921494
BATTLE	NCT02226289	P2	unknown	Neoplasm	46	—
CELIM2	NCT01802645	P2	unknown	Colorectal Cancer	91	—
RCC	NCT01399918	P2	completed	Renal Cell Carcinoma	57	—
CORIMMUNO-BEVA	NCT04344782	P2	unknown	COVID19 Pneumonia	130	—
HIGH-LIGHT	NCT02842580	P2	terminated	Colorectal Neoplasms	21	—
CBL	NCT03711240	P2	unknown	Colorectal Cancer	40	—
TASCO1	NCT02743221	P2	completed	Metastatic Colorectal Cancer	154	PMID 32497736
BEVABEL	NCT02363751	P2	completed	Collecting Duct Carcinoma (Kidney)	36	PMID 37054556
NVALT12	NCT01171170	P2	completed	Non Small Cell Lung Cancer	223	PMID 26347109
BEAT-ROP	NCT00622726	P2	unknown	Retinopathy of Prematurity	150	PMID 18536599
BEV	NCT02343549	P2	terminated	Cancer of Brain and Nervous System	13	—
CAESURA	NCT03912402	P2	unknown	Cervical Cancer	49	—
DEEPER	NCT02515734	P2	unknown	Colorectal Cancer	360	—
BEST-CP	NCT04275414	P2	completed	Coronavirus Infections	27	PMID 33547300
CARCINOSIS	NCT02591667	P2	unknown	Colorectal Cancer	30	PMID 14551293
AMG 479	NCT01327612	P2	completed	Advanced Solid Tumors	12	—
TMZ	NCT01390948	P2	completed	High Grade Glioma	124	PMID 31419298
FORBES	NCT02350530	P2	completed	Metastatic Colorectal Cancer	138	—
BRILLIANT	NCT02655536	P2	unknown	Carcinoma, Non-Small-Cell Lung	109	PMID 33067126
BBP	NCT01740258	P2	completed	Malignant Glioma	68	—
BEARRD	NCT02192970	P2	completed	Retinal Detachment	101	PMID 23582767
Beverly1	NCT00820547	P2	completed	Breast Cancer	100	PMID 27032301
S0635	NCT00436332	P2	completed	Lung Cancer	84	—
Toco-Ovar	NCT02399592	P2	completed	Ovarian Cancer	23	—
TAA	NCT02754362	P2	withdrawn	Glioblastoma	0	—
BeTRI	NCT02497157	P2	completed	Metastatic Colorectal Cancer	45	—
BOOSTER	NCT01989780	P2	completed	Metastatic Breast Cancer	160	PMID 35405087
LIBERTI	NCT02819479	P2	completed	Radiation Necrosis	10	PMID 35426830
BEV-ONCO2012	NCT01858649	P2	completed	Metastatic Colorectal Cancer	60	PMID 19276259
NOVA	NCT01847677	P2	terminated	Cancer, Ovarian	71	—
AXEBEAM	NCT00828672	P2	completed	Locally Advanced Rectal Cancer	84	—
NPC	NCT01309633	P2	completed	Nasopharyngeal Carcinoma	80	—
BACCHUS	NCT01650428	P2	completed	Rectal Cancer	20	PMID 26493588
BEVATOMOX	NCT01532804	P2	terminated	Metastatic Colorectal Cancer	83	PMID 41537257
ABCDE	NCT00925652	P2	terminated	Breast Cancer	55	PMID 39890560
ANGIO-TAX+	NCT01303497	P2	completed	Angiosarcoma	70	PMID 30305054
IMmotion150	NCT01984242	P2	completed	Renal Cell Carcinoma	305	PMID 32233107
GTN	NCT02664961	P2	terminated	Gestational Trophoblastic Neoplasia	3	—
PRIMIER	NCT02413853	P2	withdrawn	Colorectal Adenocarcinoma	0	—
VISNU-2	NCT01640444	P2	completed	Colorectal Cancer Metastatic	240	PMID 40259317
BELIEF	NCT01562028	P2	completed	Lung Cancer	109	PMID 28408243
CTB	NCT01492673	P2	completed	Neuroblastoma	9	—
CHARTA	NCT01321957	P2	completed	Metastatic Colorectal Cancer	250	PMID 22897915
BLOCK-ROP	NCT01232777	P2	withdrawn	Retinopathy of Prematurity	0	—
TRUST	NCT03085992	P2	completed	Rectal Cancer	49	—
GIM11-BERGI	NCT02175446	P2	unknown	Metastatic Breast Cancer	61	PMID 19289619
SARC016	NCT01661283	P2	completed	Malignant Peripheral Nerve Sheath Tumors	25	—
MITOBEVAEND2	NCT01770171	P2	unknown	Stage III-IV or Recurrent Endometrial Cancer	108	—
AVATAXHER	NCT01142778	P2	completed	Breast Cancer	152	PMID 25456368
ALEXANDRIA	NCT02654639	P2	terminated	Metastatic Colorectal Cancer	4	PMID 28712102
SwitchDMO	NCT01787669	P2	completed	Diabetes	19	—
BUCiL	NCT01705184	P2	completed	Non-small Cell Lung Cancer Metastatic	120	PMID 16421419
AVASTEM	NCT01190345	P2	completed	Breast Cancer	75	—
MOMA	NCT02271464	P2	completed	Metastatic Colorectal Cancer	232	PMID 29792754
TAVAREC	NCT01164189	P2	completed	Central Nervous System Tumors	155	PMID 30115593
PASSION	NCT02119026	P2	completed	Metastatic Colorectal Cancer	120	PMID 7535799
BATTLE-FL	NCT01263782	P2	completed	Lung Cancer	64	—
ART-P	NCT00942578	P2	completed	Metastatic Prostate Cancer	63	PMID 9301705
ATOM	NCT01836653	P2	completed	Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer	122	PMID 31285591
COI-B	NCT02086656	P2	completed	Colorectal Cancer Liver Metastases	46	—
QUATTRO	NCT02246049	P2	completed	Colorectal Neoplasms	69	—
MBC	NCT00428922	P2	completed	Breast Cancer	26	PMID 18316792
McCAVE	NCT02141295	P2	terminated	Colorectal Cancer	197	—
NLG207	NCT02187302	P2	completed	Metastatic Renal Cell Carcinoma	115	PMID 28950297
BRANCH	NCT01481545	P2	completed	Rectal Cancer	62	—
GALADON	NCT01690325	P2	terminated	Breast Cancer	21	—
PROMIX	NCT00957125	P2	unknown	Breast Cancer	151	PMID 27461224
CCNU	NCT01067469	P2	completed	Brain Cancer	83	—
TPCA	NCT00394433	P2	completed	Esophageal Cancer	38	—
BOS2	NCT01508000	P2	terminated	Colorectal Cancer Metastatic	44	—
ARTE	NCT01443676	P2	completed	Glioblastoma	75	PMID 29648580
AVAXEL	NCT01043484	P2	completed	Rectal Cancer	90	PMID 33246428
H3E-US-X072	NCT00614822	P2	completed	Non Small Cell Lung Cancer	50	—
ANTHALYA	NCT01739218	P2	completed	Ovarian Cancer	99	—
KRAS	NCT00819780	P2	completed	Colon Cancer	285	PMID 26049686
DIPG	NCT01182350	P2	terminated	Diffuse Intrinsic Pontine Glioma	53	PMID 29741745
MIMEB	NCT01047059	P2	completed	Non-Small-Cell Lung Carcinoma	40	—
NSCLC	NCT00874107	P2	completed	Non-Small Cell Lung Cancer	90	PMID 29486797
ReACT	NCT01498328	P2	completed	Glioblastoma	127	PMID 32034072
Prodige20	NCT01900717	P2	completed	Metastatic Colorectal Adenocarcinoma	102	PMID 31101691
GOC-B-P	NCT01206049	P2	completed	Cholangiocarcinoma	88	—
INOVA	NCT00865189	P2	completed	Rectal Cancer	91	PMID 25122693
STEAM	NCT01765582	P2	terminated	Colorectal Neoplasms	280	PMID 30552157
BEVIAC	NCT01677884	P2	completed	Colorectal Neoplasms	10	—
VEGF-ARDS	NCT01314066	P2	withdrawn	Severe Sepsis	0	PMID 16702604
BRAIN	NCT01621880	P2	completed	Nasopharyngeal Carcinoma	112	PMID 29885994
S0800	NCT00856492	P2	completed	Breast Cancer	215	—
PGA	NCT01936974	P2	terminated	Ovarian Carcinoma	7	—
CENTRAL	NCT01853813	P2	completed	Colorectal Cancer Stage II	85	—
MAVERICC	NCT01374425	P2	completed	Colorectal Cancer	376	—
105GM201	NCT01564914	P2	completed	Glioblastoma	22	—
ANGIOSWITCH	NCT02075086	P2	unknown	Colorectal Cancer	100	—
ToPPS	NCT00892710	P2	completed	Non Small Cell Lung Cancer	172	PMID 37419867
xeberecto	NCT00847119	P2	completed	Rectal Cancer	43	PMID 25886275
PEPCOL	NCT01375816	P2	terminated	Colorectal Cancer	55	—
RADBEV	NCT01031381	P2	completed	Ovarian Cancer	50	—
OLGA	NCT01759238	P2	terminated	Colorectal Cancer	1	—
CLL	NCT00448019	P2	completed	Chronic Lymphocytic Leukemia	64	PMID 25043749
NOSE	NCT01408030	P2	completed	Telangiectasia, Hereditary Hemorrhagic	123	PMID 27599329
New Beat	NCT01554059	P2	completed	Rectal Adenocarcinoma	25	PMID 25952796
CRAB	NCT00842686	P2	unknown	Locally Advanced Rectal Cancer	60	PMID 17042060
XAGastric	NCT00447330	P2	completed	Esophageal Neoplasms	60	PMID 10215831
BEV	NCT00464646	P2	completed	Breast Cancer	105	—
ABCSG 32	NCT01367028	P2	completed	Breast Cancer	100	PMID 20185313
NF2	NCT01207687	P2	completed	Vestibular Schwannoma	14	PMID 26976425
BECOX	NCT01067053	P2	unknown	Metastatic Colorectal Cancer	69	—
ABC	NCT00479674	P2	completed	Breast Cancer	41	PMID 38703993
HHT	NCT01397695	P2	completed	Hereditary Hemorrhagic Telangiectasia (HHT)	20	—
S0636	NCT00445848	P2	completed	Lung Cancer	89	—
GDC-0449	NCT00959647	P2	completed	Ovarian Cancer	19	—
NSCLC	NCT01057212	P2	terminated	Non-squamous Non-small Cell Lung Cancer	6	—
CTA	NCT00520013	P2	completed	Ovarian Cancer	60	—
NSCLC	NCT01137968	P2	completed	Non-small Cell Lung Cancer	116	—
PCA	NCT00911820	P2	completed	Esophageal Cancer	88	—
Mel47	NCT00397982	P2	completed	Recurrent Melanoma	17	PMID 24047116
HHT	NCT01402531	P2	completed	Hereditary Hemorrhagic Telangiectasia (HHT)	10	—
GBM	NCT01782976	P2	withdrawn	Glioblastoma	0	—
HHT	NCT01314274	P2	completed	HHT	15	PMID 24595923
ATAG	NCT02898012	P2	completed	Glioblastoma Multiforme	70	PMID 29472310
NSCLC	NCT00702975	P2	completed	Locally Advanced Non-Small Cell Lung Cancer	35	—
PERIMAX	NCT01540435	P2	withdrawn	Colon Cancer Liver Metastasis	0	—
RT	NCT00805961	P2	completed	Glioblastoma Multiforme	68	PMID 22706484
AVF4120s	NCT00525525	P2	completed	Glioblastoma	74	PMID 24637230
NACprotocol	NCT01641406	P2	unknown	Infiltrating Duct and Lobular Carcinoma In Situ	60	—
AVIRMA01-09	NCT01144988	P2	unknown	Recurrent Malignant Glioma	35	—
MG	NCT00953121	P2	completed	Malignant Glioma	104	PMID 21986722
RCC	NCT00913913	P2	terminated	Metastatic Renal Cell Carcinoma	8	PMID 17255302
NSCLC	NCT01368848	P2	completed	NSCLC	7	—
BEVPAC	NCT01722968	P2	completed	Breast Cancer	33	—
Vengeance	NCT01249521	P2	unknown	Metastatic Colorectal Cancer	40	—
NSCLC	NCT00130780	P2	completed	Carcinoma, Non-Small-Cell Lung	71	—
IBERA-DME	NCT01487629	P2	unknown	Diabetic Retinopathy	53	PMID 23795985
SELECT-A	NCT01674738	P2	withdrawn	Carcinoma, Non-Small-Cell Lung	0	—
EROS	NCT02821559	P2	completed	Metastatic Colorectal Cancer	37	—
SAFE	NCT00862342	P2	completed	Metastatic Colorectal Cancer	78	PMID 22782485
AVAXIRI	NCT00875771	P2	completed	Metastatic Colorectal Cancer	80	PMID 25925749
INNOVATIONS	NCT00536640	P2	completed	Carcinoma, Non-Small-Cell Lung	224	PMID 25792638
METAFORE	NCT00843440	P2	completed	Hemorrhagic Hereditary Telangiectasia	25	PMID 22396517
RCC	NCT00796757	P2	completed	Renal Cell Cancer	146	PMID 23803225
TORAVA	NCT00619268	P2	completed	Metastatic Renal Cell Carcinoma	160	PMID 21664867
VEGF	NCT00879359	P2	completed	Endometrial Carcinoma	15	—
OMEGA	NCT00467142	P2	completed	Colorectal Cancer	62	PMID 24758527
GBM	NCT00817284	P2	completed	Glioblastoma Multiforme	60	—
NSCLC	NCT00508625	P2	completed	Non-Small Cell Lung Cancer	213	PMID 22186627
FALCON	NCT00653939	P2	completed	Tumors	63	PMID 11948484
MEL0107	NCT01048554	P2	completed	Melanoma	34	—
N2	NCT00924209	P2	terminated	NSCLC	7	PMID 17762333
TEACO	NCT00296816	P2	completed	Ovarian Cancer	132	—
NILE	NCT01366131	P2	completed	Non-Squamous Non-Small Cell Lung Cancer	104	PMID 29438092
APRIORI	NCT01126866	P2	terminated	Colorectal Carcinoma	35	—
NSCLC	NCT00553800	P2	completed	Carcinoma, Non-Small-Cell Lung	32	—
TACE	NCT00576199	P2	completed	Liver Cancer	30	—
B-DOCT	NCT01359397	P2	unknown	Metastatic Gastric Cancer	0	—
BASIC	NCT00569699	P2	completed	Colorectal Cancer	56	—
BRVO	NCT01044329	P2	unknown	Branch Retinal Vein Occlusion	90	—
KARE004	NCT00660621	P2	unknown	Glioma	40	—
XELBEVOCT	NCT01203306	P2	unknown	Neuroendocrine Carcinomas	42	PMID 24628963
MACCO-A	NCT00127036	P2	terminated	Adenocarcinoma	65	—
HER2	NCT00679029	P2	terminated	HER2-negative Breast Cancer	15	—
S0536	NCT00368992	P2	completed	Adenocarcinoma of the Lung	110	—
NSCLC	NCT00356122	P2	completed	Non-Small Cell Lung Cancer	53	—
IPSS	NCT00565656	P2	terminated	Myelodysplastic Syndromes	40	—
BEV/EV	NCT00597506	P2	completed	Colorectal Adenocarcinoma	50	—
FOIB	NCT01163396	P2	completed	Colorectal Cancer Metastatic	57	PMID 20702138
MG	NCT00671970	P2	completed	Glioblastoma	57	PMID 20716591
SIRB	NCT00569335	P2	completed	Colorectal, Cancer	52	—
GFL	NCT00786643	P2	completed	Colorectal Cancer	48	—
AMBER	NCT00473590	P2	completed	Multiple Myeloma	102	—
BEV	NCT00365417	P2	completed	Breast Cancer	45	—
HORIZON I	NCT00278889	P2	completed	Colorectal Cancer	215	—
PDT	NCT00729846	P2	completed	Age Related Macular Degeneration	22	—
DCE-MRI	NCT00352521	P2	completed	Brain and Central Nervous System Tumors	20	—
BRIDGE	NCT00318136	P2	completed	Non-small Cell Lung Cancer	47	—
SALUTE	NCT00403403	P2	completed	Small Cell Lung Cancer	102	—
PASSPORT	NCT00312728	P2	completed	Non-Small Cell Lung Cancer	115	—
BEAM	NCT00434252	P2	completed	Melanoma	214	—
OVCA	NCT00129727	P2	completed	Ovarian Cancer	62	—
IOP	NCT00804921	P2	completed	Macular Edema	0	—
Tribeva-DME	NCT00874744	P2	completed	Diabetic Macular Edema	13	—
PDT	NCT00359164	P2	completed	Macular Degeneration	36	—
IBETRA	NCT00690768	P2	completed	Diabetic Retinopathy	20	PMID 19208678
Bevacizumab	NCT00336323	P2	completed	Diabetic Retinopathy	121	PMID 18185135
AC	NCT00394251	P2	completed	Breast Cancer	197	PMID 21976055
ARMAST	NCT00696592	P2	withdrawn	Neovascular Age-related Macular Degeneration	0	—
BRAIN	NCT00345163	P2	completed	Glioblastoma	167	PMID 19720927
SABRE-R	NCT00491738	P2	terminated	Renal Cell Carcinoma	16	—
S0408	NCT00118105	P2	withdrawn	Colorectal Cancer	0	PMID 16635283
SABRE-L	NCT00434226	P2	terminated	Non-Small Cell Lung Cancer	56	—
SABRE-B	NCT00434356	P2	terminated	Metastatic Breast Cancer	46	—
CRVO	NCT00370630	P2	unknown	Retinovascular Disease	15	—
TREE-2	NCT00399750	P2	completed	Colorectal Cancer	373	—
AVF3299	NCT00203372	P2	completed	Breast Cancer	6	—

Terminated and withdrawn Bevacizumab trials (370)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05375708suspendedSystemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites
NCT07323576withdrawnA Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer
NCT07146919withdrawnAssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
NCT07011550suspendedPhase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
NCT07449481withdrawnA Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
NCT05109052withdrawnTrial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
NCT06393751withdrawnTesting the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
NCT01386710suspendedRepeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
NCT01083966suspendedSuper-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
NCT02229175withdrawnLaser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema
NCT03743428suspendedBiomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)
NCT05410301withdrawnGolden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
NCT05238831withdrawnSMMART Adaptive Clinical Treatment (ACT) Trial
NCT06704724terminatedA Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
NCT05083481terminatedA Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
NCT01552434terminatedBevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
NCT03786081terminatedSafety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
NCT06332079terminatedHolmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
NCT06509906terminatedM9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
NCT03337698terminatedA Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
NCT03520686terminatedNogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT05733611terminatedRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
NCT05998941withdrawnA Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
NCT05537402terminatedLOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
NCT05200364terminatedA Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
NCT01933815suspendedDose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
NCT05983367terminatedA Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
NCT04952753terminatedStudy of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
NCT04553692terminatedPhase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
NCT05523440terminatedBevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
NCT03806049withdrawnTrial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
NCT01743950terminatedA Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
NCT05180006terminatedImpact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
NCT05776875terminatedAtezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
NCT03117972terminatedChemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels
NCT05070104withdrawnCPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
NCT05678257terminatedA Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NCT05717400terminatedImproving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
NCT06448364terminatedA Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
NCT04406272terminatedVB-111 in Surgically Accessible Recurrent/Progressive GBM
NCT05824559terminatedME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
NCT04512430terminatedNeo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
NCT05330429terminatedStudy of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
NCT03024437terminatedAtezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
NCT04732286terminatedA Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
NCT04681677terminatedRecurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
NCT05648006terminatedFirst-line Maintenance of OH2 Injection for Advanced Colorectal Cancer
NCT05448677terminatedEzurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma
NCT03693573withdrawnA Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
NCT03387085terminatedQUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
NCT06006286withdrawnA Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
NCT04074785terminatedAbemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6
NCT03940690terminatedInterest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
NCT04634604terminatedA Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP
NCT05510427withdrawnPhase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
NCT03376659terminatedDurvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
NCT04421378terminatedA Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
NCT04541173terminatedStudy of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
NCT04099836terminatedAtezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
NCT01814813terminatedVaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
NCT05886257withdrawnCandonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
NCT05359874withdrawnImprovement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW
NCT04510584withdrawnMaintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer
NCT03367871terminatedCombination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
NCT04952571terminatedCombined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
NCT02490878terminatedCorticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
NCT05431582withdrawnPhase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
NCT03708536withdrawnBevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma
NCT04466917withdrawnA Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04991350terminatedEffect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema
NCT05093608terminatedSELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
NCT03558724terminatedFluorescence Endoscopy of Esophageal Carcinoma
NCT02923739terminatedPaclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03555149terminatedA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
NCT04861948terminatedIBI188 Combination Therapy in Solid Tumors
NCT03554707withdrawnSGT-53 in Children With Recurrent or Progressive CNS Malignancies
NCT03836157withdrawnMirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
NCT03843853withdrawnPemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer
NCT02521051terminatedPhase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
NCT03272217terminatedAtezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
NCT03563144withdrawnQUILT-3.088: NANT Pancreatic Cancer Vaccine
NCT00946712terminatedS0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT01788280withdrawnPreliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
NCT02364713terminatedMV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
NCT03169777withdrawnQUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
NCT03169738withdrawnQUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
NCT03167177withdrawnQUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
NCT03167164withdrawnQUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
NCT03197571withdrawnQUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
NCT03169764withdrawnQUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
NCT03197584withdrawnQUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
NCT03175666withdrawnQUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
NCT03169790withdrawnQUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
NCT03642132terminatedAvelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
NCT03713944terminatedCarboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
NCT02695641withdrawnReduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients
NCT04954014terminatedPilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
NCT03050814terminatedStandard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
NCT04126044withdrawnA SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS
NCT02663271terminatedTTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
NCT04325698terminatedA BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
NCT03690739terminatedEvaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
NCT04067856withdrawnIntravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery
NCT03387111terminatedQUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
NCT03878524terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
NCT02982694terminatedStudy With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
NCT02842580terminatedDe-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
NCT02343549terminatedA Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
NCT02060305terminatedIntra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis
NCT01871571terminatedBevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer
NCT03037736withdrawnOutpatient Performed Pterygium Surgery Study
NCT03573986terminatedPilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
NCT02414165terminatedThe Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
NCT03368859terminatedA Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
NCT02988843terminatedStudy of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
NCT00544700terminatedBevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer
NCT03329248terminatedQUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03136406terminatedQUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT02743078terminatedOptune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
NCT03586869terminatedQUILT-3.080: NANT Pancreatic Cancer Vaccine
NCT03382886terminatedNivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
NCT02754362withdrawnA Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NCT01847677terminatedNeoadjuvant Therapy in Advanced Ovarian Cancer With Avastin
NCT02833701terminatedBevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
NCT02200354terminatedThe Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab
NCT00303628terminatedPostoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
NCT02162537terminatedTherapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases
NCT01532804terminated2nd-line Treatment of Metastatic Colorectal Cancer
NCT01312376terminatedAutologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
NCT00925652terminatedBevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
NCT03387098terminatedQUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03380689withdrawnPhase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer
NCT02664961terminatedStudy of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
NCT02413853withdrawnCombination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
NCT03161041withdrawnPerioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study
NCT01884740terminatedIntraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
NCT01478321terminatedEfficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
NCT01232777withdrawnPan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)
NCT01303679terminated1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
NCT02648711terminatedAlternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
NCT02743975terminatedNear-infrared Image Guided Surgery in Pancreatic Adenocarcinoma
NCT03176264terminatedPDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
NCT01198158terminatedEverolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
NCT02654639terminatedPh 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
NCT02250118terminatedIntrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer
NCT01940887terminatedA Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
NCT02661815terminatedA Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
NCT01339039terminatedPlerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
NCT01705392terminatedBevacizumab vs Dacarbazine in Metastatic Melanoma
NCT02141295terminatedA Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer
NCT02387957terminatedA 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
NCT02348255withdrawnNovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
NCT01578551terminatedStudy of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.
NCT01120158terminatedPaclitaxel Plus Bevacizumab for Older Patients With Breast Cancer
NCT02841332terminatedMultimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma
NCT01690325terminatedImaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)
NCT00955305terminatedPaclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
NCT01508000terminatedEfficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases
NCT00702572terminatedCarboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
NCT01201850terminatedThe Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors
NCT01495988terminatedTrial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
NCT01182350terminatedMolecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
NCT00438204terminatedPemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT01055028terminatedPaclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
NCT01582152terminatedPhase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
NCT01765582terminatedSequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer
NCT01314066withdrawnEfficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)
NCT00227617terminatedCombination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
NCT01229202withdrawnUse of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery
NCT02047214terminatedSafety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
NCT00934440terminatedA Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
NCT00520975terminatedBevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
NCT02106520terminatedEfficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
NCT01012297terminatedGemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
NCT02496286terminatedFeasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites
NCT02065466withdrawnCombo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
NCT01937715terminatedA Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
NCT01936974terminated(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
NCT01471054terminatedDexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
NCT02060955terminatedRandomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
NCT01954030terminatedPhase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
NCT01264341terminatedEfficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
NCT00324987terminatedImatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
NCT01338558withdrawnA Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab
NCT02450981withdrawnEvaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration
NCT01105702terminatedTemodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
NCT01189240terminatedRO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
NCT01063010withdrawnPilot Study of Bevacizumab (Avastin) in Patients With Septic Shock
NCT01375816terminatedLiposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
NCT01320683terminatedCombination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
NCT01086345terminatedRadiosurgery Plus Bevacizumab in Glioblastoma
NCT00804830terminatedAvastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
NCT01279681terminatedCombination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
NCT01759238terminatedChemoradiotherapy for Patients With Oligometastatic Colorectal Cancer
NCT00972335terminatedTrial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
NCT00625898terminatedBETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
NCT01069796terminatedBevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
NCT01426074withdrawnDCE-MRI PET Bevacizumab Study in Rectal Cancer
NCT01280643terminatedCombination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT00720512terminatedSecond-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab
NCT00424840terminatedPhase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
NCT02036723withdrawnSafety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
NCT01057212terminatedTrial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT00392665terminatedBevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
NCT00321100terminatedCombination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
NCT01441388withdrawnA Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
NCT00774241withdrawnPRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer
NCT00976677terminatedCarboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
NCT01256580withdrawnIntravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
NCT00964704withdrawnA Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
NCT01270438withdrawnCombination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
NCT00850577terminatedPh II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
NCT00394992terminatedAdjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer
NCT01782976withdrawnPh II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
NCT00570531terminatedPhase II Trial for Patients With Loco-Regional Esophageal Carcinoma
NCT01540435withdrawnPerioperative Treatment of Resectable Liver Metastases
NCT00960297terminatedPreoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
NCT00601926terminatedBevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT01095809terminatedEfficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema
NCT02179567terminatedDocetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC
NCT00932152terminatedFulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
NCT00913913terminatedBevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
NCT01156961withdrawnA Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
NCT00811993terminatedA Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
NCT00717990terminatedIrinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment
NCT01408953terminatedTherapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue
NCT00499369terminatedIrinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
NCT01046279terminatedHypertension Monitoring in Glioma Patients Treated With Bevacizumab
NCT00755118terminatedLohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
NCT00755157withdrawnMetronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer
NCT00356681terminatedA Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
NCT01674738withdrawnTS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV
NCT01331616withdrawnOptic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab
NCT01198548terminatedHigh-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer
NCT00866723terminatedAvastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
NCT00577109withdrawnA Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
NCT01202890terminatedStudy of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
NCT00988897withdrawnColorectal Cancer RECHALLENGE
NCT00458315withdrawnCisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
NCT00819754terminatedA Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer
NCT00766246terminatedPhase II Avastin Trial for Stage IIIB/IV NSCLC
NCT00517361terminatedPhase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
NCT00268450terminatedCisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
NCT00636298withdrawnStudy of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy
NCT00651482terminatedTreatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
NCT01293942withdrawnIXO+A in mCRC With Liver-only Metastases
NCT01090830terminatedSafety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer
NCT01167725terminatedStandard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
NCT00583622terminatedBevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
NCT00881504terminatedA Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma
NCT01821859terminatedAbraxane/Bevacizumab
NCT00709657terminatedThe Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
NCT00486759terminatedA Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
NCT00998166terminatedA Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy
NCT00523809terminatedAllogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor
NCT00418093terminatedOxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma
NCT01131039withdrawnSafety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
NCT00924209terminatedA Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer
NCT00369070terminatedA Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC
NCT01262859withdrawnPilot Study for Locally Advanced Head and Neck Cancer
NCT00609622terminatedRandomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer
NCT00626561terminatedBevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
NCT00537823terminatedPre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
NCT01126866terminatedCurative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy
NCT00845910terminatedA Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer
NCT00476827terminatedA Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
NCT00296062terminatedDose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
NCT00600210withdrawnNeoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer
NCT00523640terminatedA Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
NCT00779311terminatedA Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
NCT00281528terminatedWeekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
NCT00908219withdrawnA Study of Bevacizumab to Prevent Malignant Ascites
NCT01133990terminatedFOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
NCT00826800terminatedNeoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer
NCT00604461terminatedCarboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
NCT00280007terminatedTransarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma
NCT00127036terminatedTrial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
NCT00728845terminatedHydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
NCT00679029terminatedChemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
NCT00684996terminatedBevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT01159236withdrawnMolecular Triaging of Newly Diagnosed Breast Cancer
NCT00749567terminatedCombination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer
NCT00674011terminatedHypertension in Breast Cancer Patients Receiving Bevacizumab
NCT00565656terminatedA Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts
NCT00984438withdrawnSurgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
NCT00904852withdrawnSafety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
NCT00788606terminatedR-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma
NCT00314353terminatedStudy of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
NCT00461773terminatedRandomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
NCT01141881terminatedEvaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema
NCT00667277terminatedPhase II Study of Bevacizumab (Avastin®) in Myelofibrosis
NCT00393094terminatedBevacizumab and Irinotecan to Treat Brain Tumors
NCT00996502terminatedStudy of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
NCT00449163terminatedCombination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
NCT01052363withdrawnOXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas
NCT00531076terminatedSafety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
NCT00694200terminatedVinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer
NCT00642824terminatedA Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
NCT00426829terminatedProton Therapy and Bevacizumab for Primary Liver Tumors
NCT00408070terminatedBevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT00602329terminatedMRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
NCT00556205withdrawnBevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma
NCT00469469withdrawnTreatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma
NCT00702819terminatedPan-VEGF Blockade for the Treatment of Retinopathy of Prematurity
NCT00307723terminatedStudy of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer
NCT00567372withdrawnPOSTERIOR SUB-TENON'S Avastin
NCT00576901terminatedA Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
NCT00388700withdrawnA New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
NCT00508872terminatedFolfox-B Study for Patients With Colorectal Liver Metastases
NCT00735241withdrawnFOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma
NCT00642603terminatedA Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT00632541terminatedA Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
NCT00671645terminatedPreoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy
NCT00845104withdrawnFludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment
NCT00402883terminatedChemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
NCT00801866withdrawnAvastin for Post-photocoagulation Macular Edema
NCT00515684withdrawnCorneal Thinning During Topical Bevacizumab Therapy
NCT00326911terminatedCetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
NCT00390026withdrawnThe Avastin vs Visudyne for Neovascular AMD Study
NCT00327093terminatedElaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
NCT00378573terminatedMulticenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT00351039terminatedPhase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
NCT00804206terminatedComparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation
NCT02079519terminatedA Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma
NCT00313768terminatedRandomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
NCT00408772withdrawnOxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
NCT00536939terminatedTrial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer
NCT00566761terminatedTreatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO
NCT00404703terminatedA Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
NCT00600301withdrawnVitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study
NCT00696592withdrawnPhotodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration
NCT00571740withdrawnCetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
NCT00447031withdrawnCombination Therapy for Neovascular Age Related Macular Degeneration
NCT00440973terminatedSafety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
NCT00323011terminatedFOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
NCT00334763terminatedRadiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer
NCT01271166terminatedGlivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer
NCT00496405withdrawnUnilateral Bevacizumab for Bilateral Diabetic Macular Edema
NCT00410774terminatedGemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery
NCT00491738terminatedA Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
NCT00347698withdrawnIntravitreal Bevacizumab vs Photocoagulation for Proliferative Diabetic Retinopathy
NCT00469976withdrawnEnzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer
NCT00347399terminatedBevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
NCT00411593withdrawnPhase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)
NCT00118105withdrawnS0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
NCT00293332terminatedDocetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
NCT00434226terminatedA Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
NCT00434356terminatedA Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)
NCT00524069withdrawnGemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
NCT00407121withdrawnIntravitreal Bevacizumab for Inflammatory Neovascular Membranes
NCT00406172withdrawnIntravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)
NCT00406380withdrawnEffect of Avastin in Juxtafoveal Telangiectasias
NCT00406744terminatedEfficacy of Retreatments With Intravitreal Bevacizumab
NCT00106054terminatedNeoadjuvant Colorectal Cancer With Unresectable Liver Metastases
NCT00347165terminatedIntravitreal Bevacizumab for Age-Related Macular Degeneration
NCT00418431withdrawnIntravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
NCT00417833terminatedMultifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment
NCT00369551terminatedBevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
NCT00600262terminatedIntravitreal Bevacizumab for Diabetic Retinopathy
NCT00120172terminatedStudy of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer
NCT00599820terminatedUse of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
NCT00417716withdrawnUse of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
NCT00253526withdrawnGemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
NCT00096148terminatedIdarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00107315terminatedBevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
NCT00070122terminatedCombination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
NCT00061178withdrawnEfficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
NCT00049088terminatedBortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT00043004terminatedChemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer
NCT00023920terminatedBevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia

All Bevacizumab trials (2548)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT05620771		Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk	P2	recruiting	200	Northwestern University	Nov 2022
NCT05468359		Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients	P1/P2	recruiting	64	St. Jude Children's Research Hospital	Nov 2022
NCT02436993		Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab	P2	active not recruiting	120	University of California, Irvine	Apr 2015
NCT06492421		Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.	P2	recruiting	90	Second Affiliated Hospital of Guangzhou Medical University	Jul 2024
NCT06482801		Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT	P2	recruiting	90	Second Affiliated Hospital of Guangzhou Medical University	Jun 2024
NCT06990516		SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer	P1/P2	not yet recruiting	90	Tongji Hospital	Jun 2025
NCT06580314		Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer	P3	recruiting	880	NRG Oncology	Mar 2025
NCT07293468	BIIRTH	Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)	P2/P3	recruiting	106	Tuen Mun Hospital	Apr 2024
NCT06725121	MacroTrans	Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant	P1/P2	recruiting	48	University Health Network, Toronto	Dec 2024
NCT05863195		Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial	P3	recruiting	408	ECOG-ACRIN Cancer Research Group	Oct 2023
NCT05375708	SIRIUS	Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites	P2	suspended	93	UMC Utrecht	Dec 2025
NCT07221357		A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer	P2/P3	recruiting	990	Bristol-Myers Squibb	Dec 2025
NCT06492408		Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.	P2	recruiting	90	Second Affiliated Hospital of Guangzhou Medical University	Jul 2024
NCT06483347		Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT	P2	recruiting	90	Second Affiliated Hospital of Guangzhou Medical University	Apr 2024
NCT07359456	COLIBRI-GI	Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases	P2	not yet recruiting	130	UNICANCER	Aug 2026
NCT07472153		PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer	P2/P3	recruiting	120	N.N. Alexandrov National Cancer Centre	Jul 2025
NCT07472140		PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer	P2/P3	recruiting	120	N.N. Alexandrov National Cancer Centre	Jul 2025
NCT05797467		Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients	P3	recruiting	366	Sixth Affiliated Hospital, Sun Yat-sen University	Apr 2023
NCT05862285	UmbrellaMAX	A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study	P3	recruiting	100	Hoffmann-La Roche	Jun 2023
NCT07318558	TroFuse-021	A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)	P3	recruiting	900	Merck Sharp & Dohme LLC	Feb 2026
NCT07079631	BNT327	A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer	P1/P2	recruiting	482	BioNTech SE	Jul 2025
NCT05007132		Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer	P2	recruiting	153	Dominik Paul Modest	Dec 2021
NCT07500298		Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer	P1	recruiting	41	M.D. Anderson Cancer Center	May 2026
NCT06824467	MK-2870	A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)	P3	recruiting	770	Merck Sharp & Dohme LLC	Apr 2025
NCT07001618	IMMUNOLIFE2	Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer	P2	recruiting	162	Gustave Roussy, Cancer Campus, Grand Paris	Nov 2025
NCT05445778	GLORIOSA	Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer	P3	active not recruiting	520	AbbVie	Mar 2023
NCT06252649	CodeBreaK 301	Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation	P3	recruiting	450	Amgen	Jul 2024
NCT06954584		Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer	P3	recruiting	424	Tongji Hospital	May 2025
NCT07585279		A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer	P2/P3	not yet recruiting	408	Hebei Medical University Fourth Hospital	May 2026
NCT05183984	NIRVANA-1	Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer	P2	recruiting	390	ARCAGY/ GINECO GROUP	Feb 2022
NCT06543576		External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer	P1/P2	recruiting	35	Jonsson Comprehensive Cancer Center	Jul 2025
NCT06819007	DO-01	Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)	P3	recruiting	582	Daiichi Sankyo	Mar 2025
NCT05096715		Atezolizumab+Bevacizumab+SBRT in Unresectable HCC	P1	recruiting	20	Massachusetts General Hospital	Aug 2022
NCT07370818		To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer	P2	not yet recruiting	81	Onconic Therapeutics Inc.	Feb 2026
NCT06791512	BASKETⅢ	mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC	P3	recruiting	166	Jun Huang	Jan 2025
NCT05009082		Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer	P3	recruiting	970	AGO Study Group	Sep 2022
NCT07564141	RAINFOL™-07	Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer	P3	not yet recruiting	688	Genmab	Jul 2026
NCT07071714		A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer	P2	recruiting	200	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Jul 2025
NCT07216703	MK-2870	A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)	P3	recruiting	1,023	Merck Sharp & Dohme LLC	Jan 2026
NCT07291076	HCC	A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)	P1/P2	recruiting	198	Bristol-Myers Squibb	Mar 2026
NCT07213804	FRAmework-01	A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer	P3	recruiting	1,630	Eli Lilly and Company	Oct 2025
NCT07222800		Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer	P3	recruiting	800	Pfizer	Dec 2025
NCT07018947	ASPIRE	Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC	P2	recruiting	90	Fundacion Clinic per a la Recerca Biomédica	Jun 2026
NCT07346157	PNOC044	Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease	P1/P2	not yet recruiting	69	Sabine Mueller, MD, PhD	Jul 2026
NCT07323576	INAVO-CRC	A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer	P2	withdrawn	0	Hoffmann-La Roche	Feb 2026
NCT07381764	ROMANCE - GOIM	ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"	P2	not yet recruiting	150	Gruppo Oncologico Italia Meridionale	Mar 2026
NCT06339424	PhotonAB	Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma	P2	recruiting	45	Chang Gung Memorial Hospital	Mar 2024
NCT07271355		Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial	P3	not yet recruiting	129	City of Hope Medical Center	Jul 2026
NCT04727307	AB-LATE02	Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial	P2	active not recruiting	202	University Hospital, Montpellier	Feb 2021
NCT03942328		Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer	P1/P2	recruiting	85	Mayo Clinic	Sep 2019
NCT07490262		A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.	P2/P3	recruiting	680	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	Mar 2026
NCT07340164	TROY	Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy	P2	recruiting	116	Yonsei University	Feb 2026
NCT07239596		Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom	P1/P2	recruiting	139	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Jan 2026
NCT07263438	Phenix	Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial	P2	recruiting	59	Centre Hospitalier Universitaire Vaudois	Nov 2025
NCT07012954		ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC	P1/P2	recruiting	64	Sun Yat-sen University	Jun 2025
NCT07334301	BEACON2	A Multi-Arm, Platform Trial For Relapsed Neuroblastoma	P1/P2	recruiting	160	University of Birmingham	Nov 2024
NCT06618664		A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma	P3	recruiting	590	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Oct 2024
NCT06061809		N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma	P2	active not recruiting	34	ImmunityBio, Inc.	Aug 2024
NCT06988852		FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis	P2	recruiting	300	Tongji Hospital	May 2023
NCT07317414		β-alanine in the Treatment of Advanced Hepatocellular Carcinoma	P2	recruiting	158	Peking Union Medical College Hospital	Dec 2025
NCT07347951		A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer	P2	recruiting	30	First Affiliated Hospital of Wenzhou Medical University	Dec 2025
NCT04374305	INTUITT-NF2	Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)	P2	recruiting	109	Scott R. Plotkin, MD, PhD	Jun 2020
NCT06160206		Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma	P2	recruiting	134	Academic and Community Cancer Research United	Oct 2024
NCT05462613	REPROGRAM-02	Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer	P2/P3	recruiting	446	Centre Hospitalier Universitaire de Besancon	May 2023
NCT07239245	ATTACH	Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo	P2	recruiting	30	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Nov 2025
NCT07389265	CAPRI-3 GOIM	Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer	P3	recruiting	480	University of Campania Luigi Vanvitelli	Oct 2025
NCT06997497	MK-1084	A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)	P3	recruiting	477	Merck Sharp & Dohme LLC	Jul 2025
NCT07146919	ANGELICA	AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer	P1/P2	withdrawn	0	Centre Leon Berard	Oct 2025
NCT07361991		IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer	P1/P2	not yet recruiting	50	The First Affiliated Hospital of Zhengzhou University	Mar 2026
NCT06109272	LIVIGNO-2	A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)	P2/P3	recruiting	660	AbbVie	Jan 2024
NCT06133062	ProtonAB	Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma	P2	recruiting	45	Chang Gung Memorial Hospital	Nov 2023
NCT03424005	Morpheus-panBC	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer	P1/P2	recruiting	1,132	Hoffmann-La Roche	Mar 2018
NCT07351487	NEOTORCH-BREAST07	Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)	P2	recruiting	37	First Affiliated Hospital of Zhejiang University	Sep 2025
NCT06131840		A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors	P1	recruiting	914	Seagen, a wholly owned subsidiary of Pfizer	Nov 2023
NCT07134101	SMARTi-RC01	Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)	P2	not yet recruiting	138	The First Affiliated Hospital with Nanjing Medical University	Sep 2025
NCT06471465	BRADI	Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases	P3	recruiting	84	Institut Cancerologie de l'Ouest	Apr 2025
NCT04929223	INTRINSIC	A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)	P1	recruiting	542	Hoffmann-La Roche	Oct 2021
NCT06540729	DAB	RC48 in Combination With AK104 and Bevacizumab in OCCC	P2	recruiting	39	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Sep 2024
NCT06680258		A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy	P3	not yet recruiting	740	Tempest Therapeutics	Dec 2025
NCT06888817	BRAINS	Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases	P3	recruiting	408	The Netherlands Cancer Institute	Jun 2025
NCT05253651	MOUNTAINEER-03	A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer	P3	recruiting	400	Seagen, a wholly owned subsidiary of Pfizer	Oct 2022
NCT07011550		Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer	P2	suspended	7	M.D. Anderson Cancer Center	Aug 2025
NCT07182708	HOFIBREN	High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC	P2	not yet recruiting	62	Peking University Cancer Hospital & Institute	Oct 2025
NCT01871766		Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy	P2	active not recruiting	115	St. Jude Children's Research Hospital	Dec 2013
NCT07541781		Sitagliptin in Recurrent/Progressive Grade 4 Glioma	P1	recruiting	45	Kailin Yang, MD, PhD	Jun 2026
NCT07225270	RAINFOL-04	Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy	P3	recruiting	544	Genmab	Apr 2026
NCT06469281	MUC16	A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers	P1	recruiting	90	Regeneron Pharmaceuticals	Aug 2024
NCT07446322		FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer	P2	recruiting	60	Oncolytics Biotech	Apr 2026
NCT06917092	QLPPEC/GOG-003	QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer	P2	recruiting	30	Tianjin Medical University Cancer Institute and Hospital	May 2025
NCT01356290	MEMMAT	Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors	P2	recruiting	232	Medical University of Vienna	Apr 2014
NCT07318805		A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors	P1	recruiting	260	Pfizer	Dec 2025
NCT07525206	AndroMETa-CRC	A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer	P3	recruiting	700	AbbVie	May 2026
NCT07094893	ARIEL-ENGIC	Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status	P4	not yet recruiting	280	Gruppo Oncologico del Nord-Ovest	Apr 2026
NCT06921785	ARTEMIDE-HCC01	Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma	P3	recruiting	1,220	AstraZeneca	May 2025
NCT06928584		Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer	P2	recruiting	221	Fudan University	Mar 2025
NCT07183865	NOVELTY-R	Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)	P2	recruiting	44	Fudan University	Mar 2025
NCT07392866		A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma	P2/P3	not yet recruiting	120	Nanjing Sanhome Pharmaceutical, Co., Ltd.	Mar 2026
NCT07472647		SYS6090 Combination Therapy in Advanced Lung Cancer	P1/P2	not yet recruiting	596	Shanghai JMT-Bio Inc.	Feb 2026
NCT06890338	IV	A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.	P2	recruiting	140	AbbVie	Nov 2025
NCT05528952	TERTIO	Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma	P2	recruiting	105	Centre Hospitalier Universitaire de Besancon	Sep 2022
NCT06439485		Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion	P1/P2	recruiting	25	M.D. Anderson Cancer Center	Nov 2024
NCT07449481		A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors	P2	withdrawn	0	Tianjin Medical University Cancer Institute and Hospital	May 2026
NCT07324824		Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma	P2	recruiting	37	Sun Yat-sen University	Jan 2026
NCT07362836	FRU-RAS	Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)	P3	not yet recruiting	224	Fudan University	Jan 2026
NCT07383285		CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer	P2	not yet recruiting	106	Peking University Cancer Hospital & Institute	Feb 2026
NCT07281664		Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma	N/A	not yet recruiting	30	Third Affiliated Hospital, Sun Yat-Sen University	Jan 2026
NCT07286695		Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer	P2	not yet recruiting	292	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Dec 2025
NCT07283367		A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.	P1/P2	recruiting	502	Hansoh BioMedical R&D Company	Dec 2025
NCT06856837		- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases	P2	recruiting	140	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Oct 2025
NCT07071844	BETWEEN	BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients	P2	not yet recruiting	162	GERCOR - Multidisciplinary Oncology Cooperative Group	Sep 2025
NCT06887218		5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer	P2	recruiting	57	The Methodist Hospital Research Institute	May 2025
NCT06922383		A Clinical Study of Arfolitixorin in Patients With mCRC	P1/P2	recruiting	90	Isofol Medical AB	Apr 2025
NCT06775275		A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC	P2	recruiting	60	The First Affiliated Hospital of Guangzhou Medical University	Sep 2024
NCT06280495		Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients	P2/P3	recruiting	156	Sun Yat-sen University	Feb 2024
NCT06023862	DOVE	A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)	P2	recruiting	198	Yonsei University	Jan 2024
NCT05441475		A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients	P2	enrolling by invitation	118	Abbisko Therapeutics Co, Ltd	Dec 2021
NCT04250064	LoBULarDIPG	A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma	P2	recruiting	40	Tata Memorial Centre	Feb 2020
NCT03872661	NIBCUN	Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC	P2	recruiting	36	Sun Yat-sen University	Mar 2019
NCT07119931		A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)	P2	not yet recruiting	34	Tianjin Medical University Cancer Institute and Hospital	Sep 2025
NCT07128251	TACE	A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)	P2	not yet recruiting	47	Anhui Provincial Hospital	Aug 2025
NCT06953323		A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors	P1/P2	recruiting	86	Wigen Biomedicine Technology (Shanghai) Co., Ltd.	Jul 2025
NCT06730750		A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors	P1/P2	recruiting	360	Bristol-Myers Squibb	Feb 2025
NCT07274787		Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma	N/A	not yet recruiting	10	University of Cincinnati	Dec 2026
NCT05956821		Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age	P1/P2	recruiting	20	University of Miami	Jun 2025
NCT07228832	HARMONi-GI3	Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer	P3	recruiting	600	Summit Therapeutics	Nov 2025
NCT07318389	ASCEND-CRC	ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer	Early P1	not yet recruiting	100	M.D. Anderson Cancer Center	Jun 2026
NCT04587128		Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC	P2	active not recruiting	34	University of Wisconsin, Madison	Oct 2020
NCT01269853		Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA	P1/P2	recruiting	54	Northwell Health	Oct 2010
NCT07549412	PROCEADE-CRC-03	A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)	P3	recruiting	1,020	EMD Serono Research & Development Institute, Inc.	May 2026
NCT06976944	PRELUDE	Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer	P2	recruiting	24	Yukinori Ozaki	Jun 2025
NCT05284643		Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma	N/A	recruiting	96	University of Miami	Sep 2022
NCT04188145	BEVAMAINT	A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer	P3	active not recruiting	400	Centre Hospitalier Universitaire Dijon	Jan 2020
NCT07284849		A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer	P3	recruiting	700	Incyte Corporation	Mar 2026
NCT07481786		Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases	P3	recruiting	220	Sun Yat-sen University	Mar 2026
NCT07543510		Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma	N/A	not yet recruiting	38	Third Affiliated Hospital, Sun Yat-Sen University	May 2026
NCT07543783	TACE-HAIC	Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial	P2	not yet recruiting	38	Third Affiliated Hospital, Sun Yat-Sen University	Apr 2026
NCT05551208		Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi	P2	recruiting	42	Chongqing University Cancer Hospital	Aug 2022
NCT03899155		Pan Tumor Rollover Study	P2	recruiting	1,500	Bristol-Myers Squibb	Aug 2019
NCT05984511		TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT	N/A	recruiting	234	Third Affiliated Hospital, Sun Yat-Sen University	Aug 2023
NCT07297212	BNT327	A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma	P2	recruiting	75	BioNTech SE	Jan 2026
NCT07134413		QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC	P2	not yet recruiting	77	Guangdong Association of Clinical Trials	Aug 2025
NCT07025239		QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer	P3	not yet recruiting	430	Qilu Pharmaceutical Co., Ltd.	Jul 2025
NCT02446431	Metronomic	Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence	Early P1	recruiting	20	Miller Children's & Women's Hospital Long Beach	Jul 2014
NCT07235930		Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer	P3	recruiting	292	Zhejiang Cancer Hospital	Nov 2025
NCT07397819		Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy	P1/P2	recruiting	48	Dong sheng Zhang	Nov 2025
NCT05769010		Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases	P2	recruiting	150	Henan Cancer Hospital	Mar 2023
NCT06971744	AUTOMAIN	Autophagy Maintenance (AUTOMAIN)	P2	recruiting	38	Medical University of South Carolina	Dec 2025
NCT06551142	PanTumor-101	A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)	P1	recruiting	845	GlaxoSmithKline	Sep 2024
NCT07002346	INVIGORATE	INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma	P3	recruiting	226	Tongji Hospital	Nov 2025
NCT06576037		Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin	P1	recruiting	128	M.D. Anderson Cancer Center	Oct 2024
NCT04230187	TRIBE-C	Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer	P3	active not recruiting	528	Yanhong Deng	Sep 2020
NCT04215731	FOBEAR	Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer	P3	recruiting	582	Yanhong Deng	Mar 2020
NCT02758951	CAIRO6	Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases	P2/P3	active not recruiting	358	Koen Rovers	Jun 2017
NCT07559760		New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer	P2	recruiting	30	The First Hospital of Jilin University	Nov 2025
NCT07014215		PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy	P2	not yet recruiting	52	Anhui Provincial Cancer Hospital	Jun 2025
NCT06411600	BRAVE	Combination Therapy for BRAF-V600E Metastatic CRCm	P2	recruiting	94	Vall d'Hebron Institute of Oncology	May 2024
NCT07551778		Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors	P1/P2	not yet recruiting	20	BOE Technology Group Co., Ltd.	May 2026
NCT07514793		Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma	P2	not yet recruiting	37	Fudan University	Apr 2026
NCT07549399	CRITⅡ	SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC	P3	recruiting	204	Sixth Affiliated Hospital, Sun Yat-sen University	May 2026
NCT06750094	OrigAMI-3	A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy	P3	recruiting	700	Janssen Research & Development, LLC	Dec 2024
NCT07504588		Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy	P2	not yet recruiting	87	National Cancer Institute (NCI)	Sep 2026
NCT07515625		Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma	P2	not yet recruiting	46	Fudan University	Apr 2026
NCT06733038	AtezoTRIBE2	FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.	P3	recruiting	238	Gruppo Oncologico del Nord-Ovest	Nov 2024
NCT07466238		HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer	N/A	recruiting	40	Peking University	Mar 2026
NCT07331883	CLEAR-2	Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)	P2	recruiting	35	Ruijin Hospital	Nov 2025
NCT06265688		First In Human Study of CX-2051 in Advanced Solid Tumors	P1	recruiting	160	CytomX Therapeutics	Apr 2024
NCT06843447	MK-5909-003	A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)	P1/P2	recruiting	460	Merck Sharp & Dohme LLC	Apr 2025
NCT05546879	Liver-NET1	Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC	P1	active not recruiting	43	University Hospital, Grenoble	Mar 2023
NCT07166406		Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial	P3	recruiting	226	NRG Oncology	Feb 2026
NCT07453394		QLS5132 Combination Therapy in Advanced Solid Tumors	P1/P2	not yet recruiting	626	Qilu Pharmaceutical Co., Ltd.	Apr 2026
NCT07395063		A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.	P2	not yet recruiting	68	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	Feb 2026
NCT07278336	IV	A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer	P1	recruiting	219	AbbVie	Nov 2025
NCT07059845	FLORENZA	A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer	P2	recruiting	400	AbbVie	Nov 2025
NCT07004335	L	Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study	P4	not yet recruiting	40	Hebei Medical University Fourth Hospital	Jul 2025
NCT06264531	BevacizuMAV	Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations	P2/P3	recruiting	54	Fondation Ophtalmologique Adolphe de Rothschild	Jan 2026
NCT06951503		AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer	P3	recruiting	560	Akeso	May 2025
NCT06697197		A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors	P1/P2	recruiting	413	Bristol-Myers Squibb	Feb 2025
NCT07276100		Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab	P2	recruiting	15	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Jan 2026
NCT06771622		Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors	P1/P2	active not recruiting	500	FBD Biologics Limited	Mar 2025
NCT05797246	RRP	Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)	P2	active not recruiting	21	National Cancer Institute (NCI)	Aug 2023
NCT07557251		A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma	P1	not yet recruiting	21	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	May 2026
NCT07527858	GS-1811	Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer	P2	recruiting	170	Gilead Sciences	May 2026
NCT07391566		LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation	P1/P2	not yet recruiting	99	Luye Pharma Group Ltd.	Mar 2026
NCT07116577		Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC	P2	not yet recruiting	37	Jinan Central Hospital	Aug 2025
NCT07021950		AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer	P2	not yet recruiting	130	Sun Yat-sen University	Aug 2025
NCT06895928		A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors	P2	recruiting	400	Shanghai Hengrui Pharmaceutical Co., Ltd.	Mar 2025
NCT06878196		ctDNA-guided First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervical Cancer	N/A	not yet recruiting	20	Obstetrics & Gynecology Hospital of Fudan University	Mar 2025
NCT06737913	HAIBrave-001	HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma	P2	recruiting	76	Sun Yat-sen University	Jan 2025
NCT06755684		Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer	P2	recruiting	60	Peng Zhang	Nov 2024
NCT06786026		QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC	P2	recruiting	60	Fudan University	Oct 2024
NCT06031233	MINUTE	Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie	P4	recruiting	776	Isala	Sep 2023
NCT05482516	MRD-GI	Evaluating Novel Therapies in ctDNA Positive GI Cancers	P3	recruiting	20	Georgetown University	Mar 2023
NCT05109052		Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma	P1/P2	withdrawn	0	University of Rochester	Sep 2022
NCT05525767		Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer	P4	recruiting	75	Hebei Medical University Fourth Hospital	Mar 2022
NCT05503667		Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma	P2	recruiting	96	Shanghai Pulmonary Hospital, Shanghai, China	Feb 2022
NCT04121455	GLORIA	Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients	P1/P2	active not recruiting	117	TME Pharma AG	Sep 2019
NCT03351296	BETTER2	Two Chemotherapy Regimens Plus or Minus Bevacizumab	P2	active not recruiting	140	Gustave Roussy, Cancer Campus, Grand Paris	Jun 2018
NCT07311577		Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study	P2	recruiting	43	Jiangsu Cancer Institute & Hospital	Jan 2026
NCT07327788		QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT	P2	recruiting	38	Nanfang Hospital, Southern Medical University	Dec 2025
NCT07197008		Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis	P2	not yet recruiting	50	Li-kun Chen	Oct 2025
NCT06982924	LIBRA	A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.	P2	not yet recruiting	136	Shanghai Chest Hospital	Jun 2025
NCT07058428		FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma	P3	recruiting	258	Sun Yat-Sen University Cancer Center	Jun 2025
NCT06625775		Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors	P1	recruiting	392	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	Oct 2024
NCT07420439		Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease	P2	not yet recruiting	108	Intergroupe Francophone de Cancerologie Thoracique	May 2026
NCT07075757	BLITZ	In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment	P1	not yet recruiting	20	Assistance Publique - Hôpitaux de Paris	Oct 2025
NCT06650709	NEOCATS	NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study	P2	not yet recruiting	40	British Columbia Cancer Agency	Nov 2024
NCT07179900		Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma	P2	not yet recruiting	60	Hebei Medical University Fourth Hospital	Dec 2025
NCT07150403		Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer	P2	not yet recruiting	74	Federation Francophone de Cancerologie Digestive	Dec 2025
NCT07120451		Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker	P2	not yet recruiting	37	Fudan University	Oct 2025
NCT06787612		Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer	P2	recruiting	220	Regeneron Pharmaceuticals	May 2025
NCT07009470		A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence	N/A	active not recruiting	130	Tongji Hospital	Feb 2025
NCT06245356	TRIFLUOX-DP	Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer	P2	recruiting	73	UNICANCER	Mar 2025
NCT06796907	BEHOLD-2	A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)	P1/P2	recruiting	305	GlaxoSmithKline	Mar 2025
NCT07288034	L	Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial	P2	recruiting	535	City of Hope Medical Center	Apr 2026
NCT06948448		A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer	P2	recruiting	144	Ono Pharmaceutical Co., Ltd.	Nov 2025
NCT06735326		Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer	P2	recruiting	105	Qilu Hospital of Shandong University	Nov 2024
NCT05999812		Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer	P2	active not recruiting	22	University of Texas Southwestern Medical Center	Dec 2023
NCT07448922		A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors	P2	recruiting	280	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Apr 2026
NCT07328802		Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma	P2	not yet recruiting	25	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jan 2026
NCT06701656	JUST BREATHE	JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab	P2	recruiting	200	PPD Development, LP	Oct 2025
NCT07150208	THUMB	T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis	P2	not yet recruiting	140	Fudan University	Sep 2025
NCT06703073	JUST BREATHE	JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)	P2	recruiting	600	PPD Development, LP	Jun 2025
NCT06497985		A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients	P3	recruiting	430	Chipscreen Biosciences, Ltd.	Dec 2024
NCT06755515		A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer	P2/P3	enrolling by invitation	510	Shandong New Time Pharmaceutical Co., LTD	Sep 2024
NCT06530251	HCC	A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)	P1/P2	recruiting	280	Akeso	Sep 2024
NCT02885753	OSCAR	Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver	P3	recruiting	348	Federation Francophone de Cancerologie Digestive	Dec 2016
NCT07277270		A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors	P1	recruiting	84	GlaxoSmithKline	Dec 2025
NCT06792695	CANTOR	A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer	P2	recruiting	80	AstraZeneca	Mar 2025
NCT07518602		Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma	P2	recruiting	34	Sun Yat-sen University	Mar 2026
NCT05239741	MK-3475	Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)	P3	active not recruiting	100	Merck Sharp & Dohme LLC	Apr 2022
NCT07123441	II	A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer	P2	not yet recruiting	300	Sanjun Cai	Sep 2025
NCT07147101	HCC-IM-1	Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment	—	recruiting	150	Fudan University	Sep 2025
NCT06459687		Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer	P3	recruiting	440	Lee's Pharmaceutical Limited	Nov 2024
NCT07178717	REFISH	A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations	P2	not yet recruiting	25	Vall d'Hebron Institute of Oncology	Oct 2025
NCT07070713		Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC	P2	not yet recruiting	44	Fujian Cancer Hospital	Jul 2025
NCT05739981	MRD	Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer	P1/P2	recruiting	30	Imunon	Feb 2023
NCT06294548		A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC	P1/P2	recruiting	45	University of Alabama at Birmingham	Jul 2025
NCT06809946	DEFLECT I	Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy	P2	not yet recruiting	20	University Medical Center Groningen	Aug 2026
NCT05647122	EGRET	First in Human Study of AZD9592 in Solid Tumors	P1	active not recruiting	167	AstraZeneca	Dec 2022
NCT07059494		Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant	P4	recruiting	40	Icahn School of Medicine at Mount Sinai	Jun 2026
NCT07085169		Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC	P2	recruiting	50	Ruijin Hospital	Aug 2025
NCT07244705		A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC	P1/P2	recruiting	66	Anbogen Therapeutics, Inc.	Nov 2025
NCT07106034	ONTOP	Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial	P2	recruiting	32	Shanghai Pudong Hospital	Aug 2025
NCT06867822		Trial of ProAgio in Advanced/Metastatic Colorectal Cancer	P1	recruiting	27	University of Alabama at Birmingham	Jul 2025
NCT06823375		SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis	P2	recruiting	40	Chinese University of Hong Kong	Jul 2025
NCT06268015	BBOpCo	Botensilimab and Balstilimab Optimization in Colorectal Cancer	P2	active not recruiting	16	Nicholas DeVito, MD	Nov 2024
NCT06557096		CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC	Early P1	not yet recruiting	100	Second Affiliated Hospital of Nanchang University	Aug 2024
NCT05854498		Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer	P2	recruiting	50	University of Wisconsin, Madison	Oct 2023
NCT06936527	XS-03-II201	XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation	P1/P2	enrolling by invitation	102	NovaOnco Therapeutics Co., Ltd.	May 2025
NCT06663319		A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers	P1	recruiting	260	Janssen Research & Development, LLC	Oct 2024
NCT07051785	ARK	Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer	P2	not yet recruiting	68	Liu Huang	Jul 2025
NCT03768063	IMbrella B	A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study	P3	active not recruiting	1,000	Hoffmann-La Roche	Feb 2019
NCT07198074		Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer	P3	recruiting	255	National Cancer Institute (NCI)	Jan 2026
NCT05733598		Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC	P2	recruiting	60	Replimune, Inc.	Aug 2024
NCT05354674		Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis	—	not yet recruiting	302	Fudan University	Sep 2023
NCT07497074		JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer	P2	not yet recruiting	78	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Apr 2026
NCT07244926		Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer	P2	not yet recruiting	31	Tianjin Medical University Cancer Institute and Hospital	Dec 2025
NCT07093762		Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC	—	not yet recruiting	35	Fuzhou General Hospital	Aug 2025
NCT07150247		Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer	P2	recruiting	20	Sun Yat-sen University	Jun 2025
NCT06446206		Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer	P2	not yet recruiting	22	The First Hospital of Jilin University	Jun 2024
NCT06563986	STARLIGHT	FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer	P2	recruiting	40	UMC Utrecht	Jun 2024
NCT06510582	CHAI	Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection	P1/P2	recruiting	140	The Cooper Health System	Jun 2024
NCT06881537		CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer	P2	recruiting	15	Shanghai Changzheng Hospital	Jun 2024
NCT05867420		A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.	P1/P2	recruiting	594	AskGene Pharma, Inc.	Aug 2023
NCT05039801		IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	P1	recruiting	54	M.D. Anderson Cancer Center	Sep 2021
NCT04516447	MUIR	A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer	P1	recruiting	172	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	Oct 2020
NCT03175432		Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases	P2	active not recruiting	29	M.D. Anderson Cancer Center	Jun 2017
NCT05584670		A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors	P1/P2	recruiting	542	Sanofi	Nov 2022
NCT07535632	BEST	SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer	P2	not yet recruiting	58	Shanghai Zhongshan Hospital	Jun 2026
NCT04356729		A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma	P2	active not recruiting	30	F. Stephen Hodi, MD	Aug 2020
NCT06784947		Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer	P2	active not recruiting	13	University of Colorado, Denver	Mar 2025
NCT06478693		A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC	P1	recruiting	70	Myeloid Therapeutics	Jul 2024
NCT05101070	aCCeleR8-001	S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors	P1/P2	recruiting	282	Shionogi	May 2022
NCT06427941		A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors	P1	recruiting	392	BeOne Medicines	Jul 2024
NCT04931342	BOUQUET	A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors	P2	active not recruiting	176	Hoffmann-La Roche	Oct 2021
NCT06233942		Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors	P1	recruiting	308	BeOne Medicines	Apr 2024
NCT07089719	BASECOVID	Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)	P2	not yet recruiting	21	Assistance Publique - Hôpitaux de Paris	Oct 2025
NCT07003022		Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC	P2	recruiting	40	Fudan University	Jun 2025
NCT05585814	COBP	CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer	P2	recruiting	30	Shanghai Changzheng Hospital	May 2023
NCT07560488		Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma	P2	recruiting	43	Tianjin Medical University Cancer Institute and Hospital	Mar 2026
NCT06820463	AndroMETa-CRC	A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer	P2	recruiting	390	AbbVie	Apr 2025
NCT06839105		A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies	P1	recruiting	214	Shanghai Junshi Bioscience Co., Ltd.	Feb 2025
NCT04919629		APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	P2	recruiting	60	Roswell Park Cancer Institute	Apr 2023
NCT07193862		Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis	Early P1	recruiting	10	Northwell Health	Dec 2025
NCT06336707		HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors	P1	recruiting	1,048	Hansoh BioMedical R&D Company	Apr 2024
NCT06995105		Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma	P1/P2	recruiting	30	Zhejiang University	Apr 2025
NCT06872606	SCRIPBOT	Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer	P2	not yet recruiting	33	Sir Run Run Shaw Hospital	Apr 2025
NCT05271240	SIACI	Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM	P3	recruiting	432	Northwell Health	Apr 2022
NCT07045805		Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer	P2	not yet recruiting	66	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Jul 2025
NCT05690048	FLORA	Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)	P2	recruiting	48	Michael Dill	Jul 2025
NCT06329570		Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)	P1/P2	recruiting	10	NaviFUS Corporation	Oct 2024
NCT06360042		Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC	P2	recruiting	111	Peking University Cancer Hospital & Institute	Jan 2024
NCT05742425		Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases	P2	recruiting	30	Second Affiliated Hospital, School of Medicine, Zhejiang University	Mar 2023
NCT04649489	TALENTOP	A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev	P3	active not recruiting	501	Jia Fan	Apr 2021
NCT07503756		JS212 Combination Therapies in Metastatic Colorectal Cancer	P2	recruiting	80	Shanghai Junshi Bioscience Co., Ltd.	Apr 2026
NCT07261709		Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial	P2	not yet recruiting	236	Sun Yat-sen University	Dec 2025
NCT06893887	ICT-HCC	Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma	N/A	recruiting	300	Nanjing Tianyinshan Hospital	May 2025
NCT06860490	TASK-03	HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)	P2	recruiting	164	Fudan University	Mar 2025
NCT07470853		A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.	P1	recruiting	265	Whitehawk Therapeutics, Inc.	Mar 2026
NCT07229846	QL1706	A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation	P2	not yet recruiting	30	Yanqiao Zhang	Feb 2026
NCT07024784		A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies	P2	recruiting	377	AbbVie	Jul 2025
NCT06844474		A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC	P2	recruiting	300	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Mar 2025
NCT05334277	FOCUS-C	Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA	P2	recruiting	280	Sun Yat-sen University	May 2022
NCT07474727		A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer	P2	not yet recruiting	180	Multitude Therapeutics Inc.	Apr 2026
NCT06393751		Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer	P1/P2	withdrawn	0	National Cancer Institute (NCI)	Oct 2025
NCT07337551		Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive	P2	not yet recruiting	20	Guiying Wang	Feb 2026
NCT06728865	Better Brain	Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study	P2	recruiting	70	Li-kun Chen	Sep 2024
NCT07355764		MA-CRC-II-016 SHR-1811	P2	not yet recruiting	80	Peking Union Medical College Hospital	Dec 2025
NCT05377034	STRATUM	Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients	P2	recruiting	100	National Cancer Centre, Singapore	Oct 2022
NCT01217931		Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial	P2	active not recruiting	180	M.D. Anderson Cancer Center	Jan 2011
NCT07358520		Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients	P4	not yet recruiting	40	Fudan University	Jan 2026
NCT06789757	(HCC)	The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)	P2	recruiting	19	Inova Health Care Services	Feb 2025
NCT05797168	FONTANA	Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors	P1/P2	recruiting	506	AstraZeneca	Jun 2023
NCT00565851		Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	P3	active not recruiting	1,052	National Cancer Institute (NCI)	Dec 2007
NCT07478302		A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma	P1	recruiting	36	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Apr 2026
NCT07233850		A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers	P2	not yet recruiting	300	Shenyang Sunshine Pharmaceutical Co., LTD.	Nov 2025
NCT07080216		Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer	P1/P2	recruiting	120	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Sep 2025
NCT07054567		A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer	P2	recruiting	96	Sichuan Baili Pharmaceutical Co., Ltd.	Aug 2025
NCT06953843	NSCLC	Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases	P2	recruiting	366	Xinqiao Hospital of Chongqing	Jul 2025
NCT07009145		QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC	P2	not yet recruiting	22	Qianfoshan Hospital	Jun 2025
NCT06958484	QL1706	Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence	P2	not yet recruiting	60	The Affiliated Hospital of Xuzhou Medical University	May 2025
NCT07562490	CLEAR-04	A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer	P2	recruiting	100	Fudan University	Apr 2025
NCT06992648	REGTAS-2	Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer	P3	recruiting	302	Second Affiliated Hospital, School of Medicine, Zhejiang University	Apr 2025
NCT06584071		A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC	P1/P2	not yet recruiting	140	Biotheus Inc.	Dec 2024
NCT06590259		A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM	P2	recruiting	20	Shanghai 6th People's Hospital	Mar 2024
NCT06307249	PTST_PALBEVA	Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA	P1	recruiting	50	Lebanese University	Feb 2023
NCT05502991		Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma	P2	not yet recruiting	60	Henan Provincial People's Hospital	Dec 2022
NCT05518994		Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma	P2	not yet recruiting	70	Henan Provincial People's Hospital	Dec 2022
NCT05281471	PRROC	Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)	P3	recruiting	186	Genelux Corporation	Aug 2022
NCT04981509		Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer	P2	recruiting	65	National Cancer Institute (NCI)	Jun 2022
NCT05112861	NORSE SEVEN	A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders	P3	active not recruiting	120	Outlook Therapeutics, Inc.	Nov 2021
NCT06540261		The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer	P1	active not recruiting	65	Ono Pharmaceutical Co., Ltd.	Sep 2021
NCT03937830	TACE	Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma	P2	active not recruiting	27	National Cancer Institute (NCI)	Mar 2021
NCT04721132		Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer	P2	active not recruiting	16	M.D. Anderson Cancer Center	Feb 2021
NCT04449874		A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	P1	active not recruiting	498	Genentech, Inc.	Jul 2020
NCT04262466		Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors	P1/P2	active not recruiting	410	Immunocore Ltd	Feb 2020
NCT02925234	DRUP	The Drug Rediscovery Protocol (DRUP Trial)	P2	recruiting	1,550	The Netherlands Cancer Institute	Aug 2016
NCT01386710		Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma	P1/P2	suspended	54	Northwell Health	Sep 2011
NCT07398599		Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study	N/A	recruiting	30	Second Affiliated Hospital of Nanchang University	Feb 2026
NCT07314619		Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer	P2	not yet recruiting	30	The First Affiliated Hospital of Zhengzhou University	Dec 2025
NCT07186868	L	QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer	—	not yet recruiting	25	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Oct 2025
NCT07007767		Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）	P2	not yet recruiting	32	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Jun 2025
NCT06663306		Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC	P1	recruiting	19	Shanghai Chest Hospital	Dec 2024
NCT06096779	Kirros	A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis	P2	active not recruiting	30	Genentech, Inc.	Jul 2024
NCT05751187		Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients	P2	active not recruiting	54	Shanghai Chest Hospital	Jun 2023
NCT05588388	BELIEVE	Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases	P2	recruiting	39	Kamya Sankar	Aug 2024
NCT04607421		A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer	P3	active not recruiting	841	Pfizer	Dec 2020
NCT07111546		A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]	P2	recruiting	140	Nanjing Leads Biolabs Co.,Ltd	Oct 2025
NCT05063552		Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers	P2/P3	active not recruiting	430	National Cancer Institute (NCI)	Mar 2023
NCT04185883		Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	P1	active not recruiting	610	Amgen	Dec 2019
NCT06683703		Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases	P2	not yet recruiting	118	Beijing Biostar Pharmaceuticals Co., Ltd.	Dec 2024
NCT05029882	IV	Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab	P1	active not recruiting	520	AbbVie	Oct 2021
NCT06711471	TAS-102	Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer	P2	recruiting	31	LIN YANG	Nov 2024
NCT06035133		Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy	N/A	not yet recruiting	213	Tang-Du Hospital	Nov 2023
NCT07134218		Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer	P2/P3	not yet recruiting	180	Changhai Hospital	Oct 2025
NCT06607458	DEL-LIVER	Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease	P2	recruiting	90	Delcath Systems Inc.	Aug 2025
NCT06540326		Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab	P2	recruiting	100	Second Affiliated Hospital, School of Medicine, Zhejiang University	Nov 2024
NCT06667050	IBI305	CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer	P2	active not recruiting	58	West China Hospital	Oct 2024
NCT05185505		Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria	P4	recruiting	24	The Methodist Hospital Research Institute	Jan 2023
NCT05579366	RAINFOL-01	Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)	P1/P2	recruiting	884	Genmab	Dec 2022
NCT04486352	EndoMAP	A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer	P1/P2	recruiting	148	Alliance Foundation Trials, LLC.	Oct 2021
NCT06547385		Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer	P1	active not recruiting	40	Ono Pharmaceutical Co., Ltd.	Jan 2021
NCT06063070		First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer	P2	not yet recruiting	44	Sun Yat-sen University	Oct 2023
NCT05775159		Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer	P2	active not recruiting	294	AstraZeneca	Apr 2023
NCT07407465	CHIMERA	Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.	P2	recruiting	42	Gruppo Oncologico del Nord-Ovest	Oct 2025
NCT06092242		The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer	P2	not yet recruiting	50	The Second Affiliated Hospital of Shandong First Medical University	Oct 2023
NCT05284539	Awesome	Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer	P2	recruiting	760	Hunan Province Tumor Hospital	Apr 2022
NCT07448480	GLIOTARG	Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas	—	active not recruiting	1,000	Blokhin's Russian Cancer Research Center	Feb 2026
NCT05489211		Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)	P2	recruiting	454	AstraZeneca	Sep 2022
NCT06679985		A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma	P2	active not recruiting	72	Coherus Oncology, Inc.	Dec 2024
NCT06976671		A Study to Determine the Safety and Efficacy of Bevacizumab Administered Via Injection Into the Shoulder Joint of Participants With Adhesive Capsulitis (Frozen Shoulder)	P2	recruiting	28	Macquarie University, Australia	Sep 2024
NCT06083844		Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy	P2	recruiting	20	M.D. Anderson Cancer Center	Dec 2023
NCT04743661		131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma	P2	active not recruiting	62	Pediatric Brain Tumor Consortium	Apr 2022
NCT04687631		Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases	P3	recruiting	508	Fudan University	Jan 2021
NCT04524871	MORPHEUS-LIVER	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)	P1/P2	recruiting	518	Hoffmann-La Roche	Nov 2020
NCT03074513		Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	P2	active not recruiting	133	M.D. Anderson Cancer Center	Mar 2017
NCT02394834		An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer	—	active not recruiting	757	Takeda	May 2015
NCT04837716		Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer	P1	active not recruiting	12	M.D. Anderson Cancer Center	Mar 2021
NCT06420973		RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression	P2	recruiting	54	Peking University Cancer Hospital & Institute	May 2024
NCT06121401	IOLANTHE	First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients	P4	active not recruiting	190	Mario Negri Institute for Pharmacological Research	Sep 2023
NCT05976568		A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma	P2/P3	not yet recruiting	668	Qilu Pharmaceutical Co., Ltd.	Sep 2023
NCT07117877		Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer	P2	not yet recruiting	33	Fudan University	Sep 2025
NCT06614192	IV	A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer	P3	active not recruiting	74	AbbVie	Nov 2024
NCT06047379		Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	P1/P2	recruiting	134	Neonc Technologies, Inc.	Nov 2023
NCT05919264		FOG-001 in Locally Advanced or Metastatic Solid Tumors	P1/P2	recruiting	595	Parabilis Medicines, Inc.	May 2023
NCT05238922		Study of INCB123667 in Subjects With Advanced Solid Tumors	P1	recruiting	604	Incyte Corporation	Jul 2022
NCT07047560	II	Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study	P2	recruiting	46	Tianjin Medical University Cancer Institute and Hospital	Sep 2024
NCT07044908		TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer	P1/P2	recruiting	72	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Jul 2025
NCT07044921	II	Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.	P2	recruiting	30	Chinese PLA General Hospital	Sep 2024
NCT05828459		First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors	P1	recruiting	150	Onward Therapeutics	Jul 2023
NCT05005403		Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan	P1	recruiting	694	AbbVie	Nov 2021
NCT05030493	NCT02394834	An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer	—	active not recruiting	787	Takeda	Aug 2021
NCT04803994	TACE	The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma	P3	recruiting	434	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Jul 2021
NCT03181100		Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer	P2	active not recruiting	50	M.D. Anderson Cancer Center	Jul 2017
NCT02698254		Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy	N/A	active not recruiting	40	M.D. Anderson Cancer Center	Jul 2016
NCT01792934	ORCHESTRA	Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases	N/A	active not recruiting	478	Radboud University Medical Center	May 2013
NCT06742424		PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC	P2	recruiting	36	West China Hospital	Oct 2024
NCT02671435	MEDI4736	A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors	P1/P2	active not recruiting	383	MedImmune LLC	Feb 2016
NCT05116189		Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).	P3	active not recruiting	643	Merck Sharp & Dohme LLC	Dec 2021
NCT06445062	ON	Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors	P1/P2	recruiting	1,130	Revolution Medicines, Inc.	May 2024
NCT06703177		A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors	P1/P2	recruiting	876	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Feb 2025
NCT04634578	ROP4	Bevacizumab Treatment For Type 1 ROP	P2	active not recruiting	77	Jaeb Center for Health Research	May 2022
NCT07059949	Union-mRC	Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer	P2	not yet recruiting	80	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Jun 2025
NCT07157969		ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC	P2	recruiting	300	Peking Union Medical College Hospital	Feb 2025
NCT06493760		A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients	P2	recruiting	130	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Sep 2024
NCT05200260		Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer	P2	recruiting	220	Shanghai Gynecologic Oncology Group	Jul 2022
NCT05112965		An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)	P3	active not recruiting	49	Hoffmann-La Roche	Dec 2021
NCT05364489		Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer	P2	not yet recruiting	20	The First Affiliated Hospital of Zhengzhou University	Jun 2022
NCT06749860		Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression	P2	recruiting	58	Shanghai Pulmonary Hospital, Shanghai, China	Feb 2024
NCT07083375	QL1706	A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.	P2	not yet recruiting	56	Zhijie Wang	Aug 2025
NCT06753721		An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.	P1/P2	not yet recruiting	13	Nanfang Hospital, Southern Medical University	Dec 2024
NCT02997228		Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study	P3	active not recruiting	120	National Cancer Institute (NCI)	Jan 2018
NCT06835179		SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.	P2	not yet recruiting	28	The First Affiliated Hospital with Nanjing Medical University	Feb 2025
NCT06004245		A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors	P1	recruiting	280	Vividion Therapeutics, Inc.	Jan 2024
NCT05848739		A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors	P1	recruiting	130	Sapience Therapeutics	Jun 2023
NCT04101877	SAHLVE	The Sahlgrenska Anti-VEGF Study	P2	active not recruiting	402	Vastra Gotaland Region	Sep 2020
NCT03896074	BEAT	Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)	P2	active not recruiting	206	Fondazione Ricerca Traslazionale	Mar 2020
NCT03847428	EMERALD-2	Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment	P3	active not recruiting	908	AstraZeneca	Apr 2019
NCT05398861		Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer	P2	recruiting	79	Henan Cancer Hospital	Aug 2022
NCT02839707		Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	P2/P3	active not recruiting	444	National Cancer Institute (NCI)	Jun 2017
NCT07090525		Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions	P2	recruiting	60	Qingdao Central Hospital	Jul 2025
NCT06882915	TAS-102	Efficacy and Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study	P1	not yet recruiting	20	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jun 2026
NCT05806931	SCOTI	Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer	P2	recruiting	50	Rutgers, The State University of New Jersey	May 2023
NCT06856187	TASBEL	Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer	P2	recruiting	119	Fudan University	Feb 2025
NCT06571422		Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors	P1	active not recruiting	59	Shanghai Junshi Bioscience Co., Ltd.	Oct 2024
NCT06400472		A Study of LY4170156 in Participants With Selected Advanced Solid Tumors	P1	recruiting	495	Eli Lilly and Company	May 2024
NCT05405595		ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors	P1/P2	recruiting	186	Adagene Inc	Jun 2022
NCT05097911		Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.	P1	active not recruiting	33	National University Hospital, Singapore	Aug 2021
NCT03451370	COBRA	First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer	—	active not recruiting	121	Istituto Oncologico Veneto IRCCS	Nov 2017
NCT04857684		SBRT + Atezolizumab + Bevacizumab in Resectable HCC	Early P1	active not recruiting	20	Massachusetts General Hospital	Jun 2021
NCT05824975	KEYNOTE-G08	A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)	P1/P2	recruiting	358	GI Innovation, Inc.	May 2023
NCT06513221		A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab	P2	not yet recruiting	100	Fudan University	Jul 2024
NCT00217737		Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer	P3	active not recruiting	2,431	National Cancer Institute (NCI)	Sep 2005
NCT06401824		Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases	P2	recruiting	25	Maastricht University Medical Center	Apr 2025
NCT06908031	CRIT	SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer(CRIT)	P2	recruiting	49	Sixth Affiliated Hospital, Sun Yat-sen University	Apr 2025
NCT06876701		The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults	Early P1	not yet recruiting	10	Ruijin Hospital	Apr 2025
NCT07512674		Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer	P2	active not recruiting	33	Sir Run Run Shaw Hospital	Feb 2026
NCT06873763		Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer	P1/P2	recruiting	52	STCube, Inc.	Jun 2025
NCT06496971	BEV	A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients	P3	recruiting	32	NaviFUS Corporation	Nov 2024
NCT06782685		Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV	P1/P2	recruiting	138	Dai, Guanghai	Jun 2024
NCT05654454		A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer	P3	recruiting	620	Mabscale, LLC	May 2023
NCT05516628	EMPHASIS	Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma	P2	recruiting	30	National Cancer Centre, Singapore	Feb 2023
NCT05525858	KOSMOSII	KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II	—	recruiting	1,000	Seoul National University Bundang Hospital	Sep 2022
NCT05141721		A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer	P2/P3	active not recruiting	700	Seattle Project Corporation	Feb 2022
NCT04227028		Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC	P1	active not recruiting	5	City of Hope Medical Center	Mar 2020
NCT05231122		Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	P2	recruiting	80	Roswell Park Cancer Institute	Mar 2024
NCT01081262		Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer	P3	active not recruiting	50	National Cancer Institute (NCI)	Oct 2010
NCT05440708		A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma	P1/P2	recruiting	193	Tvardi Therapeutics, Incorporated	Mar 2023
NCT00977574		Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer	P2	active not recruiting	349	National Cancer Institute (NCI)	Sep 2009
NCT04626635	COMBINE-EGFR-1	A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers	P1/P2	active not recruiting	548	Regeneron Pharmaceuticals	Dec 2020
NCT07192185		Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab	P2	recruiting	30	Sun Yat-sen University	Sep 2025
NCT06867432		Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma	P2	not yet recruiting	20	Tianjin Medical University Cancer Institute and Hospital	Mar 2025
NCT06184698		Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer	P2	recruiting	173	Hebei Medical University Fourth Hospital	Jan 2024
NCT06718933		Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis	P1/P2	recruiting	74	Fudan University	Jan 2025
NCT05062317		ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases	P2	recruiting	120	M.D. Anderson Cancer Center	Apr 2022
NCT00334815		Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	P2	active not recruiting	29	National Cancer Institute (NCI)	Jun 2006
NCT00588770		Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	P3	active not recruiting	403	National Cancer Institute (NCI)	Aug 2008
NCT00433511		Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer	P3	active not recruiting	4,994	National Cancer Institute (NCI)	Nov 2007
NCT06271837		A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors	P2	active not recruiting	127	AstraZeneca	Feb 2024
NCT05969899		Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer	P2	active not recruiting	50	Fudan University	Jul 2023
NCT05075993		Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors	P1	active not recruiting	352	M.D. Anderson Cancer Center	Nov 2021
NCT02884648		Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery	P2	active not recruiting	35	M.D. Anderson Cancer Center	Nov 2016
NCT06801665		FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis	P2	recruiting	30	Hua Jiang	Apr 2025
NCT06566755	AK104	Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer	P3	recruiting	30	Caigang Liu	Feb 2024
NCT04404881	TrUST-HHT	Bevacizumab In Hereditary Hemorrhagic Telangiectasia	P2	active not recruiting	33	Hanny Al-Samkari, MD	Nov 2020
NCT06859775		SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer	P1/P2	recruiting	100	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Apr 2025
NCT06106308		Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	P2	active not recruiting	110	Cardiff Oncology	Feb 2024
NCT06543069		Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM	P2	recruiting	28	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Jan 2024
NCT06123884		BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer	P2/P3	recruiting	526	Bio-Thera Solutions	Dec 2023
NCT06041490		Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation	P2	not yet recruiting	88	Peking Union Medical College Hospital	Sep 2023
NCT04689347		5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.	P1/P2	recruiting	27	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Jan 2021
NCT02873962		A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib	P2	active not recruiting	72	Dana-Farber Cancer Institute	Nov 2016
NCT01083966		Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma	P1	suspended	30	Northwell Health	Aug 2011
NCT00569127		Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor	P3	active not recruiting	427	National Cancer Institute (NCI)	Dec 2007
NCT06265350		Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases	N/A	recruiting	80	Sun Yat-sen University	Feb 2024
NCT05836324		A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors	P1	recruiting	408	Incyte Corporation	Jul 2023
NCT07253896		Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab	P2	recruiting	40	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jan 2024
NCT07446452		Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study	P2	recruiting	37	The First Affiliated Hospital with Nanjing Medical University	Jan 2024
NCT02229175		Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema	P2/P3	withdrawn	0	University of California, San Francisco	Jan 2021
NCT07012798	MEDI4736	FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma	P2	recruiting	30	Tianjin Medical University Cancer Institute and Hospital	Sep 2025
NCT06696768		Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer	P1	recruiting	24	National Cancer Institute (NCI)	Jun 2025
NCT07007728		Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis	P2	not yet recruiting	54	Peking University Cancer Hospital & Institute	Jun 2025
NCT03401294	CONVERSION	Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.	P2	recruiting	32	University of Saskatchewan	May 2025
NCT06906341		Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers	P2	recruiting	270	Corcept Therapeutics	Apr 2025
NCT06764680		Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer	P2	recruiting	57	Sun Yat-sen University	Dec 2024
NCT06643793	II	Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC	P2	recruiting	30	Affiliated Hospital of Nantong University	Nov 2024
NCT06825624	ARTEMIS-102	ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer	P1	recruiting	560	Hansoh BioMedical R&D Company	Oct 2024
NCT06603376		Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer	P2	recruiting	75	Shanghai Changzheng Hospital	Sep 2024
NCT06341296		Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer	P2	recruiting	86	West China Hospital	Jun 2024
NCT07359404		Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC	P2	enrolling by invitation	60	YING FAN	Apr 2024
NCT06218810		Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer	P2	recruiting	53	Fudan University	Jan 2024
NCT06433869		The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites	P2	recruiting	60	Sun Yat-sen University	Dec 2023
NCT06107413	IV	Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab	P2	active not recruiting	280	AbbVie	Nov 2023
NCT06292286	SCENIC	Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer	N/A	recruiting	18	The University of Hong Kong	Nov 2023
NCT05540275		Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma	P2	not yet recruiting	30	Henan Provincial People's Hospital	Oct 2023
NCT06156527		A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker	P2	recruiting	120	National Cancer Center, Korea	Sep 2023
NCT05636111		Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer	P1	recruiting	34	M.D. Anderson Cancer Center	Jul 2023
NCT05844046	MONTBLANC	Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients	P2	recruiting	83	Enrico De Toni	Apr 2023
NCT05609370	LBL-007	A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer	P1/P2	active not recruiting	113	BeiGene	Jan 2023
NCT05640830	TREAZURE	Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy	P1/P2	recruiting	47	Kangbuk Samsung Hospital	Jan 2023
NCT05512351		Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma	P2	recruiting	80	Henan Provincial People's Hospital	Dec 2022
NCT05512325		Study on Gene Evolution in Glioma Under Stress Therapy	—	not yet recruiting	100	Henan Provincial People's Hospital	Dec 2022
NCT05488522		SBRT With Atezo/Bev for HCC	P1	recruiting	18	Abramson Cancer Center at Penn Medicine	Sep 2022
NCT05491811	EAGLE	Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation	P2	active not recruiting	47	Sun Yat-sen University	Aug 2022
NCT05727163		FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients	P2	recruiting	194	Sun Yat-sen University	Jul 2022
NCT04958811		Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC	P2	active not recruiting	29	Georgetown University	Dec 2021
NCT04854668		A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer	P3	active not recruiting	748	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	May 2021
NCT04181060		Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer	P3	recruiting	300	National Cancer Institute (NCI)	Dec 2020
NCT03743428	BABST-C	Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)	N/A	suspended	40	Shenzhen People's Hospital	Oct 2020
NCT04566380	ONO-4538-98	ONO-4538 Phase II Rollover Study (ONO-4538-98)	P2	recruiting	59	Ono Pharmaceutical Co., Ltd.	Sep 2020
NCT04245865	Toco-CoR	Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer	P2	active not recruiting	83	Vejle Hospital	Jun 2020
NCT03203525	P	Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer	P1	active not recruiting	38	M.D. Anderson Cancer Center	Jun 2020
NCT04180072		Atezolizumab Plus Bevacizumab With HCC and HBV Infection	N/A	active not recruiting	51	National Health Research Institutes, Taiwan	Mar 2020
NCT03869892	SOLSTICE	Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.	P3	active not recruiting	856	Institut de Recherches Internationales Servier	Mar 2019
NCT03148418		A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)	P3	active not recruiting	382	Hoffmann-La Roche	Sep 2017
NCT02847559		Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma	P2	recruiting	27	Northwestern University	Aug 2016
NCT02210117		Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery	Early P1	active not recruiting	104	M.D. Anderson Cancer Center	Nov 2014
NCT01746238		Bevacizumab/Doxorubicin/Radiation for Sarcoma	P1	active not recruiting	14	Massachusetts General Hospital	Mar 2013
NCT03303495		A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC	P3	recruiting	280	Sun Yat-sen University	Nov 2011
NCT06793813	NSCLC	Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)	P2	recruiting	44	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Jan 2024
NCT07491159		Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study	P1/P2	active not recruiting	106	Tianjin Medical University Cancer Institute and Hospital	Jul 2023
NCT05171660		Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer	P3	active not recruiting	446	Second Affiliated Hospital, School of Medicine, Zhejiang University	Feb 2022
NCT05305131	GPPB	Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer	P2	recruiting	50	National University Hospital, Singapore	Mar 2022
NCT06783647	NSCLC	A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]	P2	recruiting	230	Nanjing Leads Biolabs Co.,Ltd	Jun 2025
NCT06008119		Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer	P3	recruiting	165	Shanghai Kechow Pharma, Inc.	Oct 2023
NCT05843188		Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer	P2	active not recruiting	155	University Health Network, Toronto	Aug 2023
NCT03737643	DUO-O	Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients	P3	active not recruiting	1,407	AstraZeneca	Jan 2019
NCT05757336		Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer	P2	recruiting	50	Lu Wang, MD, PhD	Dec 2022
NCT02519348		A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma	P2	active not recruiting	433	MedImmune LLC	Oct 2015
NCT06801730	NALIRIBVRG	Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma	P2	recruiting	38	Zhifeng Tian,MD	Jan 2025
NCT06117891	REFINE-IO	An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery	—	active not recruiting	300	Bayer	Nov 2023
NCT06011772		EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer	Early P1	active not recruiting	2	Roswell Park Cancer Institute	Dec 2023
NCT06788171		PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM	P2	not yet recruiting	35	Fujian Cancer Hospital	Mar 2025
NCT05945901		A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer	P2/P3	active not recruiting	669	Jiangsu HengRui Medicine Co., Ltd.	Aug 2023
NCT05798819		A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer	P3	not yet recruiting	424	Guangzhou Gloria Biosciences Co., Ltd.	May 2023
NCT05594095		SNF Platform Study of HR+/ HER2-advanced Breast Cancer	P2	recruiting	620	Fudan University	Dec 2022
NCT07445347	BevaHHearT	Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network	—	enrolling by invitation	111	Poitiers University Hospital	Oct 2025
NCT04564898	TriComB	Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.	P1/P2	active not recruiting	48	Gruppo Oncologico del Nord-Ovest	Jan 2022
NCT03743662		Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma	P2	active not recruiting	39	Memorial Sloan Kettering Cancer Center	Nov 2018
NCT06293014		TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer	P2	recruiting	224	Henan Cancer Hospital	Feb 2024
NCT04068610	COLUMBIA-1	COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC	P1/P2	active not recruiting	61	MedImmune LLC	Sep 2019
NCT05970666		Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma	P2	recruiting	71	The First Affiliated Hospital of Xiamen University	Nov 2023
NCT05640609		Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer	P1/P2	recruiting	57	West China Hospital	Mar 2023
NCT06558227		Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma	P2	recruiting	90	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Oct 2024
NCT06512051		A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer	P1/P2	recruiting	248	Shanghai Hengrui Pharmaceutical Co., Ltd.	Jul 2024
NCT06313970		First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients	P2	recruiting	58	Fudan University	Jun 2024
NCT03178552	B-FAST	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)	P2/P3	active not recruiting	1,000	Hoffmann-La Roche	Sep 2017
NCT03141684		Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma	P2	active not recruiting	63	National Cancer Institute (NCI)	Apr 2017
NCT06125080	UTILIZABLE	The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study	P2	recruiting	78	Huihua Xiong	Oct 2023
NCT05464030	PROCEADE-CRC-01	Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)	P1	recruiting	200	EMD Serono Research & Development Institute, Inc.	Aug 2022
NCT03587311		Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	P2	active not recruiting	96	National Cancer Institute (NCI)	Oct 2018
NCT02142803		TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	P1	active not recruiting	50	National Cancer Institute (NCI)	May 2014
NCT06447662		A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.	P1	active not recruiting	64	Pfizer	Jun 2024
NCT06229340	NТО-RAS	Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations	P2	recruiting	20	N.N. Petrov National Medical Research Center of Oncology	Oct 2023
NCT06192680		Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer	P2	not yet recruiting	63	Harbin Medical University	Apr 2024
NCT05211323		A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer	P2	active not recruiting	88	National Cancer Institute (NCI)	Dec 2022
NCT06202001		Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients	P1/P2	recruiting	70	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Oct 2022
NCT03526432		Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer	P2	active not recruiting	110	University of Oklahoma	Aug 2018
NCT01061515		Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer	P1	active not recruiting	21	Washington University School of Medicine	May 2011
NCT02734004	MEDIOLA	A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.	P1/P2	active not recruiting	264	AstraZeneca	Mar 2016
NCT05904886	SKYSCRAPER-14	A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)	P3	active not recruiting	687	Hoffmann-La Roche	Sep 2023
NCT06769425	HS-10502	HS-10502 Combination Treatment in Patients With Advanced Solid Tumors	P1	recruiting	157	Jiangsu Hansoh Pharmaceutical Co., Ltd.	May 2025
NCT06838338		JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC	P1	active not recruiting	30	Jian Li	Mar 2025
NCT05410301		Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma	N/A	withdrawn	0	Varun Monga, MD	Apr 2023
NCT04563338	INTEGRATE	An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)	P2	active not recruiting	36	University Health Network, Toronto	Jun 2021
NCT04938583		Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer	P1/P2	active not recruiting	54	CanariaBio Inc.	Mar 2021
NCT04361370	OPEB-01	Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer	P2	enrolling by invitation	44	Yonsei University	Oct 2020
NCT03778957	EMERALD-1	A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma	P3	active not recruiting	724	AstraZeneca	Nov 2018
NCT02840409	LGG	Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)	P2	active not recruiting	109	The Hospital for Sick Children	Aug 2016
NCT01189643		Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor	Early P1	active not recruiting	15	Memorial Sloan Kettering Cancer Center	Aug 2010
NCT07285850	ABATE-MASLD	The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD	P2/P3	recruiting	20	Eastern Hepatobiliary Surgery Hospital	Oct 2025
NCT05407155	BETTER	Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer	N/A	active not recruiting	56	Fudan University	Jun 2022
NCT05001880		Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma	P2	recruiting	66	National Cancer Institute (NCI)	Mar 2022
NCT01684397		Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer	P1/P2	active not recruiting	51	Roswell Park Cancer Institute	Nov 2012
NCT06341309		Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer	P1/P2	not yet recruiting	20	West China Hospital	Aug 2024
NCT06539559		Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer	P2	not yet recruiting	60	Wang Jiayu	Aug 2024
NCT06403709		Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients	P2	active not recruiting	35	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Aug 2022
NCT06840002		A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer	P1/P2	recruiting	150	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Mar 2025
NCT05930665		Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma	P2	recruiting	38	Sun Yat-sen University	Nov 2023
NCT05975463		Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy	P2	not yet recruiting	30	HuiKai Li	Sep 2023
NCT06717880		A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer	P1	recruiting	260	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Jul 2023
NCT05970302		XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC	P2	recruiting	52	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Jul 2023
NCT06952452	AMD	Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)	P3	recruiting	630	Parc de Salut Mar	Nov 2022
NCT04158258		A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America	—	active not recruiting	2,907	Hoffmann-La Roche	Feb 2020
NCT01946529		Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors	P2	active not recruiting	24	St. Jude Children's Research Hospital	Dec 2013
NCT02974621		Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma	P2	active not recruiting	70	National Cancer Institute (NCI)	Dec 2017
NCT01167712		Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	P3	active not recruiting	692	National Cancer Institute (NCI)	Sep 2010
NCT06971237	IMSIRT	SIRT and Peri-immunotherapy : a New Concept	—	not yet recruiting	60	Assistance Publique - Hôpitaux de Paris	Jun 2025
NCT06434090		Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer	P1/P2	unknown	74	Sun Yat-sen University	Jun 2024
NCT06040099	EMERALD-Y90	A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE	P2	active not recruiting	58	AstraZeneca	Feb 2024
NCT04094688	SOLARIS	Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer	P3	active not recruiting	455	Alliance for Clinical Trials in Oncology	Oct 2019
NCT02971501		Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases	P2	active not recruiting	5	National Cancer Institute (NCI)	Jun 2018
NCT06210438		SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases	P2	unknown	24	Fudan University	Feb 2024
NCT05781308	ADAPTABLE	Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy	P2	active not recruiting	156	Intergroupe Francophone de Cancerologie Thoracique	Apr 2023
NCT05444088		Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma	P1/P2	unknown	129	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Aug 2022
NCT04831528		Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study	—	unknown	100	Fudan University	Apr 2021
NCT03872947		A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors	P1	active not recruiting	138	Toray Industries, Inc	Apr 2019
NCT01903330		ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme	P2	unknown	84	Epitopoietic Research Corporation	Mar 2014
NCT05627635	MSS	FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer	P1/P2	active not recruiting	20	City of Hope Medical Center	May 2023
NCT04008030	CheckMate 8HW	A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)	P3	active not recruiting	839	Bristol-Myers Squibb	Aug 2019
NCT04739202	IMMUNOGAST	Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)	P2	completed	54	Hospices Civils de Lyon	Mar 2021
NCT07117435		Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases	P1	recruiting	7	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	May 2025
NCT06747728		Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain	N/A	recruiting	20	The First Affiliated Hospital of Zhengzhou University	Mar 2024
NCT06858956	L	Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer	—	not yet recruiting	200	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Mar 2025
NCT06530784		Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma	P2	not yet recruiting	36	Shanghai Zhongshan Hospital	Jul 2024
NCT06361979		SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases	P2	unknown	30	Huihua Xiong	May 2024
NCT06241235		Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma	P1/P2	unknown	48	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Mar 2024
NCT05715840		Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)	P3	unknown	368	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Jan 2023
NCT05238831	ACT	SMMART Adaptive Clinical Treatment (ACT) Trial	Early P1	withdrawn	0	OHSU Knight Cancer Institute	Jan 2023
NCT04999761		AB122 Platform Study	P1	recruiting	917	Taiho Pharmaceutical Co., Ltd.	Jun 2021
NCT06415851		Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab	P2	unknown	36	Zhangfa Song	Jun 2024
NCT07527832		An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.	—	completed	1,000	Pfizer	Apr 2026
NCT04954339	DYNAMIC	DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab	P2	completed	40	Tae Won Kim	Oct 2021
NCT06408623		Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer	P2	unknown	48	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	May 2024
NCT04102098	IMbrave050	A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation	P3	completed	668	Hoffmann-La Roche	Dec 2019
NCT06704724		A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.	P1	terminated	30	Pfizer	Dec 2024
NCT05083481		A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors	P1/P2	terminated	226	Astellas Pharma Global Development, Inc.	Oct 2021
NCT01552434		Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	P1	terminated	154	M.D. Anderson Cancer Center	Oct 2012
NCT04776655	LIBImAb	Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB	P3	recruiting	280	Azienda USL Reggio Emilia - IRCCS	Apr 2021
NCT06225622		Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer	P1	unknown	78	Shanghai Zhongshan Hospital	Mar 2024
NCT05640726	SCRT	The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy	P2	unknown	30	Fujian Cancer Hospital	May 2023
NCT06311851	TACE	Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases	P1/P2	recruiting	40	Pardis Noor Medical Imaging and Cancer Center	Jun 2025
NCT06537297		Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases	P2	not yet recruiting	30	Hunan Province Tumor Hospital	Sep 2024
NCT01187199		Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer	P1	active not recruiting	278	M.D. Anderson Cancer Center	Aug 2010
NCT06364826		Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma	P2	unknown	60	Zhejiang Cancer Hospital	Apr 2024
NCT07187661		Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis	N/A	completed	18	Khyber Medical University Peshawar	Sep 2025
NCT04812002		Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy	P2	unknown	20	Women's Hospital School Of Medicine Zhejiang University	Apr 2021
NCT03740165	MK-3475	Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)	P3	completed	1,367	Merck Sharp & Dohme LLC	Dec 2018
NCT05296278		Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC	P2	unknown	70	Hunan Province Tumor Hospital	Dec 2023
NCT06282445	MSS	Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer	P2	recruiting	36	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	Mar 2024
NCT05992220	ALERT-HCC	Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion	P2	recruiting	138	Asan Medical Center	Oct 2022
NCT04781270		mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases	P3	unknown	308	Fudan University	Apr 2021
NCT03786081		Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer	P1/P2	terminated	214	Seagen, a wholly owned subsidiary of Pfizer	Feb 2019
NCT04732598	AMBITION	A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer	P3	completed	281	Japanese Foundation for Cancer Research	Jan 2021
NCT03694262	EndoBARR	The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)	P2	completed	30	Medical College of Wisconsin	Jul 2019
NCT06487715		Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis	P2	unknown	42	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Mar 2024
NCT06276283	WU-KONG29	DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)	P2	recruiting	60	Dizal Pharmaceuticals	Feb 2023
NCT02308527	BEACON	Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children	P2	completed	225	University of Birmingham	Jul 2013
NCT07338097		Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema	N/A	enrolling by invitation	116	CMH Multan Institute of Medical Sciences	Sep 2025
NCT04147351		A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.	P2	completed	22	National Taiwan University Hospital	Apr 2020
NCT06269445		The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer	P4	unknown	20	Sir Run Run Shaw Hospital	Jan 2024
NCT06233994		A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma	N/A	unknown	30	Changsha Taihe Hospital	Jan 2024
NCT05904457	BRISK	A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer	P2	unknown	32	Asan Medical Center	Jan 2023
NCT04595266	LIVERPEARL	Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease	P2	active not recruiting	48	Grupo Espanol Multidisciplinario del Cancer Digestivo	Jun 2021
NCT06163820	BETTER	Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases	P1/P2	recruiting	46	Melanoma and Skin Cancer Trials Limited	May 2025
NCT06139211		A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors	P1/P2	recruiting	186	Shanghai Junshi Bioscience Co., Ltd.	Jan 2024
NCT06550453		Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer	P4	recruiting	20	yangjianjun	Sep 2024
NCT07065435		RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study	P2	recruiting	74	The First Affiliated Hospital with Nanjing Medical University	Jan 2024
NCT07204574		The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer	P1/P2	recruiting	40	Chang Gung Memorial Hospital	May 2025
NCT06682247		A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer	—	not yet recruiting	200	Feng Wang	Nov 2024
NCT06363552		A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer	P2	unknown	36	Tianshu Liu	May 2024
NCT05906524		KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors	P1/P2	unknown	85	Shanghai Kanda Biotechnology Co., Ltd.	Apr 2024
NCT06285019		Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma	P2	unknown	65	Fudan University	Dec 2023
NCT06016062		A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors	P1/P2	recruiting	221	RemeGen Co., Ltd.	Sep 2023
NCT05864755		HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma	P2	unknown	30	Tianjin Medical University Cancer Institute and Hospital	Jun 2023
NCT06393166		Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer	P2	unknown	37	Zhejiang Cancer Hospital	May 2023
NCT05659290		Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer	P2	unknown	40	Nanfang Hospital, Southern Medical University	Jan 2023
NCT05444374		A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer	P2	unknown	48	Sichuan Cancer Hospital and Research Institute	Oct 2022
NCT05611645		Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence	P2	unknown	42	Huashan Hospital	Oct 2022
NCT04973293		Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer	N/A	recruiting	20	Ruijin Hospital	Oct 2022
NCT05022927		A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma	P1	active not recruiting	179	Chugai Pharmaceutical	Jun 2021
NCT06206096		PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC	P2	unknown	40	Chinese PLA General Hospital	May 2021
NCT04832776		FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases	P2	unknown	160	Fudan University	Apr 2021
NCT03390686		A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients	P3	active not recruiting	650	Prestige Biopharma Limited	Nov 2019
NCT03828227	COLAGE	QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.	P3	active not recruiting	49	GERCOR - Multidisciplinary Oncology Cooperative Group	Jun 2019
NCT02299999	SAFIR02_Breast	SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer	P2	active not recruiting	1,460	UNICANCER	Apr 2014
NCT01531595	AXOAXI	Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer	P2	active not recruiting	100	Pia Osterlund	Feb 2012
NCT06182800		Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy	P2	unknown	35	The First Affiliated Hospital of Xinxiang Medical College	Dec 2023
NCT05811793		Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.	N/A	unknown	36	Second Affiliated Hospital of Nanchang University	Apr 2023
NCT05751343		Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial	P2	recruiting	55	Sun Yat-sen University	Mar 2023
NCT05341193		PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma	P1/P2	unknown	32	Sun Yat-sen University	Apr 2022
NCT05303259	BRAIN	Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury	P2	unknown	204	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Nov 2021
NCT04982237		A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer	P3	active not recruiting	445	Akeso	Aug 2021
NCT06323382		Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma	—	recruiting	240	Sun Yat-sen University	Jan 2021
NCT05713994	CCGLC-001	Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma	—	recruiting	300	Ze-yang Ding, MD	May 2020
NCT01917877		Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab	P2	unknown	30	Qingdao Central Hospital	Aug 2013
NCT06332079	HAITI	Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients	P2	terminated	4	Gruppo Oncologico del Nord-Ovest	Mar 2024
NCT06509906		M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)	P1	terminated	3	EMD Serono Research & Development Institute, Inc.	Oct 2024
NCT06850571		Aflibercept and Bevacizumab for Diabetic Maculopathies	P4	recruiting	102	Al-Mustansiriyah University	Feb 2025
NCT05754736		Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.	P2	unknown	50	The Second Affiliated Hospital of Shandong First Medical University	Dec 2022
NCT05628038	TORCH-R	The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer	P2	recruiting	93	Fudan University	Nov 2022
NCT05163483		Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer	P2	unknown	87	Ruihua Xu	Jul 2022
NCT05192798		Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC	P2	recruiting	128	The First Affiliated Hospital of Bengbu Medical University	Jan 2022
NCT03647592		Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer	—	unknown	30	Hunan Province Tumor Hospital	Jun 2018
NCT06447727		Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM	—	unknown	30	Zhongda Hospital	May 2024
NCT06152822		Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases	P2	unknown	30	Tongji Hospital	Nov 2023
NCT05616390		Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma	P2	unknown	30	Tianjin Medical University Cancer Institute and Hospital	Nov 2022
NCT05217680	PRO-169	Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema	P3	completed	509	Laboratorios Sophia S.A de C.V.	May 2021
NCT03337698	Morpheus Lung	A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)	P1/P2	terminated	314	Hoffmann-La Roche	Dec 2017
NCT05337137	RELATIVITY-106	A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer	P1/P2	completed	83	Bristol-Myers Squibb	May 2022
NCT05908786		A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma	P1/P2	completed	62	Hoffmann-La Roche	Dec 2023
NCT07272265		The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study	N/A	completed	300	Sun Yat-sen University	Oct 2020
NCT02761070	RE-GEND	Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III	P3	unknown	146	Kyorin University	Jul 2016
NCT06308406		A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer	P1/P2	unknown	54	Jiangsu HengRui Medicine Co., Ltd.	Mar 2024
NCT06039202		Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer	P2	unknown	100	Holy Stone Healthcare Co., Ltd	Jan 2024
NCT05588297		Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases	P2	unknown	12	Shanghai Changzheng Hospital	Oct 2022
NCT03532295		Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas	P2	completed	51	Washington University School of Medicine	Apr 2020
NCT04940546		Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients	P1/P2	active not recruiting	36	Sun Yat-sen University	Jun 2021
NCT03520686		Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer	P3	terminated	102	ImmunityBio, Inc.	May 2018
NCT06377267	STROBE	Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)	P2	unknown	100	Vall d'Hebron Institute of Oncology	Feb 2024
NCT06060704		Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.	P2	unknown	33	The First Affiliated Hospital with Nanjing Medical University	Nov 2023
NCT05555901		The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer	P2	unknown	116	Fudan University	Jun 2023
NCT05799820		QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC	P2	unknown	60	Qilu Pharmaceutical Co., Ltd.	Sep 2022
NCT04739670	BELLA	Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer	P2	unknown	31	Peter MacCallum Cancer Centre, Australia	Mar 2021
NCT06827353	OVNI-B	Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency	—	recruiting	300	Centre Hospitalier Universitaire de Nīmes	Oct 2020
NCT06595355		Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin	P2/P3	recruiting	52	Isfahan University of Medical Sciences	Oct 2021
NCT05332496	CHANCE2202	TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC	—	completed	941	Zhongda Hospital	Dec 2022
NCT04660812	ARC-9	An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.	P1/P2	completed	227	Arcus Biosciences, Inc.	May 2021
NCT00861705		Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery	P2	completed	454	National Cancer Institute (NCI)	Jul 2009
NCT04017455	TARZAN	Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)	P2	active not recruiting	38	The Netherlands Cancer Institute	Oct 2019
NCT03556839	BEATcc	Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix	P3	completed	410	Grupo Español de Investigación en Cáncer de Ovario	Sep 2018
NCT03929666		A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer	P2	completed	74	Jazz Pharmaceuticals	Aug 2019
NCT05733611		RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	P2	terminated	5	Replimune, Inc.	Jun 2023
NCT05007106	MK-7684A-005	MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)	P2	completed	613	Merck Sharp & Dohme LLC	Sep 2021
NCT05821361		HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma	P2	unknown	30	Tianjin Medical University Cancer Institute and Hospital	Aug 2023
NCT05111860		Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy	P1/P2	unknown	20	Shanghai Minimally Invasive Surgery Center	Nov 2022
NCT06090656	BEST	Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)	P2	recruiting	88	Sun Yat-sen University	Mar 2023
NCT05781633		The Efficacy and Safety of Eutideron, Etoposide, and Bevacizumab in Patients With Brain Metastases From Breast Cancer.	N/A	unknown	43	Tianjin Medical University Cancer Institute and Hospital	Jul 2022
NCT03795311	FOLFIRINOX3	Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)	P1/P2	active not recruiting	32	Centre Georges Francois Leclerc	Nov 2018
NCT05480306	DeFianCe	Phase 2 Study of DKN-01 in Colorectal Cancer	P2	completed	188	Leap Therapeutics, Inc.	Aug 2022
NCT05359861		Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma	P2	completed	30	Coherus Oncology, Inc.	Apr 2022
NCT04107168		Microbiome Immunotherapy Toxicity and Response Evaluation	—	unknown	1,800	CCTU- Cancer Theme	Jul 2020
NCT07014280		Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.	P4	active not recruiting	28	Kasr El Aini Hospital	Sep 2023
NCT05883176	B-TACE	TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria	P2	unknown	35	Sun Yat-sen University	Jun 2023
NCT05998941		A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer	P2	withdrawn	0	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Aug 2023
NCT06334757		Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure	P2	unknown	46	Henan Cancer Hospital	May 2023
NCT05118776		Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM	P3	active not recruiting	136	Ascletis Pharmaceuticals Co., Ltd.	Jan 2022
NCT03363867	BEACON	BEACON - ABC in Recurrent Platinum Resistant HGSOC	P2	unknown	30	Peter MacCallum Cancer Centre, Australia	Jul 2018
NCT03452579		Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM	P2	active not recruiting	90	David Peereboom	May 2018
NCT02285959		Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme	P1	unknown	30	Global Neurosciences Institute	Jun 2014
NCT03635021	CR-SEQUENCE	Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer	P3	active not recruiting	419	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	Oct 2018
NCT01932125		An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer	P4	completed	100	Hoffmann-La Roche	Dec 2018
NCT05537402	LOST-B	LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC	P2	terminated	1	University of Texas Southwestern Medical Center	Sep 2023
NCT05065021		Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor	P2	unknown	40	University Health Network, Toronto	Feb 2023
NCT06808412		To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer	P2	recruiting	118	xiaohua li	Jul 2024
NCT05965141		Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer	P1/P2	unknown	38	Second Affiliated Hospital of Guangzhou Medical University	Aug 2023
NCT05965154		Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma	P2	unknown	22	Second Affiliated Hospital of Guangzhou Medical University	Aug 2023
NCT05200364		A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer	P1	terminated	58	Sutro Biopharma, Inc.	Mar 2022
NCT03813394	2018/00947	Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC	P1/P2	active not recruiting	48	National University Hospital, Singapore	May 2019
NCT04988607		Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC	P2	unknown	90	Guangdong Association of Clinical Trials	Aug 2021
NCT01933815		Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma	P1/P2	suspended	92	Cortice Biosciences, Inc.	Aug 2013
NCT07075562		TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion	N/A	completed	180	The First Hospital of Hebei Medical University	Jun 2021
NCT04303988		A Phase II Study of Triple-negative Breast Cancer Brain Metastases.	P2	recruiting	35	Fudan University	Mar 2020
NCT06849362		Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer	—	enrolling by invitation	200	Yue Gou	Dec 2019
NCT05665348	TRIPLET	Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy	P2/P3	completed	229	Federation Francophone de Cancerologie Digestive	Mar 2023
NCT06177288	DEBIRI	DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases	N/A	unknown	39	Fudan University	Jan 2024
NCT00601900		Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer	P3	completed	394	National Cancer Institute (NCI)	Sep 2008
NCT05839951	STAR-T	An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions	—	completed	818	Bayer	Apr 2023
NCT04042558	GFPC 06-2018	A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	P2	completed	150	Centre Francois Baclesse	Sep 2019
NCT05833126		Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation	P2	unknown	25	Shuhong Yi	Dec 2023
NCT05983367		A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer	P2	terminated	76	Inspirna, Inc.	Oct 2023
NCT05103020		Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases	P2	unknown	100	Yonsei University	Nov 2021
NCT04944069	ATTRACT	Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis	N/A	unknown	69	Second Affiliated Hospital of Nanchang University	Jul 2021
NCT04405674		Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC	P2	unknown	120	Shanghai Chest Hospital	Jul 2020
NCT03574779	OPAL	A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer	P2	completed	77	Tesaro, Inc.	Nov 2018
NCT03597581		A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer	P1	completed	89	Inspirna, Inc.	Jun 2018
NCT02681549	NSCLC	Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)	P2	completed	41	Yale University	May 2016
NCT05819060		The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab	P2	unknown	44	Fudan University	Apr 2023
NCT05750030		FMT in IT-refractory HCC - FAB-HCC Pilot Study	P2	completed	12	Medical University of Vienna	May 2023
NCT05386524		Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC	P2	unknown	41	Fudan University	Jun 2022
NCT00200200		Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer	P2	completed	73	Memorial Sloan Kettering Cancer Center	Nov 2004
NCT03353831		Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer	P3	completed	574	AGO Research GmbH	Sep 2018
NCT04925284	JEWEL-101	Study of XB002 in Subjects With Solid Tumors (JEWEL-101)	P1	completed	269	Exelixis	Jun 2021
NCT06008522	DETOUR	Safety and Feasibility of Immuno-OCT	N/A	unknown	15	University Medical Center Groningen	Apr 2024
NCT03462212	MITO25	Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination	P1/P2	unknown	290	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Mar 2021
NCT04224636	DEMAND	Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab	P2	unknown	106	Ludwig-Maximilians - University of Munich	Jun 2020
NCT03186326	SAMCO	Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer	P2	completed	132	Federation Francophone de Cancerologie Digestive	Apr 2018
NCT05792410		A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.	P1/P2	unknown	300	Jiangsu HengRui Medicine Co., Ltd.	Apr 2023
NCT03193190		A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	P1/P2	completed	341	Hoffmann-La Roche	Jul 2017
NCT00873275		Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer	P1	completed	11	City of Hope Medical Center	Mar 2009
NCT05044871	BRIGHT	Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer	P2	completed	108	Tongji Hospital	Jul 2022
NCT03798626		Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers	P1	completed	167	Novartis Pharmaceuticals	May 2019
NCT05665023		Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma	P2	unknown	37	Yonsei University	Oct 2022
NCT05247619		A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer	P2	unknown	49	Zhejiang Cancer Hospital	Jun 2022
NCT04787289		A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer	P2	recruiting	244	British Columbia Cancer Agency	Sep 2021
NCT02162563	CAIRO5	Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases	P3	completed	530	Dutch Colorectal Cancer Group	Jul 2014
NCT01950390		Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	P2	completed	169	National Cancer Institute (NCI)	Jan 2014
NCT00324805		Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery	P3	completed	1,501	National Cancer Institute (NCI)	Jul 2007
NCT02934529	AIO-KRK-0114	Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab	P3	completed	673	Ludwig-Maximilians - University of Munich	Mar 2015
NCT05299476		CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEA	P2	completed	32	Chinese PLA General Hospital	Apr 2022
NCT04952753	daNIS-3	Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC	P2	terminated	204	Novartis Pharmaceuticals	Nov 2021
NCT04553692	IGM-8444	Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers	P1	terminated	272	IGM Biosciences, Inc.	Sep 2020
NCT03818061	ATHENA	Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck	P2	completed	33	Centre Leon Berard	Mar 2019
NCT05523440		Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation	P2	terminated	9	University of Oklahoma	Feb 2023
NCT02669173		Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma	P1	completed	12	Case Comprehensive Cancer Center	Oct 2016
NCT06003998	INTERACT-II	Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab	P2	unknown	85	Catharina Ziekenhuis Eindhoven	Dec 2022
NCT04679064	NItCHE-MITO33	Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment	P3	unknown	427	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Dec 2020
NCT06124729		Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases	—	unknown	50	The First Affiliated Hospital with Nanjing Medical University	Dec 2023
NCT06370065	HCC	Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients	P2	unknown	35	Tianjin Medical University Cancer Institute and Hospital	Apr 2023
NCT05760430		The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma	P2	unknown	40	Second Affiliated Hospital, School of Medicine, Zhejiang University	Dec 2022
NCT05685836		89Zr-Bevacizumab PET/CT Imaging in NF2 Patients	—	unknown	15	Leiden University Medical Center	Oct 2022
NCT05325229		A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer	P2	unknown	94	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Aug 2022
NCT05355155		Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation	P2	unknown	15	The First Affiliated Hospital with Nanjing Medical University	May 2022
NCT05191784	GBM	GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients	P2	unknown	20	Genexine, Inc.	Jan 2022
NCT05717738	CCGLC-008	Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma	—	unknown	300	Tongji Hospital	Jan 2022
NCT05173298	HCC	Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab	—	unknown	100	CHA University	Aug 2021
NCT04974944		First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer	P2	unknown	172	Sun Yat-sen University	Jul 2021
NCT04670978		Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer	P2	unknown	96	Shandong University	Mar 2021
NCT04682210	DaDaLi	Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection	P3	unknown	246	Sun Yat-sen University	Dec 2020
NCT03806049		Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer	P3	withdrawn	0	Nordic Society of Gynaecological Oncology - Clinical Trials Unit	Dec 2019
NCT04175470		Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer	P2	completed	20	Vejle Hospital	Oct 2019
NCT02724878		Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma	P2	completed	65	Dana-Farber Cancer Institute	Jul 2016
NCT01951482		Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer	P3	completed	160	Sun Yat-sen University	Jan 2016
NCT03211741		Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema	P4	unknown	500	University Hospital, Ghent	Nov 2013
NCT01910610	STRATEGIC-1	Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer	P3	unknown	464	GERCOR - Multidisciplinary Oncology Cooperative Group	Oct 2013
NCT01706120	MITO16/MANGO-2	Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab	P4	unknown	400	National Cancer Institute, Naples	Oct 2012
NCT05638451	GBM	Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients	P2	unknown	30	Zhujiang Hospital	May 2023
NCT05468242		Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy	P2	recruiting	116	Sun Yat-sen University	Jan 2022
NCT05132413		A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer	P3	unknown	561	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Dec 2021
NCT01743950		A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab	P2	terminated	49	University of Wisconsin, Madison	Dec 2012
NCT05201326		Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma	P1	unknown	20	Ruijin Hospital	Dec 2021
NCT05180006	BIS-Program	Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy	P2	terminated	33	Gustave Roussy, Cancer Campus, Grand Paris	Feb 2022
NCT03307785		Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042	P1	completed	60	Tesaro, Inc.	Oct 2017
NCT05593328	KRAS	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation	P2	completed	23	Cardiff Oncology	Mar 2023
NCT06190093	AMD	A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)	P3	completed	400	Outlook Therapeutics, Inc.	Jan 2024
NCT05776875		Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC	P2	terminated	3	Yale University	Jun 2023
NCT05785325		RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer	P2	unknown	30	Second Affiliated Hospital, School of Medicine, Zhejiang University	Aug 2023
NCT05886465		HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial	P2	unknown	40	Sun Yat-sen University	May 2023
NCT05738317		Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment	P2	unknown	45	Xiaorong Dong	Dec 2022
NCT03912415	FERMATA	Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)	P3	unknown	316	Biocad	Oct 2019
NCT05158062		Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer	P2	unknown	35	Kosei Hasegawa, MD, PhD	Apr 2022
NCT04310176	REVOLUTION	Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer	P2	unknown	200	National Cancer Institute, Naples	May 2019
NCT06503250		A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization	—	completed	113	Hoffmann-La Roche	Jul 2024
NCT03762018	BEAT-meso	BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma	P3	completed	400	ETOP IBCSG Partners Foundation	Apr 2019
NCT03117972	CLavSyn	Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels	P2	terminated	54	Centre Hospitalier Universitaire de Besancon	Aug 2017
NCT02794571	PK	Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors	P1	completed	518	Genentech, Inc.	May 2016
NCT03498521	CUPISCO	A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site	P2	completed	529	Hoffmann-La Roche	Jul 2018
NCT05070104		CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer	P1	withdrawn	0	Cornerstone Pharmaceuticals	Mar 2023
NCT05643417		Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy	P1	unknown	80	Fudan University	Dec 2022
NCT04872582		Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study	P2	unknown	33	XIANG YANQUN	Jul 2021
NCT04659382	SIRTCI	Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer	P2	unknown	52	Federation Francophone de Cancerologie Digestive	Oct 2020
NCT04072198	NIVACOR	Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients	P2	completed	73	Gruppo Oncologico Italiano di Ricerca Clinica	Sep 2019
NCT03836066	TELMA	Atezolizumab Plus Bevacizumab in First Line NSCLC Patients	P2	completed	41	Fundación GECP	May 2019
NCT04829383	AB7	A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma	P2	completed	6	Howard S Hochster	Mar 2021
NCT05530785		Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT	N/A	unknown	35	Yongchang Zhang	Aug 2022
NCT04895137	BASKETⅡ	mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC	P2	completed	42	Sixth Affiliated Hospital, Sun Yat-sen University	May 2021
NCT04262687	POCHI	Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate	P2	unknown	55	Federation Francophone de Cancerologie Digestive	Apr 2021
NCT04705519		Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma	P2	completed	79	Peking University	Jan 2021
NCT03280563	MORPHEUS HR+BC	A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer	P1/P2	completed	144	Hoffmann-La Roche	Dec 2017
NCT05052099	COMBATBIL	Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer	P1/P2	completed	20	University Hospital, Essen	Oct 2021
NCT04109924	TAS-102	TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study	P2	completed	42	Roswell Park Cancer Institute	Dec 2019
NCT06313268		Safety of Effivia®, a Bevacizumab Biosimilar	—	completed	83	Laboratorios Liomont	Aug 2022
NCT05330065		A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion	P1/P2	unknown	55	The First Affiliated Hospital of Zhengzhou University	Aug 2022
NCT04796025	T-Double	TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study	P2	unknown	34	Sun Yat-sen University	Sep 2021
NCT01191697	CAPOX	CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer	P2	completed	37	Dana-Farber Cancer Institute	Feb 2011
NCT05678257		A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer	P2	terminated	180	NuCana plc	Apr 2023
NCT05717400		Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy	P4	terminated	2	M.D. Anderson Cancer Center	Mar 2023
NCT02820857	BEVANEC	Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer	P2	completed	153	Hospices Civils de Lyon	Sep 2017
NCT06448364	LTbR	A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination	P1	terminated	4	Pfizer	May 2024
NCT04487067	AMETHISTA	A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista	P3	completed	152	Hoffmann-La Roche	Aug 2020
NCT05507606		Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations	P2	unknown	50	Tianjin Medical University Cancer Institute and Hospital	Aug 2021
NCT04406272		VB-111 in Surgically Accessible Recurrent/Progressive GBM	P2	terminated	15	Dana-Farber Cancer Institute	Aug 2020
NCT03890952		Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma	P2	completed	40	Ulrik Lassen	Oct 2018
NCT03661723		Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma	P2	completed	60	Dana-Farber Cancer Institute	Sep 2018
NCT02138617		Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer	P2	completed	100	UNC Lineberger Comprehensive Cancer Center	May 2014
NCT02633189	BEVERLY	Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer	P3	unknown	200	National Cancer Institute, Naples	Apr 2016
NCT04735861	INOVA	Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma	P2	completed	38	Tongji Hospital	Apr 2021
NCT05824559		ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer	P1	terminated	23	MEI Pharma, Inc.	Aug 2023
NCT04245085	ABC-lung	ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma	P2	completed	95	ETOP IBCSG Partners Foundation	Sep 2020
NCT04512430		Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients	P2	terminated	4	Fundación GECP	Dec 2020
NCT02020707		Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers	P1	completed	43	Mayo Clinic	Feb 2014
NCT03326193		A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	P2	completed	105	Tesaro, Inc.	Dec 2017
NCT05760599		Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T	P2	unknown	30	Shi Ming	Feb 2023
NCT05378867	CRC	A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC	P3	unknown	126	Zhejiang Teruisi Pharmaceutical Inc.	Aug 2022
NCT05267366		Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC	P2	unknown	117	Qingdao Central Hospital	Feb 2022
NCT05617430		Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma	P2	unknown	43	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Nov 2022
NCT05170594		A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer	P2	unknown	60	The Second Affiliated Hospital of Shandong First Medical University	Dec 2021
NCT05068206		A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx	P2	unknown	120	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Oct 2021
NCT04194203		A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)	P3	completed	305	Hoffmann-La Roche	Apr 2020
NCT05330429	ELEVATE CRC	Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)	P2	terminated	77	Gilead Sciences	Jul 2022
NCT03024437		Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma	P1/P2	terminated	31	Roberto Pili	Jun 2017
NCT02017717	CheckMate 143	A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients	P3	completed	529	Bristol-Myers Squibb	Feb 2014
NCT04730999	CeLEBrATE	Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer	P2	completed	54	Gruppo Oncologico Italiano di Ricerca Clinica	Jul 2020
NCT03635567	MK-3475	Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)	P3	completed	617	Merck Sharp & Dohme LLC	Oct 2018
NCT05394233		Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC	P2	unknown	20	Sichuan Cancer Hospital and Research Institute	Jun 2022
NCT05357417		Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases	P2	unknown	100	Henan Cancer Hospital	Apr 2022
NCT04723004		Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC	P3	completed	326	Shanghai Junshi Bioscience Co., Ltd.	Oct 2020
NCT05807893	SUPER BRAIN	Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases	P2/P3	completed	40	Sun Yat-sen University	May 2023
NCT04397601	ARBITRATION	Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer	—	unknown	220	National Cancer Institute, Naples	May 2020
NCT00410956		Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery	P2	completed	22	Memorial Sloan Kettering Cancer Center	May 2007
NCT04683965		Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer	P2	unknown	27	The First Affiliated Hospital with Nanjing Medical University	Jan 2021
NCT05363722		A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma	P1	unknown	80	Shanghai Zhongshan Hospital	May 2022
NCT02743923		Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer	P3	unknown	203	The Netherlands Cancer Institute	Apr 2016
NCT01837862		A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas	P1/P2	completed	36	Julie Krystal	Oct 2013
NCT04732286		A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy	P3	terminated	100	Hoffmann-La Roche	May 2021
NCT04681677	IORT	Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab	P2	terminated	12	Xoft, Inc.	Nov 2021
NCT05648006		First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer	P2	terminated	7	Binhui Biopharmaceutical Co., Ltd.	Oct 2023
NCT05303038	Castle06(BC)	Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy	P2	unknown	15	Fudan University	May 2022
NCT04734665	NIRVANA-R	Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor	P2	unknown	44	Yonsei University	Jul 2021
NCT05262244	LEAF	Targeted Fluorescence Imaging in AMD	P1	completed	12	University Medical Center Groningen	Oct 2022
NCT03832179	STAMP	Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification	P4	completed	16	Bay Area Retina Associates	Nov 2018
NCT05310344		Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer	P2	unknown	50	Lei Li	Mar 2022
NCT03428958		A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment	P1/P2	completed	111	NuCana plc	Oct 2018
NCT03275506	NEOPEMBROV	PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .	P2	completed	91	ARCAGY/ GINECO GROUP	Feb 2018
NCT03952403	NSCLC	A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	P3	unknown	643	Shanghai Henlius Biotech	Dec 2019
NCT03991403		Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC	P3	unknown	228	Samsung Medical Center	Aug 2019
NCT05448677	ABE-LIVER	Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma	P2	terminated	3	University Hospital, Grenoble	Dec 2022
NCT03133546	BOOSTER	Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M	P2	completed	155	ETOP IBCSG Partners Foundation	May 2017
NCT05314101		TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer	P2	unknown	25	Fujian Cancer Hospital	Apr 2022
NCT04868708		A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer	P2	completed	50	Akeso	Apr 2021
NCT03475004		Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer	P2	completed	53	University of Colorado, Denver	Sep 2018
NCT02826837		LEAC-102 for Advanced Colorectal Cancer	P1/P2	unknown	30	Taiwan Leader Biotech Corp.	Sep 2022
NCT05273814		Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer	P1	unknown	30	Tianjin Medical University Cancer Institute and Hospital	Aug 2022
NCT05438108		SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC	P2	unknown	30	Huazhong University of Science and Technology	Jul 2022
NCT04997382	CLASSIC5	Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC	P2	completed	112	Hunan Province Tumor Hospital	Aug 2021
NCT03693573		A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma	P3	withdrawn	0	Hoffmann-La Roche	Jan 2019
NCT03396926		Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer	P2	completed	44	University of California, San Francisco	Apr 2018
NCT03829410		Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation	P1/P2	completed	68	Cardiff Oncology	Jun 2019
NCT04015739	BOLD	Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse	P2	unknown	74	ARCAGY/ GINECO GROUP	Mar 2019
NCT05834348	DELINOR	A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.	—	completed	5,279	Pfizer	Jun 2023
NCT03387085	TNBC	QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.	P1/P2	terminated	9	ImmunityBio, Inc.	Mar 2018
NCT06882551		Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients	P4	completed	82	Khyber Teaching Hospital	Apr 2023
NCT05675033		Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma	P2	unknown	50	Fujian Cancer Hospital	Jan 2023
NCT05332821	CHANCE2201	TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC	—	completed	1,244	Zhongda Hospital	Dec 2022
NCT04305106	BEST	Bevacizumab in Patients With Severe Covid-19	P3	unknown	588	Qilu Hospital of Shandong University	Jan 2023
NCT05396937		Efficacy and Safety of T+A+RAD in HCC	P2	unknown	42	Fudan University	Jan 2022
NCT05197504	HCC	Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy	—	completed	166	CHA University	Dec 2021
NCT04213222	ROBOT	Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases	—	unknown	300	Peking University People's Hospital	Oct 2020
NCT04575415	BELLA	Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study	—	unknown	272	Guangdong Association of Clinical Trials	Oct 2020
NCT04238169		Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC	P2	completed	60	Xinqiao Hospital of Chongqing	Sep 2020
NCT04389073		Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine	P2	unknown	138	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Apr 2020
NCT04034459	AIO-KRK-0116	FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC	P2	unknown	109	Ludwig-Maximilians - University of Munich	Nov 2016
NCT01802749	MITO16MANGO2b	Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer	P3	unknown	406	National Cancer Institute, Naples	Nov 2013
NCT01236560		Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma	P2/P3	completed	101	National Cancer Institute (NCI)	Jan 2011
NCT05411757		IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer	Early P1	unknown	12	Shandong Public Health Clinical Center	Jun 2022
NCT05263947		Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation	P2	completed	35	Tianjin Medical University Cancer Institute and Hospital	Jan 2022
NCT05603039		A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma	P1/P2	unknown	80	Qilu Pharmaceutical Co., Ltd.	Jul 2021
NCT04988191		Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer	P1/P2	unknown	44	Peking University	Dec 2020
NCT05582577		Additional Effect of Subthreshold Micropulse Laser to Intravitreous Injection of Bevacizumab on Diabetic Macular Edema	P2/P3	unknown	30	Shahid Beheshti University of Medical Sciences	Oct 2022
NCT04194359	IBI308	Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer	P2	unknown	25	Second Affiliated Hospital, School of Medicine, Zhejiang University	Feb 2021
NCT01149850		Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma	P2	completed	50	Jonsson Comprehensive Cancer Center	Apr 2010
NCT04408118	ATRACTIB	First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC	P2	completed	100	MedSIR	Oct 2020
NCT03117049	TASUKI-52	Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)	P3	completed	550	Ono Pharmaceutical Co., Ltd.	Jun 2017
NCT04973904		Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer	P2	unknown	35	Peking Union Medical College Hospital	Aug 2021
NCT02873195		Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer	P2	completed	133	Academic and Community Cancer Research United	Jul 2017
NCT06843954		Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer	P4	completed	157	Mohammed Mahmood Mohammed	Sep 2022
NCT04725448		Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma	P2	unknown	27	Sichuan Cancer Hospital and Research Institute	Apr 2021
NCT05087992		A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers	P1	completed	13	Boehringer Ingelheim	Nov 2021
NCT06006286		A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma	P1/P2	withdrawn	0	M.D. Anderson Cancer Center	Aug 2023
NCT05029973		HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC	P2	unknown	30	Tianjin Medical University Cancer Institute and Hospital	May 2021
NCT02399410		Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis	P2	completed	60	University Hospital, Ghent	Nov 2015
NCT04456699	MK-7339	Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)	P3	completed	335	Merck Sharp & Dohme LLC	Aug 2020
NCT03654833	MiST	Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma	P2	unknown	186	University of Leicester	Jan 2019
NCT05277675	RANT	Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)	N/A	unknown	160	Southwest Hospital, China	Nov 2021
NCT04939662	SUKSES-B2	Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects	P2	completed	25	Se-Hoon Lee	Jun 2021
NCT03425292		A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer	P1	completed	49	Saint John's Cancer Institute	Mar 2018
NCT03698461	CLIMB	Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab	P2	completed	20	Asan Medical Center	May 2019
NCT04074785	SCCC-06319	Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6	Early P1	terminated	10	University of Texas Southwestern Medical Center	Dec 2019
NCT03940690	COATS-VEGF	Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease	P3	terminated	18	Fondation Ophtalmologique Adolphe de Rothschild	Oct 2019
NCT06095362	TARGET-beva	Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW	P1	completed	20	University Medical Center Groningen	Nov 2021
NCT03686254		The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM	P2/P3	unknown	160	Nanfang Hospital, Southern Medical University	Jul 2018
NCT05010434		Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma	P2	unknown	46	Sun Yat-sen University	Aug 2021
NCT03476798	Clovis-001	Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium	P2	completed	49	University of Oklahoma	Jun 2018
NCT04737187	SUNLIGHT	Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients	P3	completed	492	Taiho Oncology, Inc.	Nov 2020
NCT04091217		Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma	P2	completed	43	Hoffmann-La Roche	Nov 2019
NCT03961698	MARIO-3	Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma	P2	unknown	91	Infinity Pharmaceuticals, Inc.	Dec 2019
NCT03721653	AtezoTRIBE	FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients	P2	completed	218	Gruppo Oncologico del Nord-Ovest	Nov 2018
NCT04677504		A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer	P2	completed	162	Hoffmann-La Roche	Feb 2021
NCT02386826		INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme	P1	completed	65	SCRI Development Innovations, LLC	Sep 2015
NCT03395899	ECLIPSE	Pre-operative Immunotherapy Combination Strategies in Breast Cancer	P2	completed	71	Queen Mary University of London	Dec 2017
NCT04634604	ROP3	A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP	P3	terminated	16	Jaeb Center for Health Research	Apr 2022
NCT05510427		Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification	P1	withdrawn	0	M.D. Anderson Cancer Center	Aug 2023
NCT04446416	BEV	Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients	N/A	completed	6	NaviFUS Corporation	Jul 2020
NCT03950154		Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer	P3	unknown	198	Tianjin Medical University Cancer Institute and Hospital	Jun 2019
NCT03376659		Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma	P1/P2	terminated	8	Georgetown University	Aug 2018
NCT04984980		Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer	P2	unknown	37	Fudan University	Aug 2020
NCT06199297		Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma	—	completed	188	Sun Yat-sen University	Mar 2021
NCT03126799	AvaTa	A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)	P2	unknown	128	National Cancer Center, Korea	Nov 2016
NCT02563002	MK-3475	Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)	P3	completed	307	Merck Sharp & Dohme LLC	Nov 2015
NCT01220154		Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer	P1	completed	9	David O'Malley	Apr 2011
NCT04421378		A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma	P1/P2	terminated	74	Karyopharm Therapeutics Inc	Jun 2020
NCT05160896		SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer	P2	unknown	90	Second Affiliated Hospital, School of Medicine, Zhejiang University	Nov 2021
NCT04627363		HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama	P2	unknown	30	Sun Yat-sen University	Jan 2021
NCT04541173	HCC	Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)	P2	terminated	6	Aiwu Ruth He, MD	Nov 2020
NCT04324476		A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer	P2	unknown	50	Jiangsu Cancer Institute & Hospital	Sep 2019
NCT04164069		Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab	P1	completed	9	Anne Noonan	Sep 2020
NCT04099836		Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib	P2	terminated	7	Duke University	Jul 2020
NCT05214339	D-TRIPLET	A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)	P2	unknown	30	Sun Yat-sen University	Mar 2022
NCT04217954		HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC	P2	completed	32	Peking University	Jul 2020
NCT04508452		A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC	P2	unknown	91	First Affiliated Hospital of Zhejiang University	May 2020
NCT04605796	JS001	A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)	P2	completed	54	Shanghai Junshi Bioscience Co., Ltd.	Apr 2020
NCT02456857		Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative	P2	completed	17	M.D. Anderson Cancer Center	Jan 2016
NCT01814813		Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery	P2	terminated	90	Alliance for Clinical Trials in Oncology	Jun 2013
NCT03635489		A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	P3	completed	100	Hoffmann-La Roche	Aug 2018
NCT04761614		Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer	P1	completed	13	Ning Jin	Apr 2021
NCT04843943		Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC	P1/P2	unknown	30	Fudan University	May 2021
NCT05869097		Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer	—	completed	90	Hunan Cancer Hospital	Nov 2020
NCT02312245		Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	P2	completed	13	Mayo Clinic	Jul 2015
NCT03596281	PEMBOV	Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer	P1	completed	47	Gustave Roussy, Cancer Campus, Grand Paris	Dec 2018
NCT05886257		Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T	P2	withdrawn	0	Shi Ming	Dec 2022
NCT05359874	DoT-FMI	Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW	P2	withdrawn	0	Technical University of Munich	Jun 2021
NCT04345146		Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC	P2	completed	100	Sun Yat-sen University	Jan 2020
NCT06031376		Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC	—	completed	106	Hunan Cancer Hospital	Jul 2019
NCT04674254	PROPER	Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy	P4	completed	43	Cairo University	Mar 2021
NCT04862949		Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC	—	completed	131	CHA University	May 2021
NCT04510584		Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer	P2	withdrawn	0	University Health Network, Toronto	Jul 2021
NCT03126071		Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer	P2	unknown	100	Jiangsu Cancer Institute & Hospital	Feb 2017
NCT03250832	CITRINO	Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors	P1	completed	111	Tesaro, Inc.	Aug 2017
NCT04426825		A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer	P2	completed	23	Hoffmann-La Roche	Sep 2020
NCT04733963		Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer	P2	unknown	112	Second Affiliated Hospital, School of Medicine, Zhejiang University	Mar 2021
NCT03367871		Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer	P2	terminated	17	University of Miami	Sep 2018
NCT05440578		First-line Olaparib Combined With Bevacizumab Maintenance Therapy	—	unknown	50	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Jun 2022
NCT04952571	GBM	Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)	P2	terminated	3	Beijing Sanbo Brain Hospital	Jun 2021
NCT05009017		Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients	—	unknown	272	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Jan 2021
NCT04592029		TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC	P1	unknown	36	Second Affiliated Hospital of Guangzhou Medical University	Sep 2020
NCT04425187		Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC	P2	unknown	120	Fudan University	Jun 2020
NCT03271255	ABST-C	Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)	P2	unknown	80	Shenzhen People's Hospital	May 2018
NCT05514925		Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy	P4	unknown	60	Khairallah Moncef	Nov 2017
NCT02759588		Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer	P1/P2	completed	46	Genelux Corporation	May 2016
NCT01745757	COMET	Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer	—	completed	510	UNICANCER	Jun 2012
NCT05035381		PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer	P2	unknown	10	Tianjin Medical University Cancer Institute and Hospital	Jan 2019
NCT05540951		VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer	P3	unknown	78	Fudan University	Jun 2018
NCT03093155		Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab	P2	completed	78	Yale University	Apr 2017
NCT03414983	CheckMate 9X8	An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread	P2/P3	completed	196	Bristol-Myers Squibb	Feb 2018
NCT01730950		Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma	P2	completed	182	Radiation Therapy Oncology Group	Dec 2012
NCT03904563		Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma	P2	completed	27	Sun Yat-sen University	Jan 2019
NCT02490878	BEST	Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases	P2	terminated	19	Alliance for Clinical Trials in Oncology	Apr 2016
NCT05431582		Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors	P1	withdrawn	0	M.D. Anderson Cancer Center	Dec 2022
NCT05290948		Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions	P2	unknown	57	Shahid Beheshti University of Medical Sciences	Mar 2022
NCT04517526		Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study	P2	unknown	60	Shanghai Cancer Hospital, China	Nov 2020
NCT03220932	HIPOVA-01	Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer	P3	unknown	132	Hospices Civils de Lyon	Nov 2019
NCT03708536		Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma	P3	withdrawn	0	Fujian Cancer Hospital	Nov 2018
NCT03462251	RIBBIT	Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line	P3	completed	41	iOMEDICO AG	May 2018
NCT02829931		Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas	P1	completed	33	H. Lee Moffitt Cancer Center and Research Institute	Aug 2016
NCT03434379	IMbrave150	A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma	P3	completed	558	Hoffmann-La Roche	Mar 2018
NCT04466917		A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer	P3	withdrawn	0	Amgen	May 2021
NCT00773695	HER2	A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer	P2	completed	150	Hoffmann-La Roche	Nov 2008
NCT04991350	REBEL	Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema	P4	terminated	5	Cairo University	Nov 2021
NCT04525326		Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases	P3	unknown	584	Fudan University	Oct 2020
NCT04741165	HCC	Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)	P2	unknown	72	Taizhou Hanzhong biomedical co. LTD	Jan 2021
NCT03779191		Alectinib in Combination With Bevacizumab in ALK Positive NSCLC	P2	completed	41	Instituto Nacional de Cancerologia de Mexico	Apr 2020
NCT04212793	DEPARTURE	Detection of PitNET Tissue During TSS Using Bevacizumab-800CW	P1	completed	20	University Medical Center Groningen	Oct 2020
NCT05093608		SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma	P1	terminated	2	H. Lee Moffitt Cancer Center and Research Institute	Nov 2021
NCT03558724	ORCA	Fluorescence Endoscopy of Esophageal Carcinoma	P1	terminated	25	University Medical Center Groningen	Oct 2018
NCT01588431		Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer	P2	completed	3	The University of Texas Health Science Center at San Antonio	Dec 2011
NCT04556071	AVANIRA3	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	P2	unknown	32	Xiaoxiang Chen	Nov 2020
NCT04380103		A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer	P1/P2	unknown	106	Chinese Academy of Medical Sciences	Apr 2020
NCT02923739		Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	P2	terminated	9	M.D. Anderson Cancer Center	May 2017
NCT03555149		A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)	P1/P2	terminated	96	Hoffmann-La Roche	Sep 2018
NCT01097746		First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	P2	completed	33	M.D. Anderson Cancer Center	Apr 2010
NCT05033106		Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity	P3	unknown	36	Zagazig University	Sep 2020
NCT03611179		Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer	P2	unknown	40	Nada Hassan Salah	Sep 2018
NCT04097444	QUATTRO-II	CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC	P2	unknown	112	Chugai Pharmaceutical	Oct 2019
NCT03463265		Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma	P2	completed	62	Aadi Bioscience, Inc.	Aug 2018
NCT03038100	IMagyn050	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	P3	completed	1,301	Hoffmann-La Roche	Mar 2017
NCT01113476		Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies	P1	completed	176	M.D. Anderson Cancer Center	Apr 2010
NCT04861948		IBI188 Combination Therapy in Solid Tumors	P1	terminated	9	Innovent Biologics (Suzhou) Co. Ltd.	May 2021
NCT05080803		Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome	—	completed	608	European School of Advanced Studies in Ophthalmology	Jun 2021
NCT04813913	VASCATAQ	VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer	P4	completed	13	University Hospital, Rouen	May 2019
NCT04551950		Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)	P1	completed	25	EMD Serono Research & Development Institute, Inc.	Oct 2020
NCT01130519	HLRCC	A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer	P2	completed	83	National Cancer Institute (NCI)	May 2010
NCT03746041		A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes	P1	completed	20	University of Rochester	Feb 2019
NCT03554707		SGT-53 in Children With Recurrent or Progressive CNS Malignancies	Early P1	withdrawn	0	SynerGene Therapeutics, Inc.	Jun 2022
NCT04138992		A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer	P2/P3	unknown	150	Air Force Military Medical University, China	Aug 2020
NCT03836157	IMGN853	Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer	P2	withdrawn	0	University of Oklahoma	May 2019
NCT01609790		Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors	P2	completed	137	National Cancer Institute (NCI)	Jun 2012
NCT03843853		Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer	P2	withdrawn	0	The First Affiliated Hospital with Nanjing Medical University	May 2019
NCT05083689		Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema	P2/P3	unknown	62	Shahid Beheshti University of Medical Sciences	Oct 2021
NCT03990103	IP	S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites	P2	unknown	66	China Medical University, China	Nov 2017
NCT02521051	ALK	Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer	P1/P2	terminated	11	Massachusetts General Hospital	Sep 2015
NCT05751629	COHORT-A	Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer	P2	completed	41	Tesaro, Inc.	Nov 2018
NCT02659384		Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer	P2	completed	122	European Organisation for Research and Treatment of Cancer - EORTC	Dec 2016
NCT03272217		Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer	P2	terminated	16	Arjun Balar, MD	Sep 2017
NCT02803203		Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers	P1/P2	completed	49	Memorial Sloan Kettering Cancer Center	Jun 2016
NCT03905317		Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene	P2	unknown	66	Sun Yat-sen University	Mar 2019
NCT03563144		QUILT-3.088: NANT Pancreatic Cancer Vaccine	P2	withdrawn	0	ImmunityBio, Inc.	Aug 2018
NCT00946712	S0819	S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer	P3	terminated	1,333	SWOG Cancer Research Network	Jul 2009
NCT04527068	BEVTOR	QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer	P2	unknown	50	Second Affiliated Hospital, School of Medicine, Zhejiang University	Sep 2020
NCT04003792	CRLM	Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.	P2	unknown	49	Rabin Medical Center	Jan 2020
NCT03792074		To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer	P3	unknown	560	Sinocelltech Ltd.	Feb 2019
NCT04247984		A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer	P2	completed	264	Chinese Academy of Medical Sciences	May 2018
NCT01788280		Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab	P2	withdrawn	0	University of Utah	Jan 2018
NCT01891747		A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma	P1	completed	14	Vanderbilt-Ingram Cancer Center	Jul 2013
NCT05005455		Study of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects	P1	completed	100	Innovent Biologics (Suzhou) Co. Ltd.	Jul 2021
NCT02810457	AVANA	Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer	P3	completed	731	Centus Biotherapeutics Limited	Sep 2016
NCT03082209		A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies	P1	completed	153	AbbVie	Mar 2017
NCT02394795	PARADIGM	Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC	P3	completed	823	Takeda	May 2015
NCT02364713		MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer	P2	terminated	17	Mayo Clinic	Mar 2015
NCT03925285	SNIPER	Image Guided Surgery in Sinonasal Inverted Papilloma	P1	unknown	6	University Medical Center Groningen	May 2019
NCT03631836	MARELLE01	Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma	P1	unknown	34	Assistance Publique Hopitaux De Marseille	Jan 2019
NCT03732235	EMBOBEVA	TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer	—	unknown	50	Giammaria Fiorentini	Oct 2018
NCT02919371	CASA	Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)	P1/P2	unknown	77	King Faisal Specialist Hospital & Research Center	Dec 2014
NCT01462890	BOOST	Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer	P3	completed	927	AGO Study Group	Nov 2011
NCT03169777	CRC	QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC	P1/P2	withdrawn	0	ImmunityBio, Inc.	Aug 2018
NCT03169738	NSCLC	QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors	P1/P2	withdrawn	0	ImmunityBio, Inc.	Feb 2018
NCT03167177		QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy	P1/P2	withdrawn	0	ImmunityBio, Inc.	Dec 2017
NCT03167164	MCC	QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy	P1/P2	withdrawn	0	ImmunityBio, Inc.	Dec 2017
NCT03197571		QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy	P1/P2	withdrawn	0	ImmunityBio, Inc.	Dec 2017
NCT03169764	HNSCC	QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy	P1/P2	withdrawn	0	ImmunityBio, Inc.	Dec 2017
NCT03197584		QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy	P1/P2	withdrawn	0	ImmunityBio, Inc.	Dec 2017
NCT03175666	TNBC	QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy	P1/P2	withdrawn	0	ImmunityBio, Inc.	Dec 2017
NCT03169790	NHL	QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL	P1/P2	withdrawn	0	ImmunityBio, Inc.	Dec 2017
NCT03642132	JAVELIN OVARIAN PARP 100	Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)	P3	terminated	79	Pfizer	Jul 2018
NCT03321513	DRCR AC	DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME	P3	completed	270	Jaeb Center for Health Research	Dec 2017
NCT03713944		Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer	P2	terminated	30	Nasser Hanna	Nov 2018
NCT03925233		Breast Cancer Treatment Based on Organ-like Culture	—	unknown	300	Xijing Hospital	Jan 2019
NCT02354131	AVANOVA	Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer	P1/P2	completed	108	Nordic Society of Gynaecological Oncology - Clinical Trials Unit	Feb 2015
NCT02420821	IMmotion151	A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)	P3	completed	915	Hoffmann-La Roche	May 2015
NCT03620292	COUGAR	Fluorescence Image Guided Surgery in Cholangiocarcinoma	P1/P2	unknown	12	University Medical Center Groningen	Apr 2019
NCT02695641		Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients	Early P1	withdrawn	0	Mayo Clinic	Aug 2019
NCT03164655	SULTAN	Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network	P2	completed	20	UNICANCER	Jul 2018
NCT04416035	NSCLC	A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC	P3	unknown	608	Zhejiang Teruisi Pharmaceutical Inc.	Aug 2020
NCT01004874	XRT	Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma	P2	completed	80	Duke University	Dec 2009
NCT04511715		Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy	P2/P3	unknown	100	Shahid Beheshti University of Medical Sciences	Sep 2020
NCT01811498		Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM	P1/P2	completed	31	Northwell Health	Feb 2013
NCT04753216		Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	P2	completed	3	Northwestern University	Mar 2021
NCT02039674	MK-3475	A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)	P1/P2	completed	267	Merck Sharp & Dohme LLC	Feb 2014
NCT03877601	ESCEND	Detection of Early Esophageal Cancer by NIR-FME.	P2	unknown	60	University Medical Center Groningen	Jul 2019
NCT04601688	BRVO	Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.	N/A	unknown	100	He Eye Hospital	Oct 2020
NCT04601701	CRVO	Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.	N/A	unknown	100	He Eye Hospital	Oct 2020
NCT04954014	BEVACOR	Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients	P2	terminated	21	Maimónides Biomedical Research Institute of Córdoba	Sep 2020
NCT04393220		Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma	P2	completed	60	Fuda Cancer Hospital, Guangzhou	May 2020
NCT03149003		A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy	P3	completed	221	Sumitomo Pharma America, Inc.	Dec 2017
NCT03050814		Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004	P2	terminated	30	National Cancer Institute (NCI)	Apr 2017
NCT01107626		Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer	P3	completed	1,516	ECOG-ACRIN Cancer Research Group	Oct 2010
NCT02313272	HFSRT	Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas	P1	completed	32	H. Lee Moffitt Cancer Center and Research Institute	Jul 2015
NCT04788381		The Effects of Preoperative Bevacizumab on Perioperative Complications	—	unknown	100	Second Affiliated Hospital, School of Medicine, Zhejiang University	Apr 2021
NCT00618657		Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting	P2	completed	127	University of California, Irvine	Feb 2008
NCT03196986		mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer	P3	completed	517	Beijing Mabworks Biotech Co., Ltd.	Aug 2017
NCT05113511		PK and Safety of SCT510	P1	completed	84	First Affiliated Hospital of Zhejiang University	May 2018
NCT01454102	BMS-936558	Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)	P1	completed	472	Bristol-Myers Squibb	Dec 2011
NCT04126044	CN	A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS	P1	withdrawn	0	Pfizer	Jan 2021
NCT02010606		Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma	P1	completed	39	Cedars-Sinai Medical Center	Jan 2014
NCT03834753	AMD	A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)	P3	completed	228	Outlook Therapeutics, Inc.	Jun 2019
NCT02336165	MEDI4736	Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma	P2	completed	159	Ludwig Institute for Cancer Research	Feb 2015
NCT04148898	OWONBNSCLCLM	Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis	P2	unknown	80	Second Affiliated Hospital of Nanchang University	Nov 2019
NCT02853318		Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	P2	completed	40	Roswell Park Cancer Institute	Sep 2016
NCT04553510		Treatment of Bevacizumab Followed by Steroid in RN	P2	unknown	86	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Jan 2016
NCT01217437		Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors	P2	completed	108	National Cancer Institute (NCI)	Nov 2010
NCT00942331		Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer	P3	completed	506	National Cancer Institute (NCI)	Jul 2009
NCT03063762	RCC	Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)	P1	completed	69	Hoffmann-La Roche	Mar 2017
NCT02663271		TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma	P2	terminated	10	University of Florida	Dec 2016
NCT04425681	OWBLM	Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer	P2	unknown	20	Second Affiliated Hospital of Nanchang University	Oct 2017
NCT02715531		A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors	P1	completed	243	Hoffmann-La Roche	Apr 2016
NCT04299880		Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols	P1	completed	7	Sumitomo Pharma America, Inc.	Feb 2020
NCT01015222		Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies	P1	completed	122	M.D. Anderson Cancer Center	Nov 2009
NCT01180959	HCC	Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy	P2	completed	45	M.D. Anderson Cancer Center	Apr 2011
NCT01295944		Carboplatin and Bevacizumab for Recurrent Ependymoma	P2	completed	35	National Cancer Institute (NCI)	Apr 2011
NCT02753127	CanStem303C	A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer	P3	completed	1,253	Sumitomo Pharma America, Inc.	Jun 2016
NCT02390531	ROP1	Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity	P1	completed	120	Jaeb Center for Health Research	Apr 2015
NCT04325698	CN	A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC	P3	terminated	8	Pfizer	Jun 2020
NCT02072720		Angiogenic Factor Expression During Fractionated Irradiation	Early P1	unknown	40	Amsterdam UMC, location VUmc	Feb 2014
NCT01770301	ALIENOR	Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)	P2	completed	60	ARCAGY/ GINECO GROUP	Feb 2013
NCT03032484		TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma	P2	completed	25	The University of Texas Health Science Center at San Antonio	May 2017
NCT01969708	SCORE2	Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)	P3	completed	362	The Emmes Company, LLC	Sep 2014
NCT02291289	MODUL	A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)	P2	completed	1,044	Hoffmann-La Roche	Apr 2015
NCT01468831		Minocycline to Treat Branch Retinal Vein Occlusion	P1/P2	completed	9	National Eye Institute (NEI)	Mar 2012
NCT02606305		Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer	P1/P2	completed	264	ImmunoGen, Inc.	Mar 2016
NCT03690739		Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer	P3	terminated	9	AGO Research GmbH	Aug 2019
NCT02339116	TRIBE2	Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC	P3	unknown	654	Gruppo Oncologico del Nord-Ovest	Feb 2015
NCT03577743		Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer	P2	completed	54	Assiut University	Jul 2018
NCT04516278		A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders	P3	completed	195	Outlook Therapeutics, Inc.	Oct 2020
NCT04067856		Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery	N/A	withdrawn	0	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	Jan 2020
NCT02022917		Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer	P2	completed	22	Chang Gung Memorial Hospital	Mar 2014
NCT01837251		Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer	P3	completed	682	AGO Research GmbH	May 2013
NCT01442935		Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases	P2	completed	256	UNICANCER	Feb 2011
NCT05712642		A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity	P3	completed	19	Cairo University	Feb 2020
NCT02921269		Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer	P2	completed	11	National Cancer Institute (NCI)	Mar 2017
NCT01197170		Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance	P1	completed	277	M.D. Anderson Cancer Center	Sep 2010
NCT03387111	SCC	QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed	P1/P2	terminated	4	ImmunityBio, Inc.	Jan 2018
NCT05314673		Preoperative Bevacizumab Injection in Primary Pterygium in Tunisian Patients	P4	completed	60	University Hospital Fattouma Bourguiba	Jan 2019
NCT02226289	BATTLE	Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment	P2	unknown	46	Sixth Affiliated Hospital, Sun Yat-sen University	Sep 2020
NCT01802645	CELIM2	Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases	P2	unknown	91	Technische Universität Dresden	Mar 2013
NCT03533127		A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer	P3	unknown	648	Luye Pharma Group Ltd.	Nov 2017
NCT01399918	RCC	Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)	P2	completed	57	Memorial Sloan Kettering Cancer Center	Jul 2011
NCT03607643		A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies	P1/P2	unknown	160	Leaf Vertical Inc.	Jan 2019
NCT03878524	SMMART	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	P1	terminated	2	OHSU Knight Cancer Institute	Apr 2020
NCT02366143	IMpower150	A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	P3	completed	1,202	Hoffmann-La Roche	Mar 2015
NCT01664182		Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer	P2	completed	41	National Cancer Institute (NCI)	Aug 2012
NCT04344782	CORIMMUNO-BEVA	Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort	P2	unknown	130	Assistance Publique - Hôpitaux de Paris	Apr 2020
NCT04175158		Clinical Trial in Chinese Healthy Volunteers of GB222	P1	unknown	84	Genor Biopharma Co., Ltd.	Apr 2017
NCT02982694		Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer	P2	terminated	46	Vall d'Hebron Institute of Oncology	Nov 2017
NCT00948675		Study of Participants With Advanced Non-Small Cell Lung Cancer	P3	completed	361	Eli Lilly and Company	Sep 2009
NCT02842580	HIGH-LIGHT	De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer	P2	terminated	21	Federation Francophone de Cancerologie Digestive	Sep 2016
NCT03711240	CBL	The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases	P2	unknown	40	National Cheng-Kung University Hospital	Jan 2019
NCT01966913	TAXIFIII	Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors	P1/P2	unknown	30	Assistance Publique - Hôpitaux de Paris	Apr 2012
NCT02337491		Pembrolizumab +/- Bevacizumab for Recurrent GBM	P2	completed	80	Dana-Farber Cancer Institute	Feb 2015
NCT02743221	TASCO1	A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy	P2	completed	154	Institut de Recherches Internationales Servier	Apr 2016
NCT02363751	BEVABEL	Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)	P2	completed	36	UNICANCER	Dec 2014
NCT01171170	NVALT12	Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer	P2	completed	223	Dutch Society of Physicians for Pulmonology and Tuberculosis	Jan 2011
NCT00622726	BEAT-ROP	Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity	P2	unknown	150	The University of Texas Health Science Center, Houston	Mar 2008
NCT02121990	IP	Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	P1	completed	17	Memorial Sloan Kettering Cancer Center	Apr 2014
NCT01532089		Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations	P2	completed	88	Academic and Community Cancer Research United	Mar 2012
NCT03844074	AMD	A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)	P3	completed	61	Outlook Therapeutics, Inc.	Oct 2018
NCT03394885	AdORN	Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer	P1/P2	completed	18	Duke University	Jun 2018
NCT02343549	BEV	A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)	P2	terminated	13	Wake Forest University Health Sciences	Jan 2015
NCT03912402	CAESURA	Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)	P2	unknown	49	Biocad	Dec 2018
NCT03616691		Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC	P2	unknown	46	Samsung Medical Center	Aug 2018
NCT02515734	DEEPER	A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab	P2	unknown	360	Japan Clinical Cancer Research Organization	Aug 2015
NCT02060305		Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis	P1	terminated	5	National Taiwan University Hospital	Feb 2014
NCT00952003		Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients	P2	completed	40	Arbeitsgemeinschaft medikamentoese Tumortherapie	Jul 2009
NCT00580333		Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer	P2	completed	51	Massachusetts General Hospital	Sep 2007
NCT04446793		Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer	—	no longer available	0	Cardiff Oncology	—
NCT01871571		Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer	P2	terminated	17	University of Southern California	Aug 2013
NCT00444535		Lapatinib and Bevacizumab for Metastatic Breast Cancer	P2	completed	52	Novartis Pharmaceuticals	Feb 2007
NCT03892434		Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO	P4	unknown	40	Yeungnam University College of Medicine	Mar 2019
NCT03511183		XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer	P2	unknown	66	Harbin Medical University	Mar 2018
NCT03095001		Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion	P2	unknown	70	Chinese PLA General Hospital	Jun 2017
NCT03227263	BABH	BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).	P3	completed	24	Hospices Civils de Lyon	Sep 2017
NCT04275414	BEST-CP	Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia	P2	completed	27	Qilu Hospital of Shandong University	Feb 2020
NCT02829008		Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients	P2	unknown	120	Chinese Academy of Medical Sciences	Apr 2016
NCT01290939		Bevacizumab and Lomustine for Recurrent GBM	P3	completed	592	European Organisation for Research and Treatment of Cancer - EORTC	Oct 2011
NCT00543504		Bevacizumab in Multiple Phase I Combinations	P1	completed	343	M.D. Anderson Cancer Center	Oct 2007
NCT02574078	CheckMate370	A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)	P1/P2	completed	341	Bristol-Myers Squibb	Nov 2015
NCT00989651		Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	P1	completed	431	National Cancer Institute (NCI)	Oct 2009
NCT02848443		Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer	P1	completed	78	Institut de Recherches Internationales Servier	May 2016
NCT03647956		Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors	P2	unknown	40	The University of Hong Kong	Oct 2018
NCT01818973		Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer	P2	unknown	45	Sun Yat-sen University	Mar 2013
NCT02759614		Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations	P3	completed	311	Guangdong Association of Clinical Trials	Apr 2016
NCT05427305		TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer	P3	completed	549	BioDlink Biopharm Co., Ltd.	Oct 2017
NCT04238663		Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers	P1	completed	115	mAbxience Research S.L.	Sep 2019
NCT04135898		A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects	P1	completed	88	Shanghai Institute Of Biological Products	Oct 2019
NCT03037736	OPPS	Outpatient Performed Pterygium Surgery Study	P4	withdrawn	0	University of California, San Francisco	Mar 2020
NCT02591667	CARCINOSIS	Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer	P2	unknown	30	Medical University of Vienna	Mar 2016
NCT03296163	STELLA	A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	P3	completed	627	mAbxience Research S.L.	Feb 2018
NCT01633970		A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors	P1	completed	240	Genentech, Inc.	Jul 2012
NCT04619303	OASIS	Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO	P4	completed	59	Lions Eye Institute, Perth, Western Australia	Feb 2017
NCT01327612	AMG 479	Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)	P2	completed	12	Amgen	Mar 2011
NCT01767792		Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas	P2	completed	22	University of Alabama at Birmingham	May 2013
NCT02244632		Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer	P1/P2	completed	105	Isofol Medical AB	Sep 2014
NCT01390948	TMZ	A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma	P2	completed	124	Hoffmann-La Roche	Oct 2011
NCT02389959		Intranasal Bevacizumab for HHT-Related Epistaxis	P4	completed	40	Stanford University	Aug 2014
NCT03573986		Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment	P1	terminated	2	Abramson Cancer Center at Penn Medicine	Apr 2018
NCT03913806	FLASH	FLuoresence Image Guided Surgery With A VEGF-targeted Tracer in Soft-tissue Sarcomas in Humans Approach With Bevacizumab-IRDye 800CW	P1/P2	completed	16	University Medical Center Groningen	May 2018
NCT02350530	FORBES	FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type	P2	completed	138	Sun Yat-sen University	Jan 2015
NCT02655536	BRILLIANT	Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial	P2	unknown	109	National Taiwan University Hospital	Aug 2017
NCT01525082		Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors	P2	completed	20	Shaheen Shagufta	Dec 2012
NCT01718873	OBELICS	Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer	P3	completed	230	National Cancer Institute, Naples	May 2012
NCT00885326	N2007-02	N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma	P1	completed	29	New Approaches to Neuroblastoma Therapy Consortium	Dec 2009
NCT04238650		A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers	P1	completed	49	mAbxience Research S.L.	Aug 2019
NCT00130728		A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer	P3	completed	636	Genentech, Inc.	Jun 2005
NCT02414165	Toca5	The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma	P2/P3	terminated	403	Tocagen Inc.	Nov 2015
NCT03368859		A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab	P2	terminated	70	AbbVie	Mar 2018
NCT02988843		Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors	P2	terminated	1	Masonic Cancer Center, University of Minnesota	Mar 2017
NCT03576651		A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers	P1	completed	154	JHL Biotech, Inc.	Mar 2018
NCT00544700		Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer	P3	terminated	265	Swiss Cancer Institute	Nov 2007
NCT02348008		Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:	P1/P2	completed	61	Arkadiusz Z. Dudek, MD	Mar 2015
NCT02342379		TH-302 in Combination With Bevacizumab for Glioblastoma	P2	completed	35	The University of Texas Health Science Center at San Antonio	May 2015
NCT02314377		Bevacizumab Therapy for Brain Arteriovenous Malformation	P1	completed	2	University of California, San Francisco	Jun 2016
NCT02024607		A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer	P1/P2	completed	495	Sumitomo Pharma America, Inc.	Jan 2014
NCT02174172		A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors	P1	completed	158	Hoffmann-La Roche	Aug 2014
NCT04633564		MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC	P3	completed	671	Mylan Pharmaceuticals Inc	Jan 2017
NCT01740258	BBP	Bevacizumab Beyond Progression (BBP)	P2	completed	68	Duke University	Jan 2013
NCT02954172		Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC	P3	completed	450	Innovent Biologics (Suzhou) Co. Ltd.	Nov 2016
NCT02192970	BEARRD	Bevacizumab Against Recurrent Retinal Detachment	P2	completed	101	University of Wisconsin, Madison	Jan 2015
NCT01516216		Study of Vitamin D in Untreated Metastatic Colorectal Cancer	P2	completed	139	Dana-Farber Cancer Institute	Apr 2012
NCT03329248		QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy	P1/P2	terminated	6	ImmunityBio, Inc.	Nov 2017
NCT03136406		QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy	P1/P2	terminated	3	ImmunityBio, Inc.	Aug 2017
NCT02942043		Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer	P2	unknown	87	Peking University Cancer Hospital & Institute	Oct 2016
NCT01501760	BECONNEC	Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea	P3	completed	38	University Hospital, Limoges	May 2012
NCT02665416	PK	Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors	P1	completed	94	Hoffmann-La Roche	Jan 2016
NCT02158520		Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery	P2	completed	24	Academic and Community Cancer Research United	Oct 2013
NCT02743078		Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma	P2	terminated	3	RTOG Foundation, Inc.	May 2017
NCT03821168		The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema	P2/P3	unknown	58	Shahid Beheshti University of Medical Sciences	Mar 2019
NCT03240549		Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease	P2	unknown	159	Beijing Hospital	Aug 2017
NCT00820547	Beverly1	Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients	P2	completed	100	UNICANCER	Jan 2009
NCT02292758		Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery	P2	completed	36	Academic and Community Cancer Research United	Dec 2014
NCT01588184		An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study	P4	completed	95	Hoffmann-La Roche	Jul 2012
NCT03919448		A Phase I Study Comparing Pharmacokinetics and Safety of Bevacizumab	P1	completed	112	Laboratorios Richmond S.A.C.I.F.	Apr 2019
NCT00436332	S0635	S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma	P2	completed	84	SWOG Cancer Research Network	Jul 2007
NCT03586869		QUILT-3.080: NANT Pancreatic Cancer Vaccine	P1/P2	terminated	3	ImmunityBio, Inc.	Jul 2018
NCT02857920		Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors	P1/P2	completed	45	Fuda Cancer Hospital, Guangzhou	Aug 2016
NCT02802098		Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer	Early P1	completed	25	Centro Nacional de Investigaciones Oncologicas CARLOS III	May 2016
NCT02399592	Toco-Ovar	Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer	P2	completed	23	Vejle Hospital	Mar 2015
NCT03382886	NUANCE	Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma	P1	terminated	1	University of Utah	Apr 2018
NCT01894061		NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma	P2	completed	25	Case Comprehensive Cancer Center	Sep 2013
NCT00892177		Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme	P2	completed	144	Alliance for Clinical Trials in Oncology	Oct 2009
NCT02754362	TAA	A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma	P2	withdrawn	0	NYU Langone Health	Nov 2016
NCT02497157	BeTRI	Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer	P2	completed	45	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	May 2015
NCT01989780	BOOSTER	Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer	P2	completed	160	Japan Breast Cancer Research Group	Jan 2014
NCT02876224		Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors	P1	completed	51	Hoffmann-La Roche	Sep 2016
NCT02052648		Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors	P1/P2	completed	160	NewLink Genetics Corporation	Mar 2014
NCT02393898		BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older	—	completed	76	Hoffmann-La Roche	Apr 2015
NCT02819479	LIBERTI	Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)	P2	completed	10	Norton Healthcare	Nov 2016
NCT02767219	RAFTS	The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery	P3	completed	6	Moorfields Eye Hospital NHS Foundation Trust	May 2016
NCT01858649	BEV-ONCO2012	Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.	P2	completed	60	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	May 2013
NCT00828009		BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery	P2	completed	70	ECOG-ACRIN Cancer Research Group	Jan 2011
NCT01847677	NOVA	Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin	P2	terminated	71	Grupo Español de Investigación en Cáncer de Ovario	May 2013
NCT01775644	KORALLE	An Observational Study of Avastin in Participants With Metastatic Colorectal Cancer (KORALLE)	—	completed	3,003	Hoffmann-La Roche	Dec 2012
NCT01996826		A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival	P1/P2	completed	75	Reza Dana, MD	Apr 2014
NCT02076152		FMISO PET Study of Glioblastoma	N/A	completed	11	Massachusetts General Hospital	Feb 2014
NCT00643565		A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.	P2	completed	154	Hoffmann-La Roche	Jul 2008
NCT01803282		Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors	P1	completed	236	Gilead Sciences	Mar 2013
NCT01627249	Protocol T	Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema	P3	completed	660	Jaeb Center for Health Research	Aug 2012
NCT01935492	Stop&Go	8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer	P3	completed	420	Borstkanker Onderzoek Groep	Nov 2010
NCT06559488		IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes	N/A	completed	18	Universitas Padjadjaran	Apr 2018
NCT02866903	IPOXA	Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis	P1/P2	unknown	47	Hospices Civils de Lyon	May 2017
NCT02833701		Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma	P1	terminated	9	University of Nebraska	Mar 2016
NCT02054052		Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer	P2	completed	22	Haihong Yang, MD, Pricipal investigator	Jan 2014
NCT00828672	AXEBEAM	Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer	P2	completed	84	Universitaire Ziekenhuizen KU Leuven	Jun 2009
NCT00761644		Doxil, Bevacizumab and Temsirolimus Trial	P1	completed	200	M.D. Anderson Cancer Center	Aug 2008
NCT03897192		Long-term Outcome of Zonal Outer Retinopathy in Punctate Inner Choroidopathy or Multifocal Choroiditis	—	completed	14	Changhua Christian Hospital	Oct 2018
NCT02200354		The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab	P2	terminated	20	Kobe City General Hospital	Jul 2014
NCT01309633	NPC	Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)	P2	completed	80	National University Hospital, Singapore	Sep 2011
NCT03609307		Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial	P2/P3	unknown	40	Shahid Beheshti University of Medical Sciences	Sep 2018
NCT01650428	BACCHUS	Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery	P2	completed	20	University College, London	Apr 2013
NCT00321685		Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer	P2	completed	57	National Cancer Institute (NCI)	Jul 2006
NCT00303628		Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer	P3	terminated	355	ECOG-ACRIN Cancer Research Group	May 2006
NCT02975219	Endo-light	Feasibility Study of Using Molecular Fluorescence Guided Surgery in Endometriosis	P1	unknown	10	University Medical Center Groningen	May 2017
NCT02162537	METAL2	Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases	P3	terminated	95	Centre Hospitalier Intercommunal Creteil	Dec 2013
NCT01532804	BEVATOMOX	2nd-line Treatment of Metastatic Colorectal Cancer	P2	terminated	83	Institut du Cancer de Montpellier - Val d'Aurelle	Jul 2011
NCT01312376		Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer	P1	terminated	18	Abramson Cancer Center at Penn Medicine	Mar 2011
NCT00925652	ABCDE	Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer	P2	terminated	55	Dana-Farber Cancer Institute	Sep 2010
NCT01303497	ANGIO-TAX+	Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas	P2	completed	70	Centre Oscar Lambret	Sep 2010
NCT03387098		QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy	P1/P2	terminated	4	ImmunityBio, Inc.	Dec 2017
NCT02467907		Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer	P2	completed	152	Hoffmann-La Roche	Jul 2015
NCT01984242	IMmotion150	A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma	P2	completed	305	Hoffmann-La Roche	Jan 2014
NCT03380689	SIRB2	Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer	P1	withdrawn	0	Fujian Cancer Hospital	Jan 2018
NCT02590094		Preoperative Bevacizumab and Ziv-Aflibercept Administration in PDR Subjects Undergoing PPV	N/A	completed	568	Panhandle Eye Group, LLP	Oct 2015
NCT02672995		Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial	P1	unknown	36	National Taiwan University Hospital	Jan 2018
NCT02930954		Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance	P2	unknown	180	Caicun Zhou	Nov 2016
NCT02330783		Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients	P2	unknown	106	Peking University Cancer Hospital & Institute	Dec 2014
NCT01125046		Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas	P2	completed	50	Northwestern University	Jun 2010
NCT01349660		Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme	P1/P2	completed	88	SCRI Development Innovations, LLC	Dec 2011
NCT03793400		Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor	—	completed	22	Changhua Christian Hospital	Mar 2018
NCT03246152	IMPACT	Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA	P4	completed	31	Cairo University	Oct 2017
NCT01260506		Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme	P1/P2	completed	75	Vascular Biogenics Ltd. operating as VBL Therapeutics	Dec 2010
NCT02613208	Argo	A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer	—	completed	111	Hoffmann-La Roche	Dec 2015
NCT02768389		Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma	Early P1	completed	18	Case Comprehensive Cancer Center	Sep 2016
NCT02806817		ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism	Early P1	completed	40	Centro Nacional de Investigaciones Oncologicas CARLOS III	Jul 2016
NCT02664961	GTN	Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)	P2	terminated	3	Tracon Pharmaceuticals Inc.	Mar 2016
NCT02413853	PRIMIER	Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer	P2	withdrawn	0	University of Southern California	Nov 2015
NCT01640405	VISNU-1	Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells	P3	completed	350	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	Jul 2012
NCT01640444	VISNU-2	Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)	P2	completed	240	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	Jul 2012
NCT01274624		Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer	P1	completed	36	Oncolytics Biotech	Dec 2010
NCT03161041		Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study	P2	withdrawn	0	Hospices Civils de Lyon	Sep 2018
NCT01114555		Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma	P2	completed	34	Memorial Sloan Kettering Cancer Center	Apr 2010
NCT03391219		Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients	P2/P3	unknown	36	Shahid Beheshti University of Medical Sciences	Jan 2018
NCT01976923		Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy	P3	completed	224	J. Fernando Arevalo, MD FACS	Nov 2013
NCT01884740		Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22	P1/P2	terminated	13	Weill Medical College of Cornell University	Jun 2013
NCT02015351		Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study	N/A	completed	9	University of Sao Paulo	Sep 2012
NCT01562028	BELIEF	BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)	P2	completed	109	ETOP IBCSG Partners Foundation	Jun 2012
NCT01492673	CTB	Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma	P2	completed	9	Memorial Sloan Kettering Cancer Center	Dec 2011
NCT02620800	FABLOx	Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer	P1	completed	12	Celgene	Jan 2016
NCT03882424		A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®	P1	completed	114	Zhejiang Teruisi Pharmaceutical Inc.	Jun 2018
NCT02754882		A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer	P3	completed	763	Samsung Bioepis Co., Ltd.	Jul 2016
NCT03353324	bevacizumab	Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein Occlusion	P2/P3	unknown	74	Shahid Beheshti University of Medical Sciences	Nov 2017
NCT02511405	GLOBE	A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)	P3	completed	252	Vascular Biogenics Ltd. operating as VBL Therapeutics	Aug 2015
NCT01213238		Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab	P1	completed	116	M.D. Anderson Cancer Center	Sep 2010
NCT01445509		Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors	P1	completed	50	National Cancer Institute (NCI)	Dec 2008
NCT01622543		Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer	P2	completed	109	Canadian Cancer Trials Group	Oct 2012
NCT01478321		Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas	P2	terminated	54	Northwestern University	Dec 2011
NCT01898130		Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy	P2	completed	27	Northwestern University	Nov 2013
NCT02530801	REPEAT	Strategies for Management of Recurrent Pterygium	P4	unknown	25	University of Nottingham	Jan 2017
NCT02594423		Strategies for Management of Corneal Neovascularisation	P4	unknown	40	University of Nottingham	Dec 2015
NCT02574663		TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors	P1	completed	66	TG Therapeutics, Inc.	Sep 2015
NCT03744806		Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD	—	completed	48	Medical University of Lublin	Jan 2015
NCT03148132		VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP	P4	completed	16	Universidad Autonoma de San Luis Potosí	May 2017
NCT00184015	RCC	Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)	P1/P2	unknown	50	University of Southern California	Aug 2005
NCT01321957	CHARTA	Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer	P2	completed	250	Martin-Luther-Universität Halle-Wittenberg	May 2011
NCT02946359		A+C in Metastatic Lung Adenocarcinoma Cancer	P2	unknown	60	Chinese PLA General Hospital	Jul 2016
NCT01232777	BLOCK-ROP	Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)	P2	withdrawn	0	Vision Research Foundation	Jun 2012
NCT01471470		Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer	P2	completed	31	Asan Medical Center	Jul 2010
NCT03288987		Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer	P3	completed	126	AryoGen Pharmed Co.	Oct 2016
NCT01625936		CRLX101 Plus Bevacizumab in Advanced RCC	P1	completed	22	Abramson Cancer Center at Penn Medicine	Jun 2012
NCT00720356		Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma	P2	completed	115	Northwestern University	Jul 2009
NCT02195336	BevMar	dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.	N/A	unknown	20	Karl Kölbeck	Aug 2014
NCT01996306	AXEPT	A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC	P3	completed	650	Epidemiological and Clinical Research Information Network	Dec 2013
NCT01705002	PROMITIL	Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.	P1	completed	88	Lipomedix Pharmaceuticals Inc.	Oct 2012
NCT01632722		Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets	P2	completed	79	Yonsei University	Jun 2012
NCT02488330		An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study	P3	completed	12	Hoffmann-La Roche	Aug 2015
NCT00790010		Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma	P1	completed	46	Dana-Farber Cancer Institute	Feb 2009
NCT02835833		Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors	P1	completed	21	University of Alabama at Birmingham	Jun 2016
NCT02698280		Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma	P2	completed	23	Huashan Hospital	Jul 2015
NCT02416999		Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas	N/A	unknown	30	Hebei Yanda Hospital	May 2015
NCT01303679		1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer	P3	terminated	117	ARCAGY/ GINECO GROUP	Jun 2010
NCT03668054		Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)	P3	completed	22	Laboratorio Elea Phoenix S.A.	Feb 2017
NCT01580969	RAMBO	Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma	P1/P2	completed	22	University of Utah	Jul 2012
NCT02648711	NLG207	Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors	P1	terminated	41	NewLink Genetics Corporation	Oct 2015
NCT02743975	PENGUIN	Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma	P1/P2	terminated	10	University Medical Center Groningen	Dec 2016
NCT02120287		Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme	P2	completed	16	Ajay Niranjan	May 2014
NCT01918852	SALTO	S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.	P3	completed	161	Dutch Colorectal Cancer Group	Dec 2013
NCT00408408		Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery	P3	unknown	1,206	NSABP Foundation Inc	Nov 2006
NCT01735071		Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer	P2	completed	71	Mario Negri Institute for Pharmacological Research	Jul 2013
NCT03085992	TRUST	Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer	P2	completed	49	Azienda Ospedaliero, Universitaria Pisana	Mar 2012
NCT01208103		Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma	P2	completed	30	M.D. Anderson Cancer Center	May 2011
NCT02208128	MORE	Molecular Determinants for Therapy Response on Renal Cell Carcinoma	N/A	unknown	4	Heidelberg University	May 2014
NCT02842294	COBEQOL	Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer	—	unknown	320	Centre Hospitalier Universitaire de Besancon	May 2013
NCT01131195		Metronomic Therapy in Metastatic Breast Cancer.	P3	completed	139	Swiss Cancer Institute	Jul 2010
NCT00887536		A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer	P3	completed	1,613	NSABP Foundation Inc	May 2009
NCT02314182	GRECCAR8	GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis	P3	completed	5	Hospices Civils de Lyon	Nov 2014
NCT03367182	REBECA	Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer	—	completed	50	Yonsei University	Sep 2017
NCT02093000		A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma	—	completed	201	Hoffmann-La Roche	Nov 2014
NCT02157103		A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma	P2	completed	3	Emory University	Jan 2014
NCT00952029		Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer	P2/P3	completed	492	Federation Francophone de Cancerologie Digestive	Mar 2010
NCT00265850		Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	P3	completed	2,334	Alliance for Clinical Trials in Oncology	Nov 2005
NCT03176264		PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer	P1	terminated	1	Novartis Pharmaceuticals	Sep 2017
NCT02078648		Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme	P1/P2	completed	74	Stemline Therapeutics, Inc.	May 2014
NCT00089609		Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer	P2	completed	73	National Cancer Institute (NCI)	Apr 2005
NCT01212822		Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer	P2	completed	20	Fox Chase Cancer Center	Apr 2011
NCT01229943		Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery	P2	completed	150	National Cancer Institute (NCI)	Oct 2010
NCT02623621	CIRCUS	Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer	—	completed	103	Azienda Ospedaliero, Universitaria Pisana	Nov 2015
NCT02959749		Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer	P2/P3	completed	147	Qingdao Central Hospital	Aug 2015
NCT02462304	END-DME	To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema	P4	unknown	60	The University of Hong Kong	Jun 2015
NCT02364999		A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC	P3	completed	719	Pfizer	Apr 2015
NCT02396511		TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma	P2	completed	2	Tracon Pharmaceuticals Inc.	Jan 2015
NCT02175446	GIM11-BERGI	Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients	P2	unknown	61	Consorzio Oncotech	Sep 2014
NCT02023710		Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma	P2	unknown	182	Peking University Cancer Hospital & Institute	Dec 2013
NCT01661283	SARC016	SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors	P2	completed	25	Sarcoma Alliance for Research through Collaboration	Sep 2012
NCT01770171	MITOBEVAEND2	Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer	P2	unknown	108	Catholic University of the Sacred Heart	Apr 2012
NCT01442649		Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab	P2	completed	133	UNICANCER	Dec 2010
NCT00890786		A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas	Early P1	completed	27	Children's Hospital Medical Center, Cincinnati	May 2009
NCT00780494		Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma	P2	completed	35	Stanford University	Feb 2009
NCT00450203	ST03	Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer	P2/P3	unknown	1,103	Professor David Cunningham	Oct 2007
NCT02985619	BEVATAAC	Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema	P2/P3	completed	100	University of Sao Paulo	Jul 2016
NCT01198158		Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy	P3	terminated	77	National Cancer Institute (NCI)	Sep 2010
NCT01142778	AVATAXHER	A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer	P2	completed	152	Hoffmann-La Roche	May 2010
NCT02831842		A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status	—	completed	4,278	Hoffmann-La Roche	Jun 2016
NCT02654639	ALEXANDRIA	Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer	P2	terminated	4	Georgetown University	Feb 2016
NCT02256800		Escalated Dose of Irinotecan in mCRC	N/A	completed	213	Jaw-Yuan Wang, MD, PhD	Aug 2014
NCT00610493		Bevacizumab and Temsirolimus in Patients With Advanced Malignancy	P1	completed	193	M.D. Anderson Cancer Center	Jan 2008
NCT01663727		Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer	P3	completed	481	Hoffmann-La Roche	Aug 2012
NCT01514123		Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors	P1	completed	43	Circadian Technologies Ltd.	Dec 2011
NCT00923936		Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma	P2	completed	16	National Cancer Institute (NCI)	Apr 2009
NCT01787669	SwitchDMO	Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema	P2	completed	19	University of Sydney	Jun 2013
NCT01705184	BUCiL	Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.	P2	completed	120	Intergroupe Francophone de Cancerologie Thoracique	Dec 2012
NCT04138420		Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab	—	completed	38	Federico II University	Jan 2017
NCT02250118	BEVAP	Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer	P1	terminated	1	Institut Curie	Dec 2014
NCT01190345	AVASTEM	Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer	P2	completed	75	Institut Paoli-Calmettes	May 2010
NCT00879437		Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma	P2	completed	38	Baylor College of Medicine	Sep 2009
NCT02248571	IMPROVE	Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab	P4	completed	85	iOMEDICO AG	Aug 2014
NCT01940887	E10030	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy	P3	terminated	645	Ophthotech Corporation	May 2014
NCT01967810		ANG1005 in Patients With Recurrent High-Grade Glioma	P2	completed	73	Angiochem Inc	Oct 2013
NCT01916447		A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.	P1	completed	65	Taiho Oncology, Inc.	Sep 2013
NCT02271464	MOMA	Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer	P2	completed	232	Azienda Ospedaliero, Universitaria Pisana	Mar 2012
NCT01223235		Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab	N/A	completed	22	Memorial Sloan Kettering Cancer Center	Oct 2010
NCT01206530	HCQ	FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer	P1/P2	completed	50	Abramson Cancer Center at Penn Medicine	Sep 2010
NCT00733408		Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer	P2	completed	59	University of Washington	Apr 2008
NCT01164189	TAVAREC	Bevacizumab in Recurrent Grade II and III Glioma	P2	completed	155	European Organisation for Research and Treatment of Cancer - EORTC	Feb 2011
NCT02305758		Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer	P2	completed	130	AbbVie	Dec 2014
NCT01980472		Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients	P2	unknown	50	Grupo de Investigación y Divulgación Oncológica	Aug 2013
NCT02119026	PASSION	Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer	P2	completed	120	Prof. Dr. Werner Scheithauer	Feb 2011
NCT00667342		A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma	P2	completed	43	St. Jude Children's Research Hospital	Jun 2008
NCT01106872		Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas	P1	completed	47	Mohammed M Milhem	Sep 2010
NCT05476341		A Phase I Clinical Trial of Bevacizumab Injection	P1	completed	98	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Apr 2017
NCT03083990		Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male	P1	completed	100	Innovent Biologics (Suzhou) Co. Ltd.	Mar 2017
NCT01364012		A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy	P3	completed	276	Hoffmann-La Roche	May 2011
NCT01263782	BATTLE-FL	BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer	P2	completed	64	M.D. Anderson Cancer Center	May 2011
NCT01727089		Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer	P2	completed	59	National Cancer Institute (NCI)	Nov 2012
NCT03115762		Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects	P1	unknown	126	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	Jun 2017
NCT00942578	ART-P	A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer	P2	completed	63	National Cancer Institute (NCI)	Jul 2009
NCT02661815		A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer	P1	terminated	6	Dana-Farber Cancer Institute	Jun 2016
NCT00271505		Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer	P2	completed	43	M.D. Anderson Cancer Center	Dec 2005
NCT02555800		Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis	P2	unknown	36	Centro de Investigación en. Enfermedades Infecciosas, Mexico	Dec 2014
NCT02069704	BEVZ92	Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients	P1	completed	142	mAbxience Research S.L.	Oct 2014
NCT00785291		Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer	P3	completed	799	National Cancer Institute (NCI)	Oct 2008
NCT02705274		PRP vs Bevacizumab for PDR Treatment	P2/P3	completed	30	Marashi Eye Clinic	Feb 2016
NCT01860638		A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma	P2	completed	296	Hoffmann-La Roche	Aug 2013
NCT01763671	Ultimate	Paclitaxel-bevacizumab in Advanced Lung Cancer	P3	completed	166	Intergroupe Francophone de Cancerologie Thoracique	May 2013
NCT01880385	Beva	Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer	P1	unknown	30	Association Tunisienne de lutte Contre le Cancer	Mar 2011
NCT01648348		Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme	P1/P2	completed	116	National Cancer Institute (NCI)	Nov 2012
NCT01339039	AMD3100	Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma	P1	terminated	26	Patrick Y. Wen, MD	Dec 2011
NCT01834014	ATOM ES	Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases	N/A	completed	110	EPS Corporation	May 2013
NCT01836653	ATOM	Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases	P2	completed	122	EPS Corporation	May 2013
NCT02086656	COI-B	PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES	P2	completed	46	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Jun 2013
NCT01959490		Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer	P2	completed	16	Case Comprehensive Cancer Center	Sep 2013
NCT00378703		Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer	P2	completed	361	National Cancer Institute (NCI)	Sep 2007
NCT01894451		Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy	Early P1	completed	2	Dana-Farber Cancer Institute	Jun 2015
NCT01010126		Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	P2	completed	252	National Cancer Institute (NCI)	Sep 2009
NCT01506167	ACORN	An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)	—	completed	719	Hoffmann-La Roche	Jul 2012
NCT02583568	MARGIN	Fluorescence Guided Surgery in Breast Cancer	P1/P2	completed	26	University Medical Center Groningen	Oct 2015
NCT02246049	QUATTRO	A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC	P2	completed	69	EPS Corporation	May 2014
NCT01383343		Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer	P1	completed	17	National Cancer Institute (NCI)	Aug 2011
NCT01004172		Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases	P2	completed	38	Dana-Farber Cancer Institute	Nov 2009
NCT00881751		Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer	P2	completed	95	Medical University of South Carolina	Mar 2009
NCT01705392		Bevacizumab vs Dacarbazine in Metastatic Melanoma	P2	terminated	2	Haukeland University Hospital	Jan 2013
NCT00574769		Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer	P1/P2	completed	27	University of Southern California	Feb 2010
NCT01459380		Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	P1	completed	41	National Cancer Institute (NCI)	Oct 2011
NCT00428922	MBC	Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients	P2	completed	26	Bhuvaneswari Ramaswamy	Jun 2007
NCT01209442		Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme	P2	completed	30	University of Colorado, Denver	Sep 2010
NCT02141295	McCAVE	A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer	P2	terminated	197	Hoffmann-La Roche	Jun 2014
NCT02387957		A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)	P2	terminated	63	Ophthotech Corporation	Apr 2016
NCT02348255		NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse	P2	withdrawn	0	University of California, Davis	Jan 2016
NCT02641873		A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer	P1	completed	4	Sumitomo Pharma Co., Ltd.	Dec 2015
NCT02187302	NLG207	CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)	P2	completed	115	NewLink Genetics Corporation	Jul 2014
NCT01972373	RAPIDO-TRACT	Visualization of Rectal Cancer During Endoscopy, Using a Fluorescent Tracer	P1	completed	30	University Medical Center Groningen	Oct 2013
NCT01578551		Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.	P2	terminated	25	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	May 2012
NCT01266031		Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma	P1/P2	completed	96	National Cancer Institute (NCI)	Jul 2011
NCT01290263		Amgen 386 for Recurrent Glioblastoma	P1/P2	completed	48	Dana-Farber Cancer Institute	Dec 2010
NCT01120158		Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer	P2	terminated	46	Hellenic Oncology Research Group	Sep 2009
NCT00423917		Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer	P2	completed	36	Alliance for Clinical Trials in Oncology	Aug 2007
NCT00513786		Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma	P2	completed	38	David O'Malley	Aug 2007
NCT02250599		Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma	P2	unknown	80	Sun Yat-sen University	Aug 2014
NCT02841332	IMAGLIO	Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma	N/A	terminated	6	University Hospital, Toulouse	May 2013
NCT01249638		Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC	P3	unknown	516	Ludwig-Maximilians - University of Munich	Dec 2010
NCT05718466		Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy	P3	completed	35	Henry Ford Health System	Nov 2010
NCT00433927	FOLFIRI	5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)	P3	unknown	568	PD Dr. med. Volker Heinemann	Jan 2007
NCT01481545	BRANCH	Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer	P2	completed	62	National Cancer Institute, Naples	Dec 2006
NCT00557492		Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer	P2	completed	59	Amer Zureikat	Dec 2006
NCT00227019		Phase 2 Trial of Bevacizumab in Combination With Pemetrexed	P2	completed	16	Heather Wakelee	Mar 2006
NCT03552770		Single or Combined Protocols for NV-AMD	P4	completed	109	University Hospital of Ferrara	Nov 2014
NCT00369122		Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer	P2	completed	60	National Cancer Institute (NCI)	Aug 2006
NCT02640365	DOUBLIRI	A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer	P1	completed	10	GERCOR - Multidisciplinary Oncology Cooperative Group	Nov 2015
NCT02129933	VICE	VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions	P1	completed	14	University Medical Center Groningen	Apr 2014
NCT01690325	GALADON	Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)	P2	terminated	21	West German Study Group	Sep 2012
NCT00955305		Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer	P2	terminated	175	National Cancer Institute (NCI)	Mar 2010
NCT00957125	PROMIX	A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early	P2	unknown	151	Thomas Hatschek	Sep 2008
NCT00816595		Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	P2	completed	68	Mayo Clinic	Feb 2009
NCT00288015		Bevacizumab in Treating Patients With Angiosarcoma	P2	completed	32	Northwestern University	Oct 2005
NCT01995188		A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer	P1	completed	41	Genentech, Inc.	Dec 2013
NCT01774474	PREMED	PRevention of Macular EDema After Cataract Surgery	P3	completed	1,127	Maastricht University Medical Center	Jul 2013
NCT01305213		Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer	P2	completed	107	National Cancer Institute (NCI)	Mar 2011
NCT02316327		Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab	P4	completed	19	Fundacion Clinic per a la Recerca Biomédica	Jul 2013
NCT01067469	CCNU	Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)	P2	completed	83	M.D. Anderson Cancer Center	Jan 2010
NCT00755170		Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer	P2	completed	48	Hellenic Oncology Research Group	Nov 2008
NCT00753909		Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer	P2	completed	50	Hellenic Oncology Research Group	Nov 2008
NCT00741221		Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer	P2	completed	50	Hellenic Oncology Research Group	Jun 2008
NCT00741195		Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer	P2	completed	50	Hellenic Oncology Research Group	Apr 2008
NCT00394433	TPCA	Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer	P2	completed	38	Dana-Farber Cancer Institute	Sep 2006
NCT01508000	BOS2	Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases	P2	terminated	44	European Organisation for Research and Treatment of Cancer - EORTC	Jun 2013
NCT01588990	ASCENT	A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer	P4	completed	128	Hoffmann-La Roche	Jun 2012
NCT01283048		Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma	P1	completed	32	Toni Choueiri, MD	Sep 2011
NCT00776594		Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy	P2	completed	102	Dana-Farber Cancer Institute	Oct 2008
NCT00702572		Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer	P1	terminated	25	Milton S. Hershey Medical Center	Apr 2008
NCT00651456	MAPS	Mesothelioma Avastin Plus Pemetrexed-cisplatin Study	P2/P3	completed	448	Intergroupe Francophone de Cancerologie Thoracique	Feb 2008
NCT01443676	ARTE	Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma	P2	completed	75	University of Zurich	Oct 2011
NCT01043484	AVAXEL	Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer	P2	completed	90	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	Dec 2009
NCT00614822	H3E-US-X072	Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer	P2	completed	50	Christiana Care Health Services	Nov 2007
NCT01739218	ANTHALYA	A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable	P2	completed	99	Hoffmann-La Roche	Feb 2013
NCT01201850		The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors	N/A	terminated	7	University of Colorado, Denver	Jun 2010
NCT02296567		Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients	P2/P3	unknown	80	East Florida Eye Institute	Dec 2014
NCT01831089	PM01183	Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors	P1	completed	69	PharmaMar	Sep 2013
NCT00614653		Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer	P1	completed	17	M.D. Anderson Cancer Center	Jan 2008
NCT00423930		Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer	P2	completed	44	Memorial Sloan Kettering Cancer Center	Oct 2006
NCT01344824		Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers	P2	completed	38	UNC Lineberger Comprehensive Cancer Center	Mar 2010
NCT00819780	KRAS	PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors	P2	completed	285	Amgen	Apr 2009
NCT01712347		An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer	—	completed	351	Hoffmann-La Roche	Oct 2012
NCT02663141		Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema	P2	completed	57	Tehran University of Medical Sciences	Jun 2015
NCT01495988		Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma	P2	terminated	10	Melanoma Research Foundation Breakthrough Consortium	Aug 2013
NCT01182350	DIPG	Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)	P2	terminated	53	Karen D. Wright MD	Sep 2011
NCT01063283	AVF4759	Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC	N/A	completed	20	University of Chicago	Mar 2010
NCT00923130		Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer	P2	completed	30	National Cancer Institute (NCI)	Jan 2009
NCT00438204		Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	P2	terminated	39	Barbara Ann Karmanos Cancer Institute	May 2006
NCT01351415	NSCLC	A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)	P3	completed	485	Hoffmann-La Roche	Jun 2011
NCT01055028		Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma	P2	terminated	18	Stanford University	Feb 2010
NCT01878422	ITACa	Sequential Treatment Strategy for Metastatic Colorectal Cancer	P3	completed	376	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	Nov 2007
NCT02796183		The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema	N/A	completed	20	Neon Hospital	Jan 2015
NCT01999270		Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors	P1	completed	6	Washington University School of Medicine	Apr 2013
NCT01183663	FOLFOX	Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)	P1	completed	180	M.D. Anderson Cancer Center	Aug 2010
NCT01116219		Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).	P2	completed	149	Swiss Cancer Institute	Jun 2010
NCT01047059	MIMEB	Molecular Imaging With Erlotinib and Bevacizumab	P2	completed	40	University of Cologne	Jan 2010
NCT00874107	NSCLC	Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)	P2	completed	90	HiberCell, Inc.	Jun 2009
NCT00496587		Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma	P2	completed	34	M.D. Anderson Cancer Center	Jul 2007
NCT01749384		Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	P1	completed	12	National Cancer Institute (NCI)	Dec 2012
NCT00305825		Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery	P2	completed	43	University of California, San Francisco	Aug 2004
NCT01383707		A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer	P2	completed	77	Hoffmann-La Roche	Aug 2011
NCT01498328	ReACT	A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma	P2	completed	127	Celldex Therapeutics	Dec 2011
NCT01695772		A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer	P4	completed	50	Hoffmann-La Roche	Oct 2012
NCT01551745		Salvage Ovarian FANG™ Vaccine + Bevacizumab	P2	completed	5	Gradalis, Inc.	Mar 2012
NCT01435395		Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme	P1	completed	12	Emory University	Dec 2011
NCT01417494		1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer	P2	completed	102	Federation Francophone de Cancerologie Digestive	Jul 2011
NCT01832415	ENCOURAGE	First Line Ovarian Cancer Treatment - Cohort Study	—	completed	500	ARCAGY/ GINECO GROUP	Apr 2013
NCT01582152		Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma	P1/P2	terminated	12	M.D. Anderson Cancer Center	Jul 2012
NCT01900717	Prodige20	Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)	P2	completed	102	Centre Hospitalier Universitaire Dijon	Jul 2011
NCT01186991		Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer	P2	completed	185	Genentech, Inc.	Mar 2011
NCT01206049	GOC-B-P	Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations	P2	completed	88	Vejle Hospital	Sep 2010
NCT00691379		Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer	P1/P2	completed	46	Hellenic Oncology Research Group	Apr 2008
NCT01493843		Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer	P2	completed	501	Genentech, Inc.	Jan 2012
NCT00865189	INOVA	A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer	P2	completed	91	Hoffmann-La Roche	Oct 2007
NCT01765582	STEAM	Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer	P2	terminated	280	Hoffmann-La Roche	Jan 2013
NCT02623673		Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema	—	completed	20	Retina Clinic, Sao Paulo, Brazil	Sep 2015
NCT01738646		Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients	P2	completed	48	Duke University	Jan 2013
NCT01677884	BEVIAC	Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy	P2	completed	10	Gustave Roussy, Cancer Campus, Grand Paris	Nov 2012
NCT01314066	VEGF-ARDS	Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)	P2	withdrawn	0	Weill Medical College of Cornell University	Jul 2010
NCT00227617		Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors	P2/P3	terminated	36	University of California, San Francisco	Jun 2005
NCT02901236	AvastinvsMMC	Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma	P2/P3	completed	40	Athens Vision Eye Institute	Jan 2014
NCT01229202		Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery	P4	withdrawn	0	Nova Scotia Health Authority	Jul 2008
NCT00533585	NSCLC	BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)	P1	completed	23	M.D. Anderson Cancer Center	May 2006
NCT00723255		Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer	P2	completed	53	National Cancer Institute (NCI)	Sep 2008
NCT01632228		A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma	P2	completed	135	Hoffmann-La Roche	Jun 2012
NCT00951496		Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	P3	completed	1,560	National Cancer Institute (NCI)	Aug 2009
NCT02645734		The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema	P2/P3	unknown	133	Shahid Beheshti University of Medical Sciences	—
NCT02047214		Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy	P2	terminated	17	Cortice Biosciences, Inc.	Jan 2014
NCT02005120		Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC	P2	unknown	20	Zhejiang University	Dec 2013
NCT01823081		Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema	P3	completed	74	Shahid Beheshti University of Medical Sciences	Jan 2013
NCT01621880	BRAIN	Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma	P2	completed	112	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Jun 2012
NCT01860144		An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer	—	unknown	250	Peking University	Jun 2012
NCT01428388	CRAVE	Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion	N/A	completed	150	Barnes Retina Institute	Sep 2011
NCT00856492	S0800	S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer	P2	completed	215	SWOG Cancer Research Network	Apr 2010
NCT01094184	BATMAN	A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer	P4	completed	49	Hoffmann-La Roche	Mar 2010
NCT01274273		Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer	P2	unknown	118	University of Aarhus	Oct 2009
NCT00960960		A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer	P1	completed	71	Genentech, Inc.	Aug 2009
NCT00859222		LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma	P1/P2	completed	51	Patrick Y. Wen, MD	Mar 2009
NCT00811135		A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer	P2	completed	88	Hoffmann-La Roche	Dec 2008
NCT00891527	PVS	Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis	P1/P2	completed	50	Boston Children's Hospital	Oct 2008
NCT00744718		Bevacizumab and Carboplatin for Patients With Ovarian Cancer	P2	completed	73	Vejle Hospital	Aug 2008
NCT00795665		Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma	P2	completed	7	University of California, Davis	Jun 2008
NCT01496742		A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer	P2	completed	259	Genentech, Inc.	Apr 2012
NCT00934440	5-AZ	A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma	P1/P2	terminated	11	University of Kansas Medical Center	Jun 2009
NCT02113202	FLUOFAP	Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW	P1	completed	17	University Medical Center Groningen	Mar 2014
NCT01722162		Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer	P2	completed	47	Washington University School of Medicine	Apr 2013
NCT01403610		Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab	P2	completed	28	The University of Texas Health Science Center at San Antonio	Jun 2011
NCT01295112		Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion	P2/P3	completed	68	Texas Retina Associates	May 2011
NCT01248949		A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors	P1	completed	162	MedImmune LLC	Oct 2010
NCT00868634	CARIN	Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer	P3	completed	600	iOMEDICO AG	Feb 2009
NCT00520975		Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU	P3	terminated	96	National Cancer Institute (NCI)	Nov 2007
NCT00567554	GeparQuinto	Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer	P3	completed	2,600	GBG Forschungs GmbH	Oct 2007
NCT00381797		Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma	P2	completed	97	National Cancer Institute (NCI)	Aug 2006
NCT02106520	ALEGORI	Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	P2/P3	terminated	80	Hospices Civils de Lyon	Apr 2014
NCT00976573		Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma	P2	completed	149	Alliance for Clinical Trials in Oncology	Apr 2010
NCT01012297		Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma	P3	terminated	107	National Cancer Institute (NCI)	Nov 2009
NCT00924820		A Pilot Study of Bevacizumab for Neoplastic Meningitis	P1/P2	completed	20	M.D. Anderson Cancer Center	Jun 2009
NCT00911716		TC Avastin. ICORG 08-10, V6	N/A	completed	106	Cancer Trials Ireland	Oct 2008
NCT00876993	CNS	Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors	P1	completed	26	Johns Hopkins All Children's Hospital	Sep 2008
NCT00756340		A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors	P1	completed	16	St. Jude Children's Research Hospital	Jul 2008
NCT00654836		Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer	P2	completed	32	Loyola University	Oct 2007
NCT00608972		Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer	P2	completed	31	Rutgers, The State University of New Jersey	May 2008
NCT00112840		CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer	P1/P2	completed	60	National Cancer Institute (NCI)	May 2005
NCT00943826		A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma	P3	completed	921	Hoffmann-La Roche	Jun 2009
NCT02496286		Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites	P1	terminated	10	Eastern Regional Medical Center	Jun 2015
NCT02065466		Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases	P1/P2	withdrawn	0	University of Arizona	Jul 2014
NCT01937715		A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer	P1/P2	terminated	18	Pfizer	Feb 2014
NCT02036424		Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema	P4	completed	45	Raj K. Maturi, MD	Jan 2014
NCT01936974	PGA	(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma	P2	terminated	7	Western Regional Medical Center	Sep 2013
NCT01836536	AVA-CELL	Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients	N/A	completed	30	Center Eugene Marquis	Sep 2012
NCT01121939		Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers	P2	completed	43	SCRI Development Innovations, LLC	May 2010
NCT01047293	RAD001	RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma	P1/P2	completed	47	University of Utah	May 2010
NCT00980239		HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver	P1	completed	115	M.D. Anderson Cancer Center	Sep 2009
NCT00973609	CRC	Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)	P3	completed	853	AIO-Studien-gGmbH	Aug 2009
NCT00450827		Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma	P1	completed	25	Memorial Sloan Kettering Cancer Center	Aug 2006
NCT01013285		Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma	P2	completed	70	Jonsson Comprehensive Cancer Center	Jun 2006
NCT00384176	HORIZON III	First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX	P2/P3	completed	1,814	AstraZeneca	Aug 2006
NCT01471054		Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma	P2	terminated	6	Arman Mashayekhi	Apr 2014
NCT02060955		Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan	P2	terminated	25	CytoVac A/S	Feb 2014
NCT01954030		Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure	P1	terminated	17	Annick Desjardins	Oct 2013
NCT01853813	CENTRAL	First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer	P2	completed	85	Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente	May 2013
NCT01490866		A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)	P2	completed	70	SCRI Development Innovations, LLC	Jan 2012
NCT01374425	MAVERICC	Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)	P2	completed	376	Genentech, Inc.	Aug 2011
NCT01264341		Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma	P2	terminated	39	Hellenic Cooperative Oncology Group	Dec 2010
NCT01115517		Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery	P2	completed	51	The University of Texas Health Science Center, Houston	Oct 2010
NCT00324987	S0502	Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor	P3	terminated	12	National Cancer Institute (NCI)	Apr 2008
NCT00559845		A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer	P2	completed	56	Hoffmann-La Roche	Feb 2008
NCT01966003		Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer	P3	completed	642	Amgen	Nov 2013
NCT02096874		Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema	P4	completed	50	King Khaled Eye Specialist Hospital	Jun 2013
NCT01852409		Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites	P1	unknown	18	Peking University	May 2013
NCT01564914	105GM201	A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma	P2	completed	22	Tracon Pharmaceuticals Inc.	May 2012
NCT01649947		Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II	P2	completed	32	Rutgers, The State University of New Jersey	Dec 2011
NCT01332604		GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors	P1	completed	41	Genentech, Inc.	Jul 2011
NCT02217956	CHIPASTIN	Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma	P1	completed	30	Gustave Roussy, Cancer Campus, Grand Paris	Jun 2011
NCT01222715		Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma	P2	completed	87	National Cancer Institute (NCI)	Oct 2010
NCT01343901	PICASSO	An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases	—	completed	210	Hoffmann-La Roche	Sep 2010
NCT00658697		Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer	P2	completed	42	Dana-Farber Cancer Institute	Jun 2008
NCT00354679		Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer	P2	completed	34	Memorial Sloan Kettering Cancer Center	Apr 2006
NCT02474225		Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent	—	completed	70	Prince of Songkla University	Dec 2013
NCT01777412		Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations	P1	completed	10	Johns Hopkins University	Jun 2013
NCT02075086	ANGIOSWITCH	Angiogenic Switch in Patients With Colorectal Cancer	P2	unknown	100	Grupo Hospital de Madrid	Jul 2011
NCT01338558		A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab	P3	withdrawn	0	Hoffmann-La Roche	Jun 2011
NCT01219777		Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian	P1	completed	9	Ritu Salani	Sep 2010
NCT01091259		Irinotecan and Bevacizumab for Recurrent Ovarian Cancer	P2	completed	29	NYU Langone Health	Mar 2010
NCT01007552		A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts	P2	completed	50	Roswell Park Cancer Institute	Dec 2009
NCT00892710	ToPPS	Trial of Poor Performance Status Patients (ToPPS)	P2	completed	172	SCRI Development Innovations, LLC	Jun 2009
NCT00782275		Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma	P2	completed	41	Beth Israel Deaconess Medical Center	Apr 2009
NCT02450981		Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration	P1	withdrawn	0	Biocad	—
NCT01468844		Minocycline to Treat Central Retinal Vein Occlusion	P1/P2	completed	6	National Eye Institute (NEI)	Dec 2011
NCT01962376		Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis	P4	unknown	60	Hebei Medical University	Feb 2013
NCT01201265		A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer	P2	completed	40	Hoffmann-La Roche	Feb 2011
NCT01105702		Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma	P2	terminated	28	NYU Langone Health	May 2010
NCT00883688		Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma	P2	completed	24	M.D. Anderson Cancer Center	Jul 2009
NCT00631371	INTORACT	Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects	P3	completed	791	Pfizer	Apr 2008
NCT00642759		Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer	P2	completed	36	Massachusetts General Hospital	Apr 2008
NCT00593450		Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial	P3	completed	1,208	University of Pennsylvania	Feb 2008
NCT00262847		Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	P3	completed	1,873	National Cancer Institute (NCI)	Sep 2005
NCT00098787		Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer	P2	completed	247	Eastern Cooperative Oncology Group	Sep 2005
NCT00054132		Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer	P2	completed	38	National Cancer Institute (NCI)	Dec 2002
NCT01146795		Neoadjuvant Therapy for Ovarian Cancer	P2	completed	32	Jason D. Wright	May 2010
NCT01091792	GBM	Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)	Early P1	completed	13	Dartmouth-Hitchcock Medical Center	Mar 2010
NCT01571232		Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema	P2	completed	20	Retina Macula Institute	Apr 2012
NCT01250379	TANIA	A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)	P3	completed	494	Hoffmann-La Roche	Feb 2011
NCT01239732		A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer	P3	completed	1,021	Hoffmann-La Roche	Dec 2010
NCT00974584		A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer	P1	completed	65	Genentech, Inc.	Oct 2009
NCT00886691		Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	P2	completed	150	GOG Foundation	Dec 2010
NCT01610557		Ranibizumab and Bevacizumab for Diabetic Macular Edema	P2	completed	56	National Eye Institute (NEI)	May 2012
NCT01189240		RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma	P1/P2	terminated	13	National Cancer Institute (NCI)	Dec 2010
NCT00737438		Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma	P2	completed	22	Memorial Sloan Kettering Cancer Center	Aug 2008
NCT00847119	xeberecto	Xeloda and Bevacizumab to Treat Rectal Cancer	P2	completed	43	Institut Català d'Oncologia	Sep 2007
NCT00809133	BIBW 2992	Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours	P1	completed	83	Boehringer Ingelheim	May 2007
NCT01022541		Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer	P2	completed	47	Royal Marsden NHS Foundation Trust	Jun 2006
NCT00203502		Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer	P2	completed	40	University of Arkansas	Sep 2005
NCT02354612		Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial	—	no longer available	0	Tracon Pharmaceuticals Inc.	—
NCT01478594		A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy	P2	completed	265	AVEO Pharmaceuticals, Inc.	Dec 2011
NCT01508572		VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer	P1	completed	20	University Medical Center Groningen	Oct 2011
NCT01063010		Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock	N/A	withdrawn	0	Beth Israel Deaconess Medical Center	Feb 2010
NCT01072357		Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival	P1/P2	completed	30	Reza Dana, MD	Dec 2009
NCT00911170	VEGF	PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study	P3	completed	847	Amgen	Nov 2009
NCT01623102		Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer	P2	unknown	40	Sichuan Cancer Hospital and Research Institute	Feb 2013
NCT01375816	PEPCOL	Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer	P2	terminated	55	GERCOR - Multidisciplinary Oncology Cooperative Group	May 2011
NCT01320683		Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer	P2	terminated	1	City of Hope Medical Center	Mar 2011
NCT01031381	RADBEV	Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer	P2	completed	50	University of Pittsburgh	Sep 2010
NCT01086345		Radiosurgery Plus Bevacizumab in Glioblastoma	Early P1	terminated	9	Case Comprehensive Cancer Center	Feb 2010
NCT01200121		Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers	P2	completed	53	AIO-Studien-gGmbH	Feb 2010
NCT01102595		Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma	P2	completed	102	Grupo Español de Investigación en Neurooncología	Dec 2009
NCT00762034		A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer	P3	completed	939	Eli Lilly and Company	Dec 2008
NCT00804830		Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer	P2	terminated	15	Region Skane	Apr 2008
NCT00600340	TURANDOT	2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab	P3	completed	564	Central European Cooperative Oncology Group	Apr 2008
NCT00883298		Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme	P2	completed	30	Center for Neurosciences, Tucson	Apr 2009
NCT01860586		Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.	N/A	completed	20	Wills Eye	Jun 2013
NCT01763645		A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer	P3	completed	353	Biocad	Oct 2012
NCT00887809		Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes	P2	completed	47	Memorial Sloan Kettering Cancer Center	Apr 2009
NCT00393861		Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients	P2	completed	29	Indiana University	Oct 2006
NCT00588237		Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	P2	completed	42	Memorial Sloan Kettering Cancer Center	Aug 2006
NCT00257608	ATLAS	A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)	P3	completed	1,145	Genentech, Inc.	Jan 2006
NCT01279681		Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer	P3	terminated	32	Alliance for Clinical Trials in Oncology	Jan 2011
NCT01759238	OLGA	Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer	P2	terminated	1	Universitätsklinikum Hamburg-Eppendorf	May 2013
NCT01700400		Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer	P1	completed	13	Cancer Research and Biostatistics Clinical Trials Consortium	Sep 2012
NCT01193595		Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors	P1	completed	39	Sanofi	Sep 2010
NCT00976456	65plus	Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer	P3	completed	271	PD Dr. med. Wolfgang Schuette	Sep 2009
NCT01083368		Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy	P1/P2	completed	22	Case Comprehensive Cancer Center	Jan 2009
NCT00717405		A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.	P2	completed	52	Hoffmann-La Roche	Oct 2008
NCT00448019	CLL	FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)	P2	completed	64	M.D. Anderson Cancer Center	Feb 2007
NCT01137604		A Study in Subjects With Recurrent Malignant Glioma	P2	completed	151	Eisai Inc.	Nov 2010
NCT01763450		Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer	P2	unknown	100	Liaoning Cancer Hospital & Institute	Sep 2012
NCT01652560	BIBC	Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy	—	unknown	50	LiNanlin,Ph.D, Chief Physician,Clinical Professor	Jun 2012
NCT01679327		Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer	P2	unknown	100	Chinese Academy of Medical Sciences	Mar 2012
NCT01408030	NOSE	North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	P2	completed	123	James Gossage	Aug 2011
NCT01298076		Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema	P2	completed	61	University of Sydney	Oct 2010
NCT00967330		A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma	P2	completed	182	Hoffmann-La Roche	Jun 2010
NCT00703976		Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer	P2	completed	80	University of Pittsburgh	Oct 2008
NCT02627144		Bevacizumab in Metastatic Renal Cancer	—	completed	365	Hoffmann-La Roche	Jan 2008
NCT00586443	BEP	BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	P1	completed	56	Herbert Hurwitz, MD	Nov 2007
NCT00590681		Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme	P2	completed	62	University of Chicago	Feb 2007
NCT00276575		Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors	P1	completed	65	Herbert Hurwitz, MD	Mar 2005
NCT00436215		Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer	P2	completed	55	National Cancer Institute (NCI)	Dec 2006
NCT01554059	New Beat	Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients	P2	completed	25	Sixth Affiliated Hospital, Sun Yat-sen University	Mar 2012
NCT01301716		A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors	P1	completed	75	Genentech, Inc.	Sep 2011
NCT01139723		A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors	P1	completed	54	Genentech, Inc.	Jun 2010
NCT00920868	XAD	XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib	P1	completed	22	Herbert Hurwitz, MD	May 2009
NCT00887822	AVATAR	A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer	P3	completed	202	Hoffmann-La Roche	Mar 2009
NCT01127360	LUCAS	LUCAS (Lucentis Compared to Avastin Study)	P4	completed	420	Oslo University Hospital	Mar 2009
NCT00842686	CRAB	Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study	P2	unknown	60	Institute of Oncology Ljubljana	Jan 2009
NCT00391092		A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.	P3	completed	424	Hoffmann-La Roche	Sep 2006
NCT00416494		Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer	P2	completed	50	Herbert Hurwitz, MD	Sep 2003
NCT01077713		A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer	P2	completed	86	Hoffmann-La Roche	Feb 2010
NCT00972335		Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma	P2	terminated	18	SCRI Development Innovations, LLC	Jan 2010
NCT00915603		Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer	P2	completed	113	SCRI Development Innovations, LLC	Jul 2009
NCT00673673		FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer	P2	completed	39	Yale University	May 2008
NCT00625898	BETH	BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab	P3	terminated	3,509	NSABP Foundation Inc	Apr 2008
NCT00682539	TRIASTIN	Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema	P4	completed	71	Medical University of Vienna	Oct 2007
NCT00447330	XAGastric	Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma	P2	completed	60	Duke University	Feb 2007
NCT00545077		Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women	P3	completed	380	Spanish Breast Cancer Research Group	Nov 2007
NCT00976911	AURELIA	AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer	P3	completed	361	Hoffmann-La Roche	Oct 2009
NCT01069796		Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer	P2	terminated	64	ARCAGY/ GINECO GROUP	Apr 2010
NCT00929240		A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer	P3	completed	287	Hoffmann-La Roche	Jul 2009
NCT00528567		BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer	P3	completed	2,591	Hoffmann-La Roche	Dec 2007
NCT00410605		Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma	P2	completed	39	National Cancer Institute (NCI)	Nov 2006
NCT01426074		DCE-MRI PET Bevacizumab Study in Rectal Cancer	P2	withdrawn	0	Abramson Cancer Center at Penn Medicine	Aug 2011
NCT02139579		Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer	P2	unknown	24	Sun Yat-sen University	May 2014
NCT01152203		Bendamustine and Bevacizumab for Advanced Cancers	P1	completed	59	M.D. Anderson Cancer Center	Jun 2010
NCT01405430	AVECC	Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab	N/A	completed	63	Centre Leon Berard	May 2010
NCT01280643		Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer	N/A	terminated	3	Fox Chase Cancer Center	Mar 2010
NCT01057264		HAI Abraxane With Gemcitabine and Bevacizumab	P1	completed	78	M.D. Anderson Cancer Center	Jan 2010
NCT00941499		Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab	P1	completed	140	M.D. Anderson Cancer Center	Jul 2009
NCT00511459		Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients	P2	completed	228	Amgen	Jul 2007
NCT00464646	BEV	Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer	P2	completed	105	NSABP Foundation Inc	May 2007
NCT01588704		Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma	P2	completed	42	Si-Yu Wang	Apr 2012
NCT02118831		Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF	P1/P2	completed	56	California Retina Consultants	Mar 2012
NCT01367028	ABCSG 32	A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer	P2	completed	100	Austrian Breast & Colorectal Cancer Study Group	Jun 2011
NCT00873756		A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer	P1	completed	23	Genentech, Inc.	May 2009
NCT00807573		Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment	P2	completed	44	Memorial Sloan Kettering Cancer Center	Dec 2008
NCT00659022		Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth	P2	unknown	60	Radboud University Medical Center	Jul 2008
NCT00387699		Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer	P2	completed	79	Eastern Cooperative Oncology Group	Oct 2006
NCT01251926		EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors	P1	completed	12	National Cancer Institute (NCI)	Nov 2010
NCT03334513		Refractive Error and Biometry in Retinopathy of Prematurity	—	completed	35	San Ni Chen	Apr 2011
NCT01854593		Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy	P4	completed	69	Nihon University	May 2012
NCT01207687	NF2	Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)	P2	completed	14	National Cancer Institute (NCI)	Oct 2010
NCT01067053	BECOX	Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.	P2	unknown	69	Grupo Espanol Multidisciplinario del Cancer Digestivo	Nov 2009
NCT00675259		Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer	P2	completed	33	Ohio State University Comprehensive Cancer Center	Jul 2008
NCT00720512	BEBYP	Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab	P3	terminated	184	Gruppo Oncologico del Nord-Ovest	Jun 2008
NCT00479674	ABC	Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer	P2	completed	41	Duke University	May 2007
NCT00217425		Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms	P2	completed	46	Eastern Cooperative Oncology Group	Sep 2006
NCT00424840		Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy	P1	terminated	12	University of Massachusetts, Worcester	Jun 2006
NCT00193154		OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma	P2	completed	63	SCRI Development Innovations, LLC	Feb 2003
NCT01533740		Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients	—	completed	31	University of Rome Tor Vergata	Mar 2012
NCT01399684		A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer	P2	completed	127	Genentech, Inc.	Nov 2011
NCT01399190		An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer	—	completed	68	Hoffmann-La Roche	Jul 2011
NCT00826540		Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer	P2	completed	83	Alliance for Clinical Trials in Oncology	Sep 2009
NCT00940303		OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer	P2	completed	97	Hoffmann-La Roche	Jun 2009
NCT00621049		Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC	P2	completed	112	SCRI Development Innovations, LLC	Dec 2007
NCT00462501		Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer	N/A	completed	35	Memorial Sloan Kettering Cancer Center	Mar 2007
NCT00271609		Bevacizumab for Recurrent Malignant Glioma	P2	completed	88	National Cancer Institute (NCI)	Dec 2005
NCT00621686		Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme	P2	completed	54	Alliance for Clinical Trials in Oncology	Sep 2008
NCT01205022		Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer	P1	completed	3	City of Hope Medical Center	Apr 2011
NCT01263834	Bevacizumab	Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome	P2/P3	completed	39	Prince of Songkla University	Dec 2010
NCT00968240		Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)	P1	completed	30	Northwell Health	Jul 2009
NCT01397695	HHT	Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)	P2	completed	20	University of California, San Diego	Jun 2009
NCT00856180		Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies	P2	completed	20	Dana-Farber Cancer Institute	Feb 2009
NCT00445848	S0636	S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer	P2	completed	89	SWOG Cancer Research Network	Jul 2007
NCT02036723	GALATIR	Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration	P3	withdrawn	0	Biocad	—
NCT00959647	GDC-0449	A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study	P2	completed	19	Genentech, Inc.	Sep 2009
NCT01474239		A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma	P2	completed	91	Hoffmann-La Roche	Nov 2011
NCT01332721		Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated	P1	completed	38	Tracon Pharmaceuticals Inc.	Apr 2011
NCT01449825		Hepatic Monitoring for Pazopanib	—	completed	1	GlaxoSmithKline	Dec 2010
NCT01229813	ACT2	Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.	P3	completed	233	Lund University Hospital	Oct 2010
NCT01572350	ALBA	Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema	P3	completed	105	Hospital Universitario de Canarias	Oct 2010
NCT01296815		Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity	P2	completed	14	Centro de Investigación en. Enfermedades Infecciosas, Mexico	Sep 2010
NCT01166594		Use of Bevacizumab in Trabeculectomy Surgery	P4	completed	59	Sunnybrook Health Sciences Centre	Jun 2010
NCT01057212	NSCLC	Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)	P2	terminated	6	Providence Health & Services	Feb 2010
NCT01004250		A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer	P2	completed	109	Eli Lilly and Company	Oct 2009
NCT00921167		A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas	P2	completed	32	Clinical Research Center for Solid Tumor, Korea	Jun 2009
NCT02048540		Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell	P1/P2	completed	86	Chinese PLA General Hospital	Feb 2009
NCT00925769		ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer	P1	completed	32	Hoffmann-La Roche	Jan 2009
NCT00737971	ATEMD	Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema	P4	completed	142	Rubens Belfort Jr.	Aug 2008
NCT00543842		Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer	P1	completed	19	M.D. Anderson Cancer Center	Dec 2007
NCT00541125		G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer	P2	completed	20	Federation Francophone de Cancerologie Digestive	Nov 2007
NCT00550537		Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer	P2	completed	116	Vanderbilt-Ingram Cancer Center	Oct 2007
NCT00442637	CAIRO3	Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma	P3	unknown	635	Dutch Colorectal Cancer Group	Jan 2007
NCT00392665		Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck	P2	terminated	36	Massachusetts General Hospital	Oct 2006
NCT00262067	RIBBON 1	A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)	P3	unknown	1,237	Genentech, Inc.	Dec 2005
NCT00267696		Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer	P2	completed	45	Ohio State University Comprehensive Cancer Center	Nov 2005
NCT00321100		Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab	P2	terminated	23	Fox Chase Cancer Center	Apr 2006
NCT01441388		A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.	P1	withdrawn	0	Pfizer	Dec 2011
NCT00774241		PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer	P4	withdrawn	0	Hoffmann-La Roche	Jan 2010
NCT00976677		Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer	P2	terminated	10	National Cancer Institute (NCI)	Jan 2010
NCT01321775		Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer	P2	unknown	44	Hospital Universitario Madrid Sanchinarro	Aug 2009
NCT00401817		Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma	P2	completed	11	Weill Medical College of Cornell University	Nov 2007
NCT00548548	AVAGAST	A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer	P3	completed	774	Genentech, Inc.	Sep 2007
NCT00520013	CTA	Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors	P2	completed	60	Dana-Farber Cancer Institute	Aug 2007
NCT00530907		Valproic Acid and Bevacizumab in Patients With Advanced Cancer	P1	completed	71	M.D. Anderson Cancer Center	Jun 2007
NCT00324870		Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer	P1/P2	completed	37	National Cancer Institute (NCI)	Feb 2006
NCT00026221		Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma	P2	completed	57	National Cancer Institute (NCI)	Nov 2001
NCT00992121		An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma	P1	completed	11	GlaxoSmithKline	Nov 2009
NCT01281696		Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis	P2	completed	40	National Taiwan University Hospital	Jan 2011
NCT00777673		Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.	P2	unknown	60	University of Tennessee Cancer Institute	Oct 2008
NCT00778102		A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.	P2	completed	80	Hoffmann-La Roche	Oct 2008
NCT00727753	AMD	VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)	—	completed	54	University of Zurich	Jul 2008
NCT00586508		Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas	P2	completed	81	Eli Lilly and Company	Nov 2007
NCT00537901		First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study	N/A	completed	100	King Faisal Specialist Hospital & Research Center	Oct 2007
NCT02596958	NSLC	Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants	—	completed	996	Hoffmann-La Roche	Sep 2007
NCT00557713		XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma	P2	unknown	44	Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials	Feb 2007
NCT00323869		Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer	P2	completed	48	Stanford University	Jun 2006
NCT00333775		A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer	P3	completed	736	Hoffmann-La Roche	Mar 2006
NCT00222729		Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer	P2	completed	42	University of Pittsburgh	Nov 2005
NCT01256580	CNV	Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD	N/A	withdrawn	0	Massachusetts Eye and Ear Infirmary	Aug 2010
NCT01137968	NSCLC	Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)	P2	completed	116	Geron Corporation	May 2010
NCT00455975		High-dose Bevacizumab in Advanced Renal Carcinoma Patients	P2	completed	119	SCRI Development Innovations, LLC	Feb 2007
NCT01005329		Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer	P2	completed	34	National Cancer Institute (NCI)	Nov 2009
NCT00254592		Neoadjuvant Treatment of Breast Cancer	P2	completed	43	University of California, Irvine	Oct 2005
NCT01912443		Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer	—	unknown	600	Sun Yat-sen University	Aug 2013
NCT01661946		Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye	P3	completed	10	Queen's University	Aug 2012
NCT02007174		Bevacizumab Injection for Recurrent Pterygium	—	completed	38	Instituto de Oftalmología Fundación Conde de Valenciana	Mar 2012
NCT01434147		Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy	P2	completed	25	Austrian Breast & Colorectal Cancer Study Group	Oct 2011
NCT01504724	IVB	Effect of the Adjunctive IVB Before PRP	P4	completed	30	Kyungpook National University Hospital	Aug 2011
NCT00964704		A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer	P2	withdrawn	0	Hoffmann-La Roche	Mar 2011
NCT01270438		Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer	P2	withdrawn	0	National Cancer Institute (NCI)	Dec 2010
NCT00911820	PCA	Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer	P2	completed	88	Dana-Farber Cancer Institute	Jul 2009
NCT00850577		Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer	P2	terminated	255	Bristol-Myers Squibb	Jun 2009
NCT00662129		Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer	P2	completed	50	Alliance for Clinical Trials in Oncology	Nov 2008
NCT00665990		Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia	P1	completed	49	St. Jude Children's Research Hospital	Nov 2007
NCT00394992		Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer	P3	terminated	79	Dutch Colorectal Cancer Group	Dec 2006
NCT00126490		Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer	P2	completed	19	National Cancer Institute (NCI)	Mar 2005
NCT01332929		Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis	P1	completed	21	Centre Francois Baclesse	Jun 2010
NCT00930891	CPC	Bevacizumab in Extensive Small Cell Lung Cancer	P2/P3	completed	143	Intergroupe Francophone de Cancerologie Thoracique	Sep 2009
NCT00762255		A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma	P1	completed	19	H. Lee Moffitt Cancer Center and Research Institute	Sep 2008
NCT00397982	Mel47	Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma	P2	completed	17	National Cancer Institute (NCI)	Jan 2008
NCT00434642	OCEANS	A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma	P3	completed	484	Genentech, Inc.	Apr 2007
NCT01402531	HHT	Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)	P2	completed	10	University of California, San Diego	Jul 2010
NCT00937560		A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer	P2	completed	190	Hoffmann-La Roche	Jun 2009
NCT01782976	GBM	Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)	P2	withdrawn	0	M.D. Anderson Cancer Center	Jun 2013
NCT01314274	HHT	Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)	P2	completed	15	Medical University of Vienna	Mar 2011
NCT02898012	ATAG	Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status	P2	completed	70	Assistance Publique - Hôpitaux de Paris	Oct 2010
NCT01089413	AVASTART	Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)	—	completed	201	Hoffmann-La Roche	Jan 2010
NCT00909987		Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum	P2	completed	46	Grupo Espanol Multidisciplinario del Cancer Digestivo	Mar 2009
NCT00702975	NSCLC	Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy	P2	completed	35	Radboud University Medical Center	Sep 2008
NCT00570531		Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma	P2	terminated	6	University of Michigan Rogel Cancer Center	Jun 2007
NCT01859234		89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma	N/A	unknown	20	University Medical Center Groningen	May 2013
NCT01540435	PERIMAX	Perioperative Treatment of Resectable Liver Metastases	P2	withdrawn	0	University of Regensburg	Sep 2012
NCT01743157	BBI	Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma	P1/P2	completed	24	California Pacific Medical Center Research Institute	Dec 2010
NCT00960297		Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC	P2	terminated	4	SCRI Development Innovations, LLC	Aug 2009
NCT00867321		Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer	P1/P2	completed	24	Alliance for Clinical Trials in Oncology	Apr 2009
NCT00805961	RT	RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM	P2	completed	68	SCRI Development Innovations, LLC	Jan 2009
NCT00798603		Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	P2	completed	65	Alliance for Clinical Trials in Oncology	Dec 2008
NCT00601926		Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer	P2	terminated	5	Paul Monk	Feb 2008
NCT00525525	AVF4120s	Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma	P2	completed	74	University of California, San Francisco	Sep 2007
NCT00585377		Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer	P2	completed	50	University of Utah	Aug 2007
NCT00700102		A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.	P3	completed	820	Hoffmann-La Roche	Feb 2006
NCT01309451		Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema	P4	completed	40	Maturi, Raj K., M.D., P.C.	Mar 2011
NCT01254526		Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer	P1	completed	52	Genentech, Inc.	Dec 2010
NCT01311960		Topical Bevacizumab for Preventing Recurrent Pterygium	P3	completed	24	Chulalongkorn University	Dec 2010
NCT01095809	EBEV	Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema	P3	terminated	5	Hospital Clinic of Barcelona	Apr 2010
NCT01075464		A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors	P1	completed	64	Genentech, Inc.	Feb 2010
NCT00939991	SAHA	Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas	P1/P2	completed	48	Katy Peters	Oct 2009
NCT00545870		Bevacizumab Versus Ranibizumab for Diabetic Retinopathy	P3	completed	30	Ursula Schmidt-Erfurth, M.D.	Jun 2008
NCT00719264		Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer	P2	completed	365	Novartis Pharmaceuticals	Nov 2008
NCT00418938		SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial	P2	completed	266	Amgen	Nov 2006
NCT01641406	NACprotocol	"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"	P2	unknown	60	Auxilio Mutuo Cancer Center	Mar 2011
NCT01202032	PARASOL	Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors	P1	completed	36	Centre Leon Berard	Jul 2010
NCT01144988	AVIRMA01-09	Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma	P2	unknown	35	Medical University Innsbruck	Mar 2010
NCT02179567		Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC	P2	terminated	26	Hellenic Oncology Research Group	Mar 2010
NCT00484939		A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer	P3	completed	280	Hoffmann-La Roche	Jul 2007
NCT00193492		A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma	P2	completed	60	SCRI Development Innovations, LLC	Sep 2005
NCT00159432		Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer	P2	completed	63	University of Southern California	Feb 2005
NCT01418222		FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer	P2	completed	194	Genentech, Inc.	Sep 2011
NCT00884741		Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma	P3	completed	637	National Cancer Institute (NCI)	Apr 2009
NCT01308684		A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma	P1	completed	22	Hoffmann-La Roche	May 2011
NCT01814163	ANGIOMET	Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab	—	completed	200	Spanish Lung Cancer Group	Feb 2011
NCT00993044	VIT-B	A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin	P1	completed	13	Children's Hospital Los Angeles	Sep 2009
NCT00803062		Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer	P3	completed	452	National Cancer Institute (NCI)	Apr 2009
NCT02308644		Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study	P3	completed	41	University of Sao Paulo	Feb 2009
NCT00448591		A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.	P3	completed	2,296	Hoffmann-La Roche	Sep 2006
NCT00586092		A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors	P1	completed	45	Herbert Hurwitz	Sep 2005
NCT00932152		Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer	P2	terminated	3	University of Pittsburgh	Sep 2010
NCT00949247		Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases	Early P1	completed	20	Case Comprehensive Cancer Center	Dec 2009
NCT00953121	MG	Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)	P2	completed	104	Annick Desjardins	Sep 2009
NCT00913913	RCC	Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients	P2	terminated	8	Dartmouth-Hitchcock Medical Center	Feb 2009
NCT00846027		A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer	P2	completed	90	Hoffmann-La Roche	Jan 2009
NCT00748657		Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary	P2	completed	36	National Cancer Institute (NCI)	Sep 2008
NCT00541099		Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	P2	completed	11	Barbara Ann Karmanos Cancer Institute	Jan 2008
NCT00280150		Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer	P1/P2	completed	46	UNC Lineberger Comprehensive Cancer Center	Jan 2006
NCT00217581		Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer	P2	completed	39	Barbara Ann Karmanos Cancer Institute	Oct 2004
NCT01724385		Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy	P4	completed	18	Khon Kaen University	Aug 2012
NCT01507480	ELLIPSE	The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia	P1	completed	42	Hospices Civils de Lyon	Oct 2011
NCT01256762		Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer	P2	completed	166	Geron Corporation	Nov 2010
NCT01156961	AVATAX	A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)	P4	withdrawn	0	Hoffmann-La Roche	Oct 2010
NCT01368848	NSCLC	Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)	P2	completed	7	Arbeitsgemeinschaft medikamentoese Tumortherapie	Apr 2010
NCT00849550	COBRA	Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.	P1	completed	32	Herbert Hurwitz	Jul 2009
NCT00975897		Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer	P2/P3	completed	3,240	Medical Research Council	Jul 2009
NCT00932438	DEBIRI	Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab	P1/P2	completed	70	University of Louisville	Jun 2009
NCT00845884		Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer	P1/P2	unknown	49	Rabin Medical Center	Feb 2009
NCT00811993		A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors	P1	terminated	104	Hoffmann-La Roche	Feb 2009
NCT02310295	IBeTA	Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema	N/A	completed	45	University of Sao Paulo	Jan 2009
NCT01380678	bevacizumab	Intralesional Bevacizumab Injection on Primary Pterygium	P3	unknown	206	Khon Kaen University	Jan 2009
NCT00737243		Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site	P2	completed	289	SCRI Development Innovations, LLC	Aug 2008
NCT00868192		Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma	P2	completed	38	Washington University School of Medicine	May 2008
NCT00670982		Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer	P2	completed	29	Harold J. Burstein, MD, PhD	May 2008
NCT00784446		First-line Therapy of Stage IV Colorectal Cancer	P1/P2	completed	51	University of Cologne	Apr 2008
NCT00717990		Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment	P2	terminated	15	University Hospital of Crete	Apr 2008
NCT00546156		Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer	P2	completed	104	Ian E. Krop, MD, PhD	Oct 2007
NCT00491855		Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis	P1	completed	3	M.D. Anderson Cancer Center	Jun 2007
NCT00548418		Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer	P2	completed	27	Washington University School of Medicine	Feb 2007
NCT00321646		Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy	P2	completed	42	Mary-Ellen Taplin, MD	Jun 2006
NCT00321828		Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery	P2	completed	90	NSABP Foundation Inc	Mar 2006
NCT00281840		Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer	P2	completed	30	Case Comprehensive Cancer Center	Sep 2005
NCT00137774		Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors	P2	completed	34	Dana-Farber Cancer Institute	Nov 2004
NCT00096278		Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer	P3	completed	2,710	National Cancer Institute (NCI)	Sep 2004
NCT01722968	BEVPAC	A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel	P2	completed	33	Theodoros Foukakis	Nov 2012
NCT01408953		Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue	P2	terminated	2	Tirgan, Michael H., M.D.	Feb 2012
NCT01249521	Vengeance	Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer	P2	unknown	40	Austin Health	Nov 2010
NCT00786669	VITAC	A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors	P1	completed	13	Children's Hospital Medical Center, Cincinnati	Oct 2008
NCT00626405		Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery	P2	completed	95	Alliance for Clinical Trials in Oncology	Aug 2008
NCT00499694		Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel	N/A	completed	31	Barbara Ann Karmanos Cancer Institute	Oct 2007
NCT00499369		Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy	P3	terminated	72	National Cancer Institute (NCI)	Jun 2007
NCT00428545		Bevacizumab and Bortezomib in Patients With Advanced Malignancy	P1	completed	104	M.D. Anderson Cancer Center	Jan 2007
NCT00403130		Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer	P2	completed	31	George Albert Fisher	Feb 2006
NCT00460603		Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer	P1/P2	completed	187	Pfizer	Jan 2006
NCT01131078		A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum	P2	completed	306	Hoffmann-La Roche	Jun 2005
NCT00072046		Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)	P3	completed	732	Alliance for Clinical Trials in Oncology	Oct 2003
NCT01608087		Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects	P1	completed	91	Boehringer Ingelheim	May 2012
NCT01661790		Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer	P3	completed	72	Chinese PLA General Hospital	Aug 2009
NCT00800202		A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis	P2	completed	91	Hoffmann-La Roche	Apr 2009
NCT02612077	CONCERT	Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)	—	completed	765	Hoffmann-La Roche	May 2008
NCT00600821		A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.	P2	completed	118	Pfizer	Apr 2008
NCT00398320		Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors	P2	completed	40	Pamela L. Kunz	Nov 2006
NCT00130780	NSCLC	Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC	P2	completed	71	Memorial Sloan Kettering Cancer Center	Aug 2005
NCT01744756	BRP	Subconjunctival Bevacizumab and Recurrent Pterygium	P2/P3	completed	36	Instituto de Olhos de Goiania	Feb 2012
NCT01487629	IBERA-DME	Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema	P2	unknown	53	University of Sao Paulo	Apr 2010
NCT00741988		Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer	P2	completed	82	SCRI Development Innovations, LLC	Sep 2008
NCT00700180		A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.	P2	completed	303	Hoffmann-La Roche	Sep 2008
NCT00456261		First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC	P2	completed	110	SCRI Development Innovations, LLC	Mar 2007
NCT00550927		Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer	P1	completed	42	Eli Lilly and Company	Nov 2006
NCT00281697	RIBBON 2	A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)	P3	completed	684	Genentech, Inc.	Feb 2006
NCT01046279		Hypertension Monitoring in Glioma Patients Treated With Bevacizumab	—	terminated	40	University of Zurich	Jan 2010
NCT00755118		Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc	P2	terminated	24	University Hospital of Crete	Oct 2008
NCT00755157		Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer	P2	withdrawn	0	University Hospital of Crete	Apr 2008
NCT00598156	ACT	Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva	P3	completed	249	Lund University Hospital	Jun 2007
NCT00356681		A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer	P2	terminated	282	Amgen	Dec 2006
NCT00361231		Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer	P2	completed	35	Massachusetts General Hospital	May 2006
NCT00320541		A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer	P2	completed	187	Eli Lilly and Company	May 2006
NCT00113217		Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma	P2	completed	52	M.D. Anderson Cancer Center	Feb 2005
NCT01674738	SELECT-A	TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV	P2	withdrawn	0	Aktion Bronchialkarzinom e.V.	—
NCT03170284	AVALANCHE	Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer	—	completed	150	Hoffmann-La Roche	Jun 2008
NCT02821559	EROS	Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer	P2	completed	37	Centre Hospitalier Universitaire de Besancon	Jul 2012
NCT01331616		Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab	Early P1	withdrawn	0	West Penn Allegheny Health System	Mar 2011
NCT01115491		A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme	P2	completed	32	Hoffmann-La Roche	Jun 2010
NCT01215123		An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer	—	completed	28	Hoffmann-La Roche	Jan 2010
NCT01270542	PDR	Avastin for PDR (Proliferative Diabetic Retinopathy)	N/A	completed	20	University of Southern California	Jun 2009
NCT00095459		BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors	P1	completed	57	National Cancer Institute (NCI)	Nov 2004
NCT01635803	BRVO	Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)	P2/P3	unknown	296	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Jun 2012
NCT01635790	BRDME	Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)	P2/P3	unknown	246	Prof. dr. R.O. Schlingemann	Jun 2012
NCT01198548		High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer	P2	terminated	10	Roswell Park Cancer Institute	Aug 2010
NCT01303926	ERACLE	Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer	P3	unknown	118	Gruppo Oncologico Italia Meridionale	Jan 2010
NCT00866723		Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer	P2	terminated	5	Beth Israel Deaconess Medical Center	Mar 2009
NCT00813059		Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy	P2	unknown	10	Mount Sinai Hospital, Canada	Feb 2009
NCT00862342	SAFE	Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)	P2	completed	78	Asan Medical Center	Jan 2009
NCT00846612		Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer	P1	completed	15	NYU Langone Health	Jan 2008
NCT00577109		A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.	P2	withdrawn	0	Hoffmann-La Roche	Dec 2007
NCT00602862		Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250	N/A	completed	26	Radboud University Medical Center	Jul 2007
NCT01656304		Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy	P2	completed	16	Barbara Ann Karmanos Cancer Institute	May 2007
NCT00112918		Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer	P3	completed	3,451	Hoffmann-La Roche	Dec 2004
NCT01202890		Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer	P1	terminated	1	New Mexico Cancer Research Alliance	Sep 2010
NCT01055795	BEL	Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors	P1	completed	14	Herbert Hurwitz	Mar 2010
NCT00988897		Colorectal Cancer RECHALLENGE	P2	withdrawn	0	Sanofi	Oct 2009
NCT00875771	AVAXIRI	Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients	P2	completed	80	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	Apr 2009
NCT00707889		Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer	P2	completed	159	AbbVie (prior sponsor, Abbott)	Oct 2008
NCT00667485		Rapamycin Plus Bevacizumab in Advanced Cancers	P1	completed	28	University of Chicago	Apr 2008
NCT00623805		A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer	P3	completed	123	Hoffmann-La Roche	Mar 2008
NCT00536640	INNOVATIONS	Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab	P2	completed	224	Aktion Bronchialkarzinom e.V.	Nov 2007
NCT00458315		Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor	P2	withdrawn	0	Rigshospitalet, Denmark	May 2007
NCT00392704		Treatment of Head & Neck Cancer With Chemotherapy and Radiation	P2	completed	60	SCRI Development Innovations, LLC	Dec 2006
NCT01164007		A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma	P2	completed	40	Hoffmann-La Roche	Jun 2006
NCT00819754	IXO+A	A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer	P1/P2	terminated	23	Ottawa Hospital Research Institute	Nov 2003
NCT01626339		Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter	N/A	unknown	30	University of Malaya	Apr 2012
NCT01736449		Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management	P4	completed	31	Arrowhead Regional Medical Center	Apr 2011
NCT00992849		Bevacizumab for the Treatment of Corneal Neovascularization	P2	unknown	10	Chang Gung Memorial Hospital	May 2009
NCT00775073		Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001	P2	completed	33	Gerhard Treiber	Oct 2008
NCT00766246		Phase II Avastin Trial for Stage IIIB/IV NSCLC	P2	terminated	125	Pharmatech	Oct 2008
NCT00615056		A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen	P2	completed	171	Pfizer	Mar 2008
NCT00517361		Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer	P2	terminated	11	University of Chicago	Aug 2007
NCT00364611		Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer	P2	completed	73	Sanofi	Aug 2006
NCT00268450		Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery	P2	terminated	21	Medical University of South Carolina	Sep 2005
NCT01338090	NETPET	89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors	—	completed	14	University Medical Center Groningen	Apr 2010
NCT01122966	bevazicumab	The Effect of Bevacizumab on the Trabeculectomy	P2/P3	unknown	40	Samsung Medical Center	Mar 2010
NCT00843440	METAFORE	Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study	P2	completed	25	Hospices Civils de Lyon	Mar 2009
NCT00636298		Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy	P2	withdrawn	0	Emory University	Oct 2008
NCT00651482		Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)	P2	terminated	10	Sandy Srinivas	Aug 2008
NCT00671372		A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer	P1	completed	42	Genentech, Inc.	Jul 2006
NCT01422018		Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy	N/A	unknown	10	Seoul St. Mary's Hospital	Aug 2011
NCT01293942		IXO+A in mCRC With Liver-only Metastases	P2	withdrawn	0	Ottawa Hospital Research Institute	Mar 2011
NCT01767545		Dexamethasone-implant for the Treatment of RVO	P4	completed	64	Ludwig-Maximilians - University of Munich	Sep 2010
NCT01090830	HCH003	Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer	P1/P2	terminated	7	Holy Cross Hospital, Florida	Apr 2010
NCT01686529		Bevacizumab for Primary Pterygium Treatment	P1	completed	49	Instituto de Oftalmología Fundación Conde de Valenciana	Mar 2010
NCT01017250		Radiosurgery and Avastin for Recurrent Malignant Gliomas	N/A	completed	15	Duke University	Dec 2009
NCT01014468	AxL-2009	Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration	P3	unknown	500	Instituto de Olhos de Goiania	Mar 2009
NCT00796757	RCC	A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).	P2	completed	146	Hoffmann-La Roche	Dec 2008
NCT00754351		Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer	P2	completed	48	University Hospital of Crete	Sep 2008
NCT00675597		Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer	N/A	completed	25	Memorial Sloan Kettering Cancer Center	May 2008
NCT00619268	TORAVA	Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma	P2	completed	160	Centre Leon Berard	Feb 2008
NCT00879359	VEGF	Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer	P2	completed	15	The Cleveland Clinic	Dec 2007
NCT00409565		A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer	P2	completed	48	National Cancer Institute (NCI)	Sep 2006
NCT00308516		5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer	P2	completed	66	SCRI Development Innovations, LLC	Mar 2006
NCT00305877		Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery	P2	completed	137	National Cancer Institute (NCI)	Feb 2006
NCT00126503		Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	P1/P2	completed	73	National Cancer Institute (NCI)	May 2005
NCT00177307		Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer	P2	completed	40	University of Pittsburgh	Jan 2005
NCT00049322		Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery	P2	completed	30	Jonsson Comprehensive Cancer Center	Jun 2003
NCT02054078		Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion	P2	unknown	183	Tang-Du Hospital	Jan 2012
NCT01167725		Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer	P3	terminated	340	Alliance for Clinical Trials in Oncology	Aug 2010
NCT01077739		A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin	P2	completed	75	Hoffmann-La Roche	Jul 2009
NCT00904839		BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer	P2	completed	128	Boehringer Ingelheim	May 2009
NCT00853073	Avastin	Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?	P2/P3	completed	63	Wills Eye	Feb 2009
NCT00583622		Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients	P2	terminated	13	M.D. Anderson Cancer Center	Dec 2007
NCT00390416		Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma	P2	completed	48	Memorial Sloan Kettering Cancer Center	Oct 2006
NCT00095706		Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)	P1/P2	completed	50	Translational Oncology Research International	Jun 2003
NCT01381614	IHCIS	Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)	—	completed	1	GlaxoSmithKline	Mar 2011
NCT00954642		A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors	P1	completed	24	Genentech, Inc.	Aug 2009
NCT00881504		A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma	P2	terminated	9	Georgetown University	Jun 2009
NCT00467142	OMEGA	Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery	P2	completed	62	Institut Bergonié	Jan 2007
NCT00392392		Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer	P2	completed	29	SCRI Development Innovations, LLC	Oct 2006
NCT00368875		Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer	P1/P2	completed	54	National Cancer Institute (NCI)	Jul 2006
NCT00588666		Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma	P2	completed	51	Memorial Sloan Kettering Cancer Center	May 2006
NCT00408694		Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer	P2	completed	46	National Cancer Institute (NCI)	Dec 2006
NCT01125943		Bevacizumab and Endothelium Dependent Vasodilation	N/A	completed	24	Radboud University Medical Center	Jun 2010
NCT01821859		Abraxane/Bevacizumab	P2	terminated	5	OHSU Knight Cancer Institute	Jan 2010
NCT00997191	IBeTA	Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)	P3	completed	12	University of Sao Paulo	Oct 2009
NCT00817284	GBM	Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)	P2	completed	60	Ulrik Lassen	Nov 2008
NCT00700570		A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer	P2	completed	45	Hoffmann-La Roche	Aug 2008
NCT00709657		The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion	N/A	terminated	8	Medical University of Vienna	Mar 2008
NCT00612586		Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer	P2	completed	117	Eli Lilly and Company	Feb 2008
NCT00448136		A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.	P2	completed	83	Hoffmann-La Roche	Jul 2007
NCT00486759		A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma	P3	terminated	787	Hoffmann-La Roche	Jul 2007
NCT00557232		Intraocular Bevacizumab (Avastin) for Rubeosis Iridis	P4	completed	25	Instituto de Olhos de Goiania	Nov 2006
NCT00508625	NSCLC	A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab	P2	completed	213	Amgen	Jun 2006
NCT00234052		Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer	P2	completed	51	Northwestern University	Jul 2005
NCT01381601		Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)	—	completed	1	GlaxoSmithKline	Mar 2011
NCT00851045		Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer	P2	completed	17	Bristol-Myers Squibb	Oct 2009
NCT00998166		A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy	P2	terminated	12	Columbia University	Jun 2009
NCT00854529		Subconjunctival Bevacizumab Effect on Bleb Vascularity	P2	unknown	60	Rabin Medical Center	Apr 2009
NCT00653939	FALCON	A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer	P2	completed	63	Mateon Therapeutics	Mar 2008
NCT00591734		RAD001 Plus Bevacizumab in Metastatic Melanoma	P2	completed	57	SCRI Development Innovations, LLC	Jan 2008
NCT00568048		Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery	P2	completed	62	Swiss Cancer Institute	Dec 2007
NCT00523809		Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor	P2	terminated	5	M.D. Anderson Cancer Center	Aug 2007
NCT00418093		Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma	P2	terminated	19	Dana-Farber Cancer Institute	Sep 2006
NCT00365365		Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer	P2	completed	214	Sanofi	Aug 2006
NCT01069328	NSCLC	Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)	P1	completed	33	Bayer	Jul 2006
NCT00242502		Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery	P2	completed	62	M.D. Anderson Cancer Center	Oct 2005
NCT01131039		Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer	P2	withdrawn	0	Emory University	Jan 2011
NCT01048554	MEL0107	Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System	P2	completed	34	Mt. Sinai Medical Center, Miami	Nov 2009
NCT00970684		Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer	P2	completed	13	Nathan Pennell, MD, PhD	Sep 2009
NCT00906685		Bevacizumab for Central Retinal Vein Occlusion Study	P3	completed	60	Anders Kvanta	May 2009
NCT00924209	N2	A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer	P2	terminated	7	National Cancer Institute (NCI)	Mar 2009
NCT00625651		Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer	P1/P2	completed	202	Amgen	Oct 2007
NCT00467012		Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer	P2	completed	122	Chugai Pharmaceutical	Apr 2007
NCT00602602		Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer	P2	completed	19	Abramson Cancer Center at Penn Medicine	Mar 2007
NCT00612430		Ph II Bevacizumab + Etoposide for Pts w Recurrent MG	P2	completed	59	Duke University	Mar 2007
NCT00365547		Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy	P2	completed	46	Masonic Cancer Center, University of Minnesota	Sep 2006
NCT00705874		Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma	P1	completed	172	Progen Pharmaceuticals	May 2006
NCT01051934		A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma	P1	completed	2	National Cancer Institute (NCI)	Dec 2009
NCT00577031		OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.	P4	completed	205	Hoffmann-La Roche	Feb 2008
NCT00393068		Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer	P2	completed	62	SCRI Development Innovations, LLC	Feb 2007
NCT00373256		A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer	P3	completed	488	Pfizer	Nov 2006
NCT00343044		Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers	P2	completed	40	Benaroya Research Institute	Jun 2006
NCT00296816	TEACO	TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary	P2	completed	132	Sanofi	Mar 2006
NCT00260364	TARGET	Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer	P1/P2	completed	44	Royal Marsden NHS Foundation Trust	Nov 2005
NCT00110214		Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy	P3	completed	1,050	National Cancer Institute (NCI)	Apr 2005
NCT00193258		Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma	P1/P2	completed	94	SCRI Development Innovations, LLC	Jun 2004
NCT00369070		A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC	P2	terminated	186	Amgen	Jan 2007
NCT00423696		Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery	P2	completed	145	UNICANCER	Mar 2006
NCT01262859		Pilot Study for Locally Advanced Head and Neck Cancer	P2	withdrawn	0	University of Pittsburgh	Dec 2010
NCT00667394		Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors	P2	completed	42	National Cancer Institute (NCI)	Apr 2008
NCT00609622		Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer	P2	terminated	191	Pfizer	Apr 2008
NCT00626561		Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix	P2	terminated	4	M.D. Anderson Cancer Center	Feb 2008
NCT00661778		A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer	P2	completed	50	Hoffmann-La Roche	Jul 2007
NCT00537823		Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement	P2	terminated	9	Washington University School of Medicine	Jun 2007
NCT00483834		A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer	P2	completed	50	University Health Network, Toronto	Dec 2006
NCT00366457		Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer	P2	completed	32	Massachusetts General Hospital	Aug 2006
NCT00307736		Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer	P1/P2	completed	32	Massachusetts General Hospital	May 2006
NCT00301964		Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer	P2	completed	56	National Cancer Institute (NCI)	Mar 2006
NCT00139360		Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma	P2	completed	35	Haukeland University Hospital	May 2005
NCT00118235		Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer	P2	completed	72	National Cancer Institute (NCI)	Dec 2004
NCT00100841		Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer	P2	completed	66	National Cancer Institute (NCI)	Nov 2004
NCT01838538		Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy	P2	unknown	54	Chinese PLA General Hospital	Jun 2011
NCT01366131	NILE	Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)	P2	completed	104	Genentech, Inc.	Jun 2011
NCT01126866	APRIORI	Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy	P2	terminated	35	National Center for Tumor Diseases, Heidelberg	Jun 2009
NCT00463203		Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy	P2	completed	54	Rigshospitalet, Denmark	Mar 2007
NCT00405938		Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer	P2	completed	79	SCRI Development Innovations, LLC	Nov 2006
NCT00142467		Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma	P2	completed	33	Massachusetts General Hospital	Apr 2004
NCT00553800	NSCLC	Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer	P2	completed	32	Fox Chase Cancer Center	Jul 2007
NCT00961415		AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer	P3	completed	376	Hoffmann-La Roche	Aug 2009
NCT01437618		First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer	—	completed	15	Azienda Ospedaliero, Universitaria Pisana	Jun 2009
NCT00845910		A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer	P2	terminated	22	Hoffmann-La Roche	May 2009
NCT00576199	TACE	A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer	P2	completed	30	Hoffmann-La Roche	Feb 2008
NCT00476827		A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain	P2	terminated	16	Duke University	May 2007
NCT00296062		Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer	P1	terminated	12	Case Comprehensive Cancer Center	Mar 2006
NCT00121134		Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer	N/A	completed	164	Harold J. Burstein, MD, PhD	Jun 2005
NCT00600210		Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer	P2	withdrawn	0	Leo W. Jenkins Cancer Center	Jan 2008
NCT00517595		Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC	P2	completed	48	Accelerated Community Oncology Research Network	Aug 2007
NCT00472693		Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer	P2	completed	5	Abramson Cancer Center at Penn Medicine	May 2007
NCT00468585		Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model	P1/P2	completed	62	Memorial Sloan Kettering Cancer Center	Jun 2005
NCT00523640		A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma	P2	terminated	30	University of Chicago	Mar 2005
NCT00142480		Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer	P2	completed	8	Massachusetts General Hospital	Dec 2004
NCT01359397	B-DOCT	Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer	P2	unknown	0	The Netherlands Cancer Institute	Mar 2011
NCT01091896		Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage	P2	unknown	1	University of Sao Paulo	Jan 2010
NCT01020747	RRP	Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)	P1	completed	20	Massachusetts General Hospital	Nov 2009
NCT00779311		A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer	P1	terminated	8	Accelerated Community Oncology Research Network	Oct 2008
NCT00569699	BASIC	Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)	P2	completed	56	Taiho Pharmaceutical Co., Ltd.	Oct 2007
NCT00323739		Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma	P2	completed	80	SCRI Development Innovations, LLC	May 2006
NCT00203411		Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer	P2	completed	45	Translational Oncology Research International	Mar 2006
NCT00354978		Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients	P2	completed	49	M.D. Anderson Cancer Center	Jan 2005
NCT00281528		Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer	P2	terminated	208	Celgene	Feb 2006
NCT01327222	LOW-VISION	Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)	P3	completed	20	IRCCS San Raffaele	Feb 2011
NCT00908219		A Study of Bevacizumab to Prevent Malignant Ascites	P2	withdrawn	0	Baylor College of Medicine	Jul 2009
NCT00734890		Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma	P1	completed	18	National Institutes of Health Clinical Center (CC)	Mar 2008
NCT00407563		Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer	P2	completed	48	Accelerated Community Oncology Research Network	Jan 2007
NCT00417976		Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer	P2	completed	42	Tony Bekaii-Saab	Dec 2006
NCT00335829		Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery	P2	completed	26	Yale University	May 2006
NCT00806923	NSCLC	A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	P3	completed	1,044	Hoffmann-La Roche	Feb 2005
NCT00062426		Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer	P3	completed	0	Prologue Research International	May 2003
NCT01133990		FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer	P1/P2	terminated	5	Eisai Inc.	Mar 2010
NCT00433381		Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma	P2	completed	123	National Cancer Institute (NCI)	Mar 2007
NCT00394082		ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer	P2	completed	50	Celgene	Jun 2006
NCT00826800		Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer	N/A	terminated	2	Memorial Sloan Kettering Cancer Center	Feb 2009
NCT00623233		Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer	P2	completed	52	Eli Lilly and Company	Mar 2008
NCT00604461	MPM	Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)	P1/P2	terminated	13	H. Lee Moffitt Cancer Center and Research Institute	Oct 2007
NCT00512876		Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization	N/A	completed	24	Walter Reed Army Medical Center	Aug 2007
NCT00393497		A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment	P1	completed	11	Indiana University	Apr 2007
NCT00390156		Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors	P1	completed	35	University of California, San Francisco	Aug 2006
NCT00345696		1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.	P2	completed	32	Unidad Integral de Investigación en Oncología S.L.	Jun 2006
NCT00290615		Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery	P2	completed	30	Herbert Hurwitz	Jan 2006
NCT00118261		Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer	P1	completed	17	Case Comprehensive Cancer Center	Mar 2005
NCT00091026		Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer	P2	completed	143	National Cancer Institute (NCI)	Jul 2004
NCT01044329	BRVO	Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion	P2	unknown	90	Shahid Beheshti University of Medical Sciences	Jan 2010
NCT00906516		Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme	P2	unknown	60	Bradmer Pharmaceuticals Inc.	May 2009
NCT00636610		A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer	P2	completed	199	Genentech, Inc.	May 2008
NCT00660621	KARE004	A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma	P2	unknown	40	Kentuckiana Cancer Institute	Apr 2008
NCT01306591		Bevacizumab for Neovascular Age-related Macular Degeneration	N/A	completed	210	Peking University People's Hospital	Jan 2008
NCT00642577		A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.	P3	completed	214	Hoffmann-La Roche	Jul 2007
NCT00802906	CSC	Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)	N/A	completed	12	Johann Wolfgang Goethe University Hospital	May 2007
NCT00343291		A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC	P2	completed	121	Eli Lilly and Company	Dec 2006
NCT00280007		Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma	P2	terminated	32	Medical University of Vienna	Jan 2006
NCT01203306	XELBEVOCT	Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors	P2	unknown	42	University of Turin, Italy	Jan 2006
NCT00121199		Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma	P2	completed	73	National Cancer Institute (NCI)	Jun 2005
NCT00088998		Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer	P2	completed	46	Alliance for Clinical Trials in Oncology	Dec 2004
NCT00127036	MACCO-A	Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)	P2	terminated	65	H. Lee Moffitt Cancer Center and Research Institute	Oct 2003
NCT00728845		Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer	P1/P2	terminated	8	University of Medicine and Dentistry of New Jersey	Jun 2008
NCT01288404		Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium	N/A	completed	80	Ramathibodi Hospital	Jan 2008
NCT00407459		Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma	P2	completed	77	Armando Santoro, MD	Sep 2007
NCT00276055		Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma	P1	completed	38	New Mexico Cancer Research Alliance	Nov 2005
NCT00112528		Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer	P2	completed	53	Alliance for Clinical Trials in Oncology	Jun 2005
NCT00217672		Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer	P2	completed	76	Translational Oncology Research International	May 2005
NCT00679029	HER2	Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer	P2	terminated	15	University of Nebraska	May 2008
NCT01243359		Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies	P1	completed	6	National Cancer Institute (NCI)	Oct 2010
NCT00773188		A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.	P1	completed	6	Hoffmann-La Roche	Dec 2008
NCT00698451		A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers	P2	completed	54	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Aug 2008
NCT00745498	IBDV	Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy	N/A	completed	126	Seoul National University Bundang Hospital	Jun 2008
NCT00684996		Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer	P1/P2	terminated	5	National Cancer Institute (NCI)	Jun 2008
NCT00368992	S0536	S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer	P2	completed	110	National Cancer Institute (NCI)	Aug 2006
NCT01159236		Molecular Triaging of Newly Diagnosed Breast Cancer	N/A	withdrawn	0	M.D. Anderson Cancer Center	Sep 2010
NCT00749567		Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer	P2	terminated	13	Hellenic Oncology Research Group	Jul 2008
NCT00605722		A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.	P2	completed	51	Hoffmann-La Roche	Mar 2008
NCT00674011		Hypertension in Breast Cancer Patients Receiving Bevacizumab	—	terminated	10	Dana-Farber Cancer Institute	Jan 2008
NCT00559754		A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.	P2	completed	72	Hoffmann-La Roche	Dec 2007
NCT00497497		A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)	P1	completed	20	Genentech, Inc.	Oct 2007
NCT00287222		Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma	P2	completed	21	University of Arkansas	Feb 2006
NCT00354549		Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC	P2	completed	104	Swiss Cancer Institute	Jan 2006
NCT00559715	VIBERA	Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab	P3	unknown	366	Klinikum Bremen-Mitte, gGmbH	Aug 2008
NCT00480831		A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)	P2	completed	128	Genentech, Inc.	Jun 2007
NCT00492089		Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer	P2	completed	11	National Cancer Institute (NCI)	Jun 2007
NCT00446030		Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer	P2	completed	127	Sanofi	Mar 2007
NCT00356122	NSCLC	Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)	P2	completed	53	Sanofi	Jul 2006
NCT00295503		Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma	P2	completed	53	University of Texas Southwestern Medical Center	Feb 2006
NCT00290810		Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	P2	completed	12	National Cancer Institute (NCI)	Dec 2005
NCT01227707		A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.	P2	completed	43	Hoffmann-La Roche	Nov 2005
NCT00027885		Phase II Bevacizumab + Tax In Advanced Breast Cancer	P2	completed	49	Case Comprehensive Cancer Center	Nov 2001
NCT00708448		Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients	P1	completed	26	University of Utah	Mar 2008
NCT00661154		Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project	—	completed	7	Stanford University	Feb 2008
NCT00556088	LBH589	LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors	P1	completed	40	SCRI Development Innovations, LLC	Dec 2007
NCT00565656	IPSS	A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts	P2	terminated	40	Centre Hospitalier Universitaire de Nice	Jul 2007
NCT00345761		Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer	P1/P2	completed	64	Chugai Pharmaceutical	Feb 2006
NCT01159171		A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.	P2	completed	50	Hoffmann-La Roche	Jan 2006
NCT00193219		Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer	P2	completed	36	SCRI Development Innovations, LLC	Jul 2005
NCT00460174		Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer	P2	completed	31	Northwestern University	Oct 2005
NCT00984438	BCNU	Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme	P1/P2	withdrawn	0	University of Cincinnati	Jun 2009
NCT00904852		Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme	P1	withdrawn	30	Millennium Pharmaceuticals, Inc.	Jun 2009
NCT00851136		A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)	P1	completed	9	Genentech, Inc.	May 2009
NCT00788606		R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma	P2	terminated	7	Royal Marsden NHS Foundation Trust	May 2008
NCT00705315		Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer	P1/P2	completed	46	Hellenic Oncology Research Group	May 2008
NCT00597506	BEV/EV	Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus	P2	completed	50	Herbert Hurwitz	Oct 2007
NCT00405405		Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer	P1	completed	13	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Dec 2006
NCT00365391		Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	P2	completed	27	National Cancer Institute (NCI)	Aug 2006
NCT00356889		Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors	P2	completed	56	National Cancer Institute (NCI)	May 2006
NCT00314353		Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon	P2	terminated	7	NSABP Foundation Inc	Mar 2006
NCT00203424		Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib	P2	completed	23	Translational Oncology Research International	Jan 2006
NCT01195298		Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer	P2	unknown	88	South Eastern European Research Oncology Group	May 2010
NCT00698516		Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer	P2	completed	50	GlaxoSmithKline	Jul 2008
NCT00461773		Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer	P2	terminated	5	Yale University	Mar 2007
NCT00400803		Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer	P2	completed	38	Masonic Cancer Center, University of Minnesota	Mar 2007
NCT00532909		Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer	P1	completed	13	Branimir Sikic	Jul 2006
NCT00130520		Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer	P2	completed	40	University of Arizona	Jun 2005
NCT01181609		A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum	P2	completed	54	Hoffmann-La Roche	Jun 2005
NCT00620971		Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC	P2	completed	77	Hellenic Oncology Research Group	Jan 2008
NCT01163396	FOIB	First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer	P2	completed	57	Gruppo Oncologico del Nord-Ovest	Jul 2007
NCT00671970	MG	Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)	P2	completed	57	Duke University	Feb 2007
NCT01135498		A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.	P2	completed	90	Hoffmann-La Roche	Nov 2006
NCT00268489		Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	P2	completed	48	Alliance for Clinical Trials in Oncology	May 2006
NCT00140556		Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer	Early P1	completed	28	David M. Brizel, MD	Aug 2005
NCT00126542		Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	P2	completed	35	National Cancer Institute (NCI)	Apr 2005
NCT01141881		Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema	N/A	terminated	0	Mashhad University of Medical Sciences	May 2009
NCT00667277		Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis	P2	terminated	13	Ronald Hoffman	Mar 2008
NCT00569335	SIRB	Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer	P2	completed	52	Taiho Pharmaceutical Co., Ltd.	Oct 2007
NCT00569790		Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer	P2	completed	53	Taiho Pharmaceutical Co., Ltd.	Oct 2007
NCT00520403		A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.	P2	completed	25	Hoffmann-La Roche	Sep 2007
NCT00592176		The Effect of Bevacizumab (Avastin) on Pterygium	P2	completed	5	University of Alabama at Birmingham	Aug 2007
NCT00393094		Bevacizumab and Irinotecan to Treat Brain Tumors	P2	terminated	31	National Cancer Institute (NCI)	Sep 2006
NCT00996502		Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer	P1/P2	terminated	4	Columbia University	Jul 2006
NCT00356031		Bevacizumab and Radiation Therapy for Sarcomas	P2	completed	20	Massachusetts General Hospital	Jul 2006
NCT01024504		Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer	P2	completed	46	Hellenic Oncology Research Group	Mar 2006
NCT00449163		Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer	P2	terminated	25	University of Miami	Mar 2006
NCT00365144		Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine	P2	completed	36	University of California, San Francisco	Feb 2006
NCT00786643	GFL	Study of Gamma Interfereon in Metastatic Colorectal Carcinoma	P2	completed	48	Accelerated Community Oncology Research Network	Feb 2006
NCT00022659		Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer	P2	completed	64	National Cancer Institute (NCI)	Apr 2002
NCT00055237		Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients	P2	completed	19	National Cancer Institute (NCI)	Feb 2003
NCT00776698		A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.	P1	completed	1	Hoffmann-La Roche	Apr 2009
NCT00800917		A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme	P2	completed	12	Rigshospitalet, Denmark	Nov 2008
NCT00781846	COMPLETED	Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)	P1	completed	17	Merck Sharp & Dohme LLC	Oct 2008
NCT00469443		Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC	P3	completed	330	Hellenic Oncology Research Group	Dec 2006
NCT01052363		OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas	P1	withdrawn	0	West Virginia University	Jan 2010
NCT00516295		Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma	P2	completed	7	National Cancer Institute (NCI)	Feb 2008
NCT00531960		A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.	P2	completed	124	Hoffmann-La Roche	Jan 2008
NCT00531076		Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer	P1	terminated	6	Amsterdam UMC, location VUmc	Oct 2007
NCT01068977	PRO143966	A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors	P1	completed	44	Genentech, Inc.	Aug 2007
NCT00387751		Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma	P2	completed	14	National Cancer Institute (NCI)	Aug 2006
NCT01027468		Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration	N/A	completed	160	Medical University of Vienna	Aug 2009
NCT00694200		Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer	P2	terminated	13	Hellenic Oncology Research Group	Apr 2008
NCT00642824		A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.	P2	terminated	3	Hoffmann-La Roche	May 2007
NCT00444041	ASSO-LM1	Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer	P1/P2	completed	43	Austrian Society Of Surgical Oncology	Jan 2007
NCT00328497		A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors	P2	completed	31	CASI pharmaceuticals, Inc.	May 2006
NCT00208546		Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer	P3	completed	750	Dutch Colorectal Cancer Group	Jun 2005
NCT00055692		Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer	P2	completed	46	National Cancer Institute (NCI)	Feb 2003
NCT01025934		Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy	P4	completed	0	University of Campania Luigi Vanvitelli	—
NCT00929058	BVZ1	Bevacizumab and Vasoconstriction	N/A	completed	10	Radboud University Medical Center	Jun 2009
NCT00710268		Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours	P1	completed	18	AstraZeneca	Jun 2008
NCT00501891		Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma	P2	completed	32	Duke University	Jul 2007
NCT00473590	AMBER	A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)	P2	completed	102	Genentech, Inc.	Jun 2007
NCT00426829		Proton Therapy and Bevacizumab for Primary Liver Tumors	P1	terminated	3	M.D. Anderson Cancer Center	May 2007
NCT00370552		A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer	P2	completed	136	R-Pharm	Mar 2007
NCT00365417	BEV	Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer	P2	completed	45	NSABP Foundation Inc	Aug 2006
NCT00482495		Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma	P2	completed	42	Mayo Clinic	Apr 2006
NCT01217398		Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye	P2	unknown	35	Institut Curie	Oct 2009
NCT00408070		Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer	P2	terminated	5	UConn Health	Oct 2006
NCT00602329		MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer	P2	terminated	5	Abramson Cancer Center at Penn Medicine	Feb 2006
NCT00278889	HORIZON I	Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)	P2	completed	215	AstraZeneca	Jan 2006
NCT00853021		Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney	P2	completed	26	Jorge A. Garcia, MD	Dec 2005
NCT00268359		Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas	P2	completed	68	Duke University	May 2005
NCT00556205		Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma	P2	withdrawn	0	Massachusetts General Hospital	Sep 2009
NCT00875147		Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases	—	completed	163	University of Zurich	Apr 2009
NCT00469469		Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma	P2	withdrawn	0	Dartmouth-Hitchcock Medical Center	May 2007
NCT00119262		Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer	P2	completed	226	National Cancer Institute (NCI)	Oct 2005
NCT01025349		Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer	P2	completed	20	Taipei Medical University Hospital	Jan 2005
NCT00137813		Avastin and Taxotere for Esophagogastric Cancer	P2	completed	42	Dana-Farber Cancer Institute	Aug 2004
NCT00083031		Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer	P2	completed	57	Dana-Farber Cancer Institute	Jul 2003
NCT00999791		Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema	P1	unknown	0	Shahid Beheshti University of Medical Sciences	Jul 2009
NCT00974389		S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery	P2	unknown	40	Osaka Medical College	Jul 2009
NCT00702819	BLOCK-ROP	Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity	P1	terminated	2	Vision Research Foundation	Jun 2008
NCT01069627		A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma	P2	completed	20	Hoffmann-La Roche	Dec 2006
NCT00425646		Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	P2	completed	50	University of Washington	Nov 2006
NCT00729846	PDT	Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)	P2	completed	22	California Retina Consultants	May 2006
NCT01169558		A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.	P3	completed	168	Hoffmann-La Roche	May 2006
NCT00307723		Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer	P1/P2	terminated	52	Massachusetts General Hospital	May 2006
NCT00352521	DCE-MRI	Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma	P2	completed	20	Duke University	Apr 2006
NCT00318136	BRIDGE	A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)	P2	completed	47	Genentech, Inc.	Sep 2005
NCT00137826		Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma	P2	completed	37	Dana-Farber Cancer Institute	Feb 2004
NCT00074308		Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers	P1/P2	completed	40	National Cancer Institute (NCI)	Oct 2003
NCT00025233		Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix	P2	completed	50	National Cancer Institute (NCI)	Apr 2002
NCT00567372		POSTERIOR SUB-TENON'S Avastin	P4	withdrawn	0	Asociación para Evitar la Ceguera en México	Jun 2008
NCT00576901		A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.	P2	terminated	23	Hoffmann-La Roche	Nov 2007
NCT00403403	SALUTE	A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)	P2	completed	102	Genentech, Inc.	Mar 2007
NCT00388700		A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer	P2	withdrawn	0	Galectin Therapeutics Inc.	Oct 2006
NCT00451906		A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.	P4	completed	2,252	Hoffmann-La Roche	Aug 2006
NCT00350753		Avastin and Tarceva for Upper Gastrointestinal Cancers	P2	completed	126	Rigshospitalet, Denmark	Jun 2006
NCT00312728	PASSPORT	A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)	P2	completed	115	Genentech, Inc.	Mar 2006
NCT00508872		Folfox-B Study for Patients With Colorectal Liver Metastases	P2	terminated	2	M.D. Anderson Cancer Center	Nov 2005
NCT00252564		Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer	P3	completed	247	US Oncology Research	Sep 2005
NCT00815594		Bleb Vascularity Change After Subconjunctival Injection Bevacizumab	P4	unknown	30	Capital Medical University	Dec 2008
NCT00386828		Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial	P2	completed	43	British Columbia Cancer Agency	Oct 2006
NCT00337207		Bevacizumab in Treating Patients With Recurrent or Progressive Glioma	P2	completed	55	Northwestern University	Mar 2006
NCT00251524		A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC	P2	completed	69	Veeda Oncology	Nov 2005
NCT00028990		Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer	P3	completed	722	Eastern Cooperative Oncology Group	Jan 2002
NCT00115765	PACCE	PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study	P3	completed	1,053	Amgen	Jun 2005
NCT01093235		Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer	P3	unknown	800	Cambridge University Hospitals NHS Foundation Trust	Apr 2009
NCT00740168	BevaRet	Bevacizumab Treatment and Retinal Vessel Monitoring	—	completed	20	Technische Universität Dresden	May 2007
NCT00434252	BEAM	A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma	P2	completed	214	Genentech, Inc.	Feb 2007
NCT00376701		Combination Therapy for Age-Related Macular Degeneration.	P2	completed	103	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Sep 2006
NCT00308607		Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma	P2	completed	27	University of Turku	Aug 2005
NCT00069095		A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer	P3	completed	2,035	Hoffmann-La Roche	Jul 2003
NCT00900172		Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel	—	completed	180	ECOG-ACRIN Cancer Research Group	Mar 2008
NCT00754650		A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia	P2	completed	2	Hoffmann-La Roche	Sep 2008
NCT00735241	FAST	FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma	P2/P3	withdrawn	0	Sirtex Medical	Jul 2008
NCT00642603		A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer	P2	terminated	41	Hoffmann-La Roche	May 2008
NCT00632541		A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer	P2	terminated	18	Hoosier Cancer Research Network	Oct 2007
NCT00445406		Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer	P2	completed	43	Swiss Cancer Institute	Dec 2006
NCT00360360		Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site	P2	completed	60	SCRI Development Innovations, LLC	Jul 2006
NCT00870636	ROP	Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)	—	no longer available	0	Children's Hospital Los Angeles	—
NCT00533429		Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy	P2	completed	40	Eli Lilly and Company	Oct 2007
NCT00640640	AMD	The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)	N/A	unknown	60	Sheba Medical Center	Aug 2007
NCT00129727	OVCA	Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)	P2	completed	62	Massachusetts General Hospital	Jun 2005
NCT00671645		Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy	P2	terminated	8	Austrian Breast & Colorectal Cancer Study Group	Jul 2008
NCT01311050		A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer	—	unknown	46	King Faisal Specialist Hospital & Research Center	Jan 2009
NCT00845104		Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment	P2	withdrawn	0	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium	Jan 2009
NCT00402883		Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer	P2	terminated	5	SCRI Development Innovations, LLC	Nov 2006
NCT00308529		Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer	P2	completed	55	SCRI Development Innovations, LLC	Mar 2006
NCT00294931		Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer	P2	completed	50	SCRI Development Innovations, LLC	Feb 2006
NCT00079040		Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer	P2	completed	65	National Cancer Institute (NCI)	Jan 2006
NCT00113230		Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer	P2	completed	25	M.D. Anderson Cancer Center	Feb 2005
NCT00611793		PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies	P1	completed	50	SCRI Development Innovations, LLC	Oct 2004
NCT00193622		Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site	P2	completed	50	SCRI Development Innovations, LLC	Apr 2004
NCT00801866		Avastin for Post-photocoagulation Macular Edema	P4	withdrawn	0	Asociación para Evitar la Ceguera en México	Dec 2008
NCT00515684		Corneal Thinning During Topical Bevacizumab Therapy	N/A	withdrawn	0	Yonsei University	May 2007
NCT00628810		Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer	P2	completed	86	Federation Francophone de Cancerologie Digestive	Jan 2007
NCT00673296		Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation	N/A	unknown	6	National Taiwan University Hospital	Jan 2007
NCT00367601		Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer	P2	completed	25	Nasser Hanna, M.D.	Aug 2006
NCT00463073		Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas	P2	completed	32	Rigshospitalet, Denmark	Aug 2006
NCT00531336		MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen	P2	completed	60	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery	Jul 2006
NCT00326911		Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer	P2	terminated	61	Eli Lilly and Company	May 2006
NCT00234494		Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer	P2	completed	45	Christopher Sweeney, MBBS	Nov 2005
NCT00121836		A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer	P4	completed	109	Hoffmann-La Roche	Jun 2005
NCT00804921	IOP	Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab	P2	completed	0	University of Sao Paulo	—
NCT00390026		The Avastin vs Visudyne for Neovascular AMD Study	P3	withdrawn	0	St. Erik Eye Hospital	Nov 2006
NCT00349336		A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.	P3	completed	64	Hoffmann-La Roche	Aug 2006
NCT00806169	DRP	Combined Triple Therapy in Diabetic Retinopathy (DRP)	P3	completed	40	Johann Wolfgang Goethe University Hospital	Apr 2006
NCT00805064	RVO	Combined Triple Procedure in Retinal Vein Occlusion (RVO)	P3	completed	40	Johann Wolfgang Goethe University Hospital	Jan 2006
NCT00797303	BQ-1-08-ARVO	The Effect of Bevacizumab on Corneal Neovascularization	P4	completed	8	Instituto de Olhos de Goiania	Jan 2006
NCT00556348		Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration	P4	completed	500	Instituto de Olhos de Goiania	Nov 2005
NCT00203905		A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck	P2	completed	23	University of Chicago	Jan 2004
NCT00072566		Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer	P2	completed	70	National Cancer Institute (NCI)	Dec 2003
NCT00666692	NSCLC	A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)	P1	completed	7	Abbott	Apr 2008
NCT00874744	Tribeva-DME	Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema	P2	completed	13	Universidade Federal de Goias	Mar 2008
NCT00378066		Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer	P2	completed	49	Asan Medical Center	Aug 2006
NCT00378638		Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study	P2	unknown	30	Chap, Linnea I., M.D.	Jun 2006
NCT00327093		Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases	P4	terminated	31	Hospices Civils de Lyon	May 2006
NCT01214720		A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer	P3	completed	607	Hoffmann-La Roche	Jul 2005
NCT00126633		Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer	P2	completed	53	University of California, San Francisco	Apr 2004
NCT00101686		Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.	P3	completed	547	Pfizer	Feb 2003
NCT00596297	IBEVI	Preoperative Bevacizumab for Vitreous Hemorrhage	P1/P2	completed	16	University of Sao Paulo	Nov 2007
NCT00378573		Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	P2	terminated	17	Sanofi	Jan 2007
NCT00351039		Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer	P1/P2	terminated	8	H. Lee Moffitt Cancer Center and Research Institute	Jul 2006
NCT00466687		Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma	P2	completed	34	Vanderbilt-Ingram Cancer Center	Sep 2004
NCT00738530		A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy	P3	completed	649	Hoffmann-La Roche	Jun 2004
NCT00016094		S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma	P2	completed	60	National Cancer Institute (NCI)	Apr 2001
NCT00359164	PDT	Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.	P2	completed	36	University of British Columbia	Jul 2006
NCT00710229	MANTA	Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration	P3	unknown	320	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery	Jul 2008
NCT00797485		Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery	P3	unknown	672	Southern Italy Cooperative Oncology Group	Jul 2008
NCT00804206		Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation	P4	terminated	15	Asociación para Evitar la Ceguera en México	Jul 2008
NCT00719797	TRIBE	Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer	P3	completed	509	Gruppo Oncologico del Nord-Ovest	Jul 2008
NCT00336648		Preop Chemoradiation Resectable Pancreas	P2	completed	11	M.D. Anderson Cancer Center	Jun 2006
NCT00805649	ARMD	Combined Therapy in Age-Related Macular Degeneration (ARMD)	P4	completed	150	Johann Wolfgang Goethe University Hospital	Jan 2006
NCT01041690		Efficacy of PreOperative Bevacizumab for Diabetic Eye Disease	N/A	completed	19	Cairo University	Jun 2007
NCT00370851		Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial	P3	completed	82	Shahid Beheshti University of Medical Sciences	Aug 2006
NCT00703235		Intravitreal Bevacizumab for Diabetic Macular Edema	P2/P3	unknown	0	Isfahan Ophthalmology Research Center	—
NCT00690768	IBETRA	Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA)	P2	completed	20	University of Sao Paulo	Mar 2008
NCT01032109		Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration	N/A	completed	45	Kumamoto University	Oct 2006
NCT00344617	BEVACIZUMAB	Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy	P3	unknown	50	Singapore National Eye Centre	Jun 2006
NCT02079519		A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma	P2	terminated	10	Hoffmann-La Roche	May 2006
NCT00383812		Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy	N/A	unknown	20	Asan Medical Center	May 2006
NCT00421512		A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients	P1	completed	28	Memorial Sloan Kettering Cancer Center	Mar 2006
NCT00313768		Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC	P2	terminated	23	Pfizer	Dec 2005
NCT00407719	CNV	Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)	P1	completed	10	Johns Hopkins University	Jun 2005
NCT00101348		Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer	P1/P2	completed	66	National Cancer Institute (NCI)	Jan 2005
NCT00193375		Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer	P2	completed	60	SCRI Development Innovations, LLC	Aug 2003
NCT00873236		MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer	P2	unknown	30	Mount Vernon Cancer Centre at Mount Vernon Hospital	Apr 2008
NCT00408772		Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer	P2	withdrawn	0	University of California, Davis	Jun 2007
NCT02005549		A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer	P2	completed	18	Hoffmann-La Roche	Feb 2006
NCT00250978		Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC	P1	completed	15	Memorial Sloan Kettering Cancer Center	Nov 2005
NCT02582970		A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum	P4	completed	40	Hoffmann-La Roche	May 2005
NCT00898417		Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab	—	completed	90	ECOG-ACRIN Cancer Research Group	Mar 2008
NCT00536939		Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer	P2	terminated	2	Eli Lilly and Company	Nov 2007
NCT00566761	MECROV	Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO	P4	terminated	10	Asociación para Evitar la Ceguera en México	Jun 2007
NCT00548197		Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment	P1	completed	40	Iran University of Medical Sciences	Feb 2007
NCT00531024	BEAT-AMD	Systemic Avastin Therapy in Age-Related Macular Degeneration	P2/P3	completed	30	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery	Aug 2005
NCT02013830		A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer	P2	completed	45	Hoffmann-La Roche	May 2005
NCT00217282		Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer	P2	completed	45	Mt. Sinai Medical Center, Miami	Jun 2004
NCT00681603		Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization	N/A	completed	13	National Taiwan University Hospital	Aug 2007
NCT00656435		Bevacizumab and Long Acting Gas in Diabetic Vitrectomy	P3	completed	16	National Taiwan University Hospital	Dec 2006
NCT00404703		A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer	P2	terminated	37	Hoffmann-La Roche	Aug 2006
NCT00336323	Bevacizumab	A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)	P2	completed	121	Jaeb Center for Health Research	Jun 2006
NCT00370786	AMD	Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)	P3	completed	31	Shahid Beheshti University of Medical Sciences	Nov 2005
NCT00394251	AC	Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer	P2	completed	197	Celgene	Aug 2006
NCT00600301		Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study	P3	withdrawn	0	Asociación para Evitar la Ceguera en México	Jan 2008
NCT00696592	ARMAST	Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration	P2	withdrawn	0	University of Padova	Jan 2007
NCT00468429		Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery	P4	unknown	40	Grewal Eye Institute	May 2007
NCT00451763		Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia	P3	completed	31	University of Sao Paulo	Jan 2006
NCT00571740		Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer	P2	withdrawn	0	Alliance for Clinical Trials in Oncology	—
NCT00684853		Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD	P2	unknown	50	Federal University of São Paulo	Nov 2007
NCT00447031		Combination Therapy for Neovascular Age Related Macular Degeneration	N/A	withdrawn	0	Yonsei University	Mar 2007
NCT00440973		Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer	P2	terminated	6	The Methodist Hospital Research Institute	Oct 2006
NCT00323011		FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer	P2	terminated	5	University of Southern California	May 2006
NCT00334763		Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer	P2	terminated	32	Northwestern University	May 2006
NCT00317200		A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer	P2	completed	34	Hoosier Cancer Research Network	Apr 2006
NCT01271166		Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer	P1	terminated	10	Novartis Pharmaceuticals	Oct 2007
NCT00898794		Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer	—	unknown	20	Kantonsspital Graubuenden	Oct 2007
NCT00496405		Unilateral Bevacizumab for Bilateral Diabetic Macular Edema	P4	withdrawn	0	Asociación para Evitar la Ceguera en México	Apr 2007
NCT00555594	AVASTIN	Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization	P2/P3	completed	18	Asociación para Evitar la Ceguera en México	Sep 2006
NCT00410774		Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery	P1/P2	terminated	20	University of California, San Francisco	Jul 2006
NCT00524875		Effect of Intravitreal Bevacizumab on Early Post-Vitrectomy Hemorrhage in Diabetic Patients	N/A	unknown	80	Shahid Beheshti University of Medical Sciences	Jan 2007
NCT00369889		A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer	P2	completed	18	Indiana University	Aug 2006
NCT00345163	BRAIN	A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)	P2	completed	167	Genentech, Inc.	Jul 2006
NCT00491738	SABRE-R	A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)	P2	terminated	16	Genentech, Inc.	Aug 2007
NCT00578149		Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer	P2	completed	45	Dana-Farber Cancer Institute	May 2006
NCT00347698		Intravitreal Bevacizumab vs Photocoagulation for Proliferative Diabetic Retinopathy	P2/P3	withdrawn	0	Asociación para Evitar la Ceguera en México	Mar 2006
NCT00025389		Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer	P2	completed	8	University of Chicago	Nov 2001
NCT00294359		The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer	P2/P3	completed	333	Australasian Gastro-Intestinal Trials Group	Jun 2005
NCT00116506		Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer	P2	completed	35	Dana-Farber Cancer Institute	Jan 2005
NCT00077298		Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer	P2	completed	70	National Cancer Institute (NCI)	Dec 2003
NCT00066846		Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy	P2	completed	0	National Cancer Institute (NCI)	Aug 2003
NCT00469976		Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer	P2	withdrawn	0	Eastern Cooperative Oncology Group	Jun 2007
NCT00513266		Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery	P2	unknown	35	Centre Hospitalier Universitaire Vaudois	Jun 2007
NCT00347399		Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration	P2	terminated	25	Asociación para Evitar la Ceguera en México	Mar 2006
NCT00217503		Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma	P2	completed	15	National Cancer Institute (NCI)	Jul 2005
NCT00458731		Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	P1	completed	57	National Cancer Institute (NCI)	May 2007
NCT00538005		Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma	P1/P2	unknown	54	San Diego Pacific Oncology & Hematology Associates	May 2007
NCT00411593	NSCLC	Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)	P1/P2	withdrawn	0	M.D. Anderson Cancer Center	Nov 2006
NCT00222469		Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer	P2	completed	50	University of Oklahoma	Aug 2005
NCT00114179		Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery	P2	completed	82	National Cancer Institute (NCI)	Jan 2005
NCT00544011		Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	P2	unknown	47	Hopital Jean Minjoz	Apr 2007
NCT00118105	S0408	S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer	P2	withdrawn	0	SWOG Cancer Research Network	Nov 2006
NCT00293332		Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery	P2	terminated	1	University of California, San Francisco	Dec 2005
NCT00434226	SABRE-L	A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)	P2	terminated	56	Genentech, Inc.	Mar 2007
NCT00434356	SABRE-B	A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)	P2	terminated	46	Genentech, Inc.	Mar 2007
NCT00423059		Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy	N/A	completed	20	Yonsei University	Dec 2006
NCT00370630	CRVO	Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO)	P2	unknown	15	Shahid Beheshti University of Medical Sciences	Aug 2006
NCT00370669		Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema	P3	unknown	150	Shahid Beheshti University of Medical Sciences	Nov 2005
NCT00438737		Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer	P2	unknown	100	European Organisation for Research and Treatment of Cancer - EORTC	Jan 2007
NCT00524069		Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery	N/A	withdrawn	0	Roswell Park Cancer Institute	Jan 2007
NCT00395434		Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors	P1	completed	20	Mateon Therapeutics	Sep 2006
NCT00016549		Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer	P2	completed	21	National Cancer Institute (NCI)	May 2001
NCT00467194		Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	P1	completed	27	National Cancer Centre, Singapore	Dec 2006
NCT00407121		Intravitreal Bevacizumab for Inflammatory Neovascular Membranes	P3	withdrawn	0	Asociación para Evitar la Ceguera en México	Dec 2006
NCT01920984	VL	Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy	N/A	completed	100	National Taiwan University Hospital	Jan 2005
NCT00406172	PME	Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)	P3	withdrawn	0	Asociación para Evitar la Ceguera en México	Nov 2006
NCT00406380		Effect of Avastin in Juxtafoveal Telangiectasias	P3	withdrawn	0	Asociación para Evitar la Ceguera en México	Sep 2006
NCT00370539		Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD	P3	unknown	0	Shahid Beheshti University of Medical Sciences	Sep 2006
NCT00403026		Intravitreal Bevacizumab for Retinal Disorders	N/A	unknown	150	Narayana Nethralaya	Aug 2006
NCT00406744		Efficacy of Retreatments With Intravitreal Bevacizumab	P3	terminated	20	Asociación para Evitar la Ceguera en México	May 2006
NCT00161291		Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer	P2	completed	28	University of Alabama at Birmingham	Jun 2005
NCT00095225		A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)	P2	completed	122	Genentech, Inc.	Jul 2004
NCT00404404		ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer	P2	unknown	35	Premiere Oncology	Oct 2006
NCT00387374		Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab	P2	completed	72	National Cancer Institute (NCI)	Oct 2006
NCT00165568		Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer	P2	completed	20	Dana-Farber Cancer Institute	Jul 2005
NCT00106054		Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases	P2	terminated	2	Pfizer	Jan 2006
NCT00370422		Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial	P3	unknown	0	Shahid Beheshti University of Medical Sciences	Nov 2005
NCT00347165		Intravitreal Bevacizumab for Age-Related Macular Degeneration	P2	terminated	50	Asociación para Evitar la Ceguera en México	Sep 2005
NCT00006786		Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer	P2	completed	0	Eastern Cooperative Oncology Group	Nov 2000
NCT00418431		Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy	P2/P3	withdrawn	0	Asociación para Evitar la Ceguera en México	Apr 2006
NCT00436709		Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer	N/A	unknown	75	Memorial Sloan Kettering Cancer Center	Jul 2006
NCT00417833		Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment	P2/P3	terminated	0	Asociación para Evitar la Ceguera en México	Dec 2005
NCT00047710		Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer	P1	completed	48	M.D. Anderson Cancer Center	Sep 2002
NCT00357318		Bevacizumab and Sunitinib in Treating Patients With Solid Tumors	P1	completed	60	National Cancer Institute (NCI)	Jun 2006
NCT00369551		Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer	P1	terminated	36	National Cancer Institute (NCI)	Jun 2006
NCT00600262		Intravitreal Bevacizumab for Diabetic Retinopathy	P2/P3	terminated	0	Asociación para Evitar la Ceguera en México	Dec 2005
NCT00120172		Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer	P2	terminated	40	Geriatric Oncology Consortium	May 2005
NCT00337389		Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.	P3	unknown	1,200	Mast Therapeutics, Inc.	May 2006
NCT00599820		Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks	P3	terminated	0	Asociación para Evitar la Ceguera en México	Nov 2005
NCT00417716		Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema	P3	withdrawn	0	Asociación para Evitar la Ceguera en México	Sep 2005
NCT00097019		A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed	P2	completed	53	Genentech, Inc.	Feb 2005
NCT00022607		Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma	P2	completed	0	California Cancer Consortium	Jan 2002
NCT00483782		Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	P3	completed	1,520	Medical Research Council	Apr 2006
NCT00348998		Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer	P2	unknown	18	Virginia Mason Hospital/Medical Center	Apr 2006
NCT00349557		Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer	P2	completed	18	Benaroya Research Institute	Apr 2006
NCT00426998		Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD	P2	completed	30	Retinal Consultants Medical Group	Apr 2006
NCT00318513		Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema	P1	unknown	35	Premiere Oncology of Arizona	—
NCT00370721	PDR	Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)	P3	unknown	0	Shahid Beheshti University of Medical Sciences	Mar 2006
NCT00416637		Bevacizumab in Treating Patients With Advanced Solid Tumors	P1	completed	27	Herbert Hurwitz, MD	Jan 2004
NCT00861419		To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.	P1	completed	88	Amgen	Dec 2005
NCT00255762		Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery	P2	completed	47	National Cancer Institute (NCI)	Dec 2005
NCT00370370		Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD	P3	unknown	0	Shahid Beheshti University of Medical Sciences	Nov 2005
NCT00253526		Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer	P2	withdrawn	0	National Cancer Institute (NCI)	—
NCT00052390		Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma	P2	completed	0	Memorial Sloan Kettering Cancer Center	Oct 2002
NCT00309998		Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	P2	completed	50	University of Rochester	Sep 2005
NCT00301990		Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer	P2	unknown	65	Jonsson Comprehensive Cancer Center	Sep 2005
NCT00118755		A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer	P2	completed	435	Hoffmann-La Roche	Jul 2005
NCT00081614		A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma	P2	completed	100	Genentech, Inc.	Mar 2004
NCT00399750	TREE-2	TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer	P2	completed	373	Sanofi	Nov 2002
NCT00203372	AVF3299	Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)	P2	completed	6	Translational Oncology Research International	May 2005
NCT00265824	DREAM	Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)	P3	completed	700	GERCOR - Multidisciplinary Oncology Cooperative Group	May 2005
NCT00162669		Bevacizumab in Advanced Hepatocellular Carcinoma	P2	unknown	50	Gustave Roussy, Cancer Campus, Grand Paris	May 2005
NCT00150657		Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer	P2	unknown	45	St. John Providence Health System	Nov 2004
NCT00022048		Bevacizumab in Treating Patients With Myelodysplastic Syndrome	P1/P2	completed	0	Stanford University	Aug 2001
NCT00019539		Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer	P2	completed	0	National Cancer Institute (NCI)	Nov 1998
NCT00096148		Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	P2	terminated	120	National Cancer Institute (NCI)	Oct 2004
NCT00100815		Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer	P2	completed	50	Roswell Park Cancer Institute	Aug 2004
NCT00107315		Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer	P2	terminated	16	Roswell Park Cancer Institute	Jul 2004
NCT00096967		A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study	P3	completed	100	Genentech, Inc.	Oct 2002
NCT00088894		Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	P3	completed	590	National Cancer Institute (NCI)	Jun 2004
NCT00079430		Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	P1	completed	113	National Cancer Institute (NCI)	Jun 2004
NCT00085358		Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)	P1	completed	40	National Cancer Institute (NCI)	May 2004
NCT00070122		Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer	P3	terminated	2,200	National Cancer Institute (NCI)	Apr 2004
NCT00084604		Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	P2	completed	47	National Cancer Institute (NCI)	Apr 2004
NCT00015951		Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers	P2	completed	0	University of Maryland, Baltimore	Apr 2001
NCT00109057		An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study	P2	completed	56	Genentech, Inc.	Feb 1998
NCT00085111		Bevacizumab in Treating Young Patients With Refractory Solid Tumors	P1	completed	24	National Cancer Institute (NCI)	Dec 2003
NCT00109226		A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer	P2	completed	0	Genentech, Inc.	Aug 2000
NCT00060411		A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer	P1	completed	24	National Cancer Institute (NCI)	Jun 2003
NCT00061178		Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma	P3	withdrawn	0	Genentech, Inc.	—
NCT00109070		A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer	P3	completed	0	Genentech, Inc.	Sep 2000
NCT00055913		Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	P1/P2	completed	58	National Cancer Institute (NCI)	Mar 2003
NCT00055809		Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors	P2	completed	44	National Cancer Institute (NCI)	Jan 2003
NCT00047762		Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer	P1	completed	0	Genentech, Inc.	Oct 2002
NCT00109239		A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer	P3	completed	0	Genentech, Inc.	Nov 2000
NCT00052559		Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer	P1	completed	32	National Cancer Institute (NCI)	Aug 2002
NCT00021060		Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer	P2/P3	completed	842	National Cancer Institute (NCI)	Aug 2002
NCT00049088		Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors	P1	terminated	24	National Cancer Institute (NCI)	Aug 2002
NCT00055861		Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer	P2	completed	27	National Cancer Institute (NCI)	Jul 2002
NCT00043004		Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer	P2	terminated	119	European Organisation for Research and Treatment of Cancer - EORTC	May 2002
NCT00028834		Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer	P2	completed	50	National Cancer Institute (NCI)	Feb 2002
NCT00027599		APC8015 and Bevacizumab in Treating Patients With Prostate Cancer	P2	completed	25	National Cancer Institute (NCI)	Dec 2001
NCT00027703		Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma	P2	completed	106	National Cancer Institute (NCI)	Oct 2001
NCT00025337		Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated	P3	completed	880	National Cancer Institute (NCI)	Sep 2001
NCT00023959		Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer	P1	completed	39	National Cancer Institute (NCI)	Jul 2001
NCT00023920		Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia	P2	terminated	60	National Cancer Institute (NCI)	Jul 2001
NCT00016107		Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer	P2	completed	72	National Cancer Institute (NCI)	Jun 2001
NCT00017394		Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer	P2	completed	56	National Cancer Institute (NCI)	Mar 2001
NCT00005061		Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors	P1	completed	20	European Organisation for Research and Treatment of Cancer - EORTC	Dec 1999

Bevacizumab clinical trials: frequently asked questions

How many Bevacizumab clinical trials are there?: 2548 Bevacizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 367 are actively recruiting participants. 1196 are marked completed.
Are Bevacizumab clinical trials recruiting in 2026?: Yes — 367 Bevacizumab trials are actively recruiting in 2026, with 2914 U.S. sites across 50 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Bevacizumab being studied for?: Bevacizumab is being studied for Colorectal Cancer, Metastatic Colorectal Cancer, Breast Cancer, Ovarian Cancer, Hepatocellular Carcinoma and 2189 more. The trials are grouped by indication on this page.
What phase is Bevacizumab in?: Bevacizumab clinical trials span 73 Phase 4, 336 Phase 3, 1309 Phase 2, 311 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Bevacizumab clinical trials?: The lead sponsor across the most Bevacizumab trials is National Cancer Institute (NCI), with 825 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Bevacizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed July 17, 2026.

Related pages on Hipa.ai:

Bevacizumab overview Bevacizumab evidence & publications